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ABSTRACT
Recent data has indicated that the prolonged asymptomatic phase and freedom from clinical illness 
experienced by the majority of HIV-2 infected individuals results from a lower level of virus production 
during infection than that observed in either HIV-1 infection or in the small number of HTV-2 infected 
individuals displaying relatively rapid progression to disease. The rate at which viral gene products are 
transcribed is one mechanism by which the rate of virus production can be controlled and is mediated by 
the Long Terminal Repeat (LTR) regions of the HTV-2 genome.
A limiting dilution sensitive nested PCR has been developed to amplify the HTV-2 LTR from clinically 
and phenotypically characterised infected sources, including a number of HTV-2 isolates and uncultured 
PBMC samples derived from Gambian HIV-2 infected long-term non-progressor (LTNP) and rapid 
progressor (RP) patients. Using a highly efficient cloning system LTR amplicons have been cloned into a 
firefly luciferase reporter vector. A dual luciferase reporter assay has been used to determine LTR- 
directed basal and Tat fra/wactivated levels of transcription in physiologically relevant cell lines. LTRs 
derived from LTNP patients tended to direct lower levels of basal and Tat froTuactivated transcription 
when compared to LTRs derived from RP patients. The difference between the two groups was more 
pronounced in the T cell-like Jurkat cell-line. Nucleotide sequence analyses of the LTR clones has 
revealed that the rate of general and G-to-A mutations at single functional sites within the LTR is higher 
in sequences derived from LTNP patients compared to RP patients. Taken together our data implies a 
relationship between LTR activity, sequence variation, and overall levels of virus expression in HTV-2 as 
evidenced by higher levels of circulating peripheral HTV-2 RNA in the patients with progressive disease 
profiles. Therefore, different LTR responsiveness may relate to different rates of virus production and 
disease progression rates and hence be a determinant in viral pathogenesis.
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COMMON ABBREVIATIONS
A adenine
AIDS Aquired Immune deficiency Syndrome
Amp ampicillin
bp base pair
C cytosine
DNA deoxy-ribonucleic acid
dNTP 2’ deoxyribonucleotide 5’ triphosphate
ds double stranded
E.coli Eschericia coli
EDTA ethylene-diaminetetra-acetic acid
G guanine
g, mg, jig, ng, pg gram, milligram, microgram, nanogram, picogram
g acceleration due to gravity
gpl20/gpl05 HIV-1 120kD/HIV-2 105kD Surface envelope glycoprotein
gp41/gp36 HIV-1 41kD/HIV-2 36kD Transmembrane envelope glycoprotein
HIV Human Immunodeficiency Virus
Kb kilobasepair(s) (K=1000)
kD kiloDalton
LTR Long Terminal Repeat
M, mM, jjM  molar, millimolar, micromolar
ml, mis, pi millilitre, millilitres, microlitre
MRC Medical Research Council
mRNA messenger RNA
oligo oligonucleotide
PBS phosphate buffered saline
PCR polymerase chain reaction
RNA ribonucleic acid
SIV Simian Immunodeficiency Virus
T thymidine
TAE Tris-acetate EDTA buffer
TAR Transactivation Responsive Region
TE Tris-HCL EDTA
Tris tris (hydroxymethyl) aminomethane
U uracil
V volts
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Chapter 1. 
General Introduction.
1.1 The Retroviridae
To aptly describe the remarkable nature of the retroviridae is an extremely difficult undertaking. The 
wide-ranging appeal to study this distinct family of RNA viruses surely stemmed from the discovery that 
retroviruses unequivocally contradicted the central dogma of molecular biology. In 1964 retrovirologist 
Howard Temin illustrated that infection with RNA tumour viruses such as avian sarcoma virus, was 
blocked using inhibitors of DNA synthesis. This finding suggested that DNA synthesis was required for 
the multiplication of RNA tumor viruses, indicating that genetic information could flow from RNA to 
DNA. From this, Temin went on to propose that the information of the infecting RNA was transferred to 
a DNA copy, a provirus, which then served as a template for the synthesis of viral RNA. The discovery 
of the RNA dependent DNA polymerase enzyme, reverse transcriptase, made independently by Temin 
(Temin & Mizutani et al., 1970) and Baltimore (Baltimore, 1970) in 1970, verified Temin’s intrepid 
hypothesis. The subsequent discoveiy that all RNA tumour viruses encoded a reverse transcriptase 
prompted the family of viruses to be termed retroviruses.
In addition to the contradictory flow of genetic information directed by members of the retroviridae, 
retroviruses exhibit an amazing capacity to intimately associate with host DNA. Other animal and plant 
viruses have been found to produce provirus using reverse transcriptase as part of their replication cycle, 
but retroviruses are the only viruses possessing a mechanism that enables stable proviral integration into 
host DNA. The effects caused upon integration of the retroviral provirus go someway toward 
determining the diverse pathogenesis observed within the retrovirus family, and can be used to distinguish 
between its different members.
The strikingly intimate relationship the retrovirus shares with its host is exemplified by the ability of the 
retroviral genome to be synthesized and processed entirely by host cell transcriptional machinery. As a 
result, all retroviral genomes contain a 5’ capping group and a 3* polyadenylation signal; features that are 
normally only found in newly made eukaryotic mRNA transcripts. In addition, the retroviral genome is 
associated with a highly conserved specific tRNA enabling it to prime genome replication. Taken 
together, the retrovirus family exhibits the most desirable attributes to aid complete integration into host 
cell processes, enabling successful virus host relationships to be established during viral infection.
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Retroviruses are associated with wide ranging diseases, primarily of vertebrates, including 
immunodeficiencies, neurological disorders, and malignancies which can be rapid or of long latency. The 
majority of the pathological conditions caused by retroviruses are as a result of infection with exogenous 
retroviral elements, however, retroviruses may also be present as endogenous elements. Endogenous 
retroviruses are not generally associated with pathogenic infection; they exist as integrated provirus 
within the germ line of many vertebrates and are inherited via vertical transmission. The endogenous 
proviruses are usually transcriptionally silent and are often defective, although some can be induced to 
express and replicate at low levels. The existence of such an established but largely non-pathogenic 
virus-host relationship highlights the vast diversity of virus - host interactions characteristic of the 
retrovirus family.
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1.1.1. Retrovirus morphology and general genomic organisation
Despite the variety of pathological conditions relating to retrovirus infection there appears to be a basic 
structural and genetic pattern displayed by each member of the retrovirus family. Generally, mature 
virions occur as enveloped particles lOOnm in diameter. Retroviruses have a diploid genome consisting 
of two molecules of positive sense single stranded RNA. The virion genome is encapsulated within a 
spherical or conical shaped internal nucleocapsid. As with virion structure, genomic organisation is 
conserved within the retrovirus family. All retrovirus genomes contain three structural genes that are 
identically orientated 5’ to 3’ within the genome. The group-specific antigen (gag) gene encodes the 
virion core proteins, the polymerase (pol) gene encodes reverse transcriptase and other viral enzymes, and 
the envelope (env) gene encodes the oligomeric glycoprotein spikes that are located in the surrounding 
host derived lipid envelope. The viral genome is flanked by two Long Terminal Repeat (LTR) sequences 
that contain viral promoter and enhancer elements that interact with cis- and tram- acting DNA binding 
proteins to direct viral gene expression. The basic genetic organisation of the retrovirus genome is always 
LTR-gag-pol-env-LTYL
Thin-section electron micrograph studies have revealed that despite the commonality of the virion 
structure (Gelderblom et al., 1972), retroviruses can be classified into four morphological groups (types A 
to D) in addition to the previously described genera classifications. A-particles exist as roughly spherical 
double-walled intracellular structures, 60-90nm in diameter. They are non-infectious, produced by a 
number of endogenous proviruses, and represent the immature precursors of B-type and D-type viruses. 
In comparison, B- and D- particles represent extracellular virion structures; they exist as encapsulated 
versions of A-particles. The B-particle envelope is characterised by the presence of surface projections, 
the D-particle envelope does exhibit surface projections but they are less prominent than those found on B 
particles. C-particles, unlike A-particles, lack visible intracellular structures. Immature core formation 
occurs simultaneously with virion budding. Maturation of the particle is defined by condensation of the 
core structure, this occurs within the enveloped particle, a similar process is also observed within B- 
particles. The envelope of C-particle virions does not exhibit surface spikes.
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1.1.2. Retrovirus genera taxonomy
Traditionally, retrovirus taxonomy distinguished members of the retrovirus family by pathogenicity, this 
lead to the division of three subfamilies (Teich, 1985). The first, the Oncoviridae, represented a 
subfamily of tumorogenic retroviruses that were largely exogenous; with the majority of members 
associated with pathogenic conditions. The second, the Spumaviridae, were classified as exogenous 
retroviruses that caused persistent but benign infection, characterised by vacuolation of cells in culture. 
The third, the Lentiviridae, were classified as a subfamily of retroviruses that gave rise to slowly 
developing diseases of the immune system characterised by long incubation periods. The majority of 
members within this subfamily caused benign infection in their natural hosts, but a minority were 
associated with fatal pathogenic conditions.
Retroviral classification has been more recently redefined based upon genome structure and nucleotide 
sequence relationship as well as pathogenicity, this has resulted in the recognition of seven distinct virus 
genera (Coffin, 1992) (Table 1.1, pg 30) as opposed to the traditional three subfamilies. Only three of 
the seven genera contain human retroviruses, the HTLV-BLV group, the Lentivirus group and the 
Spumavirus group
Previously characterised as the Oncoviridae the oncogenic members of this retrovirus family are now 
classified into five distinct genera (Table 1.1, pg 30). Four of the five groups contain retroviruses that 
infect avian and mammalian species; the remaining group has been shown to cause pathogenic conditions 
in humans. Studies investigating the structural and functional relationship between viral oncogenes and 
cellular proto-oncogenes have centred on retroviral examples from all five genera. Information provided 
by such studies have greatly contributed to our understanding of the molecular mechanisms involved in 
retroviral induced malignancy, signal transduction and cellular growth.
Oncogenic retroviruses have the ability to induce transformation and tumour formation by controlling the 
expression of viral or cellular oncogenes. This control is dictated by the ability of the retrovirus to either 
integrate into host DNA or incorporate parts of cellular proto-oncogenes into their genomes. In either 
mechanism oncogenic expression is controlled by the viral LTR, hence the cellular proto-oncogene 
promoter no longer controls expression levels, growth factor regulation or cell specificity. Examples of 
both mechanisms are exhibited in infection with retroviruses from the five groups discussed below.
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The avian leukosis-sarcoma virus (ALSV) group contains exogenous and endogenous retroviruses 
associated with tumor induction and leukaemias in avian species (Table 1.1, pg 30) (Payne, 1992). The 
exogenous members of the genera, with the exception of Rous-associated virus (RAV) and avian leukosis 
virus (ALV) contain oncogenes. Rous sarcoma virus (RSV) contains oncogene v-src; this gene is a 
processed version of the cellular proto-oncogene c-src, a tyrosine specific protein kinase, but contains 
major deletions (Tanaka et al., 1990, Zhou et al, 1990). Similarly, avian erythroblastosis virus (AEV) 
contains v-erb-B a deletion containing counterpart to cellular erb-B (Bruskin et a l, 1990, Miller et al,
1990). Infection with either of these viruses results in LTR directed expression of oncogenes whose 
cellular relatives are involved in signal transduction. The changes to the virally expressed oncogenic 
proteins allow them to behave independently of normal cellular transduction signals and results in the 
transformation of a normal cell to a malignant one (Miller et a l, 1990, Zhou et a l, 1990).
Retroviruses that lack oncogenes are able to induce malignancies by their ability to integrate into the host 
genome and cause a process called insertional activation. Tumours induced by oncogene-lacking 
retroviruses such as avian leukosis virus (ALV) exhibit a common feature; the provirus is always 
integrated within a particular gene of the cellular genome. In the case of ALV die proto-oncogene c-myc 
is targeted, upon proviral integration c-myc expression is solely controlled by the 3’ LTR, and results in 
the initiation of tumorigenesis (Robinson & Gagnon, 1986, Goodenow & Hayward, 1987).
The mammalian C-type group of retroviruses also contains exogenous and endogenous aetiological agents 
(Table 1.1, pg 30). The exogenous retroviruses of this genera have been shown to cause leukaemia’s and 
sarcoma’s within numerous mammalian species and many are associated with oncogenes (Kozak & 
Ruscetti, 1992). A distinguishing feature among members of this group appears to be the involvement of 
virion proteins in the oncogenic process. In murine leukaemia virus (MLV) and feline leukaemia virus 
(FLV) infection, the gag protein associates with v-abl and fins respectively, ultimately resulting in the 
activation of T-cell lymphomas (Witte et a l, 1978, Hampe et a l, 1984, Neil et a l, 1987, Neil et al,
1991). The MLV env proteins have also been linked with oncogenic induction through stimulation of 
cellular IL-2 receptors (Li & Baltimore, 1991).
Mouse mammary tumor virus (MMTV) is the best-studied member of the B-type virus group and 
represents the only infectious retrovirus of this genera (Table 1.1, pg 30). Unlike the majority of 
retroviruses discussed so far MMTV is not associated with any oncogene yet induces sporadic mammary 
adenocarcinomas in infected female mice (Morris, 1991). Exogenous and endogenous forms of MMTV
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exist, although exogenous transmission is also vertical, passing from mother to offspring via ingested 
milk. Carcinoma induction is stimulated by the random insertion of the proviral genome into a host 
proto-oncogene (int genes). The alteration of expression of int genes as a result of the MMTV promoter 
insertion has been causally linked with proliferation of tumours in the mammary gland (Nusse et al., 
1990, Nusse, 1991, Jhappan, et al., 1992).
The D-Type group of exogenous and endogenous retroviruses have only been isolated from primate 
species; the most widely studied example is Mason-Pfizer monkey virus (MPMV) (Table 1.1, pg30). 
Retroviruses from this genus exhibit A particle morphology, characterised by intracellular core formation 
prior to virion budding. In this respect, D-type retroviruses are most closely related to B-type viruses and 
spumaviruses, immature particles from both groups resemble intracistemal A particles. D-type 
retroviruses containing oncogenes have not been isolated.
Until members of the Human T-cell lymphotrophic virus/ bovine leukaemia virus group had been isolated, 
proof that retroviruses were causally involved in human neoplastic disease was lacking. With the advent 
of continuously growing cell lines, two groups independently isolated retroviruses exhibiting C type 
morphology. In 1980, a group lead by B.J. Poiez isolated Human T cell lymphotrophic virus (HTLV-1) 
from a patient exhibiting cutaneous T-cell lymphoma (Poiez et al., 1980). Two years later Yoshida et al 
isolated a C type retrovirus from a patient suffering from adult T cell leukaemia termed adult T cell 
leukaemia virus (ATLV) (Yoshida et al., 1982). Following serologic and nucleic acid analysis ATLV 
was found to exhibit equivalent divergence to isolates of HTLV-1 and was deemed a member of the 
HTLV group. HTLV-1 has been linked to a number of other diseases distinct from T cell 
lymphomas/lymphomas including tropical spastic paraparesis, HTLV-associated myelopathy, and 
immunosuppressive disorders. Unlike the majority of other oncogenic retroviruses, exogenous HTLV-1 
is not associated with any oncogene or integration site. HTLV-1 integrates into the host cell genome 
randomly and detectable expression of viral genes is not observed. It appears that oncogenesis is in some 
way related to the ability of the integrated HTLV-1 provirus to induce constant T cell proliferation. A 
malignant clone may subsequently arise and manifest into a tumor, the length of time that this process 
takes to occur may determine the long latency seen in HTLV infection.
The HTLV genome encodes the three major retroviral genes, gag, pol, and env, and two additional 
regulatory genes, tax and rex. In this respect, HTLV shows similarity to members of the lentiviridae, the 
other genera of the retrovirus family to encode regulatory genes and cause disease in humans. The tax
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protein fra/wactivates transcription directed by the HTLV-1 LTR using an indirect mechanism distinct 
from but related to /roraactivation of lentivirus transcription. By directly interacting with transcription 
factors NF-kB, CREB, and AP-1, tax is able to up-regulate levels of transcription without having to 
physically bind to the HTLV enhancer and promoter elements. Tax has also been shown to exert 
upregulatory effects upon cellular and viral promoter regions distinct from those found within the HTLV- 
1 genome. The ability of tax to flransactivate IL-2 and IL-2R promoter regions has been implicated in the 
transforming and subsequent oncogenic potential of HTLV-1. In direct analogy with members of the 
lentiviral group the regulatory protein rex regulates HTLV-1 gene expression post-transcriptionally acting 
via a rex responsive element. Transmission of HTLV occurs via sexual intercourse, infected blood 
products, and breast milk.
A second retrovirus associated with T cell malignancies has been identified that is related to but distinct 
from HTLV-1. This retrovirus, now termed HTLV-2, was isolated from a patient suffering from atypical 
haiiy-cell leukaemia (Kalyanaraman et al., 1982). HTLV-2 predominantly infects CD8+ cells as opposed 
to CD4+ cells, the preferred target of HTLV-1, however the causal link between HTLV-2 and leukaemia 
is less palpable than with HTLV-1. Nevertheless, there have been other reports of HTLV-2 in association 
with T cell malignancy, and isolation of this virus from a second patient with hairy-cell leukaemia 
provides further evidence for the etiologic role of HTLV-2 in this disease. A link between HTLV-2 and 
intravenous drug abusers (TVDA) has been widely reported with higher prevalence of infection being 
found in American patients in comparison to European patients. Neurodegenerative disorders have also 
been linked with HTLV-2 infection indicating that diseases found to be associated with HTLV-2 infection 
may mirror those linked to infection with HTLV-1.
Approximately 5% of HTLV-1 infected individuals develop symptomatic disease; considering the world 
wide infected population is thought to number between 10 and 20 million there is a significant need for 
vaccine strategies. Two animal models exist for vaccine development, bovine leukaemia virus (BLV), 
and simian T cell leukaemia virus type 1 (STLV-1). Subunit vaccine trails using monkeys have indicated 
that protection against STLV can be achieved however a vaccine candidate for human clinical trails has 
yet to be produced.
The Spumavirus group represent a group of retroviruses more commonly known as foamy viruses (Table
1.1, pg 30). Widely distributed among non-human primates, felines, and bovines, foamy viruses exhibit a
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large cellular tropism and are highly lytic in vitro, forming giant multinucleated cells (syncitia) containing 
vacuoles giving them a foamy appearance, hence the term “foamy”. Despite this distinguishing feature, 
foamy viruses appear to be innocuous in vivo, evidence linking them to disease within their natural hosts 
and humans remains tenuous. To date there has only been one reported isolation of human foamy virus 
(HFV) (Werner & Glederblom, 1979), the remaining reports of human foamy virus infection have 
resulted from zoonotic transmission of simian foamy virus (SFV) from natural host non-human primate 
sources (Heneine et al., 1998). The genome of HFV consists of the three structural genes common to all 
retroviruses; with a further four open reading frames (ORF’s), bel-1,2, 3 and SI, which encode accessory 
proteins. Bel-1 encodes the HFV frwwactivator protein, which shares homology with the frwwactivator 
protein encoded by members of the Lentiviridae, and represents the only accessory protein that is 
essential to HFV replication (Rethwilm et a l, 1991).
Members of the Lentivirus group form a distinct group of exogenous retroviruses, which cause infections 
associated with prolonged incubation periods prior to disease onset (Table 1.1, pg 30). Lentiviruses are 
capable of persistently infecting a vast array of cellular targets although they typically infect cells of the 
immune system, primarily those of monocyte/macrophage lineage.
The first member of the lentiviridae was identified in 1904. Equine infectious anaemia virus (EIAV) was 
found to cause autoimmune haemolytic anaemia and in some instances encephalopathy in horses (Vallee 
& Carre, 1904). A second disease characterised by slow progression was identified in Icelandic sheep in 
1957 (Sigurdsson et a l, 1957). The etiologic agent causing the slowly progressive pneumoencephalitic 
disease in sheep was found to be of retroviral origin and was identified as maedi/visna virus (MMV), the 
second member of the lentivirus family (Narayan & Clements, 1989). An arthritis/encephalitis virus of 
goats (caprine arthritis-encephalitis virus, or CAEV) exhibiting different properties from MMV has also 
been identified and characterised as a lentivirus (Saltarelli et al, 1990).
More recently, the molecular and biological characterisation of retroviruses that cause severe 
immunodeficiencies have resulted in their addition to the lentiviral family. Among those characterised 
are the human immunodeficiency viruses type 1 and type 2 (HIV-1, HTV-2), bovine immunodeficiency 
virus (BIV), feline immunodeficiency virus (FIV), and simian immunodeficiency virus (SIV). All have 
been causally associated with severe immunodeficiencies. The immunodeficiency viruses grouped into
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the lentivirus family having a similar genomic organisation and exhibit type C morphology. These are 
discussed in more detail in Section 1.2.
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The Retroviridae:
Genus Species
ALSV-group Rous sarcoma virus (RSV)
Avian erythroblastosis virus (AEV) 
Avian myeloblastosis virus (AMV) 
Rous-associated virus (RAV) 
RAV-0
Mammalian C-type Moloney murine leukaemia virus 
(Mo-MLV)
Abelson murine leukaemia virus (A- 
MuLV)
AKR-MuLV
Feline leukaemia virus (FeLV) 
Hamster leukosis virus 
Simian sarcoma virus (SSV)s 
Primate endogenous viruses (BaEV), 
(MAC-1), (OMC-1). 
Reticuloendotheliosis virus (REV)
B-Type viruses Mouse mammary tumor virus 
(MMTV)
D-Type viruses Mason-Pfizer monkey virus (MPMV) 
“SAIDS” viruses 
Simian Retrovirus (SRV)
HTLV-BLV group Human T-cell leukaemia 
(or lymphotropic) virus, 
(HTLV-1, HTLV-2) 
Bovine leukaemia virus
Lentivirus Human immunodeficiency virus, 
(HTV-1, HIV-2)
Simian immunodeficiency virus 
(SIV)
Feline immunodeficiency virus 
(FIV)
Bovine immunodeficiency virus 
(BIV)
Visna/maedi virus
Caprine arthritis-encephalitis
(CAEV)
Equine infectious anaemia virus 
(EIAV)
Spumavirus Simian foamy virus (SFV)
Human foamy virus (HFV) or 
Human spumareetrovirus (HSRV) 
Feline syncytium-forming virus 
(FeSV)
Table 1.1 Classification of the retroviridae (adapted from Davis et al, 1990).
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1.2 Lentiviral infections associated with immunodeficiency
1.2.1. Bovine immunodeficiency virus 
Bovine immunodeficiency virus (BIV) was originally isolated from a cachectic cow displaying 
lymphadenopathy and mild encephalitis (Van der Maaten et al., 1972). Since this isolation however, few 
investigators have reported a pathogenic link between BIV infection and disease with the possible 
exception of Carpenter et al in 1992 (Carpenter et al., 1992). Calves inoculated with BIV were found to 
develop mild follicular hyperblastia in the lymph nodes, however a similar study carried out by a different 
group failed to link BIV infection with clinical disease (Onuma et al., 1992). The significance of this 
pathogen in its natural host remains undetermined.
1.2.2 Feline immunodeficiency virus
Feline immunodeficiency virus (FIV) was first isolated in 1987 from a group of cats in Petaluma, 
California (Pedersen et al, 1987). Infected cats within the group displayed generalised lymphadenopathy 
and acute neurological disease. FIV was found to exhibit many characteristics in common with HIV 
infection in humans and was classified as a member of the lentivirus genus (Olmsted et al., 1989a, 
Olmsted et al, 1989b, Pedersen et al, 1989, Brown et al, 1994, Langley et al, 1994). Experimental and 
seroepidemiologic studies suggest that FTV is transmitted by bites and is most prevalent in high-density 
populations of free roaming cats (feral and pet). Kittens experimentally infected with FTV do not follow 
the disease course typically observed in naturally infected cats and many develop a transient fever and 
neutropenia 4 - 8  weeks after inoculation (Yamamoto et al, 1988, Pedersen et al, 1989). Under these 
circumstances, infection is associated with a generalised lymphadenopathy persisting for up to 9 months, 
after which time most cats recover. Terminal immunodeficiency is mainly found in naturally infected 
cats. Because of the molecular and biological similarities shared with HTV, FTV has been used as an 
animal model to study human immunodeficiency virus infection.
1.2.3 Simian immunodeficiency viruses
In terms of significance to immunodeficiency in humans, simian immunodeficiency viruses (SIV) 
represent the most important of all lentiviruses. SIVs are the closest known relatives to HTV; moreover, 
recent analyses have indicated that members of this group of viruses are likely to have been the 
progenitors of HTV (see section 1.4). Unlike HTV, within their natural hosts members of the SIV group 
are not associated with pathological conditions. Highly prevalent in a variety of Old World primate
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species (Desrosiers & Letvin, 1987, Desrosiers et al., 1990, Gojobori et al., 1990, Johnson et al, 1991, 
Myers & Pavlakis, 1992) strains of SIV are designated according to their species of origin. Naturally 
occurring infection has been described in sooty mangabeys (Cercocebus atys, SlV^n), mandrills (Papio 
sphinx, SrVmnd), Sykes’ monkeys (Cercopithecus mitis alboglugaris, S IV ^  and African green monkeys 
(Cercopithecus spp, SIV.^A the latter group being further sub-divided into four African green monkey 
subspecies.
SIV has also been isolated from wild caught captive chimpanzees (S IV ^  and has led to the 
characterisation of four S IV ^ strains that fall into two distinct subspecies groups analogous to those 
defining African green monkey SIV strains (Huet et al, 1990, Janssens et al, 1994, Vanden Haesevelde 
et al, 1996, Gao et al, 1999). Serological screening had, until recently, failed to detect significant 
prevalence of natural infection among wild populations of chimpanzees. However in 1999, a 
phylogenetic study reported the discovery of a recombinant SIVcpz genome derived from divergent SIV ^ 
lineages suggesting that screening of free-living adult chimpanzees from all four chimpanzee subspecies 
may reveal the existence of a natural SIVcpz reservoir (Gao et al., 1999) (see section 1.4).
In contrast to the described natural infections, SIV infection of another primate species that does lead to 
an immunodeficiency-like illness has been documented. A number of primate centres in America 
characterised SIV isolates from rhesus, pigtail, cynomologous, and stumptailed macaques (SIV ^, 
SlVmne, SIV ^, and SIVstm, respectively) presenting with diseases such as lymphomas, progressive 
multifocal leukoencephalopathy, and tuberculosis. Initially the macaque isolates were considered as 
independent strains derived from a natural macaque SIV reservoir. Screening of feral macaques however, 
did not reveal any natural SIV infection and lead to the investigation into other routes of transmission. 
Extensive research into housing and inoculation histories in conjunction with molecular characterisation 
studies has indicated that cases of macaque SIV infection are examples of zoonotic transmission (Daniel 
et al, 1985, Hirsch et al, 1989a, Hirsch et al., 1989b, Novembre et al., 1992). When compared 
phylogenetically, the macaque isolates are as equidistantly related to SlVsn, as they are to each other. It is 
likely that the macaque SIV isolates arose as a result of a number of cross species transmission events that 
probably took place in the setting of the primate centres of the 1970’s where Asian macaques are thought 
to have been housed with wild caught sooty mangabeys (Murphey-Corb et al, 1986, Mansfield et al,
1995). Ironically, the ability of the macaque SIV isolates to cause immunodeficiency-like disease in 
monkeys similar to AIDS in humans has provided an extremely valuable tool for the study of the 
pathogenesis of human lentiviruses.
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1.2.4 Isolation o f HIV-1
In 1981, the Centre for Disease Control (CDC) identified a new syndrome described as ‘Gay Related 
Immune Deficiency’ (GRID) in two previously healthy, young homosexual males. The two patients had 
presented with severe immunodeficiency characterised by profound depletion of CD4+ lymphocytes, in 
addition to Pneumocystis carinii pneumonia and Kaposi’s sarcoma (Control, 1981a) (Control, 1981b). 
Subsequently, symptoms similar to those accompanying GRID began to be described in intravenous (TV) 
drug users, transfusion recipients, haemophiliacs, and infants of IV drug dependent mothers. In 1982, 
Acquired Immunodeficiency Syndrome (AIDS) was the name chosen to describe this group of 
immunodeficiencies.
The epidemiology of the early AIDS epidemic was characterised by an increasing incidence and 
clustering of cases in large cities such as New York, suggesting the involvement of a transmissible agent. 
The profound depletion of CD4+ T lymphocytes observed in all AIDS patients was similar to the immune 
deficiency identified in cases of human and animal retroviral infection. Since human retroviral infection 
was known to cause leukaemias, lymphomas, and T cell malignancies; several laboratories predicted that 
the putative causative agent for AIDS would be a retrovirus.
In 1983, credence was lent to this prediction when an American group lead by Robert Gallo reported the 
isolation of T-cell tropic HTLV from an AIDS patient (Gallo et al, 1983). The suggestion that this 
retrovirus was the causative agent of AIDS was, however, inconsistent with the characteristic lytic 
infection of CD4+ lymphocytes observed in AIDS patients; HTLV was known to immortalise T 
lymphocytes, not kill them. In the same issue of Science a group at the Pasteur Institute lead by Luc 
Montangnier and Franfoise Barr6-Sinoussi, reported the isolation of a novel retrovirus from a patient 
displaying multiple lymphadenopathies (Barr^-Sinoussi et al., 1983). Importantly, this retrovirus, 
initially termed lymphadenopathy associated virus (LAV), was found to be distinct from HTLV I, and II, 
and was found to infect and grow to significant titres within CD4+ lymphocytes. Furthermore, LAV was 
found to kill rather than immortalised the CD4+ lymphocytes it was cultured in.
During 1984 a further two AIDS associated retroviruses were identified, the first by Gallo and colleagues 
(Gallo et al., 1984) and the second by an American group headed by Jay Levy (Levy et al., 1984). The 
second AIDS associated retrovirus to be characterised by the Gallo group while distinct from HTLV, 
showed cross-reactivity with some HTLV-I and HTLV-II proteins, and was subsequently named HTLV- 
III. The retrovirus identified by Levy et al was recovered from healthy people as well as AIDS patients
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signifying for the first time the existence of a carrier state for the AIDS virus. This retrovirus was termed 
AIDS-associated retrovirus (ARV).
Shortly after their identification, all three AIDS-associated retroviruses (LAV, HTLV-III and ARV) were 
found to exhibit similar in vitro cytopathic characteristics and some antigenic cross-reactivity to each 
other. This lead to them being recognised as members of the same group of retroviruses, termed the 
lentiviridae. Distinct from HTLV, the group of three retroviruses were named Human Immunodeficiency 
Virus (HTV) in 1986 by the International Committee on Taxonomy of Viruses (Coffin et al 1986). In 
later studies the HTLV-III strain, isolated by the Gallo group was confirmed to be the same virus as LAV, 
while ARV is considered a separate strain of HIV-1. After extensive isolation of HIV from the blood of 
many patients with AIDS and ARC, as well as from the PBMC of several clinically healthy individuals, 
the causal link between HTV and AIDS is now widely accepted.
1.2.5 Identification o f  HIV-2 
Following the identification of HTV-1 and its associated pathogenesis the alarming consequence of a 
worldwide pandemic was the subject of intense debate and investigation. Large serological screening 
studies were initiated in many countries to determine the prevalence of HIV infection. Cases of HIV-1 
had been widely reported within Central and Eastern Africa however few cases had been identified in 
West African countries. In 1985, Barin et al published data produced from a study investigating HTV 
prevalence in healthy female prostitutes attending an STD clinic in Senegal, West Africa (Barin et al., 
1985). Sera taken from the Senegalese individuals were examined for reactivity to HIV-1 and SIV 
antigens. Surprisingly the group produced stronger serological responses against S IV ^  antigens than 
against HIV-1 viral antigens, indicating that the virus that the Senegalese prostitutes had been exposed to 
was related to HIV-1, but exhibited a closer relationship to SIV. Following this discovery, in 1986 Clavel 
and co-workers isolated a new human retrovirus from the peripheral blood mononuclear cells (PBMC) of 
two West African patients exhibiting an AIDS-like illness (Clavel et al, 1986a). Analysis of this 
retrovirus showed it to be more serologically and antigenically related to SIV than HTV-1, it was therefore 
termed human immunodeficiency virus type 2 (HIV-2) and became the prototypic HIV-2 strain ROD. 
Molecular cloning and sequencing of the newly isolated retrovirus revealed the explanation for the 
stronger serological response to STV antigens reported in both the Clavel and Barin studies (Clavel et al, 
1986b). The HTV-2 genome isolated by Clavel and co-workers displayed only 42% homology with the 
HIV-1 genome, but showed 75% similarity to strains of SIV^ and S IV ^. Further molecular and
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serological examination of HIV-2 has since confirmed that it is more closely related to SIV strains than 
strains of HIV-1 (Chakrabarti et al, 1987, Franchini et al, 1987, Hirsch et al, 1989, Gao et al, 1992, 
Gao et al, 1994, Chen et al, 1996, Chen et al, 1997) (see section 1.4).
Since early studies of HTV-2 infection demonstrated little association with disease there was doubt as to 
whether HIV-2 was an etiologic agent of AIDS (Barin et al, 1985, Kanki et al, 1987). However, in 1987 
a study investigating the clinical status of 30 HIV-2 seropositive individuals revealed that HIV-2 was the 
causative agent of AIDS in 17 of the patients, while 6 remained asymptomatically infected. Further 
serological screening studies have since identified HIV-2 as the dominant HIV-type circulating West 
Africa.
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1.3 Primate lentivirus phytogeny
The genetic relationships between members of the primate lentivirus family have been established by 
phylogenetic analysis of the three major genes within the retrovirus genome, gag, pol, and env. 
Differences within these genes occur as a result of the lack of proofreading mechanisms in the retroviral 
reverse transcriptase and give rise to the diversity seen within the HIV-1, HTV-2, and SIV lineages. 
Mutation rates as high as 1 x 104 mutations per genome per replication cycle determine the pleomorphic 
nature of the primate lentiviral strains and can confer selective replication advantages and disadvantages 
(Preston et al, 1988, Roberts et al, 1988). Based on comparative genetic sequence analysis five distinct 
groups of primate lentiviruses have been identified. These are HIV-l/SIV^, HTV^/SIVan/SIVmac, 
SIVaguj, SlVmnd, and SIVsyk(Figure 1.1 A, pg 38).
Three groups contain strains isolated from three Old World African primate species, SIVagm, SIVmi,H, and 
SIV^. The remaining two groups contain a mixture of strains taken from human and primate species and 
reflect the finding that HTV-1 strains are more related phylogenetically to SIV strains derived from the 
chimpanzee, while HIV-2 strains phylogenetically cluster with strains of SIV^,.
Phylogenetic analysis of specific gene sequences further subdivides viral strains belonging to each of 
these groups into subtypes or clades. While approximately 40% divergence is observed between the five 
primate lentiviral groups; viral subtypes within these groups are approximately 10-20% divergent from 
each other.
In addition to RT-induced strain diversity, genetic diversity is introduced into each of the five primate 
lentiviral lineages by a process termed subtype recombination. Strains, which have been generated by the 
genetic recombination of two distinct viral genomes, have been identified in each of the HTV-1, HTV-2 
and STV lentiviral families. These mosaic viral strains indicate that superinfection is a process that does 
occur within each of these lentiviral infections.
Phylogenetic analysis of gag gene sequences has lead to the division of HTV-1 strains into three distinct 
phylogenetic groups. The first major group to be classified contains the majority of HTV-1 isolates and is 
termed the main group or group M. Isolates within this group have been subdivided further into ten 
distinct but phylogenetically related subtypes or clades, A-J (Louwagie et al, 1993, Myers et al, 1993). 
Circulating HTV-1 strains identified in North America and Europe largely fall into subtype B, whereas
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subtype A and D viruses have been predominantly isolated from Central Africa. Isolates identified in 
Thailand have primarily been characterised as subtype E, and subtypes F to J represent small clusters of 
isolates from patients with links to Central African countries, in particular Zaire (Kostrikis et al, 1995, 
Leitner et al, 1995). Strains within subtypes B and D share the highest degree of homology indicating 
that HTV-1 circulating America and Europe may have originated from Central Africa.
The identification of two highly divergent HIV-1 isolates derived from patients originating from the 
Cameroon lead to the classification of a second HIV-1 phylogenetic group, the “outlier” group -  O (De 
Leys et al, 1990, Gurtler et al, 1994, Vanden Haesevelde et al, 1994). This group now contains a 
number of other isolates exhibiting significant divergence from members of the group M subtypes; the 
vast majority also originate from Cameroon (Chameau et al, 1994, Loussert-Ajaka et al, 1995). A third 
phylogenetic group has most recently been defined and represents strains of HTV-1 which fail to fall into 
the M or O group classification. The group termed N (non-M/non-O) is the least widespread of all HTV-1 
lineages and thus far contains two highly divergent isolates derived from two Cameroonian patients.
Just as strains of HTV-1 exhibit high levels of divergence, isolates of HTV-2 have been shown to display 
an equivalent range of divergent genomes (Dietrich et al, 1989, Kuhnel et al, 1989, Tristem et al, 1989). 
Phylogenetic analysis of HTV-2 gag, pol, env, and LTR sequences taken from isolated HTV-2 genomes 
has identified six distinct HTV-2 subtypes, A-F (Figure 1.1B, pg 38). The majority of HTV-2 isolates 
identified so far cluster within what has been termed subtype A. The second largest group of HTV-2 
isolates form subtype B, isolates within this group display greater than 20% divergence to strains within 
subtype A. The first divergent members of this group to be identified were isolates, D205 and GH-1, 
isolated from two Ghanaian patients, one asymptomatic the other displaying AIDS related symptoms 
(Dietrich et al, 1989, Miura et al, 1990). Following the identification of the divergent isolates in subtype 
B, Gao and co-workers analysed the infecting HTV-2 strains within 12 patients originating from six 
different West African countries (Gao et al, 1994). Phylogenetic analysis of the isolates identified in this 
study defined a further three HIV-2 subtypes, C, D, and E. Detailed genetic analysis of one particular 
strain HIV-2F074 showed that pol, env, and LTR regions PCR-amplified from this patient were virtually 
identical to the corresponding regions within isolates of SIV^. This strain, isolated from a healthy 
Liberian worker, was placed in subtype D, and as described in section 1.4, provided evidence for an STV 
progenitor of HTV-2. A sixth subtype of HTV-2, termed F, was recently identified following the isolation 
of a highly divergent strain, 93SL2 (Chen et al, 1997a). This strain was found as a single occurrence in 
Sierra Leone, a region in which household pet sooty mangabeys are common.
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Figure 1.1 Neighbour-joining trees showing primate lentiviral phylogenetic relationships. (A). Primate 
lentiviral Pol sequence analysis. Brackets to the right indicate grouping of the five primate lentiviral 
lineages (adapted from Gao et al., 1999). (B). HIV-2 and SIV Gag sequence analysis showing the six 
subtypes, A-F, and clustering of HIV-2 F0784 with SIV (adapted from Chen et al., 1997).
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1.4 Origins of HTV
As more isolates of HIV-2 were obtained, mounting evidence showing the remarkable similarities to SIV 
raised the possibility that HIV-2 infection in humans had arisen as a result of a zoonotic transmission of 
SIV from monkey to man. A number of studies utilising nucleotide sequence analyses and RNA 
hybridisation technology investigated the potential primate candidates, primarily centring upon S IV ^, 
S IV ^  and SIV^. As outlined in Figure 1.1A, pg 38), phylogenetic analysis revealed that strains of 
HIV-2 clustered with SIV^ and SIVmac, while S IV ^  strains formed a less related distinct cluster (Hirsch 
et al, 1989). The clustering of SIVmac strains with strains of SIV^ was established as resulting from a 
cross-species transmission of SIVsm from infected sooty mangabeys to Asian macaques in the setting of 
the Primate Research Centres in the 1970s (Murphey-Corb et al, 1986, Mansfield et al, 1995), leaving 
SIV^ as the only known natural simian candidate for monkey to man zoonosis. Restriction mapping of 
SIVsm and HTV-2 genomes went on to demonstrate that in some cases HTV-2 isolates were as closely 
related to SIVsm isolates as to other HTV-2 isolates (Gao et al, 1992, Chen et al, 1996).
It is thought that between 20 - 30% (Chen et al, 1996) of the indigenous free-living West African sooty 
mangabey population is infected with STVsm- This population coincides with the geographical 
distribution of documented HTV-2 infection in West Africa and since the sooty mangabey monkey is 
hunted for food and kept as a domestic pet throughout West Africa the opportunity for cross-transmission 
is evident. A defining piece of evidence implicating the zoonotic transmission of STVsm to humans was 
discovered following the detailed analysis of the HTV-2 subtype D strain HTV-2F0784, identified by Gao 
and colleagues in 1994 (Gao et al, 1992, Gao et al, 1994). Several regions of the F0784 genome were 
found to be virtually identical to corresponding regions within stains of SIVsm- Moreover, with the 
addition of strains like HTV-2 F0784 to phylogenetic analysis, in 1994 Sharp et al demonstrated that HTV-2 
and SIVsm strains could no longer be separated into distinct phylogenetic lineages and should be 
considered as a single genetically diverse group of viruses (Sharp et al, 1994). In order to account for the 
existence of the genetic diversity exhibited by the strains within the HTV-2 subtypes it is thought that up 
to six independent cross-species transmissions of genetically diverse STV strains to human populations 
have occurred. In accordance with this, a seroprevalence study carried out by Chen and co-workers 
(Chen et al, 1997) has proved that substantial genetic divergence exists within the feral and household 
mangabey population that could account for the cross-species divergence observed between the subtypes
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of HIV-2. To conclude, in 1994 the accidental transmission of SIVsm to a laboratory worker showed that 
humans are susceptible to infection by SIVsm.
Up until 1999 evidence for an SIV progenitor of HIV-1 had been less conclusive, although isolates from 
chimpanzees (SIVcpz) had been shown to be antigenically closer to HTV-1 than they were to HTV-2 or 
other STV strains (Petters et al, 1989, Huet et al, 1990, Janssens et al, 1994, Vanden Haesevelde et al,
1996). Criticisms levelled at the chimpanzee as a natural host and reservoir for HTV-1 centred around the 
wide spectrum of diversity between HTV-1 and STVcpz, and the apparent low prevalence of SIVcpz 
infection in wild living animals. Up until this point only three other naturally occurring STVcpz infections 
had been identified (S W ^ g ^ i, STVcpz Gab2, STVcpz ANT) (Huet et al, 1990, Janssens et al, 1994, Vanden 
Haesevelde et al, 1996). In addition, chimps were found to be present in geographic regions of Africa 
(Teleki, 1989) where AIDS was not initially recognised.
A recent study by Gao et al, however, has provided the most persuasive evidence yet that HTV-1 was 
transmitted to humans from the chimpanzee, Pan troglodytes harbouring SIV ^ (Gao et al, 1999). In 
1999, the group at the University of Alabama identified a fourth chimp exhibiting natural SIV ^ 
infection. PCR amplification and sequence analysis revealed that the virus isolated from the fourth chimp 
was related to but distinct from known STV^ and HIV-1 strains, and was named STVcpz us. Phylogenetic 
analysis demonstrated that the four naturally occurring SIVcpz strains fell into two related yet highly 
divergent subspecies-specific phylogenetic lineages. The main group contained S IV ^ GAB1, S IV ^ Gab2, 
and SrVcpZ us, all derived from the Pan troglodytes troglodytes subspecies of chimpanzee, while SIVcpz 
ant fell into an outlier group and was obtained from a member of the Pan troglodyte schweinfurthil 
subspecies. This finding indicated that, as observed in SIVagm, STV^ had undergone host dependent 
evolution. Following this discovery, in an attempt to identify any cross-transmission events, Gao and co- 
workers re-examined the phylogenetic positions of all known strains within the SIVcpz and M, N, and O 
HTV-1 groups. All HTV-1 strains were found to phylogenetically cluster with STV^ strains infecting Pan 
troglodytes troglodytes, a primate whose natural host range coincides precisely with areas of HTV-1 group 
M, N, and O endemicity. This finding, in conjunction with the detection of subspecies-dependent 
evolution and recombination between STVcpz lineages, provides substantial evidence that wild living 
chimps must have been a widely infected long-standing natural reservoir of S IV ^  but also indicates that 
HTV-1 groups M, N, and O have arisen as a consequence of independent zoonotic transmissions of SIVcpz 
from Pan troglodytes troglodytes to man (Gao et al, 1999, Hahn et al, 2000). Initial screenings of free- 
living adult chimps have indicated that the prevalence of SIV in chimps is far lower (>2%) than in other
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primates such as African green monkeys, where it can reach 90% in adults (Santiago et al., 2002). 
However, a recent report by Santiago et al have identified a Tanzanian chimp population showing SIV 
prevalences of between 10 -  15% (Santiago et al., 2003). Only extensive screening of free-living adult 
chimps from all four subspecies, as well as human populations from corresponding geographic localities, 
will determine the extent of natural SIV ^ infection and give an indication of the frequency of zoonotic 
transmission to humans. Such studies would be able to truly verify that SIV ^ is the natural host and 
reservoir for HTV-1.
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1.5 Natural history of HTV-2 infection
1.5.1 Epidemiological aspects o f  HIV-2 infection.
Following the initial isolation of HTV-2 from West African individuals (Clavel et al, 1986a, Clavel et al, 
1987a) large-scale immunological studies have revealed that Human Immunodeficiency Virus type 2 
(HTV-2) is endemic in, although largely restricted to, the many countries of West Africa (Decock & Bran 
Vezinet, 1989). Community-based studies have shown that of all the West African countries, Guinea- 
Bissau has the highest serological prevalence of HTV-2 (Poulsen et al, 1989, Naucler et al, 1999, 
Wilkins et al, 1993, Ricard et al, 1994). Women attending mother-and-child health clinics in the Bafata 
province of this country reported an HTV-2 prevalence of 9.2%. Surrounding countries including The 
Gambia, Senegal, The Ivory Coast, and Ghana have a lower HTV-2 seroprevalence ranging from 1-2% 
(Obisesan et al, 1997, Kassim et al, 1998, Whittle et al, 1998, UNAIDS & WHO, 2000). Nevertheless, 
strikingly higher prevalences have been observed within the commercial sex worker (CSW) populations 
of these countries. CSW HTV-2 prevalences range from 8.1% in Mali (Peeters et al, 1998) to an 
alarming 27.5% in The Gambia (Hawkes et al, 1995, Langley et al, 1996, Ghys et al, 1997, Samb et al,
1997).
A number of cases of HTV-2 infection have also been described in countries with socio-economic links to 
West Africa including the United Kingdom, France, Portugal, and the south-western regions of India and 
South America (Rey et al, 1987, Cortes et al, 1989, Smallman-Raynor & Cliff, 1991, Rubsamen 
Waigmann et al, 1991, Grez et al, 1994, Quinn et al, 1994). In addition, isolated cases have been 
described in several European countries (Doerr et al, 1987, Evans et al, 1991, van der Ende et al, 1996) 
and the USA (Ayanian et al, 1989, O’Brien et al, 1992). The vast majority of cases identified outside of 
West Africa however, are either Europeans with West African sexual partners or are West African 
themselves (Smallman-Raynor & Cliff, 1991).
1.5.1.1 Age distribution
In contrast to STDs such as HTV-1 whereby the age peak distribution of infections lies within the young 
adult age group of 20-34 years (Killewo et al, 1990, Wawer et al., 1991, Wagner et al., 1993), the vast 
majority of individuals infected with HTV-2 fall into age categories of 45 years and above. A number of
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studies have outlined that HIV-2 prevalence in women is highest in age groups 35-45 years (Wilkins et 
al., 1991b, Wilkins et al, 1993), or 50-59 years (Poulsen et al, 1989), and in men 50-59 years (Poulsen et 
al, 1989, Wilkins et al, 1991b, Wilkins et al, 1993). The most likely explanation for the difference in 
age distribution between the two infections lies in the fact that people infected with HTV-2 have a greater 
chance of survival and live to an older age than individuals infected with HTV-1. This issue will be 
further discussed in section iv).
1.5.1.2 Transmission o f HIV-2
The increased incidence and clustering of early AIDS cases within the homosexual, heterosexual, 
intravenous drug user and blood transfusion recipient populations gave the first indications that an 
infectious transmissible agent was involved in the AIDS epidemic. Transmission routes, and the risk 
factors involved are similar for both HTV-1 and HTV-2 infection. Both viruses can be transmitted by 
homosexual (Gottlieb & Ackerman, 1982, Jaffe et al, 1983, Brucker et al., 1987, Pieniazek et al., 1991, 
Soriano et al, 1996) and heterosexual contact (Harris et al, 1983, Gao et al., 1993, Aaby et al, 1996, 
Ghys et al., 1997), perinatal transmission (Adjorlolo-Johnson et al, 1994, Cavaco-Silva et al., 1998), 
transfusion of blood and blood products (Dufoort et al., 1988, Poulsen et al, 1989, Faye et al., 1997), and 
intravenous needle sharing. However, few studies exist demonstrating the latter two modes of 
transmission for HTV-2. In West Africa, the principal route by which HTV-2 is transmitted is via 
heterosexual contact. The migration of female prostitutes across the region, both to and from areas of 
high endemicity has played a significant role in the spread of HTV-2 within the cities and rural 
communities of the countries in West Africa (Wilkins et al., 1991a, Pickering et al, 1992). As have 
events such as the colonial occupation of Guinea Bissau by the Portuguese, which largely account for the 
higher prevalence of HTV-2 within this country. However, a number of studies have reported that the rate 
of male to female transmission of HTV-2 is between 5- and 9-fold lower than that observed with HTV-1 
(Schim van der Loeff & Aaby, 1999). The reduced heterosexual transmission rate observed in HIV-2 
infection is thought to be related the very low plasma viral loads observed within the majority of 
asymptomatic HTV-2-infected individuals (Adjorlolo-Johnson et al, 1994, Kanki et al., 1994, Berry et al., 
1998, Cavaco-Silva et al., 1998, O’Donovan et al., 2000) (see section v). An investigation into the level 
of viral RNA (vRNA) in the cervico-vaginal secretions (CVS) of female CSWs in Cote d’Ivoire found 
virus in only 5% of HIV-2-infected women as opposed to 24% of women infected with HTV-1 (Ghys et 
al., 1997). Similar findings were also identified in female CSWs from Dakar, Senegal (Samb et al., 1997, 
Sankale et al., 1998).
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In addition to the rate of heterosexual transmission, vertical transmission of HTV-2 occurs at a much 
lower rate than documented for HTV-1 (Adjorlolo-Johnson et al., 1994,O’Donovan et al, 2000). Vertical 
transmission rates for HTV-1 in the absence of antiretroviral therapy range from between 15-35%. In 
contrast, the estimated rate of vertical HTV-2 transmission is between 0-4% (Del Mistro et al, 1992, 
Gayle et al., 1992, Andreasson et al., 1993, Cavaco-Silva et al., 1998, O’Donovan et al, 2000). A recent 
study by O’Donovan and co-workers demonstrated that the lower plasma viral loads of HTV-2 
seropositive mothers when compared to HTV-1-infected mothers related to the significantly reduced rate 
of mother to child transmission observed in HTV-2 infection (O’Donovan et al., 2000). The reduced risk 
of transmission that is associated with HTV-2 is thought to account for the slower spread of HTV-2 
infection in comparison to HTV-1. This has given rise to an endemically infected population largely 
confined to West Africa in contrast to the rapidly spreading HIV-1 pandemic.
1.5.1.3 Clinical aspects o f HIV infection
Within one to four weeks of primary infection with HTV-1 or HTV-2 a significant proportion of 
individuals experience an acute clinical illness, which manifests in influenza-like symptoms accompanied 
by high levels of virus detectable in the blood, 105 to 107 virions/ml (Gaines et al, 1987, Clark et al., 
1991, Daar et al., 1991). Documented primary infection symptoms consist of headache, muscle aches, 
sore throat, fever, swollen lymph nodes and rash (Cooper et al, 1985, Tindall et al., 1988, Besnier et al, 
1990). The symptoms of acute infection normally persist for two to three weeks but usually result in 
clinical recovery. During the acute period of infection high levels of proinflammatory cytokines 
associated with immune activation are expressed. The increase in the levels of cytokines such as 
interleukin-1[5 (IL-1P), tumour necrosis factor alpha (TNF-a) and gamma interferon (IFN-y), is thought to 
be associated with the significant CD8+ cell expansion that is observed in the second week of primaiy 
infection (Cooper et al., 1988, Pantaleo et al, 1994a, Pantaleo et al, 1994b). The appearance of this 
cytotoxic T lymphocyte (CTL) response is accompanied by a significant reduction in the level of 
infectious virus within the peripheral circulation, however, the detection of low-level viremia following 
this stage of infection indicates that HTV variants do escape this antiviral cellular immune response. 
Several studies have demonstrated that the efficiency of viral clearance and the subsequent quantity of 
peripheral viral HTV RNA remaining after primary infection, termed the “set point*’, are predictive of the 
length and severity of the disease course in both HTV-1 and HTV-2 infections (Keet et al, 1993, Mellors 
et al, 1995, Wei et al., 1995, Andersson et al., 2000). Following the cell-mediated immune response, a 
broad spectrum of antiviral antibodies can be detected within the infected individual, signifying
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seroconversion. Neutralising antibodies targeting HTV have been detected within 20 days after virus 
transmission, but in general appear approximately ten weeks post-infection.
The acute phase of HIV infection is consequently followed by a clinically asymptomatic period, which 
can persist for several years. It is this phase of infection that largely distinguishes HIV-1 from HTV-2 
infection (see section iv). During the asymptomatic period, molecular analysis has revealed that 
transcriptionally active virus is present, directing the low level expression of virion RNA, which, in the 
case of HIV-1, can be detected at all stages of infection (Michael et al, 1992, Piatek et al, 1993, Saksela 
et al., 1995). The asymptomatic phase of HTV infection is characterised by a very gradual 
lymphadenopathy. Early studies of HTV infection revealed that while a wide variety of human cells were 
susceptible to HTV, the CD4+ T-helper lymphocyte was the major target of HTV infection; CD4+ cells 
replicated HTV to the highest titres. It is the linear decline of this subset of immune cells over time, which 
eventually results in the clinical manifestation of immunodeficiency. A variety of symptoms herald the 
deterioration of the immune system and the onset of AIDS or AIDS-related complex (ARC) whether 
caused by infection with HTV-1 or HTV-2 (Mabey et al., 1988, Naucler et al, 1989, Decock at al., 1990, 
Grant et al., 1997, Poulsen et al., 1997). These include chronic fevers, diarrhoea, weight loss, oral thrush, 
and hairy leukoplakia. The presence of two or more of these symptoms characterise ARC and leads to 
the development of AIDS. Once the diagnosis of AIDS has been made, survival of the patient is often 
less than two years unless the patient is treated with antiretroviral drugs.
Patients in the symptomatic phase of infection often present with a number of opportunistic infections 
caused by pathogens classically associated with severe immunodeficiency (Mildvan et al., 1982). These 
are broadly similar for both HTV-1 and HTV-2 infections and include Pneumonocystis carinii pneumonia 
(PCP), M. tuberculosis, CMV, and malignancies such as Kaposi’s sarcoma, B-cell lymphoma and rectal 
cancers. A recent study by Ariyoshi et al found however, that Gambian patients infected with HTV-2 
were 12.4 times less likely to have Kaposi's sarcoma than patients infected with HTV-1 (Ariyoshi et al,
1998).
Several opportunistic infections can present with neurological manifestations, and a significant proportion 
of AIDS patients display an HTV-associated subacute encephalitis termed AIDS dementia complex. The 
mean survival time from the onset of severe dementia is usually less than six months.
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1.5.1.4 Pathogenicity o f HIV-2
Although a causal link between HIV-2 and AIDS was proved soon after the initial characterisation 
(Clavel et al, 1986, Brun-Vezinet et al., 1987, Albert et al, 1989), relatively few cases of HTV-2 
associated disease were identified in preliminary studies (Barin et al, 1985, Kanki et al, 1987). 
Following on from this, early community based studies demonstrated that mortality rates among HIV-2 
infected individuals were only two- to three-fold higher than rates among uninfected controls (Ricard et 
al, 1994, Poulsen et al., 1997). Similar studies performed with HTV-1 infected individuals had shown a 
rate of mortality ten-fold that of uninfected controls (Morgan et al, 1997, Nunn et al, 1997, Todd et al, 
1997). Therefore, in the vast majority of cases, infection with HIV-2 was thought to lead to a much better 
disease prognosis than infection with HTV-1.
Since then a number of comparative epidemiological studies have confirmed that progression to 
immunosuppression and AIDS following HTV-2 infection is slower than for HTV-1, and is associated with 
a relatively prolonged clinically asymptomatic period (Pepin et al., 1991, Marlink et al, 1994, Ricard et 
al., 1994, Lisse et al, 1996). In fact, due to the prolonged maintenance (>56 months) of low to 
undetectable plasma vRNA (<500 copies/ml), high CD4 cell percentages of >28%, and the lack of 
symptoms of clinical progression, the vast majority of individuals infected with HIV-2 are categorised as 
long-term-non-progressors (LTNP). In a comparison of the rate of CD4 decline over a four year period, 
Jaffar et al found that 47% of HTV-2 infected patients, versus 32% of HTV-1 infected individuals, showed 
no decline in CD4 cell percentage (Jaffar et al, 1997). In addition, in cases where CD4 cell percentage 
decline was seen, the rate of decline was significantly slower in HIV-2 patients. A recent community- 
based study performed in the remote village of Caio, Guinea-Bissau, indicated that the mortality rate of 
HIV-2-infected subjects was only 1.7-fold greater than that of HTV-uninfected controls (Berry et al, 
2002). Moreover, cases of non-progressive asymptomatic periods extending in excess of 27 years have 
been reported; HIV-2 infection in individuals over and above the age of 60 years is not uncommon 
(Ariyoshi et al, 1996).
The length of the symptomatic phase of HTV-2 infection is also thought to be longer than in HTV-1 
infection. HTV-2 AIDS patients in a Gambian hospital-based study were found to survive up to three 
times longer than HTV-1 AIDS patients (Whittle et al, 1994); similar observations were also made in a 
study of African HIV-2 AIDS patients living in Paris (Matheron et al, 1997). The lower rate of 
transmissibility and the reduced risk of mortality observed in HTV-2 infection have lead to the belief that
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HIV-2 is a less pathogenic virus than HIV-1 (Marlink et al., 1994, Whittle et al., 1994, Jaffar et al., 
1997).
Nevertheless, a number of HTV-2-infected patients displaying relatively rapid progression to AIDS, both 
in The Gambia and among West African residents in Europe have been identified (van der Ende et al, 
1996, Ariyoshi et al., 1998). The relatively small number of cases termed rapid progressors (RP) display 
a much more “HTV-1-like” disease course, and tend to have been identified in younger individuals i.e. 
those under the age of 45 years (Poulsen et al., 1989, Ricard et al., 1994, Norrgren et al., 1995, Poulsen et 
al., 1997). The rate of mortality among HTV-2-infected adults under the age of 45 years has been shown 
to be 5:1 (Norrgren et al., 1995, Poulsen et al, 1997), significantly higher than the mortality ratio of older 
HIV-2 infected individuals, suggesting a dichotomy between the progression rates in HIV-2 infection 
(Jaffar et al., 1997, Grassly et al., 1998).
The length of time between acute primary infection and the onset of symptomatic HTV infection within an 
individual is influenced by a variety of viral and host factors. However, data comparing the levels of 
peripheral blood viral HTV-2 and HIV-1 RNA has provided evidence suggesting that the slower rate of 
progression to symptomatic disease observed in the majority of HIV-2 infections may result from a 
reduced level of viral production during the asymptomatic phase of HIV-2 infection compared to HIV-1 
(Simon et al, 1993, Berry et al., 1998, Popper et al, 2000, Berry et al., 2002). In 1998, Beny and co­
workers demonstrated that HTV-1 and HTV-2 infection, could be differentiated by RNA plasma viral load 
at the early stage of disease (Beny et al, 1998). RNA virus was detectable in the plasma of all HTV-1 
infected individuals with a CD4% of >28, but was detected in only one third of matched HIV-2 infected 
subjects. In addition, a study by Andersson et al demonstrated that the plasma virus set point, i.e. the 
semi-equilibrium reached following seroconversion, was 28-fold lower in HTV-2 seroconverters 
compared to HTV-1 seroconverters (Andersson et al., 2000). It has been demonstrated that base-line 
HIV-1 and HTV-2 RNA load significantly predicts the rate of disease progression as determined by CD4+ 
decline or by death (Ariyoshi et al., 2000, Berry et al., 2002, Alabi et al, 2003). Since the level of 
proviral DNA has been found to be similar in HTV-1 and HTV-2 infections (Berry et al., 1994, Ariyoshi et 
al., 1996, Norrgren et al., 1997b, Berry et al., 1998, Sarr et al, 1999, Popper et al, 2000), it has been 
suggested that the lower plasma viral loads observed in the asymptomatic phase of HIV-2 infection reflect 
a lower rate of virus production in comparison to HTV-1 that results in the reduced pathogenicity of HTV- 
2 (Popper et al., 1999, Popper et al, 2000). To date however, the virological and/or immunological 
factors involved in determining the difference between the rates of virus production in HTV-1 and HIV-2
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infected individuals, and between HTV-2 infected individuals displaying slow progression and relatively 
rapid progression to disease have yet to be determined.
1.5.1.5 Treatment o f  HIV-2 infection
Due to the expense of antiretroviral treatment large-scale clinical trials involving the HIV-2 infected 
cohorts of West Africa have not been performed. However, a number of HIV-2 infected individuals in 
Europe have been given anti-retroviral agents (Soriano et al, 2000, Van der Ende et al, 2000, Smith et 
al, 2001). In these cases, the principles of highly active antiretroviral therapy (HARRT) seem to apply, 
whereby drug combination therapy provides an effective reduction in viral load, while single or 
suboptimal combination therapies can lead to drug resistance (Rodes et al, 2000, Van der Ende et al, 
2000, Smith et al, 2001). It is thought that the reduced virus load and virulence associated with HIV-2 
infection (see section v.) may make HARRT extremely effective within the HTV-2 infected population 
(Whittle et a l, 1998b, Smith et al, 2001). Nevertheless, since the vast majority of infections occur 
within developing countries with very low health budgets it is unlikely that these HTV-2 infected 
individuals will receive any treatment without aid intervention from the countries within the developed 
world. The distribution of antiretroviral therapy, education, treatment and prevention of STDs, and the 
development of an inexpensive yet effective vaccine for the HTV-2 infected populations of the developing 
world remain paramount.
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1.6 Genomic organisation of HTV-1 and HTV-2.
In contrast to their different pathogenicities, the genomic organisation of HTV-1 and HTV-2 is remarkably 
similar, as is the function of the gene products encoded by each of the genomes (Guyader et al, 1987). 
Nucleotide sequence analysis has revealed that the HTV-2 viral genome is approximately 9.8kb in size 
and consists of the typical retroviral LTR-gag-pot-env-LTR organisation (Figure 1.2, pg 50). As well as 
the three contiguous structural genes and the long terminal repeat sequences that direct and regulate the 
expression of the viral genome, the HTV-2 and STV genomes encode several other regulatory and 
accessory proteins; tat (flra/wactivator of transcription), rev (regulator of expression of virion proteins), 
nef (negative factor), and viral proteins vpr, vif, and vpx. The HIV-1 genome fails to encode vpx, and 
instead contains viral protein vpu, which is not present in strains of HTV-2 and STV. The primary 
transcript of HTV is a full length viral mRNA, which is translated into a 160kDa Gag-Pol precursor. As 
these two genes do not occupy the same reading frame a ribosomal frame shift is required during 
translation to prevent recognition of the gag termination codon (Jacks et al, 1988). The read-through 
process, which generates the single Gag-Pol protein, is about 5% efficient and results in the Gag protein 
outnumbering the Gag-Pol protein by approximately 20-fold (Oroszlan & Luftig, 1990). During virion 
maturation proteolytic cleavage of the Gag-Pol precursor generates viral enzymes; p64, p53 (RT) reverse 
transcriptase, p34 (IN) integrase, and pi 1 (PR) protease. The Gag gene also encodes the Gag precursor 
protein (p55), proteolytic cleavage of which generates the smaller structural proteins of the virion: p24 
(CA) Capsid, p i7 (MA) Matrix, p9 and p7 (NC) Nucleocapsid. The Env polyprotein is expressed by 
another means: splicing generates a shorter subgenomic messenger RNA, gpl60. This singly spliced 
precursor is cleaved by protease, and gives rise to the surface (SU) and transmembrane (TM) 
glycoproteins. Precursor mRNAs for the remaining regulatory and accessory proteins encoded by the 
HTV genome are produced by additional multiple splicing events.
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Figure 1.2 Genomic organisation of HIV-2. SIV shows similar organisation, however, HIV-1 encodes viral protein Vpu and not Vpx which is exclusive 
to the HIV-2 and SIV genomes.
1.7 Virion Morphology
Initially, high-resolution electron microscopy indicated that HIV virions were roughly spherical in 
structure; however, more recent scanning electron micrographs and computer simulation have indicated 
that virions are icosahedral particles about llOnm in diameter (Marx et al., 1988, Nermut et al., 1993). 
Mature virions consist of a host derived lipid bilayer envelope encapsulating the myristolated matrix 
protein pl7 (MA), this protein in turn surrounds the characteristic type C lentiviral cone-shaped 
nucleocapsid comprised of viral p24 (CA), a polypeptide approximately 240 amino acids (aa) in length 
(Figure 1.3, pg 52). The matrix protein is associated with the lipid membrane via a signal sequence 
encoded within the first 31aa of the 130aa polypeptide. This region of MA also encodes a nuclear 
localisation signal thought to be important during the early stages of replication (Martin & Freed, 1996). 
Myristolation of the MA protein is required for the production of infectious virus (Bryant & Ratner, 
1990).
The nucleocapsid core of the HTV virion contains two identical single-stranded molecules of genomic 
RNA that are closely associated with nucleocapsid protein p7 (NC-p7). The interaction between the RNA 
strands and p7 is determined by two cysteine-histidine rich zinc-finger like domains contained within this 
hydrophilic protein (Gorelick et al., 1988, 1990). Also packaged into the nucleocapsid core are the pol- 
encoded products integrase (IN-p32), protease (PR-plO) and the viral RNA-dependent DNA polymerase 
or reverse transcriptase (RT-p66/p51), together with a single molecule of transfer RNAlys, which primes 
reverse transcription of the viral genome. The reverse transcriptase and integrase enzymes function at a 
post-entry step in the viral life cycle and mediate reverse transcription of the viral RNA genome into 
double stranded DNA and the integration of the double-stranded DNA into the host genome respectively. 
Viral proteins Vif and Nef are also thought to be closely associated with the nucleocapsid core.
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Figure 1.3 Schematic diagram showing the structural organisation o f HIV (adapted from Stryer, 1988)
In accordance with a property more closely associated with a B type than a C type lentiviral particle the 
surface of the HIV virion is made up of virally encoded oligomeric envelope spikes (Chan et al., 1997, 
Fass et al., 1997, Weissenhom et al., 1997). In addition, because the lipid bilayer surrounding the virion 
particle is host-derived it also contains a number of host-cell proteins, notably MHC class I and class II 
molecules. The virally encoded glycoprotein structures are derived from a 160-kDa protein, gpl60, 
which is co-translationally translocated into the endoplasmic reticulum (E.R.) by means of an N-terminal 
signal sequence. Inside the E.R. the signal peptide is removed and the protein is extensively glycosylated, 
specific disulphide bridges are formed and the protein forms trimers. In the Golgi apparatus, the gpl60 
protein is cleaved by cellular proteases into a surface (SU-gpl20, HIV-1; SU-gpl05, HIV-2) and 
transmembrane part (TM-gp41, HIV-1; TM-gp36, HIV-2) that remain associated through non-covalent 
interactions. The resulting glycoprotein is transported to the cell membrane and presented on the surface 
of the virion (Swanstrom & Wills, 1997). It is the SU component of gpl60 which functions to adsorb the 
virion onto target cells via interactions with the cellular CD4 molecule and chemokine coreceptors.
The envelope glycoprotein is highly variable in amino acid sequence, comparison of env sequences taken 
from numerous isolates of HIV-1 has identified five hypervariable regions (V1-V5) interspersed with five 
conserved regions (C1-C5) for the gp 120 subunit (Modrow et al., 1987, Leonard et al., 1990, Myers et 
al., 1990). The conservation of the C1-C5 regions between isolates suggests that they are of biological 
significance; these regions form discontinuous structures important for interactions with the TM
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ectodomain and viral receptors on the surface of the target cell. The first four variable regions form 
surface exposed loops with disulphide bonds at their bases (Leonard et al, 1990). In addition to the 
envelope glycoprotein providing the virion with a mechanism for cellular entry, Env contains the major 
neutralising epitopes for neutralising antibodies produced during infection. Thus, the hypervariability and 
heavy glycosylation of Env modulates both the antigenicity and immunogenicity of the abundantly 
exposed protein (Profy et al., 1990).
53
1.8 Viral regulatory and accessory proteins
In addition to the essential structural and enzymatic proteins encoded by human and simian 
immunodeficiency viruses, the HIV genome encodes a number of regulatory and accessory proteins. 
Regulatory proteins Tat (/ransactivator of transcription) and Rev (regulator of expression of virion 
proteins) are essential for viral growth and have been shown to regulate viral gene expression at the 
transcriptional and post-transcriptional levels, respectively. Accessory proteins Ne£ Vif, Vpr (Vpx for 
HIV-2), and Vpu have also been shown to play a role in different steps of the virus life cycle, although 
none of these proteins are an absolute requirement for HTV replication.
Tat is synthesised at both early and late stages of the viral replication cycle and is not packaged into the 
virion. This protein binds to an RNA stem-loop element located within the viral LTR termed the 
rransactivation response (TAR) element, and functions to upregulate transcription of full-length viral 
transcripts (see section 1.11.1). The HTV-2 Tat protein is larger than HTV-1 Tat, 130 amino acids vs. 86 
(Arya, 1993), but both function to activate transcription in a similar manner. HIV-1 Tat has been shown 
to activate transcription from the HTV-1 LTR and HTV-2 LTR with equal efficiency however, HTV-2 Tat 
rransactivates expression from the HIV-1 LTR less efficiently than HTV-1 Tat. Further discussion of the 
structure, method of action and biological properties of HTV-2 Tat (Tat2) can be found in sections 1.10.4 
and 1.11.
Rev is also a protein found at the early and late stages of the virus life cycle and in an analogous manner 
to Tat, targets an RNA stem-loop structure. This structure, termed the Rev Responsive Element (RRE), is 
located within the env gene. Rev has a central role in controlling the ratio of multiply spliced and 
unspliced RNAs in the cytoplasm (Chang & Sharp, 1989), it has been shown to require a cellular nuclear 
export protein called CRM-1 for its function (Fukuda et al., 1997, Neville et al., 1997). Multimerisation 
of Rev at the RRE promotes the nuclear export of RRE-containing unspliced or singly spliced RNA. 
Despite differences between HTV-1 and HTV-2/SIV Rev proteins, the mechanism of action of these 
proteins within their respective replication cycles appear to be the same.
N ef or negative factor is a gene encoding a 27kDa myristolated cytoplasmic protein that is not essential 
for viral growth in vitro, but which is essential to the development of AIDS (Trono, 1995). The nef gene 
of HIV-1 and SIVcpz extends from the 3’ end of env into the U3 domain of the 3’ LTR, whereas in HIV-2 
and several strains of SIV the 5’ end of nef overlaps the 3’ end of env in a different translation frame.
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Initially the Nef protein was thought to suppress HIV transcription by binding to a negative regulatory 
element (NRE), located in the U3 region of the LTR (Niederman et al., 1989), however, these 
observations proved controversial (Hammes et al., 1989, Kim et al., 1989). Since then a wide variety of 
other functions have been associated with the Nef protein including enhancement of virion infectivity, 
downregulation of cell surface CD4 and class I major histocompatibility complex (MHC) (Greenberg et 
al., 1998, Mangasarian et al., 1999), upregulation of Fas-ligand (CD95L) expression on virus infected 
cells (Xu et al, 1997, Xu et al, 1999), and more recently, an anti-apoptotic effect of Nef has also been 
reported (Wolf et al., 2001). However, it remains uncertain as to which in vitro function of Nef is most 
critical for the in vivo pathogenicity of primate lentiviruses. What is apparent is that many functions 
allow Nef to play an important role in the evasion of T cell recognition by HIV.
Defects in the nef gene and the function of the Nef protein have been linked to non-progressive HIV and 
SIV infection (Tobiume et al, 2002, Tomiyama et al., 2002). Rhesus monkeys inoculated experimentally 
with SIV containing deletions of nef have low viral loads, normal CD4 T-cell numbers, and are protected 
against challenge with virulent SIV (Kestler et al, 1991, Daniel et al, 1992). Similarly, numerous 
studies have documented the presence of «^-defective HTV-1 genomes in LTNPs (Deacon et al, 1995, 
Kirchhoff et al., 1995, Mariani et al., 1996, Salvi et al., 1998, Learmont et al., 1999, Geyer et al, 2001). 
Proviral Nef sequencing has shown that 10% of HTV-2 infected patients harbour truncated Nef proteins 
(Switzer et al., 1998), higher than the prevalence seen with HTV-1 (Piguet & Trono, 1999), indicating that 
truncation of Nef may contribute to the slower disease progression rates observed in HTV-2 infections. 
More recently, a study performed by Padua and coworkers (Padua et al., 2003) has identified a mutation 
within the tetra-proline motif of the HTV-2 Nef protein that is associated with an asymptomatic phenotype 
(Fisher’s exact test p= 0.026) and low viral loads, however; the functional significance of this sequence 
change has yet to be determined. Despite these findings however, most of the nef alleles isolated from 
LTNPs of HTV-1 and HTV-2 infection are intact in the length of the coding region and in the tested 
biological function (Huang et al., 1995a, Huang et al, 1995b, Michael et al., 1995, Catucci et al., 2000), 
arguing against the role of nef'm the establishment of long-term non-progression.
None of the remaining accessory proteins including Vif, Vpr, and Vpx (Vpu in HTV-1) are absolutely 
required for HIV replication; however, cell-type specific contributions to virus production and infectivity 
have been described (Trono, 1995, Cohen et al., 1996, Madani & Kabat, 1998). Conservation of these 
sequences in vivo implies that the functions they perform are of some importance.
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1.9. The replication cycle of HIV
The replication cycle of the simian and human immunodeficiency virus can be considered as a process 
that occurs in two phases, an early, and a late phase. Adsorption of the virus particle to a cell surface 
receptor, virus entry, reverse transcription of the viral genome and integration of proviral DNA into the 
host cell genome are all considered early phase events within the life cycle. Late phase processes involve 
viral gene expression from the integrated proviral template, virion assembly, and release of the progeny 
virions following maturation (Figure 1.4, pg 56).
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Figure 1.4 Generalised replication cycle of HIV. 1 -  Viral attachment to specific target cell via 
interactions between viral envelope glycoproteins and cell surface CD4 and coreceptors. 2 -  Fusion of 
viral and target cell membranes results in viral entry and uncoating. 3 -  Reverse transcription of the 
viral RNA produces a double-stranded DNA. 4 -  Integration of the dsDNA into the host cell genome 
resulting in a stably integrated provirus. 5 -  Host cell factors transcribe the proviral DNA. 6 -  
Translation of viral mRNA produces the viral proteins. 7 -  Viral proteins and frill length viral RNA 
assemble into viral particles at the host cell membrane and acquire Env during budding. 8 -  Gag and 
Gag-Pol polyproteins are cleaved by viral protease during or shortly after budding, generating mature 
infectious virions.
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1.9.1 Viral attachment and entry
The attachment of HTV-1, HTV-2, and SIV to specific cell surface receptors is primarily mediated by 
interactions between the viral envelope glycoprotein and a 58kDa cellular glycolipid molecule called 
CD4. The CD4 antigen can be found located on the surface of T-helper lymphocytes, monocytes, 
macrophages and other cell types and was identified as the primary cellular receptor for HIV in 1984 
following immunoprecipitation studies using the HIV envelope glycoprotein (Dalglish et al., 1984, 
Klatzmann et al, 1984a). This finding was later confirmed by experiments utilising human CD4 negative 
cells, non-permissive to HIV infection. Transfection of these cells with complementary DNA encoding 
human CD4 rendered them permissive for HTV-1 binding, syncitium induction, and infection (Maddon et 
al., 1988). Epitope mapping of the CD4 receptor has revealed that HTV-1 gpl20 binds to an 
immunoglobulin-like domain situated between amino acids 40-82 (Landau et al., 1988, Peterson & Seed, 
1988, Arthos et al, 1989, Ryu et al., 1990, Wang et al., 1990).
Although CD4 is established as the primary receptor for HTV, a study in which a mouse cell expressing 
human CD4 was susceptible to HIV binding but resistant to infection indicated that the CD4 receptor was 
neither sufficient nor the sole means for viral attachment (Tersmette et al., 1989, Dragic et al, 1992, 
Broder et al, 1993, Harrington et al, 1993). This led to a search for secondary cellular receptors 
involved in the fusion and entry of HIV virions.
In 1996 Berger and co-workers identified a protein expressed from a human cDNA clone which when 
introduced into HIV-resistant mouse cells expressing human CD4 rendered them susceptible to HTV 
infection (Feng et al, 1996). Further analyses showed this fusion-inducing molecule to be a coreceptor 
for T-cell tropic HIV-1 strains although it was unable to support entry of macrophage-tropic HIV-1 
strains. This molecule, identified as Fusin/LESTR, but now termed CXCR-4, has been shown to be a 
member of the P-chemokine receptor family and has a natural ligand called stromal derived factor-1 
(SDF-1). Following this discovery, several groups investigated the possibility of blocking HTV infection 
by using (3-chemokines (Bleul et al., 1996, Feng et al, 1996, Oberlin et al., 1996). During these studies a 
P-chemokine coreceptor, CCR-5, was found to mediate the cellular entry of macrophage-tropic strains of 
HTV-1. Taken together it has been established that in addition to CD4 both T-cell tropic and macrophage- 
tropic HIV strains utilize distinct but related P-chemokine coreceptors for cell entry. HTV-2 strains utilise 
CXCR-4 and CCR-5 in a similar manner to HIV-1 (Heredia et al, 1997), however with the identification 
of several other chemokine coreceptors including CCR-1, CCR-2a, CCR-2b, CCR-3, CCR-4,
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Bonzo/STRL33, and BOB/GPR15 (Choe et al, 1996, Liao et al, 1997), strains of HTV-2 have been 
shown to be, in general, more promiscuous than HIV-1 strains in their use of coreceptors (Guillon et al, 
1998, McKnight et al, 1998, Owen et al, 1998, Unutmaz et al, 1998, Reeves et al, 1999). With ever 
increasing numbers of coreceptor molecules being identified, in addition to reports of a CD4 independent 
strain of HTV-2 derived from HTV-2ROd that can use CXCR-4 as its primary receptor (Reeves et al,
1999), the envelope-cellular receptor mechanism of cell-entry grows increasingly complex.
Envelope viruses, such as HTV, enter cells by a mechanism that results in the direct fusion of viral and 
cellular plasma membranes. The precise details of this mechanism are still unknown although the process 
is known to be pH-independent Binding of the envelope glycoprotein to CD4 is thought to trigger 
conformational changes in the surface (gpl20/gpl05) and transmembrane (gp41/gp36) regions of the 
envelope structure (Chan et al, 1997, Weissenhom et al, 1997, Kwong et al, 1998, Wyatt et al, 1998). 
These changes are thought to potentiate and enhance the interaction between the viral envelope and the 
coreceptor molecule and transform the complex into what is known as a ‘fusogenic state’ (Lapham et al, 
1996, Wu et al, 1996, Hill et al, 1997). It is thought that structural changes within the leucine zipper 
domain of gp41 cause the exposure of a hydrophobic fusion peptide located at the N-terminus of gp41 
(Moore et al, 1993, Wild et al, 1994), which inserts into the lipid bilayer of the cell plasma membrane 
inducing fusion of the viral and host cell membranes (Brasseur et al, 1988).
1.9.2 Reverse transcription 
Once inside the target cell the virus particle is partially uncoated and forms a large nucleoprotein 
complex. This complex is rapidly transported to the nucleus via interactions with host cell karyopherin 
proteins. Once inside the nucleus the heterodimeric viral enzyme reverse transcriptase (RT) catalyses the 
synthesis of a linear double-stranded DNA copy from the viral RNA genome. Reverse transcription of 
the dimeric single stranded viral RNA molecule is initiated from a host tRNAlys primer, which is 
hydrogen bonded to the primer binding site (PBS) located 100-200 nucleotides from the 5’ end of the 
viral RNA template. The viral RNA has direct repeats at its ends called R segments, which vary in 
different strains of retrovirus from 10-80 nucleotides. Following the R segment at the 5’ end of the virus 
is the U5 region of 80-100 nucleotides, whose name indicates that it is unique to the 5’ end. Preceding 
the R segment at the 3’ terminus is the U3 segment of 170-1350 nucleotides, which is unique to the 3’ 
end. Each of these segments contains viral promoter and enhancer elements crucial to viral gene
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expression and are collectively termed the viral long terminal repeat or LTR. Further discussion of the 
structure and biological properties of the HTV LTR can be found in sections 1.10,1.11, and 1.12.
Since DNA synthesis begins at a site only 100-200 nucleotides from the 5’ end of the minus RNA strand, 
the virus must utilise a mechanism called strand-transfer in order to generate a DNA copy of the entire 
RNA genome. The U5, R, and U3 regions of the viral LTR are involved in this process. The process of 
strand-transfer begins, immediately following tRNA,ys binding to the minus strand PBS. Reverse 
transcriptase interacts with this primer to catalyse the synthesis of the first DNA strand (i.e., minus strand) 
and extends it to the 5’ end of the viral RNA template, generating a short DNA sequence called minus 
strong-stop DNA. The Ribonuclease H (RNAse H) activity possessed by the reverse transcriptase 
heterodimer degrades the RNA in the DNA/RNA hybrid, effectively removing the R region at the 5’ 
terminus of the RNA template (Varmus, 1988, Goff 1990). Its removal exposes the newly synthesised 
strong-stop DNA sequence, which is complementary to the R region at the 3’ end of the RNA strand 
(DeStefano et al, 1991). The complementary regions base pair with one another signifying the first 
strand-transfer event. Minus strand DNA synthesis continues on the viral RNA template through U3 and 
into the viral genome. The result of the switching event is to add a U3 segment to the 5’ end of the minus 
strand. Generation of the plus strand of DNA involves a second transfer event whereby DNA is 
elongated to the end of the minus strand template and forms a plus strand strong-stop sequence. This 
sequence base pairs with the 3’ end of the minus strand strong stop DNA, leaving RT free to complete the 
synthesis of the double stranded DNA copy of the viral genome. Circularisation of resulting double- 
stranded DNA copy is mediated by the LTR sequences at either end of the genome leading to the 
formation of the pre-integration proviral structure.
A high degree of nucleotide variation is introduced into the DNA copy of the viral genome during the 
process of reverse transcription because reverse transcriptase lacks a 3’-5’ exonuclease proof reading 
function. Furthermore, because there are two RNA strands in each retroviral particle additional variation 
can be introduced by reverse transcriptase switching to the end of a different RNA molecule during the 
process of strand-transfer. Recombination events such as this can also occur in a cell that has been 
infected by more than one virion, variation can arise as a result of switching errors between different 
virion strands or copackaging errors. These processes lead to the generation of a diverse population of 
progeny virions, which can have altered viral properties of advantage or disadvantage to the replicative 
capacity of the population or its susceptibility to neutralisation by host immune responses (Hu & Temin, 
1990).
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1.9.3 Integration o f  viral DNA into cellular DNA
Once the reverse transcription of the viral genome is complete, the integrase enzyme binds to the double 
stranded viral DNA at the alt site in the LTR. Integrase then catalyses the removal of two bases from the 
3’ ends of the viral DNA, resulting in the exposure of a highly conserved CA dinucleotide motif (Goff, 
1992). The free hydroxyl groups’ left as a consequence of this cleavage are covalently ligated to the 5’ 
ends of IN-cleaved host-cell DNA by host cell enzymes to produce an integrated provirus (Bushman et 
al., 1990, Craigie et al., 1990, Katz etal., 1990, Engelman et al., 1991a).
The cellular DNA target site for integration of the HTV genome is not randomly selected. HTV-1 has been 
shown to preferentially insert into or near two repeated DNA elements in the human genome, LI and Alu. 
The arrangement of the chromatin structure surrounding these sites is thought to determine the 
susceptibility to integration. In addition, the LI and Alu elements have been found to share properties 
with retroviruses and have been subsequently termed retrotransposons.
1.9.4 Viral protein expression and regulation o f  expression
Once integrated into host cell DNA, the provirus relies on the complex interplay between c/s-acting viral 
DNA/RNA sequences, viral /ransactivator proteins, and host-cell transcription factors to co-ordinate the 
expression of HIV viral proteins (see section 1.10). The sequence elements that interact with the viral and 
host-cell factors are located in the promoter/enhancer region of the viral genome termed the LTR.
Since the integrated pro virus contains a 5’ and a 3’ LTR that are identical in sequence, the question arises 
as to which LTR functions as the transcriptional promoter. Studies undertaken to investigate the 
promoter activity of the 5’ and 3’ HTV-1 LTRs demonstrated that when placed upstream of a proto­
oncogene both LTRs were functional, although absolute levels of transcription directed by the 3’ LTR of 
HIV were reduced compared to the 5’ HTV LTR promoter (Klaver et al., 1994). In addition, the 
transcriptional activity of the 3’ LTR was dependent on the deletion or inactivation of the 5’ LTR. These 
results confirmed similar findings investigating the LTR activities of avian retroviruses (Fung et al., 1981, 
Neel et al, 1981, Payne et al., 1981). Since then, several groups have demonstrated that HTV gene 
expression of the integrated genome in vivo is directed exclusively by the 5’ LTR. The elongation 
complexes produced at the 5’ LTR have the ability to prevent or disrupt the assembly of pre-initiation 
complexes at the downstream 3’ LTR (Cullen et al., 1984, Klaver et al., 1994), in a mechanism termed 
transcriptional interference or promoter occlusion (Adhya & Gottesman, 1982).
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Transcription of integrated proviral DNA is directed by the cellular RNA polymerase II (RNAPII) 
enzyme and its transcription efficiency is dramatically enhanced following the expression of the viral 
transactivator protein Tat. The mechanism of regulated viral transcription is discussed in detail in section 
1.10 and 1.11.1.
Like most mammalian mRNAs, HIV transcripts are capped at the 5’ end and polyadenylated at the 3’ end. 
Capping involves the enzymatic addition of a cap group (m7G5’pppN) to the most 5’ nucleotide of each 
nascent viral transcript. The addition of this group enables the components of the cellular translational 
machinery to recognise the viral RNA (Lewis & Izaurralde, 1997). Host cell enzymes also carry out 
polyadenylation of die viral RNA. An AAUAAA (poly A) signal located within the HIV LTR directs 
polyadenylation of the 3’ end of the RNA. Because this signal is found within the LTR sequence, it is 
present at both the 5’ and 3’ end of the transcript. Polyadenylation at the 5’ site would yield a short, non­
coding RNA, reducing the amount of full-length viral RNA. In order to prevent this from occurring HIV 
has developed a regulatory mechanism involving the occlusion of the polyA signal in a stable RNA 
structure (Klasens et al, 1998, Das et al, 1999). This suboptimal setting allows both complete 
suppression of the 5’ signal due to 5’ specific inhibitory elements and full activity of the 3’ signal due to 
3’ specific enhancer elements (Das et al, 1999).
Early after infection, multiply spliced transcripts are produced predominantly, which encode the 
regulatory Tat, Rev, and Nef proteins. Expression of the viral Rev protein shifts the balance from 
multiply spliced transcripts toward the appearance in the cytoplasm of singly spliced and unspliced RNAs 
that encode the structural Gag, Pol and Env proteins. Rev is thought to influence the frequency of 
splicing by dissociating spliceosome components from viral transcripts (Chang & Sharp, 1989), thus 
accumulation of Rev will dissociate more spliceosomes resulting in fewer splicing events in new viral 
transcripts. The RRE of HTV-2 and SIV are substantially different in secondary structure to the HTV-1 
RRE. HTV-1 Rev proteins can induce HIV-2 protein expression by interacting with HIV-2 RRE, however 
HTV-2 Rev fails to activate HTV-1 protein expression (Dillon et al, 1991).
1.9.5 Virion assembly, budding and maturation
Assembly of the virion particle components begins with the accumulation of p55 Gag and pi 60 Gag-Pol 
polypeptide complexes at the inner surface of the host-cell plasma membrane (Gottlinger et al, 1989, 
Bryant et al, 1991, Zhou et al, 1994). A cis- acting packaging element located near the 5’ end of the full- 
length viral transcript directs the association of the viral genome with these polypeptide complexes by
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recognising the NC domain in the Gag polypeptide. In addition to Gag polypeptide accumulation, 
envelope glycoprotein oligomers are also targeted to the plasma membrane and, once inserted, interact 
with die MA domain of p55 Gag via the cytoplasmic domain of the TM subunit.
One of the most important events to take place during virion assembly involves the proteolytic cleavage 
of the Gag, Gag-Pol, and Env-gp polypeptide precursors. The resulting mature nucleocapsid is composed 
of fully processed gag (MA, CA, NC, p6) and pol gene products (PR, RT, RNase H, and IN) as well as 
two molecules of viral single-stranded RNA genome. The final stage of the virus life cycle is achieved 
once the nucleocapsid core buds through the host-cell membrane, producing a virion particle with a 
nucleocapsid surrounded by a lipid bilayer membrane containing envelope glycoprotein spikes and other 
host-cell membrane proteins.
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1.10 The control and regulation of HTV-2 gene expression
Viruses are obligatory intracellular parasites and are optimally adapted to use the host cell machinery for 
the production of new virus particles. In order to achieve this HIV-2 possesses a promoter region that 
contains cis-acting regulatory sequences that are recognised by host cell transcription factors. This 
enables transcription of HIV-2 encoded genes to be executed by the same enzyme system that expresses 
cellular genes, and primarily involves cellular enzyme RNA polymerase II (RNAPII). Since the activities 
of several of the cellular transcription factors that recognise elements within the HTV-2 promoter are 
altered by parameters such as cellular activation or differentiation, HIV-2 gene expression is also, in part, 
controlled by alterations in cellular signal transduction pathways. In order to put the sequence elements 
of the HIV-2 LTR into the context of the eukaiyotic transcription process when described in the next 
section of this chapter, a brief overview of eukaryotic transcription is given below.
1.10.1 Eukaryotic gene expression 
The initiation of transcription from a eukaryotic and thus the integrated HTV-2 promoter can be divided 
into three major steps: chromatin remodelling, transcription factor recruitment, and elongation.
1.10.1.1 Chromatin remodelling
Within the cell nucleus, DNA is packaged with nuclear histone proteins into a structure known as 
chromatin. Within this complex 200bp stretches of DNA become wrapped around a core of histone 
proteins to form the basic subunits of chromatin and are termed nucleosomes. This organisation exerts a 
repressive effect upon gene expression and determines that most DNA sequences are structurally 
inaccessible and functionally inactive. As a result, the efficiency of transcription initiation is determined, 
in part, by the accessibility of the promoter embedded within the chromatin structure. In order for 
transcription from a eukaryotic or an HTV promoter to be initiated remodelling of the chromatin structure 
must occur (Verdin, 1991, Verdin et al., 1993, Van Lint et al, 1996, Widlak et al., 1997, Benkirane et al, 
1998, Kadonaga, 1998, Marzio et al., 1998, Deng et al., 2001, He et al., 2002). Structural rearrangement 
of chromatin can be brought about during the process of transcription by histone acetylation (Struhl, 
1998, Berger, 2002, Eberharten & Becker, 2002). Histone acetylatransferases (HATs) have been shown 
to modify histones by covalently linking acetyl moieties to the free amino groups of the amino acids that 
make up the proteins, resulting in the removal of the positive charge that resides on the NH3+ side chain 
(Brownell & Allis, 1996). It has been speculated that the reduction of positive charges on histone
proteins might lower their affinity for DNA, resulting in a relaxation of the DNA-protein structure 
thereby facilitating the binding of sequence-specific transcription factors to the promoter DNA. Several 
multisubunit ATP-utilising enzymes which can remodel chromatin structure in vitro have been identified, 
including mammalian HAT and the CBP (CREB-binding protein)/p300 family of coactivator proteins and 
their associated cofactor (P/CAF) (Chan & La Thangue, 2001, Berger, 2002). Moreover, recent analyses 
have indicated that, in one of its many roles in the upregulation of transcription, Tat functions to recruit a 
HAT to the promoter (see section 1.1 l.lii).
1.10.1.2 Transcription factor recruitment for PIC assembly
Once chromatin remodelling has occurred the process of transcription factor recruitment and pre­
initiation complex (PIC) formation begins. The most recent and widely supported model for eukaryotic 
and thus HIV PIC assembly consists of two steps (Berk, 1999, Buratowski, 2000, Gill, 2001, Butler & 
Kadonaga, 2002).
The first step involves the binding of general transcription factors TFIID and TFIIA to the promoter 
(Coleman et al., 1999, Liu et al., 1999) (see Figure 1.5A, pg 68). TFIID is a multisubunit complex that 
has been shown to be only one of two general transcription factors to have sequence specific DNA- 
binding activity. Importantly, TFIID recognises the TATA box located within the eukaryotic or HIV-2 
promoter as its DNA target. The TFIID complex is composed of the TATA-binding protein (TBP), a 
small protein of 30 kDa, and a number of tightly complexed TBP-associated factors (TAFs) (Burley & 
Roeder, 1996). In recognising the TATA sequence the TBP subunit of TFIID binds to the minor groove 
of the promoter DNA, forming a ‘saddle’ around the double helix (Kim et al., 1993). In effect, the inner 
surface of TBP binds to the DNA while the larger outer surface is available for interaction with other 
proteins. Crystal structures of eukaryotic TBP bound to short TATA-box-containing promoter fragments 
have revealed that binding of TBP to the promoter highly distorts the DNA, causing it to bend 75-80° 
towards the major groove (Kim et al., 1993, Coulombe & Burton, 1999). This process is thought to 
promote the second step of PIC assembly, which involves the binding of a holoenzyme complex 
containing RNA polymerase II (RNAPII) and the remaining GTFs required to initiate transcription 
(Koleske et al, 1995). The TFIID complex as a whole typically protects the region from -45 to -10 in a 
eukaryotic promoter, encompassing the TATA box and its surrounding nucleotides. General transcription 
factor TFIIA has been found to stimulate the rate and extent of TFIID binding and acts to stabilize the 
DNA-TFIID complex (Coleman et al., 1999, Liu et al., 1999). After joining the complex, TFIIA extends
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protection of the TFIID region further upstream (Figure 1.5A, pg 68), although it is not clear if this factor 
remains associated when the PIC is fully assembled.
The second step of PIC assembly involves the recruitment to the DNA-TFIID-TFIIA complex of the 
holoenzyme containing RNAPII and a number of associated GTFs (Figure 1.5B, pg 68). While the 
composition of the definitive holoenzyme has yet to be determined, general transcription factors TFIIB, 
TFIIE, TFIIF, and TFIIH have been shown to play crucial roles (Orphanides et al, 1996). TFIIB, the 
only other general transcription factor to possess sequence specific DNA-binding activity, is thought to 
interact with TFIID and the DNA major groove, binding to a bipartite sequence termed the “IIB 
recognition element” (BRE) located nine base pairs upstream, (and seven base pairs downstream) of the 
eukaryotic TATA element (Lagrange et al., 1998, Littlefield et al, 1999). Binding of TFIIB to the BRE 
has been shown to stabilize the bend in the DNA and determine the orientation of TBP binding to the 
TATA element, in effect setting the direction of the DNA distortion (Nikolov et al, 1995, Lagrange et al, 
1996). TFIIF is a GTF composed of two subunits, RNA polymerase-associating protein 74 (RAP74) and 
RAP30, and has been shown to be an absolute requirement of eukaryotic transcription both in vivo and in 
vitro (Lei et al, 1999, Yan et al, 1999). The RAP30 subunit of TFIIF binds directly to RNAPII and to 
TFIIB and mediates the delivery of the RNAPII-containing holoenzyme to the PIC. General transcription 
factors TFIIE and TFIIH have also been identified within the holoenzyme complex. The presence of 
TFIIH within the PIC is particularly significant in transcription initiation as it is the only GTF to possess 
enzymatic properties, containing two helicase subunits, XPD and XPB, and a cyclin dependent protein 
kinase subunit, which acts to phosphorylate the CTD of RNAPII (Tirode et al, 1999) (see section 
l.lO.liii).
Binding of the holoenzyme and its associated general transcription factors cause further distortion of the 
DNA resulting in slight strand separation. It has been proposed that the separation of the DNA strands is 
enough to allow the XPB helicase subunit of TFIIH access to single-stranded DNA to catalyse open- 
complex formation in the presence of ATP (Coulombe & Burton, 1999). The process of DNA unwinding 
allows RNAPII to read, and transcribe from, the coding strand of the DNA (Tirode et al, 1999).
Significantly, the complex interactions between TFIID, RNAPII, TFIIB, and the TATA and BRE 
elements (that result in conformational changes in DNA structure) determine the location of the open 
complex and thus the transcriptional start site position o f+1 (Kim et al, 1997).
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The rate at which general transcription factors are recruited to the promoter, and thus the rate at which 
transcription initiation can occur, is dependent on activator proteins that usually have binding sites 
upstream of the TATA box element. Activator proteins exert their influence upon the rate of transcription 
by either binding to and recruiting one or more of the general transcription factors described above, or in 
binding to the promoter in an upstream position they enhance the binding stability of recruited general 
transcription factors (Blau et al, 1996, Gill, 2001). The properties of such proteins and their binding sites 
within the HTV-2 promoter will be discussed in detail in section 1.10.2.
1.10.1.3 Promoter clearance and elongation
The third and final stage in the process of transcription initiation is termed promoter clearance. The 
mechanisms involved in this process are still not fully understood, however, they result in the transition of 
the PIC to an elongation complex.
Initial studies into the third stage of transcription initiation had documented a rate-limiting step in vivo. 
Following the initiation of RNA synthesis, PICs were shown to stall and accumulate 20 to 40 nucleotides 
downstream of the eukaryotic and HTV promoter (Kao et al., 1987, Kessler & Mathews, 1992). How 
these PICs were transformed into complexes generating full-length transcripts was undetermined until 
extensive analyses were performed upon the RNAPII enzyme within the PICs themselves. The data 
generated by these analyses demonstrated that the release of the stalled pre-initiation complexes and their 
transformation into elongating complexes required the phosphorylation of the CTD of the largest RNAPII 
subunit (Marciniak & Sharp, 1991, Marshall, et al, 1996, Okamoto, et al, 1996).
The CTD of RNAPII contains multiple heptapeptide tandem repeats of Tyr-Ser-Pro-Thr-Ser-Pro-Ser. 
Within preinitiation complexes (Layboum & Dahmus, 1989) and in early elongation complexes in vitro 
(Marshall, et al., 1996) the serine residues within the multiple tandem repeats of the CTD were found to 
be hypophosphorylated (RNAPIIa). During the process of promoter clearance and productive elongation 
however, the serine residues within the CTD were found to be exclusively hyperphosphorylated 
(RNAPIIo).
The protein kinase responsible for the initial phosphorylation of the CTD of RNAPII during promoter 
clearance has been shown to be the cyclin-dependent kinase subunit (cdk7) of general transcription factor 
TFIIH, in association with cyclin H and MAT1 (collectively known as cyclin-dependent kinase activating 
kinase CAK) (Goodrich & Tjian, 1994, Tirode et al., 1999) (Figure 1.5C, pg 68). The allosteric changes 
in the conformation of RNAPII induced by CAK phosphorylation of the CTD are thought to release the
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PIC from the promoter by disrupting the contacts between the CTD and other transcription factors such as 
TFIID which do not remain with the elongation complex (Zawel, et al., 1995) (Figure 1.5D, pg 68). 
When the melted region or the RNA transcript reaches a certain critical length RNAPII releases its 
contacts with the promoter DNA and associated general transcription factors, thus entering the elongation 
phase of transcription. In support of this model, TBP cannot associate with RNAPIIo (Usheva, et al.,
1992).
More recent analyses have indicated that while the CAK complex of TFIIH may facilitate promoter 
clearance, it does not appear to be the kinase required during the elongation process. Identification of 
human positive transcription elongation factor b (P-TEFb) has lead to the proposal that the kinase subunit 
of this factor is responsible for the hypeiphosphorylation of the CTD, and subsequent elongation of the 
RNA transcript (Peng et al., 1998). The kinase subunit of P-TEFb is composed of cyclin-dependent 
kinase 9 (cdk9), and cyclin T1 (CycTl), although a small proportion of the factor (<10%) is associated 
with either cyclin T2a or cyclin T2b (Peng et al, 1998). This factor has been shown to 
hyperphosphorylate the CTD and is sensitive the kinase inhibitor 5,6-dichloro-l-P-D- 
ribofuranosylbenzimidazole (DRB), a well-known inhibitor of transcription elongation (Marshall et al.,
1996). The large conformational changes induced by RNAPII CTD hyperphosphoiylation permit 
RNAPII to interact with a wide variety of elongation factors as well as with proteins involved in mRNA 
processing (Hirose & Manley, 2000).
Notably, several studies have recently demonstrated that the HTV frarasactivator protein Tat mediates its 
enhancement of gene expression by recruiting P-TEFb to the promoter, effectively increasing the rate of 
elongation (Alonso et al., 1994, Mancebo et al., 1997, Zhu et al, 1997, Fujinaga et al., 1998, Wimmer et 
al., 1999), this will be further discussed in section 1.11.1.
Transcription termination is coupled to 3’ end processing, which involves cleavage of the transcript and 
poly (A) addition (Guntaka et al., 1993). Recent reports indicate that transcription by RNAPII and pre- 
mRNA processing are linked in a number of ways, since essential subunits for mRNA capping, splicing 
and polyadenylation associate with the RNAPII enzyme during transcription (Neugebauer & Roth, 1997).
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Figure 1.5 Diagram of the processes involved in the initiation of transcription from a eukaryotic (or an 
integrated HIV-2) promoter. (A). Initially the PIC is assembled, general transcription factor TFIIH binds 
to the TATA box together with TFIIA. (B). The second step of PIC assembly involves recruitment to the 
promoter of a holoenzyme containing RNAPII and the remaining GTFs required to initiate transcription. 
(C). The cyclin-dependent kinase subunit (cdk7) of GTF TFIIH catalyses the phosphorylation of the CTD 
of RNAPII, leading to a progression of conformational changes in DNA, RNAPII, and the GTFs that 
result in the formation of an open complex capable of forming the first phosphodiester bond. (D). 
Phosphorylation of the CTD of RNAPII has converted the pre-initiation complex into to an elongation 
complex. Contacts between the CTD and other transcription factors such as TFIID, which do not remain 
with the elongation complex, are disrupted and the elongation complex is free to move down the gene 
producing the RNA transcript.
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1.10.2 The structure o f the HIV-2 Long Terminal Repeat (LTR).
As described in section 1.10.1, the complex array of putative regulatoiy elements that interact with the 
viral and cellular factors to cause the expression of all HTV-2 encoded genes, are located within the region 
of the HTV-2 genome termed the LTR. Complementary experiments and nucleotide sequence analyses of 
the original HTV-2 isolate (ROD) have revealed that the HTV-2 LTR is a prototypic enhancer-promoter 
unit, 854bp in length (Guyader et al., 1987). Further analyses have identified three distinct internal 
domains within the LTR termed U3, R, and U5 (Figure 1.6A, pg 71) (Guyader et al., 1987, Arya & Gallo, 
1988).
The U3 domain of the HIV-2 LTR has been mapped between nucleotides -556 to -1 (Figure 1.6A, pg 
71), relative to the start site of transcription, and contains most of the transcription factor binding 
elements required to direct HTV-2 gene expression (Guyader et al., 1987, Tong-Starksen et al, 1990). 
This domain can be further trisected into core, enhancer, and modulatory regions, corresponding to the 
nature of the binding elements located within them (see section 1.10.3).
The R domain of the HTV-2 LTR has been shown to contain sequences required for the transcriptional 
response to the viral fra/wactivator protein Tat. This region, mapped to nucleotides +1 to +173, relative 
to the start site of transcription (Figure 1.6A, pg 71), encodes an RNA sequence element that forms the 
fransoctivation response element (TAR), a structure only found in human and simian immunodeficiency 
viruses (Guyader et al, 1987, Tong-Starksen et al., 1990) (see section 1.10.4).
The U5 domain of the HTV-2 LTR is contained between nucleotides +174 to +299 (Figure 1.6A, pg 71), 
and may encode sequences that negatively regulate HTV-2 transcription (Guyader et al, 1987, Tong- 
Starksen et al, 1990, Arya, 1991) (see section 1.10.5).
Computer alignments of HTV LTR sequences have shown that all of the elements of the HTV-2 LTR are 
larger than the corresponding elements within the HTV-1 LTR (respectively (U3) 456 HTV-1; 556 HTV-2; 
(R) 97; HTV-1; 173; HIV-2; and (U5) 82; HIV-1; 120; HIV-2) (Guyader et al 1987). The entire HIV-2 
LTR shares only 40% sequence homology with the HTV-1 LTR, although, some core transcriptional 
elements display 50% sequence similarity (Tong-Starksen et al, 1990). As with the rest of the genome 
the HTV-2 LTR shares much greater sequence similarity with the SIV LTR (Chakrabarti et al, 1987, 
Franchini et al, 1987). In particular, at least three modulatory transcription factor binding sites within the 
U3 domain of the HTV-2 and STV LTRs share 75% sequence homology and are distinct from any element
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located in the modulatoiy region of the HIV-1 LTR (Hirsch et al, 1989b, Renjifo et al, 1990, Hannibal et 
al, 1994).
The location and function of the cis-and trans-acting sequences located within the U3, R and U5 domains 
of the HIV-2 LTR have been determined in studies using gel retardation and deoxyribonuclease (DNase) I 
footprinting assays, in addition to plasmids containing LTR promoters linked to reporter genes such as 
bacterial chloramphenicol acetyl transferase or firefly luciferase. Site-directed mutagenesis of the binding 
elements has established whether their effect on gene expression is positive or negative and has also 
revealed synergyistic interactions between the transcription factors that bind them. Several studies have 
extended this approach by constructing HIV proviruses that contain mutations in potential regulatory 
regions. The growth properties of these mutant viruses have been compared to those of wild-type virus. 
Identification of the cellular factors that bind to the regulatory elements has been achieved using 
oligonucleotide affinity chromatography, X gtl 1 expression cloning, and somatic cell genetics.
The next section of this chapter will describe the sequence elements and transcription factors shown to 
play a role in gene expression directed by the HTV-2 LTR. Data concerning the function of the HTV-2 
LTR elements and their binding factors are limited in comparison to HIV-1, although the function of 
several of the core binding sites have been shown to be analogous (Aiya & Gallo, 1988, Tong-Starksen et 
al, 1990). Wherever possible data derived from HTV-2 LTR analyses has been described, however, some 
details included have been derived from analyses carried out on the HIV-1 LTR.
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Figure 1.6 Schematic representation of the HIV-2 pROD10 Long Terminal Repeat (LTR) (A) The domain structure of the HIV-2 LTR. The boundaries and sizes of the putative 
U3, R and U5 domains are shown (Guyader et al 1987). (B) Diagram of the cloned region of the HIV-2 LTR. Relevant sites within the HIV-2 LTR are identified. Those sites 
located within the core promoter region of U3 are shown in green, those within the enhancer region of U3 are shown in turquoise, and those within the modulatory region of 
U3 are shown in blue. (C) Sequence of the region of the HIV-2 LTR (ROD) from nucleotides -200 to +123. This region of the HIV-2 LTR contains the majority of the 
functionally relevant transcription factor binding elements identified thus far; the sequences of these elements are underlined.
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1.10.3 The structure andfunction o f the binding elements within the U3 domain o f the HIV-2
LTR.
1.10.3.1 The core region ofU3
The transcription factor binding sites defined within the core region of U3 have been shown to be 
essential to both basal and Tat-induced HTV gene expression (Guyader et al., 1987, Aiya & Gallo, 1988, 
Tong-Starksen et al, 1990, Arya, 1993). In addition, all are analogous to the fundamental core sequence 
elements usually found within a generic eukaryotic/mammalian promoter. Taken together the elements 
within this region constitute the shortest sequence at which RNAPII can initiate viral gene expression 
(Figure 1.6B and C, pg 71).
1.10.3.1a.The TATA box and its surrounding nucleotides 
As in the mammalian promoter, of central importance to the HTV-2 promoter is the highly conserved A-T 
rich TATA box motif that is located 30bp upstream from the transcriptional start site (Figure 1.6B and C, 
pg 71). Extensive analyses of the HTV-1 and HTV-2 LTR have ascertained that the TATA element is 
critical for both basal and Tat-induced gene expression (Guyader et al., 1987, Aiya & Gallo, 1988, 
Jakobovits et al, 1988, Jones et al, 1988, Garcia et al., 1989, Tong-Starksen et al., 1990, Berkhout & 
Jeang, 1992, Rittner et al., 1995). The explanation for the fundamental influence that this 8bp motif has 
on both basal and activated levels of transcription lies in it acting as the initial DNA target site for the 
TATA-binding protein (TBP), the 38-kDa component of general transcription factor TFIID (Berkhout & 
Jeang, 1992, Gaynor, 1992, Ou et al., 1994, Coulombe & Burton, 1999, Patjkoglou et al., 1999, Ranish et 
al., 1999). As described in section 1.10.1, the binding of the complex of cellular factors that constitute 
TFHD is a prerequisite to the progressive assembly of the pre-initiation complex (PIC), the aggregation of 
general transcription factors and RNA polymerase II required for the initiation of transcription.
By acting as the binding site for TFIID, the HTV-2 TATA element defines the window within which 
transcription initiation and open complex formation can occur. In determining the location of the open 
complex, the interactions between, RNAPII, the general transcription factors and their binding elements 
define the actual position of the transcriptional start site position +1 (Kim et al., 1997, Coulombe & 
Burton, 1999).
In vitro and in vivo transcription analyses of the HTV-1 and HTV-2 LTR indicate that mutation of the 
TATA element dramatically decreases HIV gene expression (Arya & Gallo, 1988, Jakobovits et al., 1988,
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Garcia et al, 1989, Tong-Starksen et al, 1990, Berkhout & Jeang, 1992, Rittner et al, 1995). Garcia et 
al demonstrated that disruption of the HTV-1 TATA sequence caused loss of DNAse protection between 
nucleotides -42 - -4, the region to which TFIID binds, and showed that this loss was accompanied by 
marked decreases in Tat-induced transcriptional activation and HTV specific mRNA (Garcia et al, 1989). 
Similarly Jakobovits et al, showed severely impaired transcription rates from both HTV-1 and HTV-2 
LTRs with mutations in the TATA element (Jakobovits et al, 1988). Moreover, proviral constructs 
containing the TATA sequence mutations investigated by Garcia et al not only directed severely impaired 
levels of HTV gene expression but also failed to generate progeny virus (Harrich et al., 1990).
Many of the studies that have characterised the effects of mutations within the HTV-1 TATA element 
have also revealed that sequences immediately flanking this motif are important in modulating HTV gene 
expression and may play a role in HTV TATA element function. In a study carried out by Berkhout et al 
thirty nucleotides immediately flanking the HTV-1 TATA motif were replaced with the corresponding 
sequences from the HTLV promoter (Berkhout & Jeang, 1992). The HTLV/HTV hybrid promoter did not 
work nearly as well as the wild type HTV promoter. In addition, transcription analyses carried out by 
several groups have demonstrated that site-directed mutagenesis of sequences immediately 5’ and 3’ to 
the HTV-1 TATA box results in marked decreases in both basal and Tat-induced gene expression (Garcia 
et al, 1989, Berkout & Jeang, 1992, Ou et al., 1994, Rittner et al, 1995). In eukaryotic transcription, this 
region of the promoter provides the recognition sequences for the general transcription factor TFIIB, a 
factor that plays a central role in PIC formation and stability (Lagrange et al., 1997). Changes to the 
nucleotides 7bp upstream and 9bp downstream of the TATA box which encompass the eukaryotic TFIIB 
recognition element (BRE) have been shown to result in reduced levels of transcription initiation as a 
consequence of decreased TFIIB binding. While a consensus BRE has not been identified in the HTV-1 
or HIV-2 LTRs, competition analyses suggest that the region flanking the HTV TATA box may contain 
multiple recognition sequences for distinct cellular proteins that are required for stabilization of, or 
interaction with, factors which bind to the TATA enhancer region (Garcia et al., 1989, Berkout & Jeang, 
1992, Ou et al., 1994).
1.10.3.1b. The HIV-2 Initiator element 
Originally, the initiator (Inr) element was defined as a 17 bp motif that surrounded the RNA initiation site 
in TATA-less promoters (Smale & Baltimore, 1989) and contained all the information necessary for 
determining specific initiation of transcription by RNA polymerase II. Since then, several studies have
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reportedly found similar elements within mammalian promoters, leading to the establishment of a loose 
consensus sequence for mammalian Inr of YCA+1NTYY where Y is a pyrimidine and N is any nucleotide 
(Javahery et al, 1994).
A region sharing this loose consensus sequence and which appears necessary for promoter activity has 
been identified within the start site region of the HTV-2 LTR. Extensive deletion and substitution 
analyses have revealed that significant reductions in transcriptional activity are observed if the sequences 
between residues -6 and +30 of the HIV-1 and the HTV-2 LTR are mutated (Jones et al, 1988, Rittner et 
al., 1995). More detailed analyses of this region has revealed that residues +11 to +20 have no real effect 
upon promoter strength indicating that the HTV Inr may be a bipartite initiator element or two elements 
positioned between residues -6/+4 and +21/+30 which act synergistically to increase promoter activity 
(Zenzie-Gregory et al., 1993, Rittner et al, 1995).
The precise mechanism by which the Inr element contributes to promoter activity is as yet undetermined 
although it appears that the HTV Inr requires precise positioning relative to the TATA box in order for it 
to influence the rate of transcription initiation. A study investigating the significance of core promoter 
element positioning in the HTV-1 LTR demonstrated a 3-4 fold reduction in transcription initiation rates 
when the TATA box and HTV-1 Inr were separated by 15 and 22 nucleotides (Rittner et al, 1995). No 
comparative studies exist for the HTV-2 LTR although in accordance with the function of other analogous 
elements, similar effects could be expected.
Speculation as to the identity of potential Inr-binding proteins (ITF) has predicted that the Inr might be 
required for transcription initiation based on its participation in the co-operative binding of the general 
transcription factor TFIID along with the TATA box. Binding studies have however, failed to prove that 
TFIID or any of its subunits bind to any Inr element. More recently, a study carried out by Roy et al has 
shown that the HTV-1 initiator element could be bound by TFH-I, a 120-kDa general transcription factor 
known to be involved in transcription initiation (Roy et al, 1991). It has been suggested that interaction 
of the initiator binding protein with a member or members of the pre-initiation complex may in some way 
facilitate complex formation. Thus in binding to the HTV Inr TFH-I could potentially interact with TFIID, 
the central transcription factor of the PIC, and influence transcription initiation via a stabilising or 
recruitment effect. This would explain the functional requirement of the HIV Inr to be in close proximity 
to the TATA box. Comprehensive analysis of the HIV-1 and HTV-2 Inr and the factors which bind to 
them have yet to be completed.
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1.10.3.1c. SP1-binding sites 
It has been widely established that the PIC containing the GTFs and RNAPII bound to the TATA element 
and its surrounding nucleotides can produce only a low rate of transcription initiation. This rate is 
enhanced during development or in response to extracellular signals by the binding of transcription 
factors known as activators to promoter binding sites upstream of the TATA box (Blau et al, 1996, Gill, 
2001). In binding to promoter DNA activator proteins increase the rate of transcription initiation by 
enhancing the recruitment, binding, and stability of general transcription factors involved in the assembly 
of the pre-initiation complex. Experiments carried out using protein affinity resins have identified several 
activator proteins that target components of the PIC such as TFILA, TFIIB, TFIIE, TFIIF, and TFIIH 
(Berk, 1999, Gill, 2001). The binding sites for several of these activator proteins are found in a wide 
variety of genes and once bound with the appropriate factor result in increased transcription in all tissues. 
The SP1 binding site is an example of this and is bound by the cellular activator protein SP1 (Blau et al.,
1996).
The HIV-2 LTR contains three consensus SP1 binding sites within the core region of the U3 domain, 
immediately 5’ to the TATA box (Arya & Gallo, 1988, Tong-Starksen et al, 1990) (Figure 1.6B and C, 
pg 71). Mutagenesis studies have indicated that the three G-C rich sequences extending from -49 to -83 
relative to the start site of transcription are functionally important in HIV-2 directed basal and Tat 
rransactivated gene expression (Arya & Gallo, 1988, Tong-Starksen et al, 1990, Pagtakhan & Tong- 
Starksen, 1997). Analyses of the HIV-1 LTR have also revealed the presence of three SP1 binding sites 
that have functional similarity to those described in the HTV-2 LTR (Nabel & Baltimore, 1987, Harrich et 
al, 1989). Sequential mutation of the SP-1 sites within the HTV-1 LTR has been shown to result in a 
progressive decline in basal and Tat-induced gene expression and production of full-length RNA 
transcripts (Ross et al, 1991, Rittner et al, 1995). Constructs containing mutations in all three HTV-2 
SP1 binding sites exhibit severe decreases in HTV-2 gene expression and transcription initiation rates 
(Pagtakhan & Tong-Starksen, 1997). Moreover, HTV-1 proviral constructs displaying this phenotype are 
unable to generate progeny virions in some cell types (Harrich et al, 1990, Parrot et al., 1991, Ross et al, 
1991, Rittner et al., 1995).
In contrast, reports of the enhanced activity of naturally occurring HIV-1 promoters possessing additional 
SP-1 sites underline the significant influence that these sites have upon the level of HIV gene expression. 
Two such reports have demonstrated that natural HTV LTR variants containing four (Koken et al, 1992) 
and five SP-1 sites (Rousseau et al., 1997) respectively were able to outgrow isogenic constructs
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containing three SP-1 binding sites. More recently, Berkhout et al described the duplication of the 
complete SP-1 region through prolonged culturing of an attenuated HTV-1 subtype B virus (Berkhout et 
al., 1999). This resulted in a stronger LTR promoter with six SP-1 sites, and yielded a fitter virus.
Protein-protein interaction studies have revealed that the SP-1 protein mediates its effect on HIV gene 
expression by interacting with a subunit of the general transcription factor TFIID, the central member in 
the pre-initiation complex (Rittner et al, 1995, Blau et al., 1996). By specifically binding to TBP- 
associated factor nl 10 (TAFnl 10) via its glutamine-rich activation domain, the SP-1 protein is thought to 
enhance the recruitment, stability, and anchoring of TFIID to the TATA element of the HTV promoter 
(Hoey et al, 1993, Weinzierl et al., 1993, Rittner et al, 1995). Consistent with a role for the SP-1 protein 
in the recruitment and stabilisation of TATA binding cellular transcription factors, several studies have 
demonstrated that the spacing between the SP-1 sites and the TATA box in the HTV-1 and HIV-2 LTRs 
(Huang & Jeang, 1993, Rittner et al., 1995, Pagtakhan & Tong-Starksen, 1997) is crucial for efficient 
viral gene expression. Any increases in the distance between the TATA and SP1 sites results in 
significant decreases in viral gene expression.
In addition to its role in transcription initiation, a number of studies have shown that the SP-1 protein 
exerts positive effects upon Tat-induced gene expression (Rittner et al, 1995, Blau et al, 1996, 
Pagtakhan & Tong-Starksen, 1997). Although suggestions of direct interaction between the two proteins 
have been made, a study by Pagtakhan et al has revealed that this is not the case with HTV-2 (Pagtakhan 
& Tong-Starksen, 1997). While /ransactivation of the HTV-2 LTR by Tat requires cis-acting binding sites 
for SP1, mutagenesis of the activation domains of both proteins has demonstrated that the requirement is 
not dependent on direct SPl-Tat interaction (Pagtakhan & Tong-Starksen, 1997). The transcriptional 
synergy observed between the two proteins is thought to be mediated indirectly through another member 
of the PIC, leading to an overall enhancement in levels of recruitment, stability and processivity of the 
PIC.
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1.10.3.2 The enhancer region ofU3 
1.10.3.2a. The NF-kB  site
The most well studied transcription factor that binds to the sequences within the enhancer region of the 
HIV-2 U3 domain is NF-kB. Unlike the HTV-1 LTR that possess two functional NF-kB binding elements 
(Gaynor, 1992), both the HIV-2 and SIV LTRs contain only one 10-bp consensus NF-kB sequence 
(GGGACTTTCCC), located between nucleotides -110 to -100 (Arya & Gallo, 1988, Renjifo et al, 1990, 
Tong-Starksen et al, 1990) (Figure 1.6B and C, pg 71).
NF-kB is ubiquitously expressed, but its function is negatively regulated by an inhibitory protein termed 
IkB (Baeuerie & Baltimore, 1988). In binding to NF-kB, IkB masks a nuclear localisation sequence 
required for the translocation of the NF-kB protein from the cytoplasm to the nucleus of the cell. 
Phosphorylation of IkB by protein kinase C (PKC) results in its dissociation from the NF-kB protein 
leaving it free to translocate into the nucleus of the cell and bind to its promoter recognition sequence 
(Baeuerie & Baltimore, 1988, Nolan et al., 1991). A number of cell stimuli induce the degradation of IkB 
including several cytokines (TNF-a and IL-1), T-cell activation signals, and physical/chemical stress 
(phorbol 12-myristate 13-acetate (PMA), phytohemagglutinin (PHA), and UV etc (Beg & Baldwin,
1993).
Both HTV-1 and HTV-2 transcription is dependent on the integrity of the NF-kB sites within their LTRs. 
Mutation of the NF-kB motifs in HTV-1 (Kawakami et al., 1988, Ross et al, 1991, Berkhout & Jeang,
1992, West et al., 2001) and HTV-2 (Tong-Starksen et al., 1990, Markovitz et al., 1992, Hannibal et al,
1993, Hilfinger et al 1993, Hannibal et al., 1994, Bassuk et a l, 1997) LTR CAT constructs has been 
shown to result in marked decreases in basal and Tat-induced levels of gene expression following 
transfection.
Because the NF-kB protein plays such a significant role in promoter function, several groups predicted 
that the HTV-1 promoter, containing two NF-kB sites, would be more active than the HTV-2 promoter 
containing only one site. It was suggested that this might provide an explanation for the reduced 
pathogenicity of HTV-2 compared to HTV-1. Comparisons of the transcription levels directed by LTR 
constructs within T cells activated by pharmacologic agents such as PMA and PHA, revealed little 
difference between the overall activity of the LTRs from HTV-1 and HTV-2 (Markovitz et al, 1990, Tong- 
Starksen et al., 1990, Hannibal et al., 1993). Differences were noted, however, when physiologic agents
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such as TNF-a, anti-CD3 antibodies, and CD3-specific antigens were used to stimulate T cell activation 
(Hannibal et al., 1993, Hilfinger et al, 1993). When transfected in the presence of TNF-a, HIV-1 
constructs directed a significantly higher transcriptional response to T cell activation compared to the 
response directed by the HTV-2 LTR. In contrast, transfection studies revealed that when T cells were 
stimulated by incubation with anti-CD3 antibodies or by antigen specific CD3 receptor recognition, HTV- 
2 transcription was activated nearly as well as with PMA and PHA, while HIV-1 transcription was 
induced significantly less than it was by PMA and PHA (Hannibal et al., 1993, Hilfinger et al, 1993, 
Hannibal et al, 1994). The differential effects of T cell receptor (TCR)-CD3 complex and TNF-a 
receptor signalling on the HTV LTRs correlated with results in whole-virus replication studies (Markovitz 
et al, 1990). These studies gave the first indication that the transcriptional regulation of the HTV-2 
promoter was different to that of the HTV-1 promoter. It appears that the HTV-1 LTR is stimulated more 
effectively by TNF-a, a cytokine that acts primarily through NF-kB elements to activate virus replication, 
in any T cell bearing its receptor. In contrast, the HTV-2 LTR appears to be more effectively stimulated 
by the calcium-mediated signal transduction pathway activated by soluble anti-CD3 antibodies and TCR 
mediated antigen recognition (Hannibal et al, 1993, Hilfinger et al, 1993, Hannibal et al., 1994). This 
method of activation, however, is clonally specific and thus a limited event. It has been suggested that the 
difference in regulation of the two promoters, rather than a difference in overall activity, may provide a 
mechanism by which the difference in pathogenicity of the two viruses is determined. However, further 
evidence outlining the mechanisms by which this may occur is required.
In addition to its response to cellular activation, the NF-kB protein is involved in synergistic interactions 
with two other activator proteins that play important roles in HTV gene expression, namely SP1 and Tat 
(Ross et al., 1991, Liu et al., 1992, Perkins et al, 1993, Moses et al., 1994). A study by Ross et al has 
shown that the arrangement and spacing of adjacent NF-kB and SP1 binding sites in the native 
configuration of the HTV-1 LTR contribute significantly to virus replication (Ross et al, 1991). It has 
been suggested that SP1 and NF-kB direct a high level of specificity to HTV gene activation by 
functioning as stereospecific architectural components of enhancer complexes. In this role, the 
interactions between proteins such as NF-kB, SP1, and Tat enhance transcription factor recruitment 
and/or binding stability of the already bound transcription factors within the pre-initiation complexes. 
Thus changes in the relative positions or orientations of the protein-binding sites within the HTV LTR 
leads to the inactivation of the promoter.
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1.10.3.3 The modulatory region ofU3
The modulatory region of the U3 domain has been mapped between nucleotides -110 and -180 and 
contains cis-acting transcriptional regulatory elements that, in conjunction with the NF-kB element, 
modulate the HIV-2 transcriptional response to cellular activation (Markovitz et al., 1990, Markovitz et 
al, 1992, Hannibal et al., 1993, Hilfinger et al, 1993, Hannibal et al, 1994, Clark et al., 1995) (Figure 
1.6B and C, pg 71). While investigating HTV-2 NF-kB site function in response to T-cell stimulation, the 
discovery was made that, in contrast to HTV-1, several upstream transcription factor binding sites in 
addition to NF-kB were required to activate HTV-2 transcription in T-cells (Markovitz et al, 1990, 
Markovitz et al, 1992). Earlier studies had revealed that mutation of the NF-kB elements within the 
HTV-1 LTR resulted in the complete abrogation of the transcriptional response to T cell activation (Nabel 
& Baltimore, 1987). In contrast, the transcriptional response to T cell activation directed by the HTV-2 
LTR was merely reduced following mutation of the HTV-2 NF-kB element (Markovitz et al, 1990). 
Complete inhibition of the transcriptional response was only achieved following the mutation of the 
sequences upstream of the HIV-2 NF-kB element. These studies demonstrated that the collection of 
transcription factor binding sites controlling the transcriptional regulation of the HTV-2 LTR were distinct 
from those found within the HIV-1 LTR, and indicated that transcriptional regulation of the HIV-2 LTR 
appeared to be a much more complex process than for HTV-1.
At present four upstream modulatoiy elements have been identified within the HTV-2 LTR, and extensive 
data have been generated concerning the sequence and function of each of them (Markovitz et al, 1990, 
Markovitz et al., 1992, Hannibal et al., 1993, Hilfinger et al., 1993, Hannibal et al, 1994, Clark et al., 
1995). Significantly, these elements are distinct from any found within the modulatory region of the 
HTV-1 LTR, but are conserved among HTV-2 isolates. Moreover, comparative analysis of the HTV-2 and 
STV modulatory promoter regions has revealed 75% homology, with STV LTR sequences containing at 
least two of the four cw-acting inducible transcription factor binding elements found within the HTV-2 
LTR (Renjifo et al, 1990, POhlman et al., 1998). Most interestingly, detailed analyses of the sites within 
the modulatoiy region have shown that they act synergistically to control both basal and activated levels 
of transcription (see section 1.10.3iiic).
1.10.3.3a. The PuBl, PuB2, andperi-ets (pets) elements 
The first HTV-2 modulatory site to be identified was termed purine rich box 1 (PuBl) located between 
nucleotides -174 and -159 relative to the start site of transcription (Figure 1.6C, pg 71). In 1990
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Markovitz and co-workers demonstrated that mutation of the sequences between nucleotides -174 to -  
159, containing the putative PuBl site, completely abrogated the transcriptional response to PMA, 
directed by a ANFkB-HTV-2 LTR (Ivfarkovitz et al, 1990). This effect was also seen when other 
pharmacologic stimulants such as phytohemagglutinin (PHA) were used to induce T-cell activation.
Following the discovery of the PuBl element, several internal LTR deletion and substitution mutants 
were generated to examine the importance of die spacing between the PuBl and NF-kB sites. In 
characterising these mutations further transcriptional decreases were noted and lead to the discovery of 
two additional c/s-acting elements required for the regulation of the HTV-2 LTR in response to T-cell 
stimulation (Markovitz et al, 1992, Hannibal et al, 1993, Hilfinger et al, 1993, Hannibal et al, 1994). 
The first c/s-acting element was a purine-rich sequence conserved amongst HIV-2 and STV isolates and 
located between nucleotides -142 and -137 relative to the start of transcription (see Figure 1.6B and C, 
pg 71). This element shared significant homology with the PuBl site and was subsequently termed 
purine-rich box 2 (PuB2) (Markovitz et al, 1992). The next element to be identified was a TG-rich 
element (TTGGTCAGGG) located immediately upstream of the PuB2 site termed the proximal-e/s (pets) 
site (Markovitz et al, 1992) (see Figurel .6 B. and C, pg 71).
The PuBl and PuB2 elements within the HIV-2 promoter have been shown to bind proteins belonging to 
the Ets family of proto-oncogenes (Leiden et al, 1992, Markovitz et al, 1992). Ets binding motifs 
usually provide the recognition sequence for the ets binding factor Ets-1, and are commonly found in 
other type C mammalian retroviruses, excluding HTV-1 (Markovitz et al, 1992). However, Ets-1 was 
found not to recognise either PuBl or PuB2. Instead recombinant studies revealed that both purine rich 
elements bound E74-like factor-1 (Elf-1) a member of the Ets proto-oncogene family which is related to 
the Drosophila E74 transcription factor (Bhat et al, 1989, Ben-David et al, 1991, Thompson et al, 1991, 
Leiden et al, 1992, Markovitz et al., 1992, Thompson et al, 1992, Wang et al., 1992). In particular, Elf- 
1 binds to the core pentanucleotide motif (AGGAA), located within each of the purine-rich sequences of 
PuBl and PuB2 (see Figure 1.6C, pg 71).
DNase footprinting analysis and electrophoretic mobility shift assays (EMSAs) performed with the pets 
site have found that this site is constitutively bound by an autoantigen termed DEK, a protein usually 
involved in chromosomal translocation in acute myelogenous leukaemia (Fu & Markovitz, 1996, Fu et 
al, 1997). More recent analyses have indicated that intracellular levels of DEK can be modulated in 
response to cell stimulation and differentiation by phorbol esters such as 12-O-tetradecanoylphorbol-13-
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acetate (TPA) (Faulkner et al, 2001). TPA acts to stimulate signalling cascades such as the protein 
kinase C (PKC) pathway that are usually triggered in response to T-cell receptor activation by antibody or 
antigen. The study by Faulkner et al demonstrated that in response to TPA, a protein phosphatase PP2A 
triggers the dephosphorylation of DEK through an interaction with the PKC pathway resulting in its 
exchange for another as yet unidentified pets binding factor (Faulkner et al, 2001). This exchange is 
accompanied by an increase in the level of transcription directed by the HTV-2 LTR. Interestingly, 
okadaic acid (OKA) a well-known inhibitor of PP2A has been shown to activate HTV-1 transcription, 
leading to the assumption that PP2A would suppress HTV-1 transcription. The finding that PP2A appears 
to boost transcription regulated by the HIV-2 LTR could represent another difference of transcriptional 
regulation between the two viruses (Faulkner et al, 2001).
Mutation of the PuBl, PuB2, NF-kB or pets site has been shown to reduce markedly basal transcription 
and the induction of transcription from the HTV-2 LTR following T-cell stimulation (Markovitz et al, 
1992, Hannibal et al, 1993, Hannibal et al, 1994). Alteration of these c/s-acting elements leads to 
correctly initiated, although markedly diminished; levels of RNA indicating that the sites act to determine 
the rate of transcription initiation. In addition to their role in the transcriptional response to T cell 
stimulation, transfection analysis in monocytes at various stages of differentiation has revealed that the 
PuBl, PuB2 and pets sites are required along with the NF-kB element, to direct basal and activated levels 
of gene expression in these cell lines (Hilfinger et al, 1993). This is again in contrast to HTV-1 regulation 
in which developmentally controlled expression from the LTR in monocytes, as in T cells, is mediated 
largely through the NF-kB sites alone (Griffin et al, 1989).
1.10.3.3b. The Peri-tcB element 
While characterising modulatory site function in immature and mature monocytes a fourth c/s-acting 
element was identified and shown to be required for the function of the HIV-2 LTR following monocytic 
stimulation (Clark et al, 1995). The peri-KB element, named for its close proximity to the NF-kB site, is 
located between nucleotides -127 and -109, and is highly conserved among isolates of HTV-2 and closely 
related strains of STV (see Figure 1.6B and C, pg 71). Transfection studies have demonstrated that this 
site displays a unique property not identified in any of the previously described c/s-acting elements, peri- 
KB functions to influence HIV-2 LTR activity in a cell-type specific manner. LTR constructs containing 
changes to the nucleotides encompassing the peri-KB sequence direct reduced levels of basal and
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activated transcription in monocytic cell lines, but direct levels of gene expression indistinguishable from 
wild type promoter constructs when transfected into T cell lines (Clark et al, 1995).
Analysis of the peri-KB site has revealed that an as yet unidentified nuclear factor is bound to the site in 
both peripheral blood monocytes and T cells. It has been proposed that the cell specificity of the peri-kB 
site is determined either by a different protein binding to this site in monocytes versus T cells or by 
differential modification of the binding protein in monocytes and T cells (Clark et al, 1995).
1.10.3.3 c. Cis-acting binding factors and transcriptional synergy 
Following the identification of the inducible c/s-acting elements upstream of the HTV-2 NF-kB site much 
work was put into characterising the mechanism by which these sites exerted their functional influence 
upon the rate of transcription directed by the HIV-2 LTR. When inserted upstream of the simian virus 40 
promoter, multiple copies of the PuBl site were found to be insufficient to confer PMA or PHA 
responsiveness within T-cells. This indicated that PuBl required the presence of the other c/s-acting 
enhancer elements to provide PMA responsiveness to the HIV-2 LTR. Further mutation analyses 
confirmed that the functional effects exerted by the cis-acting elements within the modulatory region of 
the HIV-2 LTR, at the basal and activated levels, required the collective presence of each of the four 
elements (Markovitz et al., 1992, Hilfinger et al., 1993, Hannibal et al., 1994). It has been suggested that 
the transcriptional synergy displayed by the modulatory elements within the HTV-2 LTR is mediated by 
specific interactions between the transcription factors that recognise and bind to them.
Several experimental systems have shown that members of the Ets family of proto-oncogenes readily 
interact with other transcription factors involved in promoter activation, and in doing so enhance either 
general transcription factor recruitment or stabilize their binding (Wang et al, 1994, John et al., 1995, 
Sun et al, 1995). Moreover, synergistic regulation by two of the transcription factors that bind to the 
modulatory elements in the HIV-2 LTR has been shown to control, at least in part, transcription directed 
by the HTLV-1 enhancer (Clark et al, 1993). The study by Clark et al has demonstrated functionally 
significant interactions between the Ets-related PuB binding factor, and the pets binding factor DEK 
(Clark et al, 1993). It has been postulated that the transcriptional synergism exerted by the c/s-acting 
inducible elements within the HTV-2 LTR is determined by the interactions between, Elf-1, bound to 
PuBl and PuB2, and the pets binding factor and NF-kB proteins bound to the pets and NF-kB sites
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respectively (see Figure 1.7, pg 84). In the case of monocytes, the peri-KB binding factor also appears to 
be involved in, and required for the synergistic induction of transcription from the HIV-2 LTR.
Thus, the transcription factors which bind to the c/s-acting modulatory elements within the HTV-2 LTR 
function as highly stereospecific architectural components of 3-D nucleoprotein transcriptional 
complexes. The influence that they exert upon the level of HTV-2 gene expression is dependent on the 
relative positions of their binding sites within the promoter and upon their orientation to the proteins with 
which they interact. In binding to the c/s-acting sites within the modulatoiy region of die LTR the 
transcription factors are thought to enhance the recruitment of members of the PIC and/or additional 
cofactors to the promoter, and to increase the stability of transcription factors that are already bound to 
the HIV-2 LTR (see Figure 1.7, pg 84).
Binding of the PuBl and PuB2 binding factor, Elf-1, is constitutive (Markovitz et al, 1992, Leiden et al., 
1992, Fu & Markovitz, 1996, Fu et al., 1997), and does not appear to change following cellular 
stimulation, therefore posttranslational modification of this DNA-binding protein via
phosphorylation/dephosphorylation is likely required for translational regulation (Fu & Markovitz, 1996, 
Fu et al., 1997). Such modifications have already been shown to play an important role in the regulation 
of HIV-2 transcription by DEK and the second unidentified pets binding factor (Faulkner et al, 2001). 
The posttranslational changes are likely to affect the stereospecific interaction between the proteins bound 
to the HTV-2 LTR in a way that promotes an increase in the rate of transcription initiation via 
transcription or cofactor recruitment and stability. This results in an overall increase in HIV-2 gene 
expression (Hilfinger et al., 1993, Clark et al., 1995, Fu & Markovitz, 1996, Fu et al, 1997, Faulkner et 
al., 2001).
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Figure 1.7 Model for transcriptional activation of the HIV-2 LTR by upstream factors. Initiation of HIV-2 transcription depends upon the binding of general 
transcription factors TBP and TAFs (see section 1.10.1) to the promoter. Transcriptional activation of the HIV-2 LTR also requires the transcription factors SP1, NF- 
k B , Elf-1, DEK, and peri- k B  binding proteins to bind to their respective recognition elements within the enhancer and modulatory regions of the promoter. In doing 
so the upstream factors and SP1 help to recruit general transcription factors (TFIIA-J and RNAPII) to the LTR and stabilise the preinitiation complex (PIC). 
Activation of transcription by the Elf-1, DEK, and peri- k B  binding proteins has been shown to be synergistic, thus in addition to the interactions these proteins share 
with general transcription factors they also require interaction with each other. In these positions, the upstream factors that bind to the HIV-2 LTR act as stereospecific 
architectural components of the transcriptional complex. (Adapted from Jones & Peterlin, 1994).
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1.10.4 The structure and function o f the binding elements within the R domain o f the HIV-2
LTR
1.10.4.1 The trans-activation response (TAR) RNA element
The R region of the HIV-2 LTR extends from nucleotide +1 to + 173 relative to the start of transcription 
(Figure 1.6A, pg 71). Chemical and enzymatic analyses of this region have demonstrated that it encodes 
the recognition site for the viral fransactivator protein Tat and a number of associated cellular proteins 
(Guyader et al 1987, Arya & Gallo, 1988, Fenrick et al., 1989, Chang & Jeang, 1992, Elangovan et al., 
1992, Rhim & Rice, 1993). In the presence of Tat the level of gene expression directed by the HIV-2 
LTR is markedly increased in a process called rra/wactivation (see section 1.11.1). The Tat responsive 
sequence responsible for mediating this effect has been mapped between nucleotides +1 and +123 of R 
relative to the start of transcription (Emerman et al., 1987, Guyader et al., 1987); this sequence encodes a 
3-D RNA structure termed the HIV-2 transacXwztion response element or TAR. The HIV-2 TAR
element folds into a structure containing three stem-loop hairpins and can be found at the 5’ end of all
HIV-2 nascent transcripts (Figure 1.8, pg 85). In contrast, the HIV-1 TAR (TAR1) element is smaller 
than that of HIV-2 (TAR2) at only 45 nucleotides in length, and configures into a less complex single
stem-loop structure (Figure 1.8, pg 85).
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Figure 1.8 Comparison of the primary and predicted secondary structures of HIV-1 TAR and HIV-2 TAR 
(TAR2). The critical functional elements in TAR are the terminal hexanucelotide loops and the 5’ proximal 
bulges. The position of the loop and bulge sequences in both the HIV-1 and HIV-2 TARs are indicated, (adapted 
from Garcia-Martinez et al., 1995).
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Extensive investigations into the function of TAR have revealed that it acts as the binding site for the Tat 
protein and its associated host cell proteins during the process of transcriptional frwwactivation, properly 
positioning them for functional interactions with the transcription factors of die pre-initiation complex 
(PIC) (see section 1.11.1) (Arya & Gallo 1988, Berkhout et al., 1990, Rhim & Rice, 1993).
The three stem-loop structures of TAR2 are formed by the basepairing of the nucleotides between 
position +1 and +123 relative to the start site of transcription (see Figure 1.8, pg 85). Deletion analyses of 
the nucleotides within these three structures have revealed that the first stem-loop structure (stem-loopi) 
is more critical for Tat transactivation than the second stem-loop structure (stem-loop2), and that the third 
stem-loop structure is not required at all (Fenrick et al., 1989, Rhim & Rice, 1993, Browning et al,
1997). Stem-loop2 has been shown to mediate Tat transactivation, all be it at a reduced level (30% that 
of WT), in die presence of an altered stem-loopi (Fenrick et al., 1989, Berkhout et al., 1990, Garcia- 
Martinez et al, 1995). However, in the context of a fully functioning stem-loopi, mutation of stem-loop2 
has little or no measurable effect on transcription levels in the presence of Tat (Fenrick et al, 1989, Rhim 
& Rice, 1993, Browning et al., 1997). Fenrick et al has suggested that the limited involvement in 
/ronsactivation of stem-loop2 is due to its distance from the cap site, since decreasing the distance by 
deletion significantly increased /ramactivation of stem-loop2 by Tat2 (Fenrick et al., 1989).
Extensive analyses of the sequence and secondary structure of TAR2 have revealed a number of 
functionally significant features. Both stem-loopi and stem-loop2 possess highly conserved dinucleotide 
bulges within the promoter-proximal arm of the stem regions, in addition to conserved unpaired 
hexanucleotide loop motifs at the apical tips of the hairpin structures (Fenrick et al, 1989, Rhim & Rice, 
1994a). These features are similar in position, sequence, and structure to the trinucleotide bulge and 
hexanucleotide loop motifs found within the single hairpin structure of TAR1 (Rhim & Rice, 1994a). As 
with HTV-1 TAR, the dinucleotide bulges of the hairpin structures in TAR2 have been shown to provide 
the binding motifs for the HIV-2 Tat protein (Rhim & Rice, 1993, Rhim & Rice, 1994a). More recent 
analysis has suggested that the nucleotide basepairs immediately above and below the bulge motif are 
also involved in the Tat2-TAR2 binding interaction (Berkout et al, 1990, Chang & Jeang, 1992, Churcher 
et al, 1993, Brodsky et al., 1998). Studies of the solution structure of TAR1 indicate that the bulge motif 
of TAR induces a bend in the RNA helix that distorts the local structure and widens the major groove in 
the double stranded RNA stem to expose hydrogen-bonding contacts that are important for stabilising the 
binding of Tat (Weeks et al, 1990, Colvin & Garcia, 1992, Delling et al, 1992).
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Protein binding studies have demonstrated that deletion of the dinucleotide bulge motifs within stem- 
loopi and 2 markedly reduces Tat2 binding in vitro and largely abolishes the transactivation of 
transcription via the TAR2 element in vivo (Rhim & Rice, 1994a, Garcia-Martinez et al, 1995). Removal 
of the bulge within stem-loopi only, reduces Tat transactivation in vivo by approximately 70%, while 
deletion of the bulge in stem-loop2 has no measurable effect on transcription levels. Nonetheless, 
removal of either dinucleotide bulge has been shown to simplify the in vitro Tat2-TAR2 binding pattern, 
suggesting that other interactions in addition to those directed by the dinucleotide bulge of stem-loopi are 
involved in the recruitment of Tat2 to TAR2 (Dingwall et al, 1990, Rhim & Rice, 1994a, Garcia- 
Martinez et al, 1995, Browning et al, 1997).
While mutagenesis of the TAR hexanucleotide loop sequences CUGGGA and CUGGGU was not found 
to result in a loss in Tat binding, preliminary functional analyses of these mutants revealed that Tat 
/ra/wactivation of transcription was completely inhibited. This finding indicated that a loop-binding 
factor in addition to the Tat2 protein was required to induce Tat fransactivation of transcription. After an 
extensive search, cyclin-Tl (CycTl), a subunit of the positive transcription elongation factor complex (P- 
TEFb), has been identified as the cellular cofactor that recognises the loop sequences of TAR in vivo 
(Bienias z e ta l ,  1998, Fujinaga et al, 1998, Garber et al, 1998a, Garber et al., 1998b, Wei et al., 1998). 
In particular, studies using the HIV-1 TAR loop sequence as a model have demonstrated that the first and 
third guanidine residues within the hexanucelotide loop sequence are critical for the recruitment of CycTl 
to TAR (Richter et al, 2002a, Richter et al, 2002b). The identification of the TAR loop-binding cofactor 
has lead to a greater understanding of the mechanism by which Tat causes an increase in the level of HTV 
gene expression (see section 1.11.1).
In addition to the functional motifs of TAR2, proper folding of the stem-loop structures is required. A 
study characterising the effects of disrupting the basepairing in the upper and lower stems of stem-loops 1 
and 2 showed marked reductions in Tat-induced transcription and simplified binding patterns (Browning 
et al, 1997). This study has indicated that more yet unidentified cellular factors may bind to the TAR 
region of HTV-2, some of which may be involved in mediating the Tat response in vivo. Further analyses 
are required to fully characterise the HTV-2 TAR region and the factors for which it is a target.
The TAR element has been found to play several roles in other steps of the viral life cycle (Klaver & 
Berkhout, 1994). Specifically, both the 5’ and 3’ TAR structures have been shown to contribute to 
optimal packaging of the viral genome into virion particles (McBride & Panganiban, 1997, McBride et
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al, 1997, Das et al., 1998, Harrich et al, 2000). In addition the TAR hairpins have been reported to play 
a role in reverse transcription, however these additional TAR functions have yet to be fully explored 
(Harrich et al, 1996, Das et al, 1998).
1.10.5 The structure and function o f  the binding elements within the US domain o f  the HIV-2
LTR
Unlike the U3 and R domains of the HTV-2 LTR, deletion analyses performed on the U5 domain have 
failed to reveal the presence of functionally significant transcription factor binding sites (Arya, 1991). A 
study by Aiya reported that the sequences within U5 could downmodulate HIV-2 LTR-directed gene 
expression, however this effect appeared to be dependent upon the length of U5 rather than the identity of 
the nucleotides within the sequence (Arya, 1991). Furthermore, the repressive effect of the downstream 
sequence of U5 appeared to be cell-type dependent. Finally, the downmodulation was not observed at the 
Tat-induced or T-cell activated level of gene expression, indicating perhaps only a minor role for these 
sequences in the regulation of HTV-2 gene expression (Arya, 1991).
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1.11 The HIV-2 Tat protein
Of the known lentiviruses, HIV-1, HIV-2, SIV, and EIAV encode Tat proteins that markedly increase 
levels of transcription through leader TAR RNA structures (Jones & Peterlin, 1994). The Tat protein of 
HIV-2 is a potent /ransactivator of transcription from the HIV-2 LTR and has been shown to be essential 
for efficient viral replication. Full length HIV-2 Tat (ROD isolate) is expressed early in infection and is 
encoded by two separate exons, producing a protein 130 amino acid residues in length (Arya et al., 1987, 
Emerman et al., 1987).
Genetic and biochemical experiments have established that, like many transcriptional activators, Tat2 has 
a modular structure, with an RNA binding domain and a strong transcriptional activation domain (Chang 
& Jeang, 1992, Arya, 1993, Rhim & Rice, 1994b, Pagtakhan & Tong-Starksen, 1995) (see Figure 1.9, pg 
89). The RNA binding domain consists of a stretch of positively charged basic amino acid residues that 
direct Tat to the HIV-2 TAR RNA element where it binds in a 1:1 complex (Elangovan et al., 1992, Jones 
& Peterlin, 1994). Positively charged amino acid residues encompassed by the arginine-rich basic 
domain interact with the negatively charged phosphate backbone of the TAR RNA determining a high 
Tat:TAR binding affinity (Frankel, 1992, Gait & Kam, 1993). The basic region within the RNA binding 
domain of Tat also contains a nuclear localisation signal, which functions to target the protein to the cell 
nucleus following expression.
Tat-2
N-term. cys core basic C-term. exon2
1 50 66 77 90 99 130
exon junction
Figure 1.9 Schematic representation of the two exon Tat-2 (HIV-2 pROD,0) protein. The junction 
between the exon 1 and exon 2 is indicated. The TAR binding domain is located within the basic region 
in exon 1. This region also serves as a nuclear localisation signal. The independent activation domain of 
Tat2 includes the amino-terminal, cysteine-rich, and core regions of the protein (Rhim & Rice, 1994b, 
Pagtakhan & Tong-Starksen, 1995).
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The activation domain of Tat2 can be subdivided into three regions: the non-conserved amino-terminal 
domain, the cysteine-rich domain, and the hydrophobic core domain (Arya, 1993, Rhim & Rice, 1994b, 
Pagtakhan & Tong-Starksen, 1995) (see Figure 1.9, pg 89). The amino-terminal domain contains several 
non-conserved acidic amino acids that are predicted to form an amphipathic a-helix. This region also 
contains a number of proline residues; which are presumed to introduce turns in this structural element. 
The cysteine-rich domain as its name suggests contains seven highly conserved cysteine residues, of 
which six are critical for Tat2 function (Sadaie et al., 1988, Arya, 1993, Rhim & Rice, 1994b, Pagtakhan 
& Tong-Starksen, 1995), these residues have been shown to be involved in intramolecular disulphide 
bridge formation (Koken et a l, 1994). The central core region is the most conserved domain of Tat2 and 
contains residues which have been shown to enhance the affinity and specificity of the Tat:TAR 
interaction both in vitro and in vivo.
The second exon of Tat2 encodes a conserved carboxy-terminal domain that has been shown to contribute 
to optimal frawsactivation of the HIV-2 LTR (Arya, 1993, Tong-Starksen et a l, 1993). A study by Rhim 
& Rice demonstrated that this exon contributed to /ra/wactivation of the HIV-2 LTR by increasing the 
binding affinity to HIV-2 TAR RNA (Rhim & Rice, 1994b).
1.11.1. Mechanism o f Tat action
The identification of the stage of transcription at which Tat exerts its function, and the mechanism by 
which it markedly increases the level of gene expression has been widely investigated. Although Tat has 
been shown to have modest effects on the initiation of RNA synthesis, it has now been established that 
Tat functions to enhance the efficiency of transcriptional elongation (Marciniak & Sharp, 1991, Berkhout 
& Jeang, 1992, Kato et al., 1992, Lapsia et al., 1993, Garcia-Martinez et al, 1995, Rittner et al., 1995, 
Blau et al., 1996, Fujinaga et al., 1998).
In the absence of Tat, the majority of correctly initiated RNAPII transcription complexes stall or 
terminate transcription prematurely, 20 - 40 nucleotides downstream of the HTV LTR (Kao et al., 1987, 
Kessler & Mathews, 1992) (Figure 1.10A, pg 94). This gives rise to an abundance of short or non- 
processive transcripts but relatively few full-length transcripts. In contrast to activator proteins such as 
SP1 which enhance the rate of transcription initiation and skew polymerase distribution with a sharp drop 
in density immediately downstream from the 5* end of the template, Tat acts to enhance the processivity 
of paused RNAPII complexes and gives rise to a uniform distribution of polymerases along the gene, 
resulting in a large increase in the number of full-length transcripts and relatively few truncated
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transcripts (Feinberg et al, 1991, Garcia-Martinez et al., 1995, Rittner et al., 1995, Blau et al., 1996, 
Bourgeois et a l, 2002).
1.11.1.1 Tat interacts with a CTD kinase to phosphorylate the RNAPII CTD
As described in section 1.10.1, studies of eukaryotic transcription have revealed that the release of the 
stalled RNAPII transcription complexes and their transition into elongation complexes requires the 
phosphorylation of the C-terminal domain (CTD) of the largest RNAPII subunit. Extensive analyses of 
the HIV /ransactivation process have revealed that activation of transcription by Tat also involves the 
CTD of RNAPII (Chun & Jeang, 1996, Okamoto et al., 1996, Parada & Roeder, 1996, Yang et al., 1996).
Initial findings suggested that, once anchored to the promoter by the TAR element, the HIV Tat protein 
enhanced the processivity of stalled transcription complexes by directly interacting with the CTD of 
RNAPII. However, in finding that TAR-dependent /ra/wactivation by Tat was blocked effectively by the 
kinase inhibitor 5, 6-dichloro-l-P-D-ribofuranosyl-benzimidazole (DRB), several studies indicated that it 
was more likely that the interaction between Tat and TAR affected a CTD kinase-dependent step in the 
elongation process (Marciniak & Sharp, 1991).
Following the identification of a Tat-associated kinase (TAK) that bound specifically to the Tat protein in 
vitro, it was postulated that, the activation domain of Tat acted to recruit a kinase to the promoter in 
binding to TAR, resulting in the phosphorylation of the CTD of RNAPII (Herrmann & Rice, 1993, 
Herrmann & Rice, 1995). In accordance with this, a study by Yang and co-workers in 1996 demonstrated 
that the Tat-TAK interaction correlated precisely with the ability of wild type and mutant HTV-1, HTV-2, 
and EIAV Tat proteins to stimulate transcription in vivo (Yang et al, 1996).
The actual identity of the Tat-associated kinase followed the discoveiy of the human form of the 
Drosophila positive elongation factor b (P-TEFb). Microsequence analyses of human P-TEFb revealed 
that it was indistinguishable from the Tat-associated kinase complex-TAK (Cujec et al, 1997, Yang et 
al., 1997, Zhu et al., 1997). Positive elongation factor b (P-TEFb) is composed of at least two subunits: 
the catalytic subunit cyclin-dependent kinase CDK9 (previously named PITALRE) and the regulatory 
subunit cyclin T1 (CycTl) (Yang et al., 1997, Zhu et al., 1997, Wei et al, 1998). Following its discoveiy 
several groups went on to demonstrated that P-TEFb bound specifically to the activation domain of Tat, 
and that this interaction was eliminated by mutations that abrogated Tat-induced transcription (Zhu et al.,
1997). Furthermore, P-TEFb was found to bind to the Tat proteins of HIV-2 and EIAV which both
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appear to function through the same cofactor as HTV-1 Tat (Carroll et al., 1992, Madore & Cullen, 1993). 
Antibodies directed against a 20-residue peptide from the carboxyl terminus of P-TEFb simultaneously 
removed TAK activity and rendered HeLa nuclear extracts dependent on P-TEFb for efficient elongation. 
Most importantly, HNE depleted of P-TEFb were unable to support Tat-induced transcription. Finally, 
phosphorylation of the RNAPII CTD by P-TEFb was found to be DRB-sensitive.
Several groups have since confirmed the observations made by Zhu et al, and have demonstrated that P- 
TEFb is required for HIV Tat /ramactivation in vivo and in vitro (Mancebo et al., 1997, Fujinaga et al, 
1998, Zhou et al, 1998, Bieniasz et al., 1999a). As in eukaryotic elongation, the CDK9 kinase subunit of 
P-TEFb acts to hyperphosphorylate the CTD of RNAPII at serine 2 and serine 5 (Zhou et a l, 2000), 
converting the pre-initiation complex into a highly processive elongation complex (Kim et a l, 2002) 
(Figure 1.10B, pg 94). Because P-TEFb is a limiting transcription factor and is not associated with 
RNAPII initiation or elongation complexes (Marshall & Price 1995, Marshall et a l, 1996) Tat is thought 
to increase the rate of elongation by recruiting P-TEFb to RNAPII through binding to TAR, effectively 
increasing the local concentration at the promoter (Garcia-Martinez et al, 1997a, Garber et al., 1998a, 
Bieniasz et a l, 1999a, Ping &Rana, 1999). The interactions between Tat, P-TEFb and TAR are thought 
to induce conformational changes in the CDK9 enzyme that result in its activation (Bieniasz et a l, 1998, 
Chen et al., 1999, Fujinaga et al., 1999, Garber et al., 1998b, Ivanov et al., 1999, Kwak et al., 1999), the 
subsequent phosphorylation of the CTD of RNAPII by CDK9 (Kim et al., 2002), and the release of the 
elongating complex from TAR (Keen et al., 1997). In addition, Tat-activated CDK9 has been shown to 
phosphoiylate the positive elongation factor Spt5 in parallel to the hyperphosphoiylation of the CTD of 
RNAPII during HTV-1 transcription (Wu-Baer et al., 1998, Ivanov et al, 2000, Kim & Sharp, 2001, 
Bourgeois et a l, 2002). Once phosphoiylated Spt5 acts as a complementary factor for Tat-activated 
transcription by inhibiting premature RNA release from the numerous pause sites within the HTV genome. 
The exact mechanism by which CDK9 becomes activated by Tat however, remains unclear (Kim et al., 
2002).
Recent studies have demonstrated that the affinity and specificity of the Tat-TAR interaction is governed 
by the cyclin T1 protein associated with CDK9 within the P-TEFb complex. CDK9-associated cyclin T1 
interacts directly with the Tat activation domain when Tat binds to P-TEFb and confers the requirement 
for the hexanucelotide loop sequences of TAR that mutational analysis has demonstrated are required for 
Tat-induced activation of transcription. Several studies have demonstrated that cyclin T1 is the TAR 
RNA loop-binding cofactor for Tat and have shown that, while required for transactivation by Tat,
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neither CDK9 nor cyclin T1 can bind TAR alone. The Tat-CDK9-cyclin T1 heterodimer has been shown 
to have a far-higher affinity for TAR than Tat alone (Bieniasz et a l, 1998, Garber et a l, 1998a, Garber et 
al, 1998b, Wei et a l, 1998), and has lead to the conclusion that Tat complexes with P-TEFb before 
binding to TAR, leading to CDK9-directed phosphorylation of the CTD of RNAPII and cyclin T l- 
enhanced Tat-TAR binding avidity and stability (Figure 1.10B, pg 94).
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Figure 1.10 Diagram showing the mechanism o f /ra/wactivation by Tat. (A). In the absence of Tat, 
elongation complexes are not highly processive and pause or abort transcription 20-40 nucleotides 
downstream from the start site o f transcription (Kao et al, 1987, Kessler & Mathews, 1992). (B). It is 
proposed that Tat enhances the processivity of paused RNAPII complexes by recruiting the human 
positive elongation factor pTEFb to the TAR element (Garcia-Martinez et al, 1997a, Garber et al, 1998a, 
Bieniasz et al, 1999a, Ping &Rana, 1999). The cyclin T1 subunit o f pTEFb mediates the loop sequence 
specificity to the Tat-pTEFb complex and in binding to Tat enhances Tats binding affinity for TAR 
(Bieniasz et al, 1998; Garber et al, 1998a; Garber et al, 1998b; Wei et al, 1998). Once bound to TAR, 
the cyclin-dependent kinase 9 (CDK9) subunit o f pTEFb hyperphosphorylates the CTD o f RNAPII, 
inducing conformational changes to the enzyme that result in the formation of a highly processive 
elongation complex and an increase in the number o f full-length transcripts (Zhou et al, 2000, Kim et al, 
2002).
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The identification of CycTl as the loop-binding cofactor for Tat also led to a molecular explanation for 
several key aspects of Tat function. For example, to function the Tat binding domain has been shown to 
require the presence of the activation domain; in complexing with P-TEFb the activation domain of Tat 
recruits the loop-binding cofactor in addition to its transactivating kinase subunit, thereby mediating 
binding specificity as well as functional specificity. In addition, transfected rodent cells will only support 
low levels of Tat rransactivation as a result of poor TAR recognition. A recent study by Fujinaga and co­
workers comparing the amino acid sequences of cloned human and mouse cyclin T has revealed that a 
single point mutation at position 261 in mouse cyclin T is responsible for this phenotype (Fujinaga et al., 
1999). Introduction of human cyclin T into rodent cells increases levels of Tat /ransactivation, and the 
reciprocal exchange of the tyrosine at position 261 to the cysteine found in human cyclin T renders mouse 
cyclin T fully functional for the effects of Tat in cells (Garber et al., 1998b, Fujinaga et a l, 1999).
Previously, several groups have provided data demonstrating that the Tat2 protein is only poorly able to 
activate transcription via the HTV-1 TAR element, (Arya et al., 1987, Emerman et al, 1987, Fenrick et 
al, 1989, Berkhout et al., 1990) yet the Tati protein is able to fully /rawactivate TAR2 in addition to its 
own TAR1 target despite differences in TAR1 and TAR2 structure. Yeast-two hybrid studies analysing 
cyclin T interactions with both the Tati and Tat2 proteins have revealed that these two proteins differ 
significantly in terms of their TAR RNA sequence specificity. The human cyclin Tl-Tatl complex binds 
to both TAR1 and TAR2 with equal efficiency, in contrast the human cyclin Tl-Tat2 complex binds to 
TAR1 approximately 10-fold less well than to TAR2. Significantly, the differences seen in Tat-CycTl 
RNA binding activity correlate exactly with the ability of these two distinct Tat proteins to activate gene 
expression, thus explaining their differential abilities to activate heterologous LTR promoters (Bieniasz et 
al, 1999b, Bieniasz et a l, 1999c). Furthermore, Tat2 is able to bind to cyclin T2A and cyclin T2B, 
alternative cyclin partners of CDK9, a property not possessed by Tati, although these interactions are 
functionally abortive in that neither form can be recruited to TAR.
1.11.1.2 Tat recruits histone Acetyltransferase (HAT) proteins to the integrated HIV LTR promoter to 
mediate chromatin remodelling
Finally, more recent analyses has demonstrated that the optimal activity of Tat is further dictated by its 
association with a second class of cellular proteins, termed Tat-associated histone acetyltransferases 
(TAHs) (Benkirane et al., 1998, Hottiger & Nabel, 1998, Marzio et al., 1998, Kieman et a l, 1999, Deng 
et al, 2001, Hsia & Shi, 2002, Kino et al., 2002). As previously described in section 1.10.1 the process
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of transcription from an integrated promoter requires the rearrangement of the repressive chromatin 
structure in which it is bound (Kadonaga, 1998). Analyses of the chromatin structure of several stably 
integrated HIV-1 templates, using nuclease hypersensitivity and restriction endonuclease accessibility, 
indicate that the LTR is incorporated into two distinct nucleosomal regions, separated by a nuclease- 
hypersensitive region containing the TATA box and SP1/NF-kB binding sites (Verdin et al., 1993, El 
Kharroubi et a l, 1998). When packaged into this repressive structure the HTV LTR is rendered 
transcriptionally silent in the absence of any stimuli (Verdin, 1991, Verdin et al., 1993, Van Lint et al., 
1996, Widlak et al, 1997, Benkirane et al., 1998, Marzio et al., 1998, Deng et al., 2001, He et al., 2002). 
The HTV Tat protein has been found to form a ternary complex with two highly homologous histone 
acetyltransferases, CBP/p300 and P/CAF, both in vivo and in vitro and in doing so targets them to the 
viral promoter (Hottiger et a l, 1998, Kieman et al., 1999). Following their recruitment CBP/p300 and 
P/CAF function to acetylate the histone proteins around which the promoter DNA is wound. This process 
results in the rearrangement of the chromatin structure encompassing the HTV LTR promoter such that it 
can be accessed by transcription factors, allowing the process of transcription to begin (Hottiger et al,
1998, Kieman et al., 1999). In effect, the Tat protein acts as the trigger that de-represses the 
chromatinised LTR promoter and allows it to function.
As the number of cellular cofactors that are found to associate with HTV Tat in vivo grows (Brady et al,
1999, Deng et a l, 2001, Ping et a l, 2001, Bharucha et a l, 2002, Kino et al., 2002), the mechanisms by 
which Tat exerts its roles within HIV replication are being revealed and appear increasingly complex 
(Marcello et al., 2001).
1.11.2. Effects o f Tat on expression o f heterologous viral and cellular genes 
In addition to the role that the Tat protein plays in elongation enhancement, transcriptional synergy, and 
chromatin rearrangement, several investigators have shown that Tat functions to affect expression of 
selected viral and cellular genes in both infected and uninfected cells, stimulates cell growth, and induces 
apoptosis and T cell anergy. Most notably it has been demonstrated that Tat can activate the expression 
of several cytokines, including transforming growth factor-p, TNF, IL-2, and IL-6 (Chang et a l, 1995). 
In contrast, Tat has been implicated in the downregulation of the MHC class 1 promoter (Howcroft et al, 
1993), however this effect was found to be transient and limited (Verhoef et al., 1998). In addition, Tat 
decreases the production of C-C chemokines that inhibit HIV-1 replication (Zagury et al., 1998), and 
increases the expression of chemokine receptors that mediate infection by HTV-1 (Huang et a l, 1998a).
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Mammalian cells have been shown to produce exogenous Tat, which is subsequently endocytosed by 
neighbouring cells and transported to the nucleus. In this way, Tat is able to exert its pleiotrophic effects 
upon cells that may not even be infected with HTV. HIV-1 Tat has been shown to stimulate growth of 
Kaposi’s sarcoma (KS) cells and promotes adhesion of KS and normal vascular cells (Barillari et al, 
1993, Ensoli et a l, 1993, Albini et a l, 1995). In contrast, neither HIV-2 nor SIV Tat proteins have been 
associated with KS lesions.
Finally, a number of reports have indicated that Tat may play a role in dysregulation of the immune 
system. A study by Viscidi et al demonstrated that antigen-induced lymphocyte proliferation can be 
inhibited by the Tat protein (Viscidi et a l, 1989). In addition, Zagury and co-workers have recently 
reported that Tat may induce the generation of suppressor cells in populations of uninfected T cells, that 
may downregulate the immune response (Zagury et a l, 1998). Furthermore high anti-Tat antibody titres 
have been correlated with long term survival of HIV-1 infection, while Tat-specific CTL frequencies 
inversely correlate with progression to AIDS (Reiss et a l, 1991, van Baalen et a l, 1997). Taken together 
these findings support the notion that the Tat protein itself may play a role in HIV pathogenesis.
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1.12 Biological relevance of the HTV-2 Long Terminal Repeat
The pathogenesis of HTV is closely related to plasma viral loads which are in turn influenced by the 
replicative capacity of the infecting virus population; differences in replicative capacities and plasma viral 
loads have been clearly associated with differences in rates of disease progression in HTV infection 
(Connor & Ho, 1994, Ho et al, 1995, Wei et al., 1995, Mellors et a l, 1996, O’Brien et al, 1996, de Wolf 
et a l, 1997, Mellors et a l, 1997, Stein et al, 1997, Berry et a l, 1998, Andersson et a l, 2000, Ariyoshi et 
al, 2000, Popper et a l, 2000, Berry et al., 2002, Alabi et al., 2003). It has been suggested that the 
prolonged asymptomatic phase and freedom from clinical illness experienced by the majority of HIV-2 
infected individuals results from a lower level of virus production during infection than that observed in 
either HIV-1 infection or HTV-2 infected individuals displaying relatively rapid progression to disease 
(Berry et a l, 1998, Andersson et al., 2000, Ariyoshi et a l, 2000, Popper et al., 2000, Berry et al., 2002). 
It has been suggested that the level of virus production maybe lower as a result of more effective immune 
control of infection or results from a viral population of lower replicative capacity (Albert et a l, 1990, 
Tong-Starksen et al., 1990, Hannibal et al., 1993, Akimoto et al., 1998, Grassly et al., 1998, Sekigawa et 
al., 1998, Reeves et al., 1999, Kokkotou et al., 2000).
The rate of virus production within an infected individual is determined in part by the potential of the 
viral LTR to support the transcription of the virally encoded genes utilising the cw-acting sequences in the 
promoter that interact with the cellular and viral transcription factors. Therefore, the sequences of the 
HIV-2 LTR have the potential to influence the replicative capacity of the viral population and thus the 
pathogenesis of HIV-2 infection.
In support of a role for the LTR in the control of replicative capacity, analyses of cultured HTV-1 isolates 
have revealed that increased replicative capacity in permissive cell lines can be attributed to variant LTR 
sequences. For example, Golub et al showed that a 24bp insertion 5’ to the NF-kB sites in the HTV-1 
LTR was responsible for a 3-fold increase in the replicative capacity of an HIV-1 isolate (Golub et al., 
1990). Furthermore, Zhang and co-workers have described HIV-1 variants with deletions to the NFAT 
sites of the LTR, these variants were found to replicate faster and were more cytopathic in vitro than 
parental strains (Zhang et al., 1997a). More recently, duplication of the SP1 region through prolonged 
culturing of an attenuated HIV-1 subtype B virus was reported, this LTR variant was a stronger promoter 
with six SP1 sites and yielded a fitter virus (Berkout et a l, 1999).
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In addition, several groups have provided evidence of enhanced replicative capacity associated with 
genetic variation within the promoter regions of naturally occurring HTV-1 isolates. Koken et al screened 
for 5’ HTV-1 LTR variants from 17 patients and identified an LTR variant with a fourth SP1 site that 
could outgrow an isogenic construct with three SP1 sites, as well as length variants with a 5’-CTG-3’ 
motif insertion 5’ of NF-kB sites that could confer a marginal decrease in transcription and replicative 
capacity (Koken et al., 1992).
In evaluating group M HIV-1 LTR sequences from viral subtypes A through G Jeeninga et al have 
recently reported notable differences in the replication of the subtypes which may be due to genetic 
variation in the LTR promoter (Jeeninga et al., 2000). The LTR taken from a subtype E isolate displayed 
three-fold higher basal activity than a subtype B LTR; when introduced into the subtype B isolate the 
LTR core promoter elements of subtype E confeiTed increased replication rates.
Most interestingly, Fang and co-workers have identified specific sequence changes within the LTR of 
virus taken from an HTV-1-infected individual that correlate with the transition from a long-term non­
progressive infection to a progressive infection (Fang et a l, 2001). This study suggests that a large 
deletion in one of the SP1 binding sites of the HTV-1 LTR played a role in decreasing virus replication 
within this patient, resulting in low viral loads and long-term nonprogressive infection. Extensive 
functional and sequence analyses of the SP1 promoter region during the transition from nonprogressive to 
progressive infection indicated that the transition to high viral loads and rapidly progressive infection 
within this patient were related to the proliferation of a viral population that had intact SP1 and promoter 
sequences.
Despite the evidence supporting a determining role for the LTR in HTV replicative capacity and 
pathogenesis, several investigations comparing the sequence and function of the LTRs from a number of 
different LTNP and RP HIV-1 infected cohorts have failed to identify any temporal enrichment of 
particular LTR sequences during infection (Delassus et a l, 1991, Delassus et a l, 1992), or a general 
correlation between promoter activity and disease state (Estable et a l, 1996, Rousseau et al, 1997, Zhang 
et al, 1997b, Quiflones-Mateu et al, 1998, Visco-Comandini et al, 1999, G6mez-Rom£n et a l, 2000). 
Nevertheless, comparative functional and sequence analyses have yet to be performed upon cohorts of 
HTV-2 infected patients exhibiting different rates of disease progression.
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1.13 Project rationale and objectives
Since the majority of research into the pathogenic significance of the HTV LTR has centred on samples 
taken from HIV-1 infected individuals, characterisation of the genotypic and phenotypic properties of 
uncultured HIV-2 LTR variants is required Molecular and biochemical analyses of the region upstream 
of the HTV-2 LTR core promoter have identified several modulatory cis-acting elements that are 
conserved amongst FDV-2/SrV isolates, but distinct in sequence and function from those elements located 
in the corresponding region of the HIV-1 LTR (Markovitz et a l, 1990, Markovitz et al., 1992, Clark et 
al., 1995). These elements have been shown to regulate differentially expression from the HIV-2 LTR in 
comparison to the HTV-1 LTR (Hannibal et al, 1993, Hilfinger et al., 1993, Hannibal et a l, 1994). It has 
been suggested that the difference in regulation of these two promoters may, by virtue of the relationship 
between promoter activity, replicative capacity, and disease prognosis, provide a mechanism by which the 
difference in pathogenicity of the two viruses is determined (Hannibal et al, 1993, Hilfinger et al., 1993, 
Hannibal et a l, 1994, Faulkner et al, 2001). Similarly, it is possible that differences or changes in the 
function of the HTV-2 LTR and/or its regulation could provide a mechanism by which the pathogenicity 
of HTV-2 the subsequent rate of disease progression is virally determined. It is possible that the lower 
level of virus production and extended asymptomatic phase observed within the majority of HTV-2 
infections results from an infecting population that has attenuated promoter function in comparison to the 
populations found within HTV-2 infected individuals exhibiting rapid progression to disease or HTV-1- 
infected individuals. An investigation into the function of naturally occurring and isolated HTV-2 LTR 
genotypes derived from individuals displaying a variety of disease progression status would enable an 
assessment of the role, if any, that the HIV-2 LTR plays in the determination of disease progression rate 
and HTV-2 pathogenicity.
While the majority of countries in the Western world can treat and control HIV infection using highly 
active antiretroviral drug therapy (HAART), the continents most affected by HTV, Africa and Asia, are 
the least able to afford, or administer, HAART effectively. At present in many of these countries, funding 
is only available to treat STDs in an effort to reduce the spread of HTV infection. Therefore, development 
of a vaccine offers the most likely and affordable means to prevent and control the spread of HIV in these 
areas. While the provision of a preventative vaccine is required, a vaccine based prophylactic treatment 
for those already infected is also a major goal. In this vein characterisation of the determinants of HTV 
pathogenesis may help guide the development of treatments or vaccines to delay the onset of AIDS in 
both HIV-2 and HIV-1 infections. In addition, details of die mechanisms that determine the prolonged
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asymptomatic period observed in HTV-2 infection prior to the onset of AIDS are extremely important to 
the development of strategies aimed at extending the asymptomatic phase of HIV-1 infection. In 
summary, the HTV-2 infection provides a most valuable in vivo and ex vivo comparator with HIV-1 in 
terms of pathogenesis, control of viral replication and viral phylogeny.
The aims of this project are two-fold. Firstly, to develop and optimise efficient PCR amplification, 
cloning, transfection, and luciferase reporter assay procedures for the rapid and reproducible recovery and 
measurement of HTV-2 LTR activity from high and very low copy number uncultured PBMC-derived 
DNA samples alike. Using a dual luciferase reporter assay we aim to accurately and reproducibly study 
the function of isolate and naturally occurring HTV-2 LTR genotypes derived from clinically 
characterised individuals exhibiting different disease progression statuses, at both basal and activated 
levels, within two biologically relevant cell lines. Secondly, amplified HTV-2 LTRs that have been 
functionally characterised will be sequenced in order to assess genetic heterogeneity. This will provide 
an assessment of the biological significance of functional and genetic diversity in the HTV-2 LTR with 
respect to viral pathogenicity and clinical disease progression.
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Chapter 2. 
Materials and Methods.
2.1 Materials
2.1.1 HIV-2 Infected Material/Sources
2.1.1.1 HIV-2 Isolates
CBL Series - Chester Beatty Laboratory (CBL) viral isolates (MRC ADP) 20-24. Isolated from Gambian 
patients exhibiting a differing range of in vitro phenotypes that correlate with the patients’ clinical status. 
The five Gambian HTV-2 strains (CBL 20-24) were isolated at the Institute for Cancer Research, Chester 
Beatty Laboratories, London (Schultz et al., 1990) and range from a highly cytopathic and fast replicating 
virus from a patient who died of AIDS (CBL 20), to noncytopathic slow replicating virus from an 
asymptomatic patient (CBL 24) (Schulz et a l, 1990). Isolates were cultured in H9 or C8166 cells at 
37°C in 5% C02 in category III facilities. DNA was extracted from each isolate using the method 
described in section 2.2.2.1a, all procedures were carried out in class I cabinets using gamma irradiated 
sterile plasticware (Falcon) by colleagues at the Chester Beatty Laboratories.
2.1.1.2 HIV-2 Clinical Material - The Gambian Cohort-
Several PBMC samples from HTV-2 seropositive patients attending the STD clinic at the MRC hospital 
in Fajara, The Gambia, were obtained for the purpose of this study. The samples obtained were selected 
from a clinically defined longitudinal cohort consisting of patients who had entered the clinic and been 
characterised by clinical and laboratory examination (performed by colleagues at the MRC laboratories, 
Fajara, The Gambia). Patients recruited into this study exhibited either rapid progression to AIDS in 
comparison to normal clinical cases of HTV-2, or long term non progression where the patient was 
asymptomatic and has to date not developed any symptoms associated with progression to AIDS. 
Patients were sampled at 6 monthly intervals by colleagues at the MRC laboratories, Fajara, The Gambia, 
and disease progression was defined on the basis of CD4% decline over the period of clinical follow-up. 
Non-progressors were classified as having stable CD4% for more than 56 months, while rapid progressor 
patients were those with CD4% declining from greater than 20% to less than 13% within 20 months. In 
addition to CD4 status, patients were characterised according to plasma viral and proviral loads 
(determined by Dr. N. Berry, NIBSC, see section 2.2.1). Proviral DNA was extracted using the method 
described in section 2.2.2.1b, and stored at -20°C.
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2.1.2 Bacterial Strains
Bacterial strains were grown at 37°C aerobically in 2xTY media (Appendix I). Bacterial manipulations 
were carried out using aseptic techniques with sterile glass and plasticware.
Strain Use
SCS-1 Plasmid purification, calcium chloride transformation and ampicillin 
resistance screening, recA+.
XL-1 Blue Plasmid purification, calcium chloride transformation and ampicillin 
resistance screening.
Epicurian coli® 
SCS-1
Supercompetent recA deficient cells harbouring an uncharacteristic mutation 
that improves transformation efficiency. Reduced homologous 
recombination of propagated DNA. (Stratagene)
Table 2.1 Bacterial strains
2.1.3 Mammalian Cell Lines
All mammalian cell lines were grown at 37°C in 5% C02 humid atmosphere using sterile tissue grade 
reagents and gamma irradiated plasticware (Falcon). Tissue culture procedures were carried out in a 
class II laminar flow cabinet.
Cell Line Source Growth
Medium
Description
293 Dr. J. McKeating DMEM + 
10% FCS
Human embryonic kidney cell, 
transformed with sheared adenovirus 
type 5 DNA
Jurkat Clone 
E6-1
MRC ARP RPMI 1640 
+ 10% FCS
Human T-cell leukaemia cell line, clone 
of Jurkat-FHCRC.
THP-1 MRC ARP RPMI 1640 
+ 10% FCS
Human acute monocytic leukaemia cell 
line derived from macrophage lineage 
(CD14+; CD 15+).
Table 2.2 Mammalian cell-lines
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2.1.4 Plasmid Vectors
Plasmid stocks were stored resuspended in sterile dH20  at -20°C, as E.Coli glycerol stocks also stored at 
-20°C and agar plate grids at 4°C.
Name Source Description
PGL3-Enhancer
(pGL3E)
Promega Ltd Mammalian reporter vector containing a firefly 
luciferase reporter gene downstream of a polylinker, 
permitting insertion of upstream promoter elements. 
pGL3E contains an SV40 enhancer located 
downstream of the luciferase gene and the poly(A) 
signal resulting in transcription of luc+ at higher 
levels.
pGL3-Control
(pGL3C)
Promega Ltd Mammalian reporter vector containing a firefly 
luciferase reporter gene downstream of an SV40 
promoter. pGL3C also contains an SV40 enhancer 
located downstream of the luciferase gene and a 
poly(A) signal.
pRL-TK Promega Ltd Renilla luciferase internal control vector containing a cDNA 
(Rluc) encoding Renilla luciferase downstream of the herpes 
simplex virus thymidine kinase (HSV-TK) promoter. 
Provides low to moderate levels of Renilla luciferase 
expression in cotransfected mammalian cells.
pRL-CMV Promega Ltd Renilla luciferase internal control vector containing a cDNA 
(Rluc) encoding Renilla luciferase downstream of the 
cytomegalovirus (CMV) enhancer and early promoter 
elements. Provides high-level Renilla luciferase expression 
in cotransfected mammalian cells.
pRL-SV40 Promega Ltd Renilla luciferase control vector containing a cDNA (Rluc) 
encoding Renilla luciferase downstream of the SV40 
enhancer and early promoter elements. Provides high-level 
Renilla luciferase expression in cotransfected mammalian 
cells.
RSVtat2 Dr.D.
Markovitz
Mammalian expression vector containing an HIV-2 tat gene 
downstream of the Rous Sarcoma Virus promoter.
pRODi0 MRC ARP Infectious molecular clone of HIV-2, based on HIV-2ROd
Table 2.3 Plasmid vectors
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2.1.5 Enzymes
Enzymes were used according to manufactures instructions with regard to optimal working temperatures 
and buffer requirements. Digestions requiring more than one restriction endonuclease were carried out in 
buffers that allowed > 70% activity for each enzyme, according to the manufacturers supplied data.
Enzyme Manufacturer
RNAse Sigma-Aldrich Company Ltd, Dorset, UK.
Pfu TurboIM DNA Polymerase Stratagene Europe Amsterdam, The 
Netherlands.
Restriction Endonucleases Boehringer-Mannheim, Lewes, UK. Promega 
Ltd, Southampton, UK. New England Biolabs 
(UK) Ltd, Hertfordshire, UK.
Shrimp Alkaline Phosphatase United States Biochemicals
T4 DNA Ligase Promega Ltd. Southampton, UK
Thermo Sequenase DNA Polymerase Amersham pharmacia biotech, 
Buckinghamshire, UK.
Table 2.4 Enzymes and manufacturers used 
2.1.6 Oligonucleotides
The design of oligonucleotides is described for each polymerase chain reaction individually. All primers 
were obtained from Oswel DNA Service, Southampton, UK.
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2.2 Methods
2.2.1 Patient Characterisation.
2.2.1.1 CD4+ cell Status
An estimation of the percentage of CD4 positive cells from HIV-2 positive whole heparinised blood was 
obtained using fluorescent activated cell sorting (Becton-Dickinson) after staining with an anti-CD4 
monoclonal antibody (performed by colleagues at the MRC laboratories Fajara, The Gambia). Light 
microscopy was used to estimate the total white cell count and lymphocyte percentage. CD4 percentages 
(CD4%) were established as being a more robust measurement than absolute CD4 counts and were 
therefore used in studies in The Gambia.
2.2.1.2 DNA viral load
HTV-2 proviral DNA load was assessed by Dr N Berry, NIBSC. Peripheral blood mononuclear cells 
were prepared from heparinised whole blood using Lymphoprep™ (Micromed Diagnostics). A PCR 
compatible extraction buffer and proteinase K was used to extract cellular DNA. The concentration of 
cellular DNA was measured by fluorometry using a TK100 fluorormeter (Hoefer Scientific Instruments) 
and fluorescent staining with Hoescht 33258 dye, DNA concentration was adjusted to 60pg/ml. HTV-2 
proviral load was quantified by nested PCR amplification of a highly conserved region within the long 
terminal repeat, followed by a solid-phase radiometric incorporation assay (Berry et al., 1994).
2.2.1.3 ENA viral load
RNA viral load was determined by Dr N Berry, NIBSC. RNA was prepared from 200fil patient plasma 
using a silica-based guanidinium isothiocyanate extraction method. RNA samples were subjected to 
cDNA reaction using Superscript II reverse transcriptase, (Gibco BRL) cDNA copy number was 
determined by limit dilution analysis and quantitative RNA estimations by chemiluminescence. The 
lowest detection range for this assay system was calculated to be 200 copies of HTV-2 RNA per ml of 
plasma (Berry et a l, 1998).
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2.2.2 DNA analysis and manipulation
2.2.2.1 Extraction and quantification o f cellular DNA.
2.2.2. la  HIV-2 Isolates.
DNA was extracted from a subset of five virus isolates from the series of isolates collectively known as 
the Chester Beatty Laboratory (CBL) series. The five Gambian HIV-2 strains (CBL 20-24) isolated at 
the Institute for Cancer Research, Chester Beatty Laboratories, London (Schultz et al., 1990), were 
established in continuous cell lines. Each isolate was cultured at 37°C in 5% CO2, all procedures were 
carried out in class I cabinets under categoiy III facilities using gamma irradiated sterile plasticware 
(Falcon). Infected cells were thawed rapidly at 37°C, pelleted by centrifugation, and washed in PBS 
(Appendix I). Cell pellets were resuspended in a lysis buffer containing 0.1% SDS and 10fig/ml 
Proteinase K. Virus inactivation and cell lysis was achieved by incubation at 65°C for 2 hours. DNA 
was extracted from lysed cells using a phenol-chloroform, ethanol precipitation method. 0.5mls of 
phenol:chloroform:isoamyl alcohol (25:24:1) was mixed with lysed cells in a polypropylene tube, until an 
emulsion formed. Following centrifugation the aqueous phase was removed, a further chloroform 
extraction was performed to remove trace amounts of phenol. DNA was precipitated by the addition of 2 
volumes of ice cold absolute alcohol and 1/10th 3M sodium acetate, pH4, followed by incubation at - 
20°C overnight. Precipitated DNA was pelleted in a bench microfuge at 13000rpm for 30 minutes, 
washed with 70% ethanol, resuspended in sterile TE buffer (Appendix I) and stored at -20°C. All 
procedures were performed by colleagues at the Chester Beatty Laboratories, London.
2.2.2.1b Patient Peripheral Blood Mononuclear Cells 
Cellular DNA was prepared from aliquots of peripheral blood mononuclear cells using a QIAamp Midi 
Blood Kit (Qiagen) according to the manufacturers instructions. PBMCs had been isolated using 
Lymphoprep (Mycomed Ltd) by colleagues in The Gambia, transported to London on dry ice, and stored 
at -70°C in freezing medium (Appendix I). Each aliquot of frozen cells was thawed rapidly in a 37°C 
water bath, equilibrated to room temperature, and treated according to the kit instructions (Qiagen). 
DNA was eluted in sterile distilled water and stored at -20°C.
2.2.2.2 Measurement o f DNA concentration by fluorometry
The concentrations of DNA prepared from virus isolate, PBMC, or bacterial plasmid transformation was 
measured by fluorometry. DNA concentrations were measured by a 96 well plate format fluorescent dye-
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binding assay using a Fluoroskan Ascent FL (Fluorometer/Luminometer, Life Sciences International 
(UK) Ltd). The assay accurately measured a DNA concentration range from 5 to 1600fig/ml (equivalent 
to the DNA from 106 to 3x10® cells in 1 ml). The fluorometer was standardised using seven calf thymus 
DNA standards (32ng/ml to 3200Qng/ml), and measured excitation and emission wavelengths of 355nm 
and 460nm respectively. An aliquot of 150pl of standard or diluent (Appendix I) was dispensed into 
black flat-bottom microtitre wells (Nunc) as shown in Figure 2.1, pg 108, followed by 3pi of sample 
DNA to the test wells. An aliquot of Hoecht 33258 dye was diluted 1:200 with assay diluent (Appendix 
I) such that each well containing standard or test DNA would receive 50pl of the diluted dye solution. 
The diluted Hoecht was dispensed into the wells and the plate was placed in a rotating plate shaker for 
approximately ten seconds and placed in the dark for five minutes before reading. The plate was then 
loaded into the fluorometer and DNA concentrations were measured and calculated using Labsystems 
Fluoroscan Ascent software.
Blank Std 4 T1 T5 T9 T13 T17 T21 T25 T29 T33 T37
Blank Std 4 T1 T5 T9 T13 T17 T21 T25 T29 T33 T37
Std 1 Std 5 T2 T6 T10 T14 T18 T22 T26 T30 T34 T38
Std 1 Std 5 T2 T6 T10 T14 T18 T22 T26 T30 T34 T38
Std 2 Std 6 T3 T7 T il T15 T19 T23 T27 T31 T35 T39
Std 2 Std 6 T3 T7 T il T15 T19 T23 T27 T31 T35 T39
Std 3 Std 7 T4 T8 T12 T16 T20 T24 T28 T32 T36 T40
Std 3 Std 7 T4 T8 T12 T16 T20 T24 T28 T32 T36 T40
Blank = diluent only, T= Test, Std 7 Standard.
Figure 2.1 Diagram of the sample positions within the black flat-bottom microtitre plate (Nunc).
2.2.2.3 PCR Amplification o f HIV-2 Long Terminal Repeat.
A nested PCR method was developed for the amplification of the 3’ LTR region by targeting HTV-2 
proviral DNA from clinical material, in vitro infected-cell provirus, and HTV-2 molecular clones. The 
PCR method described below was adapted from the original PCR methods for in vitro amplification of 
specific DNA sequences (Mullis & Faloona, 1987). The initial nested PCR protocol described was 
further optimised for HIV-2 LTR amplification from patient material exhibiting low proviral copy
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number (<200 copies/ml). The resulting PCR was limiting dilution sensitive and capable therefore of 
amplifying from a single molecule of HIV-2.
2.2.2.3a Oligonucleotide design and synthesis 
Oligonucleotide primers were designed to target the U3, R, and part of the U5 region of the HIV-2 LTR. 
Primer sequences were determined following reference to published HTV-2 sequences recorded in the 
Los Alamos Database. Sequences were analysed using Microgenie software (Beckman Instruments Ltd). 
All primers were designed to be between 18 and 25 nucleotides in length and have as near possible a 50% 
G/C content. Oligonucleotides were synthesised by Oswel DNA Service (University of Southampton). 
The theoretical melting temperature (Tm) for each primer was calculated according to:
Tm = 4 (G+C) + (A+T) minus 5°C
Second round primers were designed at positions +8934 and +180 according to the numbering of HIV-2 
ROD, GenBank accession number Ml 5390. LTR regions outside of these sites had been shown to be 
superfluous to LTR function (Guyader et al., 1987, Arya & Gallo, 1988, Markovitz et al, 1990, Tong- 
Starksen et al., 1990, Arya, 1991, Markovitz et a l, 1992, Hannibal et al., 1993, Hilfinger et a l, 1993, 
Hannibal et al, 1994, Clark et a l, 1995). The second round cloning primers were designed to contain 5’ 
restriction endonuclease sites, which matched sites, found within the polylinker region of firefly 
luciferase reporter vector pGL3E (Promega Ltd). The primers used in this study are listed in Table 2.5,
pg 110.
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Primers for nested amplification o f HIV-2 Long Terminal Repeat (LTR).
Palindromic restriction endonuclease sequences are shown underlined, ACGCGT = M u I  and AGATCT = Bgl II
Primer Name Orientation Location (nt)a Sequence
Z4544 Sense Outer 8557-8582 5’ ATGGGTGCGAGTGGATCCAAGAAGC 3’
Y6461 Antisense Outer 287-313 5’ TTCGGGCGCCAACCTGCTAGGGATTTT 3’
T5169 Sense Inner 8934-8949 5’ GCCCGTACGCGTGGGGGGACTGGAAGGG 3’
T5170 Antisense Outer 180-197 5’ GGCCAGATCTAGAGATGGGARCACACAC 3’
Table 2.5 Oligonucleotide primer sequences for nested PCR amplification of HIV-2 Long Terminal Repeat. a Sequences numbered according to HIV-2 ROD, 
GenBank accession number M15390.
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2.2.2.3b Nested PCR amplification o f HIV-2 LTR from virus isolate, molecular clone and high copy 
number clinical material
The HIV-2 LTR was amplified from patient provirus, isolate-derived proviral DNA, and molecular clone 
plasmid DNA, by a two round nested PCR using specific sense and antisense oligonucleotide primers 
(see Table 2.5, pgl 10). First round reaction conditions were lOOmM KC1, lOOmM (NFL^SCty, 200mM 
Tris-HCl (pH 8.8), 20mM MgSC>4 , 1% Triton X-100 and lmg/ml BSA), (lOx cloned Pyrococcus 
furiosus {Pfu) Turbo buffer (Stratagene)), 200pM of each dNTP (A, C, G, and T), 5 units cloned Pfu 
Turbo DNA polymerase (Stratagene) and 0.1 pM of each outer primer, in a reaction volume of 50pl. The 
reaction mixture was overlaid with 30pl of light white mineral oil. First round cycling conditions were 
preceded by a pre-melting step of 94°C for 4 mins for 1 cycle, followed by 94°C 1 min, 50°C 1 min, 
72°C 1.5mins for 35 cycles and one cycle at 72°C for 7 mins then cooled and maintained at 1°C.
For second round PCR amplification 2pl of first round PCR product was transferred into 50pl of the 
following second round reaction mixture, lOOmM KC1, lOOmM (NH4 )2 S0 4 , 200mM Tris-HCl (pH 8.8), 
20mM MgSC>4 , 1% Triton X-100 and lOOOpg/ml BSA), (lOx cloned Pyrococcus furiosus {Pfu) Turbo 
buffer (Stratagene)), 200pM of each dNTP (A, C, G, and T), 5 units cloned Pfu Turbo DNA polymerase 
(Stratagene). 0.1 pM of each second round cloning primer instead of the outer primers was added in a 
reaction volume of 50pl, the reaction mixture was then overlaid with 30pl of light white mineral oil.
Second round cycling conditions: 94°C for 4 mins for 1 cycle, 94°C for 45 secs, 54°C for 45 secs, 72°C
for 1 min for 30 cycles, followed by 72°C for 7 mins then cooled and maintained at 1°C. Amplification 
reactions were performed on a DNA thermal Robocyler (Stratagene).
Amplified PCR products were visualised by loading lOpl of second round reaction mixture onto a 1% 
agarose gel containing 0.5mg/ml ethidium bromide (Appendix I). The gel was electrophoresed at lOOv 
for 30 mins in lxTAE buffer (Appendix I), and photographed under ultra violet illumination.
2.2.2.4 PCR optimisation to single copy sensitivity
2.2.2.4a Robocyclerm  determination o f optimum PCR annealing temperature 
Initial estimations of the optimal primer theoretical melting temperature (Tm) were made using the 
equation in section 2.2.2.3a. The experimental temperature optimum for the second round primer pair 
was determined using the Robocycler 480™ (Stratagene). In contrast to other thermocycling machines,
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this machine contained four heating blocks independently thermally controlled, for each step of the PCR. 
A robotic arm moved the reaction tubes into each block (set at the required temperature) for the duration 
of each stage of the PCR cycle, as opposed to a single block determining the heating and cooling cycles. 
The block designated for the annealing reaction has the ability to heat either to a single temperature, or to 
a temperature gradient spanning the width of the block. The heating block can accommodate 40 reaction 
tubes in a 5 x 8 well format. This allows for the PCR annealing temperature optimisation of five samples 
over the range of eight different temperatures. The temperature gradient facility of the Robocycler 480 
was utilised to determine the optimal annealing temperature of the primer pair used in the second round 
HIV-2 LTR PCR. Second round PCR conditions were designed with an annealing reaction temperature 
gradient that included the calculated theoretical melting temperature of each second round primer.
The first round PCR conditions matched those described in section 2.2.2.3b. The reaction conditions for 
the second round were lOOmM KC1, lOOmM (NH4 )2 S0 4 , 200mM Tris-HCl (pH 8.8), 20mM MgSC>4 , 
1% Triton X-100 and lmg/ml BSA), (lOx cloned Pyrococcus furiosus {Pfu) Turbo buffer (Stratagene)), 
200pM of each dNTP (A, C, G, and T), 5 units cloned Pfu Turbo DNA polymerase (Stratagene). 0.1 pM 
of each second round cloning primer was added to a reaction volume of 50pl. Eight tubes were aliquoted 
with 50pl of second round reaction mixture. Two microlitre aliquots of first round PCR product were 
transferred to each of the eight tubes and each reaction mixture was overlaid with 30pl of light white 
mineral oil. The thermocycling programme for the second round was preceded by a pre-melting step of 
94°C for 4 mins for 1 cycle, followed by 94°C for 45 seconds, 48°C-62°C in two degree increments 
(eight temperatures over eight wells of the block) for 45 seconds, 72°C for 1 min for 30 cycles, followed
by 72°C for 7 mins then cooled and maintained at 1°C. PCR products were visualised as described in 
section 2.2.2.3b.
2.2.2.4b Determination o f nested PCR sensitivity by limiting end-point dilution 
The sensitivity of the second round primer pair was assessed by limiting end-point dilution. A first round 
reaction mixture was prepared as described in section 2.2.2.3b and distributed into ten sets of four tubes 
in the following manner, each tube ultimately containing 20pl. The first tube was aliquoted with 95 pi of 
reaction mixture, to this tube, 5 pi of sample DNA was added, and the mixture was vortexed for 5 
seconds. The remaining three tubes of the first set of four were aliquoted with 20pl of reaction mix from 
the first tube, the final 20pl was then transferred into 80pl of reaction mixture in the first tube of the
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second set of four. Twenty microlitre aliquots were transferred into the remaining tubes of the second 
set, this continued until 20pl was diluted in 60pl reaction mixture in the first tube of the final set. This 
method resulted in a dilution series of sample DNA of 1, 1/5, 1/25, 1/125, 1/625, and so on. Second 
round nested PCR reaction conditions matched those described in section 2.2.2.4a and were prepared 
using 2pl transfers from first round PCR reactions. Second round cycling conditions were as follows:
94°C for 4 mins for 1 cycle, 94°C for 45 secs, 50°C for 45 secs, 72°C for 1 min for 30 cycles, followed 
by 72°C for 7 mins then cooled and maintained at 1°C. Amplification reactions were performed on a 
DNA thermal Robocyler (Stratagene) and analysed by gel electrophoresis. Wells were scored PCR 
positive or negative and the frequency of zero (Fo) amplification products in each set of four tubes was 
scored. According to the zero term of the Poisson probability theory the average number of DNA 
molecules per tube (p) can be assessed by inserting the number of non-amplifications per set into the 
Poisson equation:
[i = -In Fo
The natural logarithm (In) of the fraction of negative values (Fo) is proportional to the mean of the 
number of positive reactions (p) for each group. Taking the dilution factor into account the number of 
DNA molecules per microlitre of test sample could be calculated providing a measurement of the copy 
number of HTV-2 molecules. The presence of a Poisson distribution end point indicates that the primer 
pairing in the nested PCR is capable of amplifying from a single molecule of DNA.
2.2.2.5 Amplification o f HIV-2 LTR from low copy number patient material using a limiting dilution 
sensitive nested PCR
The HTV-2 LTR was amplified from low copy number patient provirus by a two round nested PCR which 
had be shown to be limiting dilution sensitive. The specific sense and antisense oligonucleotide primers 
were the same pairs as those described in section 2.2.2.3 (see Table 2.5, pg 110). First round reaction 
conditions were lOOmM KC1, lOOmM (NH4 )2 S0 4 , 200mM Tris-HCl (pH 8.8), 20mM MgS(>4 , 1% 
Triton X-100 and lmg/ml BSA), (lOx cloned Pyrococcus furiosus {Pfu) Turbo buffer (Stratagene)), 
200pM of each dNTP (A, C, G, and T), 5 units cloned Pfu Turbo DNA polymerase (Stratagene) and 
0.1 pM of each outer primer, in a reaction volume of 50pl. The reaction mixture was overlaid with 30pl 
of light white mineral oil. First round cycling conditions were preceded by a pre-melting step of 94°C for 
4 mins for 1 cycle, followed by 94°C 1 min, 50°C 1 min, 72°C 1.5mins for 35 cycles and one cycle at
72°C for 7 mins then cooled and maintained at 1°C.
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For second round PCR amplification 2|il of first round PCR product was transferred into 50pl of the 
following second round reaction mixture, lOOmM KC1, lOOmM (NH4 )2 S0 4 , 200mM Tris-HCl (pH 8.8), 
20mM MgS0 4 , 1% Triton X-100 and lmg/ml BSA), (lOx cloned Pyrococcus furiosus (Pfu) Turbo buffer 
(Stratagene)), 200pM of each dNTP (A, C, G, and T), 5 units cloned Pfu Turbo DNA polymerase 
(Stratagene). 0.1 pM of each second round cloning primer instead of the outer primers was added in a 
reaction volume of 50pl, the reaction mixture was then overlaid with 30pl of light white mineral oil. 
Second round cycling conditions: 94°C for 4 mins for 1 cycle, 94°C for 45 secs, 50°C for 45 secs, 72°C
for 1 min for 30 cycles, followed by 72°C for 7 mins then cooled and maintained at 1°C. Amplification 
reactions were performed on a DNA thermal Robocyler (Stratagene).
Amplified PCR products were visualised as before, by loading 10pi of second round reaction mixture 
onto a 1% agarose gel containing 0.5mg/ml ethidium bromide (Appendix I). The gel was 
electrophoresed at lOOv for 30 mins in lxTAE (Appendix I) buffer, and photographed under ultra violet 
illumination.
2.2.2.6 Isolation and purification ofPCR-amplified products
PCR products were isolated using agarose gel electrophoresis, this procedure removed residual enzyme 
and excess primers contained within the PCR reaction mixture. The 764bp LTR band was resolved by 
loading 40pl of a 50pl PCR onto a 1% agarose gel containing 0.5mg/ml ethidium bromide (Appendix 1); 
the gel was electrophoresed at 100V for 1 hour. The LTR band was visualised using low level UV 
irradiation and excised from the gel using a sterile scalpel blade. DNA was extracted from the agarose 
slice using the GeneClean™ (Bio 101, La Jolla, CA) silica resin procedure or the QIAquick™ (Qiagen) 
column extraction method according to manufacturers instructions. Purified PCR products were 
resuspended in 20pl of sterile dH20  and stored at -20°C.
2.2.3 Cloning o f HIV-2 L TR PCR products
2.2.3.1 Restriction endonuclease digestion o f amplified LTR PCR products
To enable efficient cloning of PCR amplified LTRs into the firefly luciferase reporter vector pGL3E 
(Promega Ltd), PCR product were digested with restriction endonucleases. The flanking restriction sites
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incorporated into the PCR products by the inner cloning primers matched two sites contained within the 
polylinker region of pGL3E. Once digested the PCR product contained complementary ends to those of 
the digested linearised reporter vector, enabling the formation of a complete double-stranded circularised
plasmid containing an LTR insert. Digestion reactions were carried out at 37°C for 2 hours in 20pl 
volumes. lOpl of purified PCR product: 0.5 Units Mlu I, 0.5 Units Bgl II, 2pl lOx Buffer H (Appendix 
I)(Boehringer Manheim), was made to the total reaction volume with dH20. Following incubation, 
restriction endonucleases were removed from this mixture using Strataclean™ Resin according to the 
manufacturers instructions (Stratagene) and stored at -20°C.
2.2.3.2 Linearisation o f Firefly Luciferase Reporter Plasmid pGL3E (Promega Ltd)
To enable efficient cloning of PCR amplified LTRs into the firefly luciferase containing reporter plasmid 
it was necessary to linearise the vector using Mlul and BgUI sites found within the polylinker region, 
matching those designed into the second round primers, lpg of pGL3E was added to 20 units Mlul 
(Boehringer Mannhiem) in lx Buffer H (Appendix I) (Boehringer Mannhiem) and incubated for 1 hour at 
37°C; residual enzyme was removed with 5pi Strataclean™ resin (Stratagene). This was followed by 
addition of 20 units Bglll (Boehringer Mannhiem) and incubation at 37°C for a further 1 hour.
2.2.3.3 Dephosphorylation o f Linearised Firefly Luciferase Plasmid
Following restriction endonuclease digestion linearised pGL3E was dephosphorylated to prevent self­
ligation. 1 Unit of Shrimp Alkaline Phosphatase (United States Biochemicals) was added to the digestion 
reaction mixture and incubated at 37°C for 15 mins. Inactivation of Phosphatase was achieved by a 
further incubation for 15 mins at 65°C.
2.2.3.4 Cloning ofPCR amplified LTR into linearised pGL3E
Restriction endonuclease digested PCR products were ligated into linearised pGL3E using 4 Units of T4 
DNA ligase (Promega Ltd) in a total ligation mixture volume of 20pl. The mixture contained the 
appropriate dilution of manufacturer-supplied buffer (Appendix I) and a vector to insert ratio of 1:3, 1:5, 
or 1:10. Ligation reactions were carried out at 12°C overnight. Protocols using the vector to insert ratio 
of 1:10 routinely gave optimum ligation efficiencies o f70-80%.
2.2.3.5 Preparation and transformation o f competent E.coli
115
A vented conical flask containing 50mls of 2xTY broth (Appendix I) was inoculated with 500pl of an 
overnight culture of SCS-1, or XL-lBlue E.coli. Cultures were grown for 3 hours at 37°C in an orbital 
shaker to ensure complete aeration. Cultures were chilled on ice for lGmins and cells were pelleted in a 
prechilled centrifuge at 4000 rpm at 4°C for 10 mins. Cells were resuspended in 25ml ice-cold 0.1M 
Calcium Chloride (Appendix 1) and incubated on ice for 1 hour. Following incubation, cells were 
repelleted as before and gently resuspended with ice-cold 0.1M Calcium Chloride to a final volume of 
2.5ml. Competent cells were either transformed immediately or stored at 4°C packed in ice for up to 5 
days.
Transformations were carried out using lOOjil of competent cells and up to lpg of DNA. DNA was 
added to round-bottomed transformation tubes (Falcon) and overlaid with competent cells using a cut 
200pl pipette tip; mixtures were swirled gently and incubated on ice for 1 hour. Cells were heat-shocked 
at 42°C in a water bath for 90 seconds and put back on ice for 10 mins prior to plating out on selection 
media containing the appropriate antibiotic (Appendix I). Competency of cells was tested by 
transforming lng of a commercially prepared antibiotic resistance plasmid such as pGL3E (Promega 
Ltd).
2.2.3.6 Transformation o f commercially available competent cells
Epicurian coli® SCS-1 supercompetent cells (Stratagene) were transformed according to manufacturers 
instructions, and plated out onto selection media containing the appropriate antibiotic.
2.2.3.7 PCR Screening o f bacterial transformants
Ampicillin resistant colonies were screened for the presence of the LTR sequence by picking colonies, 
using a flamed loop, directly into an eppendorf containing 20pl of PCR mix used in second round PCR 
amplification reactions (section 2.2.2.5). Cycling conditions were the same as those used in the second 
round PCR reaction although only 25 cycles of the reaction was necessary. Primers were able to reach 
their target as the first cycle of heating lysed the bacterial cells. Colonies, which contained a plasmid 
with an LTR insert, were identified using 1% agarose gel electrophoresis. Cloning efficiency was 
calculated by dividing the number of positive clones by the total number of colonies tested. Positive 
colonies were grown up as overnight cultures in 3mls 2x TY broth (Appendix I) supplemented with
ampicillin at lOOmg/ml and were placed in a rotary shaker at 37°C (section 2.2.3.8).
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2.2.3.8 Growth o f Bacterial Strains
For plasmid DNA purification bacterial strains were grown aerobically in 2xTY broth (Appendix 1) at 
37°C in an orbital shaker for 16 hours. Bacterial screening and colony isolation was carried out by 
growing cultures on 2xTY 1.5% agarose plates (Appendix I); bacterial transformants were selected by the 
addition of ampicillin at lOOmg/ml. Bacteria were stored as glycerol stocks (500pl overnight culture plus 
500fil autoclaved glycerol) at -20°C, or sealed agar plate grids at 4°C.
2.2.3.9 Isolation o f plasmid DNA
Plasmid DNA was extracted from either 3ml or 25ml overnight cultures using a QIAgen mini kit or 
QIAgen midi kit (Qiagen) respectively. Bacterial colonies or glycerol stocks were picked directly into 
bijoux’s containing sterile 2xTY broth (Appendix I) supplemented with ampicillin at lOOmg/ml. 
Cultures were grown overnight at 37°C in an orbital shaker and plasmid DNA was isolated using 
modified alkaline lysis kits according to the manufacturers instructions (Qiagen). Purified DNA was 
resuspended in sterile dH20 and stored at -20°C.
2.2.3.10 Restriction endonuclease digestion verification o f HIV-2 LTR clone construct
The presence of the HIV-2 LTR in the purified reporter construct was verified by restriction 
endonuclease digestion using the two endonucleases used to clone the insert into the construct. Digestion
reactions were carried out in lOpl volumes for 2 hours at 37°C. 1 pi of purified LTR construct: 0.5 Units 
Mlu /, 0.5 Units Bgl //, lpl lOx Buffer H (Appendix 1) (Boehringer Manheim), was made to the total 
reaction volume with dH20. Following incubation the mixture was loaded onto a 1% agarose gel 
containing 0.5mg/ml ethidium bromide (Appendix I) and electrophoresed at lOOv for 30 mins in lxTAE 
buffer (Appendix I) to ensure fragment resolution.
2.2.4 Mammalian Cell Culture Techniques
2.2.4.1 Adherent cell lines
2.2.4. la  293 Human Epithelial Kidney Cells 
293 cells derived from human embryonic kidney cells were cultured in complete tissue culture medium 
DMEM (Appendix I), in T75 vented top flasks (Falcon) and incubated horizontally at 37°C in a 5% C02
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humid atmosphere. Cells were split when approaching 90% confluence and maintained at a 
concentration of between 2x105 and 2x106 cells per ml. Monolayers were washed once with sterile PBS 
(Appendix I) after which the cells were overlaid with 2mls of 0.5pM filter sterile PBS 0.05% 0.5M 
EDTA. The monolayers were incubated under these conditions for 10 minutes at 37°C following which 
cells were removed from the surface of the plastic by several sharp smacks of the flask against the palm. 
The EDTA containing cell mixture was then pipetted up and down to dissociate cell clumps and an 
aliquot was removed and placed into a clean flask containing 15mls of complete media (Appendix I).
2.2.4.2 Suspension cell lines
2.2.4.2a Jurkat and THP-l 
Jurkat, a T cell line derived from Human T-cell leukaemia, and THP-l, a monocyte like cell line derived 
from Human acute monocytic leukaemia, were grown in T75 and T150 vented top flasks (Falcon) 
containing 30ml or 80ml complete media RPMI (Appendix I) respectively. Flasks were incubated at 
37°C in C02 humid atmosphere and were passaged approximately eveiy three days. Cells were pelleted 
by centrifugation at 1200rpm for 8 minutes in sterile 20ml tubes, pellets were washed once in warm 
media and cells were then re-pelleted. Finally, pellets were resuspended in 1 ml of complete media and 
aliquots of cell suspension were transferred into clean flasks containing complete media RPMI 
(Appendix I).
2.2.4.3 Cryogenic storage o f mammalian cell lines
Aliquots of adherent and suspension cell lines were preserved long term by storage in liquid nitrogen. 
Cells were pelleted by centrifugation at 1200rpm for 10 minutes in sterile 20 ml tubes. Cell pellets were 
resuspended in 1ml of freezing media (10% DMSO, 40% FCS, 50% RPMI or DMEM) and transferred to 
Nunc Cryovials (Gibco BRL). Cells were placed at -70°C overnight after which they were transferred to 
a liquid nitrogen stack for long term storage.
2.2.4.4 Transfection o f adherent cell lines
2.2.4.4a Calcium phosphate transfection 
24 hours prior to transfection adherent cell monolayers at 70% confluence 12 well dishes were seeded at 
a concentration of approximately 1 x 105 cells per ml. After 24 hours, media was removed from each 
well and cell monolayers were washed twice with filter sterile PBS (Appendix I), overlaid with fresh
serum free medium and incubated for 3-4 hours at 37°C. Each monolayer was transfected with 2.5pg of
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DNA consisting of “experimental” reporters or substituted with Herring Sperm DNA (HSDNA). DNA 
was mixed with 6.2pl 2M CaCl2 and distilled water to a total volume of 50pl in a sterile plastic bijoux. 
This mixture was combined with 50pl of 2 x Hepes Buffered Saline (Appendix I) (added dropwise), 
complete incorporation was ensured by rapid air bubbling of the mixture with a pipette. Incubation at 
room temperature for 20 minutes allowed the formation of lOOpl of white precipitate that was added 
dropwise onto the cell monolayers. Plates were incubated at 37°C for a further 4 hours, after which time 
the medium was removed and monolayers were washed once with one volume of filter sterile PBS 
(Appendix I) followed by one volume of serum free medium. Cell monolayers were overlaid with 1 ml of 
serum free DMEM and incubated for 12-16 hours at 37°C, this medium was replaced with 1 ml of 
complete 10% FCS DMEM (Appendix I) and cells were incubated for a further 24 hours. Cell 
monolayers were harvested 36-48 hours post transfection as described in section 2.2.4.5.
2.2.4.5 Harvesting o f transfected adherent cell lines
Prior to harvesting adherent cell monolayers, medium was removed from each well and monolayers 
washed twice, gently, with one volume of filter sterile PBS (Appendix I). Cells were overlaid with 250pl 
of Passive Lysis Buffer (Promega Ltd.) and placed on a rocking table for 30 minutes. Cell lysates were 
pipetted up and down to disperse any remaining attached cells and transferred to 0.5ml polypropylene 
tubes. Cell debris was pelleted by pulse centrifugation and lysates were stored at -70°C.
2.2.4.6 Transfection o f suspension cell lines
2.2.4.6a Super Feet™ Transfection 
24 hours prior to transfection growing suspension cells at concentrations of between 2x10s and 2xl06 
cells per ml were passaged into fresh T75/T150 cm2 flasks at a 1:2 ratio as described in section 2.2.4.2a. 
On the day of transfection cells were pelleted, resuspended and seeded into 6 well dishes, each well 
receiving 2 x 106 cells in 1.6 ml of complete 10% FCS RPMI (Appendix I), and incubated at 37°C and 
5% C02. 2fig of DNA dissolved in sterile distilled water were diluted with RPMI containing no serum, 
proteins or antibiotics to a total volume of lOOpl in a sterile eppendorf. This solution was vortexed for 3 
seconds to ensure uniform mixing. 8 pi of SuperFect™ (Qiagen) was added to the DNA solution that was 
subsequently vortexed for 10 seconds and incubated at room temperature for 5-10 minutes allowing the 
activated dendrimer - DNA complexes to form. Following incubation, lml of complete 10% FCS RPMI 
was added to the tube containing the transfection complexes and the mixture was pipetted up and down
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twice, then immediately added dropwise onto the cells. Uniform distribution of the complexes in the well 
was achieved by gently swirling the dish. Plates were incubated at 37°C and 5% C02. 36-48 hours post 
transfection cells were harvested by centrifugation as described in section 2.2.4.7.
2.2.4.6b Effectene™ Transfection 
Cells were prepared as described above. 2pg of DNA dissolved in sterile distilled water were diluted 
with DNA-condensation buffer EC, to a total volume of lOOpl in a sterile eppendorf containing 3.2|il of 
Enhancer. This solution was vortexed for 3 seconds to ensure uniform mixing. 4pl of Effectene™ were 
added to the DNA solution that was subsequently vortexed for 10 seconds and incubated at room 
temperature for 5-10 minutes allowing non-liposomal lipid - DNA complexes to form. Following 
incubation, 1ml of complete 10% FCS RPMI was added to the tube containing the transfection 
complexes and the mixture was pipetted up and down twice, then immediately added dropwise onto the 
cells. Uniform distribution of the complexes in the well was achieved by gently swirling the dish. Plates 
were incubated at 37°C and 5% C02. Post transfection procedures were as described in section 2.2.4.7.
2.2.4.7 Harvesting o f transfected suspension cell lines
36-48 hours post transfection plates cells were harvested. Using a plastic Pasteur pipette cells were 
transferred from the well into a plastic 15ml conical centrifuge tube. Cells were pelleted by 
centrifugation at 1200rpm for 7 minutes where after medium was removed and the pellet was 
resuspended with lOOpl of Passive Lysis Buffer (Promega Ltd.). Cell lysates were transferred to 0.5ml 
polypropylene tubes and cleared of cell debris by pulse centrifugation, lysates were stored at -70°C.
2.2.5 Detection o f reporter gene expression
2.2.5.1 Determination o f LTR activity by Dual Luciferase Assay
The functional activity of each LTR clone was taken as a measurement of firefly luciferase expression. 
Transfection efficiency was assessed by Renilla luciferase expression and used to normalise LTR activity 
values. By measuring chemiluminescence a dual luciferase assay was used to quantify the expression 
from each of the two luciferase reporter vectors within prepared cell lysates. Firefly luciferase has an 
enzyme structure distinct from Renilla luciferase and has, therefore, different substrate requirements. 
The photon signal produced from firefly luciferase was achieved upon addition of luciferin and ATP. 
This reaction was quenched while simultaneously activating photon emission from Renilla luciferase by a
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reagent containing coelenterazine. The assay was performed using 20pl of thawed lysate dispensed into 
the well of a black 96 well flat-bottomed plate (Nunc). The firefly luciferase reporter assay was initiated 
by the addition of lOOpl of Luciferase Assay Reagent II (LARII) (Promega Ltd) to the well (Figure 2.2, 
pg 122). Chemiluminescence produced from the firefly luciferase reaction was measured immediately 
using a 96 well plate reading Canberra-Packard Luminometer. Quenching of firefly luciferase 
luminescence, and concomitant activation of Renilla luciferase was accomplished by the addition of 
lOOpl of Stop & Glo™ Reagent (Promega Ltd) to each well (Figure 2.2, pg 122). The luminescent signal 
produced from the Renilla luciferase reaction was measured immediately also using a 96 well plate 
reading Canberra-Packard Luminometer. The luminescent signal from the firefly reaction was quenched 
by at least a factor of 105 (to < 0.001% residual light output) within 1 second following the addition of 
Stop & Glo™ Reagent. Complete activation of Renilla luciferase is also achieved within the 1-second 
period. LTR activity is represented by the firefly luminescent signal divided or “normalised” by the 
Renilla luminescent signal. The assay could be performed immediately following lysate preparation or 
following the storage of the lysate at -20°C.
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Figure 2.2 Schematic diagram of the dual luciferase assay. Reactions were performed in a black 96 well 
flat-bottomed plate (Nunc) to avoid cross-talk or leaching of luminescence between wells. LARII and 
Stop & Glo™ reagents were added using a multichannel pipette. Each plate reading was completed in 
approximately 5 minutes.
2.2.5.2 Determination o f backgroundfirefly and Renilla luciferase activity by Dual Luciferase Assay 
Background activity was assessed by assaying the cell lysate from a transfection of firefly luciferase 
reporter vector pGL3E lacking an HIV-2 LTR, made up to a total DNA concentration (according to the 
cell-line used) with HSDNA (an internal control plasmid lacking a promoter region was not available as 
negative control DNA for the pRL-TK plasmid). Two background activity measurements were made. 
Firstly, firefly luciferase background was measured following the addition of the firefly luciferase 
substrate (DLAI) to the cell lysate; secondly, Renilla luciferase background was measured following the 
addition of the Renilla luciferase substrate (DLAII). The first background measurement was subtracted 
from all firefly luciferase measurements; the second background measurement was subtracted from all 
Renilla luciferase measurements.
2.2.6 Automated DNA dye-primer cycle sequencing
Sequencing of all HTV-2 LTR clones was undertaken utilizing the Thermo Sequenase™ pre-mixed cycle 
sequencing kit (Amersham International pic) for use with the ™Vistra DNA Sequencer 725 (Amersham 
International pic, Molecular Dynamics Inc, USA). The sequencing protocol involved repeated cycles of 
thermal denaturation, annealing, and extension/termination reactions. Fluorescent dye-primers were used 
in the sequencing reactions in conjunction with dideoxynucleotides (ddNTP’s); ddNTP incorporation into 
newly synthesised DNA resulted in chain termination. Electrophoresis of reaction products was carried 
out on a denaturing polyacrylamide/urea gel; fluorescence from the labelled DNA was detected using the 
™Vistra DNA Sequencer 725. High quality template DNA was essential to obtain the best results from 
the kit, and was prepared using the Qiagen Midi kit (Qiagen) as described in section 2.2.3.9. The 
sequencing protocol used resulted in > 98.5% accurately read bases, 400bp beyond the 3’-end of the 
primer used.
2.2.6.1 Sequencing Oligonucleotides
Dideoxynucleotide sequencing reactions were performed using Texas Red™ (Oswel) labelled primers 
that had a single fluorescent moiety covalently coupled to the 5’ end. Texas Red™ is a fluorescent 
reporter molecule, which has an absorption maximum at 596nm and an emission maximum at 615nm. 
The incorporation of a Texas Red™ coupled primer into newly synthesised DNA results in the ability to 
detect reaction product sequences by fluorescence, a quicker and safer alternative to using radioactivity. 
The sequencing protocol routinely resulted in 400 accurately sequenced bases from the 3’ end of the 
primer, thus to ensure the entire 758bp cloned LTR region was sequenced, three fluorescent dye labelled 
primers were designed. Two primers were designed to flank the cloned LTR region and were therefore 
located within the pGL3E firefly luciferase vector. The third primer was designed to bind within the 
cloned LTR region; this conferred overlap of the flanking sequencing fragments and enabled a complete 
and accurate sequence to be obtained. All primers used in the sequencing reactions are listed in Table 
2.6, pg 124.
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Primers for DNA sequencing of HIV-2 Long Terminal Repeat (LTR)
All primers used in the sequencing protocol described in section 2.2.6 were labelled with Texas Red™ dye and were synthesised by Oswel.
Primer Name Orientation Location Sequence
C2280 Sense 5006-5025‘ 5’ CTAGCAAAATAGGCTGTCCC 3’
C2281 Antisense 1
O
s
00 5’ CTTTATGTTTTTGGCGTCTTCC 3’
Y5152 Sense 9244-9269° 5 ’ CCAGAGGAATTTGGGCACAAGTCAGG 3 ’
Table 2.6 Oligonucleotide primer sequences for the cycle sequencing of HTV-2 LTR. ‘Sequences numbered according to the plasmid map for pGL3E, (Promega Ltd). 
b Sequences numbered according to HIV-2 ROD, GenBank accession number M l5390.
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2.2.6.2 Sequencing o f double stranded DNA
Two pmoles or six microlitres of the DNA template were added to 2pmoles (1 pmole/pl) of the 
appropriate sequencing primer and 18 pi of distilled water. This mixture was divided equally between 
four polypropylene microfuge tubes, each tube pre-dispensed with 2 pi of pre-mixed enzyme/termination 
reagent which consisted of either ddATP, ddGTP, ddCTP, or ddTTP and Thermo Sequenase DNA 
polymerase. When all of the reactions had been prepared they were overlaid with light mineral oil and 
pulse centrifuged for 10 seconds to ensure all reagents were below the mineral oil layer. The sequencing 
reactions were carried out using a Perkin Elmer thermal cycling machine. The thermocycling programme 
for the sequencing reactions was preceded by a pre-melting step of 94°C for 4 minutes. The conditions 
thereafter were 94°C for 30 seconds, 50 °C for 15 seconds and 72 °C for 30 seconds over 25 cycles 
followed by a 4 °C soak. Before loading reaction products on the gel, samples were mixed with loading 
dye (Appendix I) and the total volume of the reaction was reduced. Sequencing reactions were recovered 
from under the mineral oil and dispensed into the wells of a conical bottomed 96 well plate (Nunc), each 
well-contained 3 pi of loading dye (Appendix I). The mixture was pipetted up and down to ensure 
uniform dispersal and the 96 well plate was placed on top of a pre-heated 80°C heat block. The plate and 
heat block were put into a vacuum desiccator until the reaction/loading dye mixture had been reduced 
from a volume of 11 pi to a volume of 3 pi. Reaction products were loaded onto a gel immediately or 
stored at 20 °C until required.
2.2.6.3 Sequence electrophoresis
The sequencing reaction products were resolved on a 6% denaturing polyacrylamide/urea gel (Appendix 
I). The glass sequencing plates were cleaned by washing first with an alkaline detergent solution of 10% 
Decon followed by distilled water and finally 70% ethanol, plates were dried with soft paper tissues. The 
plates were aligned according to their bevelled edges and spaced by one opaque plastic spacer and one 
transparent acrylic spacer with protruding tabs. The spacer with protruding tabs was positioned to align 
with the entry point of the ™Vistra DNA Sequencer 725 laser. The plates were placed in a horizontal 
position for gel pouring and were held together with bulldog clips.
The 6% denaturing polyacrylamide/urea gel was degassed for three minutes in a vacuum dessicator prior 
to the addition of 150pl of ammonium peroxodisulphate (Appendix I) and 15(il of TEMED. On addition 
of these two reagents the gel was poured immediately using a 50ml syringe, a plastic surface former was 
inserted between the gel plates and the gel was left to polymerise for 60 minutes. Once polymerised the
gel was placed in the ™Vistra DNA Sequencer 725 and the anode and cathode reservoirs were filled with 
lx TBE buffer (Appendix I). The surface former was removed and the gel surface was flushed with 
reservoir buffer to remove excess urea.
Before sample loading, the gel was preheated by running it at 1000 volts and 17 milliamps for 10 
minutes. Following this period a paper sharks tooth comb was inserted into the gel surface and 3 pi 
aliquots of sequenced products were loaded into each well. All empty wells were aliquoted with 3 pi of 
2:1:1 loading dye/salt solution/water to prevent track distortion. The gel was run at 1400 volts at 22-27 
milliamps for 9 hours in lx TBE buffer (Appendix I).
2.2.6.4 Sequence detection
The ™Vistra DNA Sequencer 725 contained a low power, helium-neon laser that generated light at 
594. lnm in the yellow region of the visible spectrum. At a distance of 30cm from the sample wells the 
DNA fragments from the sequencing reactions were illuminated by the laser beam, which entered 
through the protruding tabs of the transparent spacer and traversed the entire width of the gel. 
Flourescence from the labelled DNA passed through a window behind the gel and was focussed through 
a band-pass filter onto a 512-element photodiode array detector. The detected signal was digitalised and 
transmitted to the computer, which generated a fluorescent intensity profile of the gel. In this way the 
computer identified the position of each DNA band and automatically called the bases. The automatic 
base calling was checked manually and corrected where necessary. Overlapping sequence profiles were 
aligned into contiguous sequences by downloading the computer generated information into a sequencing 
programme called Sequencher (Gene Codes Corporation).
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Chapter 3.
PCR Amplification of HIV-2 LTR genotypes.
3.1 Introduction
In order to investigate comprehensively the relationship between HIV-2 LTR function, the replicative 
phenotype of the virus and/or the progression status of the infected patient, it was necessary to produce 
accurate DNA copies of the LTR from virus originating from a variety sources that included 
phenotypically and clinically characterised viral isolates and patient-derived material. It is possible to 
amplify selectively specific DNA sequences using the Polymerase Chain Reaction (PCR) (Mullis & 
Faloona, 1987). This application involves a series of denaturation, annealing, and extension reactions 
primed by specific oligonucleotide sequences. The following chapter describes how this technique has 
been used to target and amplify LTR sequences from molecular clones, viral isolates, and patient-derived 
material.
The clinical material of interest in this study was derived from patients with disparate proviral DNA loads 
relating to their disease progression rates (see section 3.2.1.3). Proviral load measurements from 
asymptomatic non-progressing patients were extremely low (<1000 copies per 105 CD4+ cells), whereas 
rapidly progressing patients exhibited proviral loads of >50,000 copies per 105 CD4+ cells (determined by 
Dr. N. Berry, NIBSC, see section 2.2.1.3). PCR amplification from DNA containing high numbers of 
proviral copies did not prove to be problematic, however amplification of the LTR region from LTNP 
patients was much less successful. Optimisation of first and second round PCR conditions was required in 
order to obtain LTR amplicons from low copy number LTNP PBMC material. This chapter describes the 
optimisation and application of a nested PCR that is capable of amplifying the HIV-2 LTR from a single 
copy of proviral DNA using molecular clone, viral isolate, or patient PBMC derived DNA as starting 
material.
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3.2 Establishment of a nested PCR for the amplification of the HTV-2 Long
Terminal Repeat (LTR)
3.2.1 HIV-2 sources fo r  Long Terminal Repeat PCR amplification
The HTV-2 LTR region was amplified from a wide variety of sources including, molecular clone (n=l), 
viral isolate (n=5), and patient material (n=6). Molecular clone and viral isolates were characterised 
phenotypically (Clavel et al. 1986b, Shultz et al., 1990), and patient sources were characterised clinically 
(K.Ariyoshi & N.Berry, personal communication). This was essential in an evaluation of the relationship 
between LTR function and HIV-2 pathogenesis. The HTV-2 LTR was PCR amplified from the following 
sources:
3.2.1.1 HIV-2 Molecular Clone
pRODio - A full-length infectious clone, containing the complete proviral sequence from the isolate HTV- 
2 ROD (Clavel et al, 1986a, Clavel et al, 1986b).
3.2.1.2 HIV-2 Isolates
CBL Series - Chester Beatty Laboratory (CBL) 20-24, five viral isolates (MRC ADP) obtained from five 
different HIV-2 infected Gambian patients. The five Gambian HTV-2 strains (CBL 20-24) exhibit a range 
of in vitro phenotypes that have been correlated to the clinical status of the patients at the time of 
sampling. The phenotypes range from a highly cytopathic and fast replicating virus from a patient who 
died of AIDS (CBL 20), to non-cytopathic slow replicating virus from an asymptomatic patient (CBL 24) 
(Schulz et al., 1990) (see Chapter 5 section 5.2 & Table 5.1, pg 192). Isolates were grown on H9 or 
C8166 cells before DNA extraction (performed by colleagues at the Chester Beatty Laboratories, see 
section 2.2.2.1a) and LTR cloning.
3.2.1.3 HIV-2 Clinical Material
The Gambian Cohort - PBMC samples were obtained from six HTV-2 seropositive patients attending the 
MRC hospital in Fajara, The Gambia. Each of the six patients had been recruited to a longitudinal study 
in which patient samples were taken at six monthly intervals (Ariyoshi et al., 2000). Disease progression 
rates were determined based on clinical data, decline of CD4% over the period of follow-up (determined 
by colleagues at the MRC laboratories, Fajara, The Gambia, see section 2.2.1.1), and plasma viral load 
measurements (performed by Dr. N. Berry, NIBSC, London, see section 2.2.1.3). Rapid progressor (RP)
patients were defined as those with CD4 declining from greater than 20% to less than 13% within 20 
months, and whose plasma viral load measurements exceeded 50,000 copies/ml (RP1-RP3). Long-term 
non-progressor (LTNP) patients had stable CD4 counts for more than 56 months, and had plasma viral 
load measurements of <1000 copies/ml (LTNP1-LTNP3) (see Table 3.1, pg 132, and Chapter 6 section 
6.2). DNA was extracted from PBMC samples using a Qiagen™ Blood Kit (Qiagen) (see section 
2.2.2.1b) and quantified by fluorometry (see section 2.2.2.2). LTRs were cloned from PBMC samples 
obtained as close to the time of RNA viral load measurements as possible.
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3.2.2 Generation o f HIV-2 Long Terminal Repeat PCR Products
Several publications have demonstrated that the functionally relevant transcription factor binding sites in 
the HIV-2 LTR are located within the U3 and R sections of the promoter (Guyader et al 1987, Arya & 
Gallo, 1988, Markovitz et al, 1990, Arya, 1991, Markovitz et al., 1992, Hannibal et a l, 1993, Hannibal 
et al, 1994, Clark et al, 1995). Oligonucleotide primers were designed to target a 764bp region of the 
HTV-2 LTR encompassing the U3 and R segments of the LTR in addition to 35bps of the U5 section of 
the promoter. HTV-2 amplicons spanned nucleotide positions -556 to +208 of the promoter relative to the 
start site of transcription (see Figure 1.6, pg 71). Primer sequences were determined following reference 
to published HTV-2 sequences recorded in the Los Alamos Database (see Table 2.5, pg 110). Theoretical 
melting temperatures (Tms) and DNA polymerase requirements were also considered in the design of the 
primers (see section 2.2.2.3a). All oligonucleotide primers were between 18 and 25 nucleotides in length 
and had an approximately 50% G/C content (Table 2.5, pg 110). Oligonucleotides were synthesised by 
Oswel DNA Service (University of Southampton). The Tm for each primer was calculated according to:
Tm = 4 (G+C) + (A+T) minus 5°C 
The second round cloning primers were designed to contain 5’ restriction endonuclease sites, which 
matched sites found within the polylinker region of the reporter vector chosen for use in this study (see 
Appendix II Figure II. 1, pg 348). The primers designed for use in this study are listed in Chapter 2 Table 
2.5, pg 110.
3.2.2.1 PCR Amplification o f the HIV-2 LTR from Viral Isolate and Molecular Clone material 
Amplification from virus isolate and molecular clone material was attempted using DNA derived from 
each of the five CBL isolates (20-24) and the molecular clone pRODio (see section 2.2.2.3b), A product 
equivalent to the expected amplicon of 764bp was generated from each of the six DNA samples (Figure
3.1, pg 131). PCR products were extracted and gel purified for restriction endonuclease cloning 
according to the protocol set out in 2.2.2.6.
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Figure 3.1 Nested PCR amplification of 764bp HIV-2 LTR from viral isolate and molecular 
clone sources using second round primers T5169 and T5170. Track 1: Molecular clone 
pRODIO, 2-6 Viral isolate DNA samples (2: CBL 20, 3: CBL21, 4: CBL22, 5: CBL23, 6: 
CBL24), 7: DNA marker.
3.2.2.2 PCR amplification o f the HIV-2 LTR from PBMC-derived patient DNA (Gambian cohort)
PCR amplification was attempted using PBMC-derived DNA from six different Gambian patients, three 
patients characterised as rapid progressors (RPs), the remaining three patients as long-term non- 
progressors (LTNPs) (see section 2.2.2.3b). HIV-2 LTR PCR products were generated from three of the 
six original samples, RP1, RP2, and RP3, the three patients characterised as RPs (Figure 3.2, pg 132). 
Partially successful PCR amplification was achieved with one LTNP sample (LTNP3), represented by a 
faint band seen in track 3 (Figure 3.2 -  arrowed, pg 132), the remaining two LTNP samples (LTNP1 -  
track 9, and LTNP2 -  track 4) failed to amplify under the conditions of the PCR protocol described in 
section 2.2.2.3b. Successfully amplified PCR products were extracted and gel purified for restriction 
endonuclease cloning according to the protocol set out in 2.2.2.6.
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Figure 3.2 Nested PCR amplification of 764bp HIV-2 LTR from PBMC-derived patient DNA 
using second round primers T5169 and T5170. Tracks 1:DNA marker, 2:molecular clone 
pRODIO (positive control), 3-7, and 9 Gambian patient DNA (3:LTNP3, 4:LTNP2, 5:RP2, 
6.RP1, 7:RP3,9:LTNP1, 10:DNA marker).
D N A  S a m p l e C D 4 %
(determined by colleagues 
at the MRC Laboratories, 
Fajara, The Gambia, see 
section 2 .2 .1.1)
P l a s m a  H I V - 2  R N A  
l e v e l s  ( c o p i e s  p e r  m l )
(determined by Dr.N.Berry, 
see section 2.2.1.3)
A m p l i f i c a t i o n  o f  
L T R  f r o m  p r o v i r a l  
D N A
R P 1 9 1 0 3 0 0 0 P o s i t i v e
R P 2 22 5 5 4 5 0 p o s i t i v e
R P 3 1 3 1 8 3 0 0 0 p o s i t i v e
L T N P 1 4 1 u n d e t e c t a b l e n e g a t i v e
L T N P 2 4 9 u n d e t e c t a b l e n e g a t i v e
L T N P 3 4 8 u n d e t e c t a b l e w e a k
Table 3.1 Summary of clinical parameters of Gambian cohort patients. Undetectable RNA loads are 
considered to be <200copies/ml. Amplification success of the HIV-2 LTR region from patient 
proviral DNA is indicated.
3.2.2.3 Optimisation o f the HIV-2 LTR nested PCR
In an attempt to increase the sensitivity of the PCR, modifications were made to the first and second round 
amplification reactions. PCR optimisation was performed using DNA derived from LTNP3 since partial 
amplification had been achieved with DNA from this patient. Initially changes to magnesium 
concentration and DNA polymerase were made, however, amplification was not improved (data not 
shown). Following this, the amount of patient template introduced into the first round reaction mixture 
was increased from 300ng to 600ng (quantified by fluorometry, section 2.22.2) and second round 
reactions were performed at a range of different annealing temperatures in order to identify the 
experimental optimum temperature for the primer pairing (see 2.2.2.4a). Second round PCR reactions had 
previously been performed at an annealing temperature of 54°C. In this set of experiments second round 
reactions were performed at temperatures ranging from 48°C to 62°C, increasing by increments of 2°C 
with each reaction.
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B. 600ng
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Figure 3.3 Nested PCR amplification performed using (A) 300ng and (B) 600ng PBMC-derived 
DNA from patient LTNP3. Reactions were performed over a second round annealing temperature 
gradient from 48°C to 62°C. (A) 300ng DNA PCR, Tracks 1-8: annealing temperatures 62°C to 
48°C in increments of 2°C. (B) 600ng DNA PCR, Tracks 1-8: annealing temperatures 62°C to 
48°C in increments of 2°C.
Amplification of the 764bp LTR region was found to be more successful when the first round DNA 
template input was 600ng as opposed to 300ng, regardless of the second round annealing temperature (see 
Figure 3.3, track 5 (A) vs. track 5 Figure 3.3 (B), track 6 (A) vs. track 6 (B), pg 134). However, 
differences in amplification between the annealing temperatures within the range were also demonstrated. 
PCR amplification of the 764bp LTR fragment was found to increase with each 2°C decrease in second 
round reaction temperature (Figure 3.3, pg 134). Optimal PCR amplification of the 764bp LTR fragment 
was achieved at a second round annealing temperature of 50°C (Track 7 Figure 3.3 (B), pg 134), with a 
600ng DNA input.
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3.2.2.4 Assessment o f optimised HIV-2 LTR PCR performance by limiting dilution 
Ultimately the goal of PCR optimisation is to achieve single copy sensitivity, that being the ability of the 
chosen PCR assay to produce detectable amplicons from a single HIV-2 molecule. A nested PCR capable 
of such sensitivity would increase the likelihood of successful amplification from low copy number 
material. In order to assess the single copy performance of the newly optimised PCR, limiting dilution 
analysis was performed (2.2.2.4b). A PCR that demonstrates a Poisson distribution of end-point 
molecules by limiting dilution, on the basis of probability represents single molecule amplification 
(Simmonds et al., 1990).
4/4 4/4 3/4 1/4
Figure 3.4 Limiting dilution PCR performed using PBMC-derived DNA from LTNP3 and second 
round primers T5169 and T5170. Tracks 1:DNA marker, 2-5:DNA input volume = n, 6-9:DNA input 
volume = n/5, 10-13:DNA input volume = n/25, 14-17:DNA input volume = n/625. The frequency of 
negatives or Fo = 0.75 is achieved at a 625 fold dilution of the original DNA sample, n = 2pl of DNA.
The results shown in Figure 3.4, pg 135, clearly demonstrate a Poisson distribution of end-point molecules 
(Simmonds et al, 1990). Using the optimised PCR protocol, the HIV-2 LTR PCR second round primer 
pairing was sensitive enough to produce an LTR amplicon from a single copy of the HIV-2 genome.
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3.2.2.5 Amplification o f HIV-2 LTR from low copy number patient material (Gambian cohort) using a 
limiting dilution sensitive nested PCR
The PCR amplification of the HIV-2 LTR from LTNP low copy number PBMC-derived DNA was 
attempted using the newly optimised nested PCR protocol (see section 2.2.2.5). HIV-2 LTR PCR 
products were obtained for all three samples, LTNP1, LTNP2, and LTNP3 (Figure 3.5, pg 136). PCR 
products were extracted and gel purified for restriction endonuclease cloning.
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Figure 3.5 Limiting dilution sensitive nested PCR amplification of 764bp HIV-2 LTR from three 
LTNP Gambian patient DNA samples using second round primers T5169 and T5170. Tracks 1: 
LTNP1,2: LTNP2, 3: LTNP3, 4: DNA marker.
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3.3 Summary and discussion
The functional study of a genomic element necessarily requires the generation of an accurate and complete 
copy of the region in question. With the advent of PCR technology, generation of such a copy is possible 
through the direct amplification of a defined genomic sequence. In order to generate representative HTV-2 
LTR regions, oligonucleotide primer sequences had to be designed to encompass defined LTR sequences. 
The parameters of the HTV-2 LTR have been determined in a number of studies based upon sequence and 
functional analysis (Guyader et al, 1987, Arya & Gallo, 1988).
In 1987, Guyader et al published the genomic organisation and nucleotide sequence of an integrated 
proviral DNA from the ROD isolate of HTV-2 (Guyader et al., 1987). The limits of the HTV-2 LTR and 
its internal U3, R, and U5 domains were defined by a combination of sequence analysis and 
complementary DNA synthesis. The U3 region was found be 556bp long, the R region 173 bp, and the 
U5 element 125bp. As stated previously, sequence elements of functional significance to gene expression 
within the HTV-2 LTR were identified in later studies (Arya & Gallo, 1988, Markovitz et a l, 1990, Tong- 
Starksen et a l, 1990, Arya, 1991, Markovitz et a l, 1992, Hannibal et al., 1993, Hilfinger et a l, 1993, 
Hannibal et al, 1994, Clark et al, 1995). The core enhancer region and upstream regulatory elements are 
contained within the 556bp of the U3 region (Guyader et al., 1987, Aiya & Gallo, 1988, Markovitz et al, 
1990, Tong-Starksen et a l, 1990, Arya, 1991, Markovitz et al, 1992, Hannibal et a l, 1993, Hilfinger et 
al, 1993, Hannibal et al, 1994, Clark et a l, 1995). The R region encodes a /ra/wactivation responsive 
element (TAR), which is essential for Tat t/wwactivated gene expression (Guyader et al 1987, Arya & 
Gallo, 1988, Fenrick et al, 1989, Chang & Jeang, 1992, Elangovan et al, 1992, Rhim & Rice, 1993). 
However, mutational analysis of the 125bp making up the U5 region of the LTR has indicated that the 
sequences within this region do not significantly influence LTR directed gene expression (Arya, 1991).
For this study, oligonucleotide primers were designed to amplify the region of the HIV-2 LTR of 
functional significance to gene expression. The amplified LTR sequence represents 764bp of the original 
854bp HTV-2 LTR, the amplicon contains the entire U3 (556bp) and R (173bp) regions of the LTR, in 
addition to 35bp of U5. The defined region of the HTV-2 LTR selected for functional analysis in this 
study is considered to be the functionally relevant transcriptional unit and these parameters have been the 
chosen for study in several other functional investigations (Guyader et al, 1987, Arya & Gallo, 1988,
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Markovitz et a l, 1990, Tong-Starksen et a l, 1990, Arya, 1991, Markovitz et al, 1992, Hannibal et al, 
1993, Hilfinger ef al, 1993, Hannibal etal., 1994, Clark et al, 1995).
PCR amplification of the HIV-2 LTR from molecular clone, viral isolate, and high copy number RP 
patient material was readily achieved using conditions of high nested PCR stringency. It is likely that the 
high copy number and good quality of the DNA templates derived from these sources resulted in 
successful PCR amplification. However, the initial PCR protocol failed to generate LTR PCR products 
from the DNA derived from the PBMCs of the three LTNP patients. Since extraction of LTNP and RP 
DNA was performed using the same materials and protocol (see section 2.2.2.1b), it is unlikely that PCR 
inhibitors from the extraction process caused the failure to amplify from LTNP-derived DNA. Moreover, 
carry over of inhibitors with an extract input of only 1-2pi into a 50jnl first round PCR volume would be 
negligible.
Previous studies concerned with PCR amplification from HIV-2 infected PBMC material have 
experienced similar difficulties when trying to amplify from asymptomatic patient samples (Grankvist et 
al, 1992, Simon et a l, 1993, Berry et a l, 1994). A study by Simon et al found that the ability to detect 
the HIV-2 genome by nested PCR was a reflection of the level of virus within the patient, and correlated 
with CD4 counts (Simon et a l, 1993). Positive PCR amplification was achieved with only one out of 14 
patients with CD4+ counts of >500 x 106/1, in contrast, amplification was achieved with six out of six 
patients with CD4+ counts of <200 x 106/1. The inability to detect HTV-2 DNA by PCR from patients 
exhibiting high CD4+ counts and no signs of disease progression in this and other studies has been 
attributed to the low numbers of the HIV-2 genome carried within the PBMCs of these infected 
individuals (Grankvist et a l, 1992, Simon e ta l, 1993, Berry e ta l, 1994).
A characteristic of the LTNP patients in this study (Table 3.1, pg 132), and in general (Simmonds et al, 
1990, Beny et a l, 1994, Ariyoshi et a l, 1996, Berry et al, 1998, Popper et a l, 2000), is veiy low to 
undetectable proviral loads (1 copy/1000 - 1 copy/10,000 PBMCs); in contrast, rapidly progressing 
patients exhibit high proviral loads (up to 1 copy/10 PBMCs). It is likely therefore, that amplification 
from the three LTNP samples failed, in part, because of the low number of proviral copies of HIV-2 
within the extracted PBMC-derived DNA used as first round template.
Nevertheless, the observation of partial PCR amplification seen in track 3 of Figure 3.2 (arrowed), pg 132, 
demonstrates that there was at least one copy of the HTV-2 template within the PCR mixture performed
with the DNA from LTNP3, and shows therefore that the conditions of the nested PCR described in 
section 2.2.2.3b were not optimal for the second round oligonucleotide primer pairing. In this situation 
the likelihood of successful PCR amplification is greatly reduced and it is probable that this was also a 
significant factor in the failure to amplify from the low copy number LTNP-derived material.
The aim of an optimal PCR is to achieve successful amplification from a single molecule of DNA 
(Simmonds et a l, 1990). To increase the likelihood of successful amplification from all low copy number 
LTNP samples, nested PCR conditions were further optimised in an attempt to achieve single copy 
sensitivity. Initially, changes were made to DNA polymerase and MgCl2 concentrations. It was hoped 
that by increasing the concentrations of DNA polymerase and/or MgCl2 within the PCR reaction mixture, 
the likelihood of successful PCR amplification would be increased since both components can be limiting 
in a PCR reaction. Amplification from the DNA template derived from LTNP3 was not achieved 
however, when these parameters were altered (data not shown), suggesting that free molecules of DNA 
polymerase and Mg2+ were present within the PCR mixture and that other factors were limiting the 
reaction.
Following MgCl2 concentration, DNA polymerase, and buffer (especially salt), the DNA template 
concentration and PCR annealing temperatures exert a strong influence over the result of a PCR. These 
two parameters were optimised further in an attempt to improve the sensitivity of die nested PCR. First 
round template input was increased from 300ng to 600ng, and the second round annealing temperature 
was reduced by 4°C to 50 °C. These steps together effectively increased both the number of proviral 
targets and further enhanced the conditions for second round primer annealing. The data presented in 
Figure 3.3, pg 134, clearly demonstrates that PCR amplification of the HIV-2 LTR from low copy number 
template was greatly enhanced by the increasing initial template concentration and lowering the stringency 
of second round reaction conditions. The failure to amplify the HIV-2 LTR from LTNP PBMC-derived 
DNA under the initial nested PCR conditions likely resulted from the quantity of proviral DNA in the 
PBMC-derived DNA being too small, and the second round annealing temperature being too high for the 
second round primer pairing.
When performed using a limiting dilution method (Simmonds et a l, 1990), the optimised HIV-2 LTR 
nested PCR gave an end-point dilution series that demonstrated single copy sensitivity. All subsequent
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PCR experiments were performed with 600ng of DNA template as a first round input, and second round 
annealing reactions were carried out at 50°C rather than 54°C.
Optimisation of the first and second round PCR conditions resulted in a nested PCR that is capable of 
amplifying the LTR region from a single molecule of HIV-2 derived from a wide variety of sources 
(Simmonds et al., 1990). This enabled the successful PCR amplification of the HTV-2 LTR from 
molecular clone, isolate, and high and low copy number patient DNA.
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Chapter 4. 
Optimisation of Cloning, Transfection, and Reporter Gene Detection Procedures 
for the Measurement of HTV-2 LTR Activity.
4.1 Introduction
Characterisation of promoter elements can be successfully achieved through the use of the reporter assay. 
This technique involves attaching the promoter element under investigation to a gene encoding a reporter 
molecule; the amount of reporter protein synthesised under various conditions is presumed to reflect the 
ability of the inserted sequence to promote transcription. Reporter assays have been extensively used in 
the characterisation of retroviral promoter and enhancer elements, particularly in the analyses of both the 
HIV-1 (Golub et al., 1990, Koken et al., 1992, Estable et al., 1996, Rousseau et al., 1997 Zhang et al., 
1997b), and HIV-2 LTRs (Markovitz et al., 1990, Tong-Starksen et al., 1990, Arya, 1991, Markovitz et 
al, 1992, Hannibal et al., 1993, Hilfinger et al., 1993, Hannibal et a l, 1994, Clark et al., 1995, Faulkner 
et al., 2001). Initial studies utilised either P-galactosidase or Chloramphenicol Acetyltransferase (CAT) 
reporter assays, however, more recent analyses have involved the use of luciferase reporter systems that 
have greater sensitivity and a better dynamic range, and that are quicker to perform (Alam & Cook, 1990, 
Van Lint et al., 1997, Zhang et a l, 1997, Jeeninga et al., 2000).
The principal aim of this study was to assess and compare the activity of a variety of HTV-2 promoters of 
unknown activities; it was crucial therefore to select a rapid, sensitive, and reproducible reporter system 
capable of detecting a wide range of promoter activities. The advantages and disadvantages of the 
various reporter systems available are discussed in this chapter, and the features of the reporter assay 
system utilised in this study are outlined in the first section.
The procedure by which the genetic element under investigation is inserted into the reporter vector must 
be both rapid and reliable. The chapter describes the cloning of PCR amplified HTV-2 LTRs into the 
firefly luciferase reporter vector pGL3E in the second section.
The third section of this chapter describes the optimisation of a dual-luciferase reporter assay used to 
detect reporter gene expression in the measurement of HTV-2 LTR activity. Experiments to determine the 
linear range, stability, and reproducibility of the detection assay have been described.
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An assay based upon a reporter system relies on the ability to introduce the promoter-containing reporter 
vector into the cell-type of interest. The process by which DNA is introduced into cells is called 
transfection. A transfection can be either transient or stable, and can be carried out by a number of 
different techniques. Transient transfections involve the introduction of DNA into mammalian cells 
followed by a 2-4 day incubation period in which transcription of the transfected reporter gene takes 
place. After the incubation period, transfected cells are harvested and can be analysed for the presence of 
the reporter molecule. Stable transfections result in the integration of the transfected gene within the 
chromosomal DNA, a process directed by antibiotic selection. The fourth and last section of this chapter 
discusses the vast array of techniques, reagents, and cell lines that are available for the transient 
transfection of DNA. Experiments to determine the most efficient and reproducible transfection protocol 
for each particular cell line used in the study are described.
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4.2 Reporter assay systems for the measurement of promoter activity
There are a number of different reporter systems currently available, including [3-galactosidase, 
Chloramphenicol Acetyltransferase (CAT) and luciferase reporter assays; all have particular advantages 
and disadvantages. Common to all systems, the promoter region under investigation must be placed 
directly upstream of the reporter gene, within a reporter vector lacking an endogenous promoter. 
Fundamental to the concept of the reporter assay, the reporter gene must direct transcription of a reporter 
protein that is absent from the host cell and does not alter host cell physiology. The assay utilised to 
detect the reporter molecule must be simple yet efficient and, above all, extremely sensitive. In addition, 
the assay must exhibit a broad linear range of detection enabling the analysis of both large and small 
changes in promoter activity.
4.2.1 Choice o f mammalian cell line
Ideally, studies investigating the activity of the transcriptional regulatory elements within the retroviral 
genome would be carried out in the primary cells that the virus naturally infects. However, it is widely 
known that primary cells such as CD4+ T lymphocytes and macrophages are refractory to many DNA 
transfection techniques. A small number of studies have successfully transfected primary cells, but at 
very low efficiencies (Horvat et al, 1989, Hazan et a l, 1990). Moreover, successful transfection of HTV 
reporter vectors into primary T cells has been shown to require preactivation, confounding studies 
assessing transcriptional activity at the basal level and transcriptional responses to other T-cell activation 
signals.
The vast majority of reporter gene assays are performed by transfecting transiently reporter vectors into 
established mammalian cell lines. In general, these cell lines show higher transfection efficiencies than 
primary cells, and are widely used for transient transfection. These include HEK293, Jurkat, HL-60s, 
CEM, and THP-1 cell lines. When selecting a mammalian cell line for use in a reporter assay-based 
study two of the most important considerations are the transfection efficiency of the cell line and its 
biological relevance to the virus under investigation. The Jurkat and THP-1 cell lines have been 
extensively used in the transient transfection of reporter vectors containing HIV-1 and HTV-2 promoter 
regions (Markovitz et a l, 1992, Hilfinger et al, 1993, Clark et a l, 1995, Estable et a l, 1996, Van Lint et 
al, 1997). Both cell lines are non-adherent and show high transfection efficiencies. In addition, Jurkat is 
a T cell-like cell line and THP-1 is a monocyte-like cell line. Both primary T cells and monocytes are
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infected by HIV-1 and HTV-2, and both types of cells have been shown to play important roles in HIV 
infection (Klatzmann et a l, 1984b, Ho et al., 1986, Gendehnan et a l, 1989, Ho et al., 1995, Spina et al., 
1997, Woods et al., 1997). The human embryonic kidney cell line (293HEK) has also been extensively 
used in transient transfection analysis due to its high transfection efficiency and tolerance of a wide range 
of transfection techniques. The HEK293 cell line has been chosen for its ease of use in several of the 
initial dual-luciferase assay optimisation experiments within this study, while the more biologically 
relevant Jurkat and THP-1 cell lines have been reserved for transfection experiments which assess and 
compare the activities of the PCR-amplified HTV-2 LTRs.
4.2.2 Choice o f reporter assay system
The most attractive features of a luciferase based reporter assay are its sensitivity and speed. In 
comparison, the P-galactosidase (p-gal), and Chloramphenicol Acetyltransferase (CAT) reporter assays 
currently available are less sensitive and more time consuming (Alam & Cook, 1990), however, on 
average, they are cheaper. Most luciferase assays can measure enzyme expression over an extremely 
broad linear range that extends over at least eight orders of magnitude; by comparison, CAT and P-gal 
reporter assays display linear ranges of between four and six orders of magnitude. In a direct comparison 
with a CAT reporter assay Alam et al showed that the luciferase reporter assay was 100 fold more 
sensitive (Alam & Cook, 1990).
Another significant disadvantage displayed by both P-gal and CAT reporter assays is that they are end­
point assays, consequently a prolonged period of incubation post-harvesting (12-16 hours) is required 
before reporter gene expression levels can be determined. In contrast, luciferase reporter assays do not 
require such incubation periods and therefore, are considerably quicker to perform, for example levels of 
luciferase gene expression can be measured within one hour post-harvesting. The luciferase assay does 
have two disadvantages, the first of these is related to cost, both the reagents and detection device i.e. a 
luminometer, required to perform the luciferase assay are more expensive than the corresponding 
materials needed to perform either the P-gal or CAT reporter assays. Secondly, although many 
manufacturers have improved the half-life of luciferase, the stability of the signal emitted by the reporter 
molecule is short lived. Potentially this creates detection problems, particularly if a large number of 
samples are being analysed in a single experiment.
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Taking into account the advantages and disadvantages of all three assays the luciferase based reporter 
system was selected for use in this study. The superior sensitivity and speed of this assay are suited to 
this study since a large number of HTV-2 promoters of unknown activities were to be assessed. Choosing 
the luciferase system also avoided the use of radioactivity.
4.2.3 Features o f the duat-luciferase reporter assay system 
The luciferase based reporter assay system selected for use in this study involves the simultaneous 
cotransfection of two distinct luciferase reporter vectors, and is thus termed a dual luciferase assay. The 
first vector acts as an experimental reporter vector into which the promoter region under investigation is 
inserted; the second provides an internal control to which measurement of the experimental reporter is 
normalised. The process of normalisation effectively eliminates the inherent experimental variability that 
arises from differences in transfection efficiencies and the number and health of cultured cells. The 
experimental reporter vector in this system - pGL3E (Promega Ltd) (Appendix II, Figure II. 1, pg 348) 
contains the firefly luciferase (Photinus pyralis) gene, which encodes a 61kDa monomeric enzyme that 
does not require post-translational processing and therefore functions as a genetic reporter immediately 
following translation. The second reporter vector encodes the sea-pansy or Renilla luciferase (Renilla 
reniformis) enzyme, a 36kDa monomeric protein distinct from firefly luciferase in evolutionary origin, 
structure, and substrate requirement. This makes it possible to discriminate selectively between the 
bioluminescent reactions catalysed by the two different luciferase enzymes, enabling both firefly and 
Renilla luciferase signals to be measured within a single well.
In order to determine the activity of a promoter using this system, the promoter under investigation is 
cloned into the firefly luciferase reporter vector (pGL3E) directly upstream of the firefly luciferase gene. 
Mammalian cells are then cotransfected with both the firefly and Renilla luciferase reporter vectors. 
Approximately 48 hours post-cotransfection the cells are harvested and assayed for the detection of both 
firefly and Renilla luciferase chemiluminescence in a single well assay performed in a 96 well plate 
(Figure 4.1, pg 147).
Firstly, the assay measures the chemiluminescent signal emitted from the reaction catalysed by the firefly 
luciferase enzyme encoded by the experimental vector pGL3E (Promega Ltd) following the addition of a 
beetle luciferin substrate. The firefly luciferase chemiluminescent signal is directly related to the level of 
firefly luciferase expression, which is in turn directly related to the activity of the inserted promoter under 
investigation. Secondly, the assay measures the chemiluminescent signal emitted from the reaction
145
catalysed by the Renilla luciferase enzyme encoded by the “internal control” reporter vector following the 
addition of a reagent that quenches firefly luciferase luminescence while simultaneously activating the 
luminescent reaction catalysed by Renilla luciferase. Each firefly luciferase reporter value is divided by 
the Renilla luciferase value generated by the cotransfected “internal control” reporter, giving a measure of 
the activity of the inserted promoter that is normalised for differences in transfection efficiency and the 
health and number of transfected cells.
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Figure 4.1 Schematic diagram outlining the procedures involved in the dual-luciferase reporter system 
used to measure HIV-2 LTR activity.
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4.2.4 Features and requirements o f the firefly luciferase reporter vector
Fundamental considerations when choosing a promoterless luciferase reporter vector included, luciferase 
expression levels directed by the vector, in vivo vector stability, levels of background luciferase 
expression directed by the vector, and flexibility to perform genetic manipulations. The firefly luciferase 
vector, pGL3-Enhancer (pGL3E, Promega Ltd) (Appendix II, II. 1), was selected to assess quantitatively 
the activity of the LTR region derived from the various HTV-2 infected sources. The pGL3E reporter 
vector does lack a promoter region, but contains an SV40 enhancer located downstream of the firefly 
luciferase gene and the poly(A) signal. The inclusion of the SV40 enhancer is an important and unique 
feature of pGL3E, in that it acts to aid the verification of functional promoter elements inserted into the 
vector by increasing the overall level of firefly luciferase expression. The functional activities of the 
LTRs under investigation were unknown prior to the study, as was the transfectability of the cell lines to 
be used; therefore this particular feature of pGL3E increased the likelihood a signal being detected. A 
summary of the features which influenced the selection of pGL3E are written below:
• pGL3E contained an SV40 enhancer located downstream of the firefly luciferase gene and the poly(A) 
signal which aided the verification of functional promoter elements inserted into the vector by 
increasing the level of firefly luciferase gene transcription.
• pGL3E contained a multiple cloning site containing several restriction sites. This polylinker region 
was found upstream of the luciferase gene and allowed the rapid and efficient insertion of DNA 
promoter elements.
• An ampicillin-resistance gene, P-lactamase, and a high copy number prokaryotic origin of replication 
allowed pGL3E selection, maintenance, and manipulation in E.coli hosts.
• pGL3E contained the SV40 late poly(A) signal which increased the efficiency of transcription, 
termination and polyadenylation of the luciferase transcripts.
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4.3 Cloning of HTV-2 LTR PCR products into the firefly luciferase reporter vector 
pGL3E
Amplified HTV-2 LTR PCR products were readily cloned into firefly luciferase reporter vector pGL3E 
using an efficient restriction endonuclease cloning protocol. Once optimised, this protocol achieved high 
frequencies of LTR positive clones from viral isolate, molecular clone, and patient derived amplification 
products.
4.3.1 Linearisation ofpGL3E
To enable efficient cloning of PCR amplified LTRs into the firefly luciferase reporter vector it was first 
necessary to linearise the vector. This was achieved by restriction endonuclease digestion performed with 
two restriction endonucleases targeted to M lul and Bglll sites within the polylinker region of pGL3E 
(Appendix II, Figure II. 1, pg 348). The restriction endonuclease sites matched those designed into the 
second round PCR primers (Table 2.5, pg 110). Optimisation of the linearisation protocol was achieved 
by varying enzyme manufacturer, order of enzyme addition, and time of incubation. The efficiency of 
linearisation was evaluated by transforming 5 pi of the resulting digestion mixture into E.coli and 
counting transformants.
The protocol resulting in optimal linearisation was; digest lpg of pGL3E with 20 units Mlul (Boehringer 
Mannhiem) in lx Buffer H (Boehringer Mannhiem) for 1 hour at 37°C, residual enzyme was removed 
with 5pl Strataclean™ resin (Stratagene). This was followed by addition of 20 units Bglll (Boehringer 
Mannhiem) and incubation at 37°C for a further 1 hour. Following restriction endonuclease digestion 
linearised pGL3E was dephosphorylated to prevent self-ligation. 1 Unit of Shrimp Alkaline Phosphatase 
(United States Biochemicals) was added to the digestion reaction mixture and incubated at 37°C for 20 
mins. Inactivation of Phosphatase was achieved by a further incubation for 15 mins at 65°C. This 
protocol routinely gave rise to fewer than 8 transformants per microlitre of digestion product, indicating 
very efficient linearisation.
4.3.2 Restriction endonuclease digestion o f amplified HIV-2 LTR PCR products
To enable the efficient cloning of PCR amplified LTRs into the firefly luciferase vector pGL3E, PCR 
products were also digested with restriction endonucleases M hJ and Bglll (Boehringer Mannhiem). The
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PCR products contained sites for both enzymes since they were designed into the sequences of the second 
round PCR primers. The conditions for digestion of the PCR amplified LTRs are described in section
2.2.3.1.
4.3.3 Cloning o f LTR PCR product into firefly luciferase reporter vector
Following digestion, the amplified LTRs were cloned into the linearised firefly reporter vector pGL3E; 
complementary annealing of the digested ends of both vector and PCR product resulted in the formation 
of a complete double-stranded circularised vector containing an LTR insert (Figure 4.1, pg 147). 
Optimisation of the ligation protocol was achieved by varying the vector to LTR insert ratio. Reaction 
ratios of 1:3 ,1:5, and 1:10 (vector to insert) were routinely performed according to the protocol described 
in section 2.2.3.4. This range of ratios compensated for any variation in template concentration that arose 
from amplification or gel purification steps relating to the PCR product, or bacterial DNA purification 
techniques relating to the vector. The efficiency of ligation was evaluated by transforming 5 pi of the 
resulting ligation mixture into E.coli and growing transformants on selective agar at 37°C overnight (see 
section 2.2.3.5). Colonies containing circularised vector possessing an LTR insert were screened by PCR 
(see section 2.2.3.7). The effects of varying the amount of vector to insert in the cloning reaction are 
shown in Figure 4.2, pg 151.
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Figure 4.2 Gel photograph of PCR screen of bacterial transformants for HIV-2 LTR inserts. A 764bp 
band identifies LTR positive clones. Individual pGL3E vector batches routinely achieved cloning 
efficiencies of up to 80%. Tracks 1-20: (5pl transformation of 1:10 vector to insert cloning ratio, 11 
positive colonies), 21-30: (5pl transformation of 1:5 vector to insert cloning ratio, 3 positive colonies), 
31-40: (5pl transformation of 1:3 vector to insert cloning ratio, 0 positive colonies). DNA markers track 
is not shown.
These results clearly demonstrate that the efficiency of cloning was dramatically increased as the ratio of 
insert to vector was increased. In general, vector to insert ratios of 1:10 produced the highest frequency 
of HIV-2 LTR PCR positive colonies. This protocol routinely achieved cloning efficiencies of 70-80%.
4.3.4 Verification o f LTR done constructs by restriction endonuclease digestion
PCR positive colonies were picked into selective broth and cultured overnight at 37°C (see section 
2.2.3.8), vector DNA was extracted from the overnight cultures using a Qiagen Midi Kit (Qiagen) (see 
section 2.2.3.9). Restriction endonuclease digestion reactions were performed with Bglll and Mlul 
(Boehringer Mannhiem) according to the protocol described in section 2.2.3.10, in order to verify the 
presence of the LTR insert within the reporter construct purified from overnight cultures. Following 
digestion, LTR containing constructs released a 764bp LTR fragment and a 5.064Kb vector backbone. 
The fragments released on digestion were resolved by agarose gel electrophoresis and appeared as two 
distinct bands correlating to the expected molecular weights (Figure 4.3, pg 152). All LTR clone 
constructs were verified in this way before being utilised in subsequent experiments. The number of 
clones obtained from each of the different sources is listed in Table 4.1, pg 152. Purified construct DNA 
was stored at -20°C until required.
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Figure 4.3 Bglll and Mlul digestion of pGL3E-LTR clones derived from the Gambian cohort. Tracks 1 
and 16 DNA marker, 2-5: RP3 derived clones, 6-8: LTNP1 derived clones, 9-11: LTNP3 derived clones, 
12-15: RP1 derived clones.
DNA Source Total number of 
pGL3E-LTR clones
pRODio 3
CBL20 7
CBL21 5
CBL22 10
CBL23 7
CBL24 13
LTNP1 (Gambian cohort) 8
LTNP2 (Gambian cohort) 9
LTNP3 (Gambian cohort) 8
RP1 (Gambian cohort) 10
RP2 (Gambian cohort) 8
RP3 (Gambian cohort) 7
Table 4.1 Summary of the number of pGL3E-HIV-2 LTR clones obtained from various HIV-2 sources
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4.4 Evaluation and optimisation of the dual-luciferase detection assay
Before performing the large-scale cotransfection studies to assess and compare the activities of the PCR- 
amplified HIV-2 LTRs, several experiments were carried out to evaluate and optimise the dual-luciferase 
detection assay. Due to its high transfectability and rapid growth the HEK293 cell line was initially used 
to assess the optimal conditions for the detection of both firefly and Renilla luciferase. HEK293 cells 
were transfected in 12 well dishes according to die standard calcium phosphate transient transfection 
protocol described in section 2.2.4.4a. Subsequent sections of this chapter go on to describe the 
optimisation of Jurkat and THP-1 cotransfection procedures using the optimised dual-luciferase detection 
assay.
4.4.1 Stability and dynamic range o f the firefly luciferase signal
Initially an experiment was carried out to determine the range of quantum efficiency and stability of the 
chemiluminescent signal emitted from the reaction catalysed by firefly luciferase. A serial dilution was 
carried out from a firefly luciferase stock concentration of lpg/pl, such that chemiluminescence was 
measured from concentrations of firefly luciferase between 0.1 pg and 10pg per well. Dilutions were 
made in Passive Lysis Buffer (Promega Ltd). lOOpl aliquots of beetle luciferin firefly luciferase substrate 
(Promega Ltd) were added to each dilution and chemiluminescence was measured using a Canberra 
Packard scintillation counter. Following the initial measurement at one minute post-mixing, readings for 
each dilution were taken at five-minute intervals over the course of a twenty-minute period (Figure 4.4, 
pg 154). The results indicated that firefly luciferase chemiluminescence could be successfully detected 
over a linear range extending at least seven orders of magnitude. The data also suggested that the 
chemiluminescent signal was relatively stable over the entire linear range; only a two-fold drop in activity 
was observed over the twenty-minute period. The largest drop in activity over time was observed at the 
highest concentration of firefly luciferase, perhaps due to limiting amounts of substrate. However, since 
the Canberra Packard scintillation counter takes less than five minutes to read an entire 96 well plate, the 
results indicated that the drop in activity experienced by experimental samples in such a plate while 
measuring the firefly and Renilla luciferase signals would be negligible.
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Fig 4.4 Titration curve of firefly luciferase chemiluminescence over time to test the dynamic range and 
stability of firefly luciferase detection using the dual luciferase assay system.
4.4.2 Efficiency o f firefly luciferase quenching
The dual-luciferase detection assay is performed within a single well. The assay involves first detecting 
the firefly luciferase signal following the addition of a beetle luciferin substrate and is followed by the 
addition of a reagent termed ‘Stop and Glo’™ (Promega Ltd) (see section 2.2.5.1), a chemical which 
simultaneously quenches the firefly luciferase-catalysed reaction while activating the Renilla luciferase- 
catalysed reaction, the chemiluminescence of which is then detected. In order to obtain an accurate 
Renilla luciferase reading the firefly luciferase reaction must be completely quenched by ‘Stop and 
Glo’™. Any residual light output from the firefly luciferase reaction would artificially enhance the light 
output obtained from the Renilla luciferase reaction, the value of which is used to normalise the firefly 
luciferase value. It was therefore necessary to demonstrate that the firefly luciferase chemiluminescence 
was quenched effectively under the reaction conditions utilised in these studies. A 1:1000 dilution from a 
firefly luciferase stock concentration of lpg/pl was made and added to a well of a 96 well plate. 100pl of 
beetle luciferin substrate was added to this sample and firefly luciferase chemiluminescence was 
measured. The reaction was then quenched by the addition of lOOpl of ‘Stop and Glo’™ reagent, and 
residual light output was measured (Figure 4.5, pg 155).
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Figure 4.5 Measurement of luciferase activities before and after the addition o f ‘Stop and Glo’™ reagent
The graph in Figure 4.5, pg 155, shows that the ‘Stop and Glo’™ reagent did successfully quench the 
firefly luciferase-catalysed reaction. Firefly luciferase luminescence was quenched by greater than 5 
orders of magnitude.
4.4.3 Choice o f Renilla luciferase interna! control vector
Cotransfection of vectors that contain strong promoter/enhancer elements can potentially lead to 
reductions in reporter gene expression due to the competition for transcription factors between the 
promoters of the co-transfected vectors (Farr & Roman, 1992). The occurrence and magnitude of the 
tram effects is dependent both on the activity of the genetic regulatory elements present in the co­
transfected vectors, and the relative ratio of experimental and control vectors. Since the firefly luciferase 
expression directed by the HIV-2 LTR within the firefly luciferase reporter vector was to be normalised 
by the value given by Renilla luciferase expression directed by the internal control reporter vector, it was 
essential to minimise any potential tram effect between the promoters within each cotransfected vector. 
If these effects were not reduced, Renilla luciferase expression directed by the internal control reporter 
might be down regulated, resulting in an inflated HIV-2 LTR activity value following normalisation. 
Conversely, if the tram effects between the two promoters negatively affected the HIV-2 promoter within
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the firefly luciferase reporter vector, the activity value for the experimental HTV-2 LTR would be 
artificially reduced following normalisation.
Three Renilla luciferase reporter vectors were available for use as internal control reporter vectors for 
cotransfection with the firefly luciferase vector, details of each are summarised below:
pRL-CMV -  this vector contains the CMV immediate-early enhancer/promoter region, which provides 
strong, constitutive expression of Renilla luciferase in a variety of cell types (Appendix II, Figure II.4, pg 
351).
pRL-TK — this vector contains the herpes simplex virus thymidine kinase (HSV-TK) promoter region 
upstream of the Renilla luciferase gene (Appendix II, Figure II.3, pg 350). The HSV-TK promoter 
provides low-level, constitutive expression in cells of both embryonal and mature mammalian tissues 
(Wagner et a l, 1985, Stewart et al., 1987).
pRL-SV40 -  this vector contains the SV40 early enhancer/promoter region, which provides strong, 
constitutive expression of Renilla luciferase in a variety of cell types (Appendix II, Figure II.5, pg 352).
In order to select the luciferase reporter vector pairing that experienced the lowest tram  effects when co­
transfected, the tram  effects between the promoters in each of the three control reporter vectors and the 
HTV-2 pRODio LTR that had been inserted into the experimental firefly luciferase vector pGL3E - (3E- 
ROD) were assessed and compared. Three sets of cotransfections were performed with each internal 
control vector. Firstly, HEK 293 cells were co-transfected in 12 well dishes with 1.25pg of pRL-TK, 
pRL-SV40, or pRL-CMV and 1.25fig of pGL3E according to the protocol described in section 2.2.4.4a. 
Since the firefly luciferase vector pGL3E lacked a promoter region, the level of Renilla luciferase gene 
expression detected in each cotransfection gave a measure of the activity of the corresponding HSV-TK, 
CMV, or SV40 promoter, in the absence of any tram  effects.
Secondly, HEK 293 cells were cotransfected in 12 well dishes with 1.25pg of pRL-TK, pRL-SV40, or 
pRL-CMV and 1.25jxg of pGL3C. This vector differed from pGL3E in that it contained the early SV40 
promoter region as well as the SV40 early enhancer (Appendix II, Figure II.2, pg 349), co-transfecting 
this vector with each of the internal control vectors provided a positive control for firefly luciferase 
expression.
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Finally, HEK 293 cells were co-transfected in 12 well dishes with 1.25pg of pRL-TK, pRL-SV40, or 
pRL-CMV and 1.25pg of 3E-ROD (pGL3E containing the HTV-2 pROD10 LTR). The level of Renilla 
and firefly luciferase expression detected in this set of cotransfections gave an indication of the activity of 
the HSV-TK, CMV, SV40 and HTV-2 pRODio promoter regions in the presence of any tram  effects 
between the co-transfected promoters. All transfections were performed in duplicate at an internal control 
vector:experimental reporter vector ratio of 1:1. Following 48h of incubation, cells were harvested and 
lysed according to the protocol described in section 2.2.4.5 and the firefly and Renilla luciferase enzyme 
activity measured using the dual-luciferase assay system (Promega Ltd) and luminometry (Canberra- 
Packard Topcount) (see section 2.2.5). Firefly and Renilla luciferase background activity was assessed 
(section 2.2.5.2) and subtracted from all corresponding measurements. Results are presented as the mean 
firefly and Renilla luciferase activity for each reporter vector cotransfection, with each mean activity 
value being calculated from a duplicate cotransfection. The mean firefly and Renilla luciferase activities 
derived in each of the three sets of cotransfections, i.e. internal control vector : pGL3E, internal control 
vector : pGL3C, and internal control vector : 3E-ROD have been plotted for each of the three internal 
control vectors (Figure 4.6, pg 158).
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Fig 4.6 Comparison of firefly and Renilla luciferase expression in three sets of cotransfections performed 
with each of three internal control Renilla luciferase vectors. (A) Columns 1-2: firefly and Renilla 
luciferase expression from a pGL3E : pRL-CMV cotransfection, 3-4: firefly and Renilla luciferase 
expression from a pGL3C : pRL-CMV cotransfection, 5-6: firefly and Renilla luciferase expression from 
a 3E-ROD : pRL-CMV cotransfection. (B) columns 1-2: firefly and Renilla luciferase expression from a 
pGL3E : pRL-TK cotransfection, 3-4: firefly and Renilla luciferase expression from a pGL3C : pRL-TK 
cotransfection, 5-6: firefly and Renilla luciferase expression from a 3E-ROD : pRL-TK cotransfection. 
(C) columns 1-2: firefly and Renilla luciferase expression from a pGL3E : pRL-SV40 cotransfection, 3-4: 
firefly and Renilla luciferase expression from a pGL3C : pRL-SV40 cotransfection, 5-6: firefly and 
Renilla luciferase expression from a 3E-ROD : pRL-SV40 cotransfection. All transfections were 
performed in duplicate at an internal control vector:experimental reporter vector ratio of 1:1.
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4.4.3.1 Tram effects experienced by the promoters contained within the internal control vectors 
The blue columns of the graphs shown in Figure 4.6, pg 158, represent the mean Renilla luciferase 
expression corresponding to the activity of the CMV, HSV-TK, and SV40 promoters when co-transfected 
with the firefly luciferase vectors pGL3E, pGL3C, and 3E-ROD (Figure 4.6, pg 158). In addition, the red 
columns of the graphs show firefly luciferase expression directed by the enhancer or promoter regions 
within the pGL3E, pGL3C, and 3E-ROD vectors when cotransfected with each of the three internal 
control reporter vectors (Figure 4.6, pg 158).
Analyses of the Renilla luciferase expression directed by the promoters within the three internal control 
vectors in each of the three sets of cotransfections revealed an inversely proportional association between 
the activity of the promoters directing the expression of Renilla luciferase and the activity of the promoter 
regions directing expression of firefly luciferase. As firefly luciferase expression increased, as observed 
in the cotransfections performed with pGL3C or 3E-ROD when compared to the pGL3E cotransfections 
(Figure 4.6 A), B) and C), pg 158), Renilla luciferase expression directed by the corresponding 
cotransfected internal control vector was seen to decrease. This association was observed when the 
cotransfections were performed with pRL-CMV, pRL-TK, and pRL-SV40. In each of the three sets of 
cotransfections the highest level of Renilla luciferase activity was observed when the internal control 
vector was co-transfected with pGL3E, the reporter vector directing the lowest level of firefly luciferase 
expression. Taken together these results indicated that the CMV, HSV-TK, and SV40 promoters within 
the Renilla luciferase internal control vectors pRL-CMV, pRL-TK, and pRL-SV40 respectively, 
experienced considerable tram  effects when co-transfected with a firefly luciferase reporter vector 
containing either the SV40 promoter, in the case of pGL3C or, more importantly, the HIV-2 pROD10 LTR 
within 3E-ROD.
By dividing the Renilla luciferase expression value measured for each internal control vector in the 
internal control:pGL3E cotransfection, by the Renilla luciferase expression value measured for each 
internal control vector in the internal control:3E-ROD cotransfection, the fold decrease in internal control 
promoter activity observed following cotransfection with the reporter vector containing the HTV-2 
pRODjo LTR was calculated for the CMV, HSV-TK, and SV40 promoters. In Figure 4.7, pg 160, the 
graph demonstrates that the activity of the SV40 promoter was most affected following cotransfection 
with 3E-ROD. The tram  effects between the SV40 promoter and the HTV-2 pRODl0 LTR resulted in a 
790-fold reduction in SV40 promoter activity. Conversely, the results suggested that the HSV-TK
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promoter region within pRL-TK experienced the least tram effects when co-transfected with 3E-ROD, 
with its activity being reduced approximately 258-fold below its activity when co-transfected with 
promoterless pGL3E.
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Figure 4.7 Comparison of down regulation experienced by the CMV, HSV-TK, and SV40 promoters 
within each of three Renilla luciferase internal control reporter vectors, when cotransfected with the 
firefly luciferase reporter vector pGL3E containing an HIV-2 pROD10 LTR upstream of the firefly 
luciferase gene, at a ratio of 1:1.
4.4.3.2 Tram effects experienced by the HIV-2 pRODl0 LTR within thepGL3E vector 
Analyses of the level of firefly luciferase expression measured in each of the three sets of cotransfections 
(see Figure 4.6 A), B), and C), pg 158) revealed that regardless of which internal control vector it was co­
transfected with, the HIV-2 pROD10 LTR inserted into the pGL3E reporter vector (3E-ROD) directed 
significantly higher levels of firefly luciferase expression than the promoterless pGL3E reporter vector, or 
the SV40 promoter within the pGL3C reporter vector (Figure 4.6, pg 158). The difference between the 
level of firefly luciferase expression directed by pGL3E and that directed by 3E-ROD is taken a measure 
of the increase in transcriptional activity directed by the pGL3E vector upon insertion of the HIV-2 
pRODio LTR. In the absence of any tram effects between the pROD,0 LTR and the promoter within the 
co-transfected internal control vector, the increase in activity between the pGL3E and 3 E-ROD firefly 
luciferase values would be the same whether co-transfected with pRL-CMV, pRL-TK, or pRL-SV40. In 
Figure 4.8, pg 161, the graph showing the calculated increases between the pGL3E and 3E-ROD firefly
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luciferase values when co-transfected with pRL-CMV, pRL-TK, and pRL-SV40 showed that this was not 
the case. The largest difference between the two values occurred when cotransfections were performed 
using the pRL-SV40 vector. The 795-fold increase in activity of the pGL3E vector possessing an HIV-2 
pRODio LTR was significantly higher than the increases of 280.8-fold and 310.5-fold directed by the 
same vector in the presence of the CMV and HSV-TK promoters respectively. This result demonstrated 
that the activity of the HIV-2 pRODio LTR was adversely affected least when cotransfected with pRL- 
SV40, the reporter vector containing the SV40 promoter.
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Figure 4.8 Comparison of the fold increase in firefly luciferase expression between the pGL3E vector 
lacking a promoter and the 3E-ROD vector containing the HIV-2 pROD10 LTR, when cotransfected with 
each of three Renilla luciferase internal control reporter vectors, pRL-CMV, pRL-TK, and pRL-SV40, at 
a ratio of 1:1.
The promoters within an optimal internal control vector -  experimental reporter vector pairing would not 
experience any trans effects when cotransfected. While our results indicated that the HIV-2 pROD10 
LTR appeared to experience the lowest trans effects when cotransfected with pRL-SV40 (Figure 4.8, pg 
161), the SV40 promoter within this vector appeared to experience the highest trans effects of the internal 
controls tested when co-transfected with 3E-ROD (Figure 4.7, pg 160). This could potentially lead to 
problems with Renilla luciferase detection, affecting the ability of pRL-SV40 to act as an efficient and 
reproducible internal control vector. The results shown in Figure 4.6, pg 158, and Figure 4.7, pg 160,
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demonstrated that the HSV-TK promoter contained in pRL-TK experienced the least trans effects of all 
the internal control vectors when co-transfected with 3E-ROD. Moreover, second to pRL-SV40, pRL-TK 
exerted the lowest trans effects upon the HIV-2 pRODio LTR (Figure 4.8, pg 161). Based on these 
findings the pRL-TK vector was selected for use as the internal control vector in all further cotransfection 
experiments.
4.4.4 Selection o f the cotransfection ratio ofpRL-TK : pGL3E-HIV-2 LTR
A previous study demonstrating the trans effects experienced by the promoters contained within co­
transfected vectors indicated that such effects might be reduced by increasing the ratio between the co­
transfected vectors (Farr & Roman, 1992). In order to determine the optimal cotransfection ratio of 
experimental reporter vector DNA to internal control vector DNA, the trans effects between the HIV-2 
pRODio LTR and the HSV-TK promoter in the firefly and Renilla luciferase reporter vectors respectively, 
were assessed over a range of different cotransfection ratios. HEK293 cells were co-transfected in 12 
well dishes with different ratios of 3E-ROD and pRL-TK DNA according to die protocol described in 
section 2.2.4.4a. Exact 3E-ROD - pRL-TK ratios are given in the legend of Figure 4.9, pg 163. 
Following 48h, cells were harvested and lysed according to the protocol described in section 2.2.4.5 and 
the firefly and Renilla luciferase enzyme activity measured using the dual-luciferase assay system 
(Promega Ltd) and luminometry (Canberra-Packard Topcount) (see section 2.2.5). Firefly and Renilla 
luciferase background activity was assessed (section 2.2.S.2) and subtracted from all corresponding 
measurements. Firefly and Renilla luciferase values measured at each ratio were plotted and are shown in 
Figure 4.9, pg 163. The results shown in Figure 4.9, pg 163, indicate an inversely proportional 
relationship between the amount of pRL-TK within the transfection mixture and the promoter activity of 
the HIV-2 pROD10 LTR. The amount of 3E-ROD within each of the cotransfection mixtures was kept 
constant, while the level of internal control Renilla luciferase reporter vector, pRL-TK was reduced by 
dilution. If the trans effects experienced by the two promoters were the same at each ratio, the level of 
firefly luciferase expression directed by the HTV-2 pROD10 LTR would be constant. The results shown in 
Figure 4.9, pg 163, demonstrated that this was not the case. As the level of pRL-TK within the 
cotransfection mixture was reduced, with increasing pRL-TK:3E-ROD ratios, the level of firefly 
luciferase gene expression directed by the HTV-2 pRODio LTR increased. The highest level of firefly 
luciferase expression directed by the HIV-2 pRODio LTR was observed at the highest dilution of pRL-
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TK, 1:50. These data suggested that negative trans effects between the two promoters were being 
experienced and could be reduced by increasing the ratio between the two reporter vectors.
Although optimal firefly luciferase gene expression was obtained at the pRL-TK:3E-ROD ratio of 1:50, 
levels of Renilla luciferase expression at this ratio, and ratios of 1:40 and 1:20, were at the lower end of 
detectability by the dual-luciferase assay. The optimal ratio of cotransfection has to be a compromise 
between a reduction of trans effects between the promoters, and the quantity of vector required to give a 
reproducible and detectable level of reporter gene expression. Therefore all subsequent cotransfections 
were performed at a pRL-TK:3E-ROD ratio of 1:10. This ratio provided some reduction in the trans 
effects experienced between the two promoters, but still ensured detectable levels of reporter gene 
expression.
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Figure 4.9 Comparison of firefly and Renilla luciferase expression at different cotransfection ratios. 
Columns 1-2 represent firefly and Renilla luciferase expression directed when 1.25pg 3E-ROD and 
1.25fig of pRL-TK (2.5pg total DNA, 1:1 pRL-TK: 3E-ROD ratio) were cotransfected into HEK293 
cells.
Columns 3-4 represent firefly and Renilla luciferase expression directed when 1.25pg 3E-ROD, 0.125pg 
pRL-TK, and 1.125|xg of HSDNA (2.5pg total DNA, 1:10 pRL-TK: 3E-ROD ratio) were cotransfected. 
Columns 5-6 represent firefly and Renilla luciferase expression directed when 1.25pg 3E-ROD, 12.5ng 
pRL-TK, and 1.2375pg of HSDNA (2.5pg total DNA, 1:20 pRL-TK: 3E-ROD ratio) were cotransfected. 
Columns 7-8 represent firefly and Renilla luciferase expression directed when 1.25pg 3E-ROD, 1.25ng 
pRL-TK, and 1.249pg of HSDNA (2.5pg total DNA, 1:40 pRL-TK: 3E-ROD ratio) were cotransfected. 
Columns 9-10 represent firefly and Renilla luciferase expression directed when 1.25pg 3E-ROD, 0.125ng 
pRL-TK, and 1.249pg of HSDNA (2.5pg total DNA, 1:50 pRL-TK: 3E-ROD ratio) were cotransfected.
163
4.4.5 Repeatability o f the dual-luciferase detection assay 
In order to determine the repeatability of the dual-luciferase detection assay, the lysates from ten different 
LTR clone cotransfections (performed and prepared according to the protocols described in sections 
2.2.4.4a and 2.2.4.5) were assayed in duplicate using the dual-luciferase assay (see section 2.2.5). Firefly 
and Renilla luciferase background activity was assessed (section 2.2.5.2) and subtracted from all 
corresponding measurements. The normalised firefly luciferase values (normalised = firefly luciferase 
value divided by the Renilla luciferase value measured in the same well) for each of the ten lysates were 
plotted against their duplicate values in order to assess the variation between wells assayed in duplicate. 
The high correlation coefficient obtained (R2 = 0.9888) when regression analysis was performed on this 
data set indicated that very little variation was observed between the two normalised luciferase values 
produced from the duplicate detection assays (Figure 4.10, pg 165). Therefore, samples were assayed in 
singlicate only from this point on.
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Figure 4.10 Comparison of normalised firefly luciferase chemiluminescence from the same transfected 
cell lysate measured in duplicate wells (n=10). Regression analysis of well A chemiluminescent values 
plotted against well B chemiluminescent values is shown.
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4.5 Transient cotransfection of Jurkat and THP-1 cells
Transient transfection allows the rapid analysis of regulatoiy elements through reporter gene expression. 
When cells are transiently transfected, the DNA is introduced into the nucleus of the cell but does not 
integrate into the chromosomes. This means that many copies of the gene of interest are present, leading 
to high levels of expressed protein. Every cell type has a characteristic set of requirements for optimal 
introduction of vector DNA. Several different transient transfection techniques are currently available; 
the technique used is an important factor in determining the transfection efficiency of the cell type. In 
order to obtain the most favourable cotransfection conditions for the Jurkat and THP-1 cell lines in which 
the comparative HTV-2 LTR studies were to be performed, a number of optimisation experiments were 
carried out.
4.5.1 Transient cotransfection o f nonadherent cell lines
Transient transfection protocols utilising DEAE-dextran- or calcium phosphate-mediated gene transfer 
have been widely used to transfect non-adherent cell lines such as the Jurkat T-cell-like cell-line, and the 
THP-1 monocyte-like cell-line. Both techniques produce a chemical environment that induces the 
attachment of DNA to the cell surface; the DNA is then endocytosed and transported to the cell nucleus. 
Although these techniques are relatively simple and reproducible, both induce significant cytotoxic 
effects and require transfected cells to be temporarily grown in reduced serum conditions. This often 
leads to slow recovery rates for transfected cells, resulting in reduced levels of protein expression. Non­
adherent cultures are also commonly transfected by electroporation, a technique that uses an electric field 
to open up pores in the cell, through which die DNA diffuses. A significant disadvantage of this 
technique is that approximately 5-fold greater quantities of DNA and cells are needed than in either of the 
above two methods.
At the time of this study two new transfection reagents became available that claimed to result in 
outstanding transfection efficiencies while being significantly less toxic to cells than the previously 
described transfection reagents (Qiagen). The first was Superfect (Qiagen), this reagent is a specifically 
designed activated dendrimer possessing branches, radiating in a spherical structure that terminate in 
charged amino groups. When complexed with DNA the Superfect complex possesses a net positive 
charge which allow it to bind to negatively charged receptors (e.g. sialylated glycoproteins) on the surface 
of eukaryotic cells. Endocytosis and transport to the cellular nucleus follows. The second reagent, called
166
Effectene (Qiagen), is a non-liposomal lipid reagent that transfers DNA into mammalian cells in 
combination with a special DNA-condensing reagent, named ‘enhancer’. Since this study called for large 
numbers of transfection experiments to be performed with the non-adherent Jurkat and THP-1 cell-lines, 
we opted to use the new reagents, based upon their enhanced transfection efficiencies and the reduced 
potential for cytotoxic effects in comparison to the more classical transfection techniques.
Optimal transfection is influenced by several parameters, including cell density, cell type, the amount of 
DNA transfected, and the transfection reagent to DNA ratio. Jurkat and THP-1 cell-lines were transfected 
using both Superfect and Effectene reagents in an attempt to establish which reagent directed the highest 
transfection efficiency in which cell-line.
4.5.2 Optimisation o f transient cotransfections using Superfect and Effectene transfection 
reagents.
In order to determine which transfection reagent directed the greatest transfection efficiency in which 
cell-line four sets of cotransfections were performed. Each cell-line was cotransfected using each 
transfection reagent, over a range of DNA concentrations at a number of different DNA:transfection 
reagent ratios, such that the conditions, in addition to the transfection reagent, giving the greatest 
transfection efficiency in each cell-line could be determined simultaneously. The level of reporter gene 
expression directed in the optimal Superfect transfection for Jurkat and for THP-1 cells was compared to 
the level of reporter gene expression directed in the optimal Effectene transfection in each cell-line. In 
this way, it was possible to determine whether Superfect or Effectene directed the greatest transfection 
efficiencies in each cell-line, and at what DNA concentration and DNA:transfection reagent ratio.
4.5.2.1 Transfection o f Jurkat cells using Superfect
When following the Superfect protocol, Jurkat cells were cotransfected in 6-well dishes, each well was 
seeded with approximately 2 x 106 cells. Each of three different amounts of DNA (lpg, 2pg, and 4pg of 
3E-ROD and pRL-TK DNA at a ratio of 10:1) were transfected into Jurkat cells using three different 
DNA:Superfect reagent ratios (1:2,1:5 and 1:10); according to the protocol described in section 2.2.4.6a. 
Exact amounts of DNA and Superfect are given in the legend of Figure 4.11, pg 169. Cotransfections 
were performed in duplicate. Following 48h of incubation, cells were harvested and lysed according the 
protocol described in section 2.2.4.7, and the firefly and Renilla luciferase enzyme activity measured 
using the dual-luciferase assay system (Promega Ltd) and luminometry (Canberra-Packard Topcount)
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(see section 2.2.5). Firefly and Renilla luciferase background activity was assessed (section 2.2.5.2) and 
subtracted from all corresponding measurements. Each firefly luciferase activity measurement 
corresponding to the enzyme expression directed by the HTV-2 pROD10 LTR was normalised for 
transfection variation by dividing it by the corresponding cotransfected Renilla luciferase activity 
measurement. Results are presented as the mean normalised firefly luciferase activity for each 
experiment, with each value being calculated from a duplicate cotransfection (Figure 4.11, pg 169).
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Figure 4.11 Evaluation of the optimal Superfect (Qiagen) cotransfection conditions in the Jurkat cell line. 
Columns 1-3 represent normalised firefly luciferase activity directed by the pROD,0LTR when 900ng 3E- 
ROD, 90ng of pRL-TK, and lOng HSDNA (lpg total DNA) were transfected with increasing levels of 
transfection reagent, 1.8pl (1:2), 3.6pl (1:5) and 9pl (1:10) of Superfect respectively.
Columns 4-6 represent normalised firefly luciferase activity directed by the pROD|0LTR when 1800ng 
3E-ROD, 180ng pRL-TK, and 20ng HSDNA (2pg total DNA) were transfected with increasing levels of 
transfection reagent, 3.6pl (1:2), 9pl (1:5) and 18pi 1:10) of Superfect respectively.
Columns 7-9 represent normalised firefly luciferase activity directed by the pROD,0LTR when 3600ng 
3E-ROD, 360ng pRL-TK, and 40ng HSDNA (4pg total DNA) were transfected with increasing levels of 
transfection reagent, 7.2pl (1:2), 18pl (1:5) and 36pl (1:10) of Superfect respectively. Cotransfections 
were performed in duplicate.
The results in Figure 4.11, pg 169, indicated the existence of two inversely proportional relationships. 
The first was between DNA:Superfect ratio and reporter gene expression, the second between DNA 
concentration and reporter gene expression. Regardless of whether cotransfections were performed with 
a total DNA concentration of 1, 2, or 4pg, levels of reporter gene expression were seen to decrease as the 
ratio between the DNA and Superfect reagent in the cotransfection mixture increased. At each of the 
three DNA concentrations (1,2, and 4pg), cotransfections performed at the DNA:Superfect ratio of 1:10 
directed the lowest levels of normalised luciferase activity while, (with the exception of the cotransfection 
performed with lpg DNA, DNA:Superfect ratio 1:2) cotransfections performed at ratio of 1:2 directed the 
highest levels of normalised luciferase activities (Figure 4.11, columns 3, 6, and 9, vs. columns 1, 4, and 
7, pg 169).
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In addition, at each ratio a gradual decrease in normalised firefly luciferase activity was noted as the DNA 
concentration within the cotransfection mixture was increased from lpg to 2pg to 4|ng (Figure 4.11, 
columns 2 vs. 5 vs. 8, and columns 3 vs. 6 vs. 9, pg 169). Each of the three cotransfections performed 
with lpg of DNA (Figure 4.11, columns 1-3, pg 169) directed higher levels of normalised luciferase 
activity than the three cotransfections performed with 4pg of DNA (Figure 4.11, columns 7-9, pg 169). 
The highest levels of normalised luciferase activity were observed when either lpg of DNA was 
transfected with Superfect at a 1:5 dilution, or 2pg of DNA was transfected with Superfect at a 1:2 
dilution. The lowest levels of activity were found in cotransfections performed with the highest 
concentration of DNA (4pg) and DNA:Superfect ratio (1:10).
4.S.2.2 Transfection o f Jurkat cells using Effectene
When following the Effectene protocol, Jurkat cells were cotransfected in 6-well dishes, each well was 
seeded with approximately 2 x 106 cells. As with the Superfect optimisation, Jurkats were transfected 
with three different amounts of DNA (0.2pg, 0.4pg, and 0.8pg of 3E-ROD and pRL-TK DNA at a ratio 
of 10:1) using three different DNA:Effectene reagent ratios (1:10, 1:25 and 1:50); according to the 
protocol described in section 2.2.4.6b. The ‘enhancer’ reagent volume within each cotransfection mixture 
was adjusted with respect to the Effectene reagent. Exact amounts of DNA, Effectene, and ‘enhancer’ are 
given in the legend of Figure 4.12, pg 171. Cotransfections were performed in duplicate. Following 48h 
of incubation, cells were harvested and lysed according the protocol described in section 2.2.4.7, and the 
firefly and Renilla luciferase enzyme activity measured using the dual-luciferase assay system (Promega 
Ltd) and luminometiy (Canberra-Packard Topcount) (see section 2.2.5). Firefly and Renilla luciferase 
background activity was assessed (section 2.2.5.2) and subtracted from all corresponding measurements. 
Each firefly luciferase activity measurement was normalised for transfection variation by dividing it by 
the corresponding cotransfected Renilla luciferase activity measurement. Results are presented as the 
mean normalised firefly luciferase activity for each experiment, with each value being calculated from a 
duplicate cotransfection (Figure 4.12, pg 171).
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Figure 4.12 Evaluation of the optimal Effectene (Qiagen) cotransfection conditions in the Jurkat cell line. 
Columns 1-3 represent normalised firefly luciferase activity directed by the pROD10LTR when 180ng 3E- 
ROD, 18ng pRL-TK, 2ng HSDNA (0.2pg total DNA) were transfected with 1.6fil of ‘enhancer’ and 
increasing levels of transfection reagent, 2pl (1:10), 5pl (1:25) and lOpl (1:50) of Effectene respectively. 
Columns 4-6 represent normalised firefly luciferase activity directed by the pROD10LTR when 360ng 3E- 
ROD, 36ng pRL-TK, and 4ng HSDNA (0.4pg total DNA) were transfected with 3.2(il of ‘enhancer’ and 
increasing levels of transfection reagent, 4pl (1:10), 10pl (1:25) and 20pl 1:50) of Effectene respectively. 
Columns 7-9 represent normalised firefly luciferase activity directed by the pROD10LTR when 720ng 3E- 
ROD, 72ng pRL-TK, and 8ng HSDNA (0.8pg total DNA) were transfected with 6.4pl of ‘enhancer’ and 
increasing levels of transfection reagent, 8pl (1:10), 20pl (1:25) and 40pl (1:50) of Effectene respectively. 
Cotransfections were performed in duplicate.
The results shown in Figure 4.12, pg 171, indicated the existence of two directly proportional 
relationships. In direct contrast to the Superfect data (Figure 4.11, pg 169) normalised firefly luciferase 
activity was found to increase as the DNA:Effectene ratio was increased within the cotransfection 
mixture. At each of the three DNA concentrations, levels of normalised luciferase activities directed in 
cotransfections performed at a DNA:Effectene ratio of 1:50 were higher than activities directed in 
cotransfections performed at the 1:10 ratio (with the exception of the 0.8pg 1:50 cotransfection, column 
9).
In addition, levels of normalised firefly luciferase activity were found to increase at each of the 
DNA:Effectene ratios as the total amount of cotransfected DNA in the cotransfection mixture was 
increased. At each ratio normalised firefly luciferase activities were seen to increase as DNA 
concentration was increased from 0.2pg to 0.4pg to 0.8pg (Figure 4.12, columns 1 vs. 4 vs. 7, and
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columns 2 vs. 5 vs. 8, pg 171). Following this it was expected that the cotransfection performed with the 
greatest amount of DNA (0.8pg) at the highest DNA:Effectene ratio (1:50) would direct the highest level 
of normalised firefly luciferase activity, however the activity measured for this cotransfection was 
unexpectedly low. Cotransfections performed with either 0.8pg of DNA at a DNA:Eflfectene ratio of 
1:25, or with 0.4pg of DNA at a DNA:Effectene ratio of 1:50 were found to direct the highest levels of 
normalised firefly luciferase activity.
When the normalised firefly luciferase activity value obtained under optimal conditions for the Superfect 
transfection reagent (Figure 4.11, column 4, pg 169) was compared to the normalised firefly luciferase 
activity obtained in the optimal Effectene reagent transfection in Jurkat cells (Figure 4.12, column 6, pg 
171) it became clear that Superfect directed the highest transfection efficiency (Figure 4.13, pg 172). The 
cotransfection performed using 2pg of DNA at a 1:2 ratio with Superfect gave a normalised firefly 
luciferase activity value that was approximately 2-fold higher than the activity directed when reporter 
vectors were cotransfected with 0.4pg of DNA at a DNA:Eflfectene ratio of 1:50 (Figure 4.13, pg 172). 
Therefore, all further transfection experiments using Jurkat cells were performed in 6-well dishes, using 
2pg of DNA at a 1:2 ratio with Superfect.
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Figure 4.13 Comparison of normalised firefly luciferase expression directed by 3E-ROD in the Jurkat 
cell-line when cotransfected in optimal conditions using Superfect or Effectene as the transfection 
reagent.
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4.5.2.3 Transfection o f THP-1 cells using Superfect
2 x 106 THP-1 cells were cotransfected in 6-well dishes using a similar pipetting scheme to the one 
described for Jurkat cells (see section 4.5.2.1), in order to determine the optimum transfection conditions 
for THP-1 cells when using the Superfect reagent. Cells were cotransfected with three different amounts 
of DNA (lpg, 2pg, and 4pg of 3E-ROD and pRL-TK DNA at a ratio of 10:1) at three different 
DNA:Superfect reagent ratios (1:2, 1:5 and 1:10); according to the protocol described in section 2.2.4.6a. 
Exact amounts of DNA and Superfect are given in the legend of Figure 4.14, pg 174. Cotransfections 
were performed in duplicate. Following 48h of incubation, cells were harvested and lysed according the 
protocol described in section 2.2.4.7, and the firefly and Renilla luciferase enzyme activity measured 
using the dual-luciferase assay system (Promega Ltd) and luminometry (Canberra-Packard Topcount) 
(see section 2.2.5). Firefly and Renilla luciferase background activity was assessed (section 2.2.5.2) and 
subtracted from all corresponding measurements. Firefly luciferase activity was normalised for 
transfection variation by dividing it by the corresponding cotransfected Renilla luciferase activity 
measurement. Results are presented as the mean normalised firefly luciferase activity for each 
experiment, with each value being calculated from a duplicate cotransfection (Figure 4.14, pg 174).
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Figure 4.14 Evaluation of the optimal Superfect (Qiagen) cotransfection conditions in the THP-1 cell line. 
Columns 1-3 represent normalised firefly luciferase activity directed by the pROD,0LTR when 900ng 3E- 
ROD, 90ng of pRL-TK, and lOng HSDNA (lpg total DNA) were transfected with increasing levels of 
transfection reagent, 1.8(il (1:2), 3.6fil (1:5) and 9pl (1:10) of Superfect respectively.
Columns 4-6 represent normalised firefly luciferase activity directed by the pROD10LTR when 1800ng 
3E-ROD, 180ng pRL-TK, and 20ng HSDNA (2|ig total DNA) were transfected with increasing levels of 
transfection reagent, 3.6pl (1:2), 9fil (1:5) and 18fil 1:10) of Superfect respectively.
Columns 7-9 represent normalised firefly luciferase activity directed by the pROD10LTR when 3600ng 
3E-ROD, 360ng pRL-TK, and 40ng HSDNA (4fig total DNA) were transfected with increasing levels of 
transfection reagent, 7.2pl (1:2), 18fil (1:5) and 36pl (1:10) of Superfect respectively. Cotransfections 
were performed in duplicate.
The results in Figure 4.14, pg 174, demonstrated that THP-1 cells behaved similarly to Jurkat cells when 
cotransfected with the Superfect reagent, although the effects of changing the DNA concentration and 
DNA:Superfect ratio on transfection efficiency appeared to be more significant. The two inversely 
proportional relationships that were observed in Figure 4.11, pg 169, were also observed in Figure 4.14, 
pg 174, but appeared more pronounced. Normalised firefly luciferase activities were found to decrease 
significantly at each of the three DNA concentrations when the DNA:Superfect ratio was increased 
(Figure 4.14, columns 1, 4, and 7 vs. columns 3, 6, and 9, pg 174). Cotransfections performed at a 
DNA:Superfect ratio of 1:10 directed significantly lower levels of normalised luciferase activity than 
cotransfections performed at a ratio of 1:2 or 1:5, irrespective of the total cotransfected DNA 
concentration (i.e. 1, 2 or 4(ig). At each of the three DNA concentrations the DNA:Superfect ratio of 1:2 
directed the highest levels of normalised luciferase activity.
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In addition, the level of normalised firefly luciferase activity at each DNA:Superfect ratio was found to 
decrease significantly as the DNA concentration within the cotransfection mixture was increased from 
lpg to 2pg to 4fig (Figure 4.11, columns 2 vs. 5 vs. 8, and columns 3 vs. 6 vs. 9, pg 169). Normalised 
firefly luciferase activities from the cotransfections performed with 4pg of DNA (Figure 4.14, columns 7- 
9, pg 174) directed significantly lower activities than the activities from the three cotransfections 
performed with l|ig of DNA (Figure 4.14, columns 1-3, pg 174). The highest levels of normalised 
luciferase activity were observed when lpg of DNA was transfected with Superfect at a 1:2 dilution. As 
observed with Jurkat cells the lowest levels of activity were found in cotransfections performed with the 
highest concentration of DNA (4pg) and DNA:Superfect ratio (1:10). However, even at optimal 
cotransfection conditions overall levels of normalised firefly luciferase activity directed by THP-1 cells 
were much lower.
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4.5.2.4 Transfection ofTHP-1 cells using Effectene
2 x 106 THP-1 cells were cotransfected in 6-well dishes using a similar pipetting scheme to the one 
described for Jurkat cells (see section 4.5.2.2), in order to determine the optimum transfection conditions 
for THP-1 cells when using the Effectene reagent. Cells were cotransfected with three different amounts 
of DNA (0.2pg, 0.4pg and 0.8pg) using three different DNA:Eflfectene reagent ratios (1:10, 1:25 and 
1:50); according to the protocol described in section 2.2.4.6b. The ‘enhancer’ reagent volume within each 
cotransfection mixture was adjusted with respect to the Effectene reagent. Exact amounts of DNA, 
Effectene, and ‘enhancer’ are given in the legend of Figure 4.15, pg 177. Cotransfections were performed 
in duplicate. Following 48h of incubation, cells were harvested and lysed according the protocol 
described in section 2.2.4.7, and the firefly and Renilla luciferase enzyme activity measured using the 
dual-luciferase assay system (Promega Ltd) and luminometry (Canberra-Packard Topcount) (see section 
2.2.5). Firefly and Renilla luciferase background activity was assessed (section 2.2.5.2) and subtracted 
from all corresponding measurements. Each firefly luciferase activity measurement was normalised for 
transfection variation by dividing it by the corresponding cotransfected Renilla luciferase activity 
measurement. Results are presented as the mean normalised firefly luciferase activity for each duplicate 
cotransfection (Figure 4.15, pg 177).
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Figure 4.15 Evaluation of the optimum reporter DNA:Effectene transfection ratio in the THP-1 cell line. 
Columns 1-3 represent normalised firefly luciferase activity directed by the pROD|0LTR when 180ng 3E- 
ROD, 18ng pRL-TK, 2ng HSDNA (0.2pg total DNA) were transfected with 1.6pl of ‘enhancer’ and 
increasing levels of transfection reagent, 2pl (1:10), 5pl (1:25) and 10pl (1:50) of Effectene respectively. 
Columns 4-6 represent normalised firefly luciferase activity directed by the pROD10LTR when 360ng 3E- 
ROD, 36ng pRL-TK, and 4ng HSDNA (0.4pg total DNA) were transfected with 3.2pl of ‘enhancer’ and 
increasing levels of transfection reagent, 4pl (1:10), lOpl (1:25) and 20pl 1:50) of Effectene respectively. 
Columns 7-9 represent normalised firefly luciferase activity directed by the pROD]0LTR when 720ng 3E- 
ROD, 72ng pRL-TK, and 8ng HSDNA (0.8pg total DNA) were transfected with 6.4fil of ‘enhancer’ and 
increasing levels of transfection reagent, 8pl (1:10), 20pl (1:25) and 40pl (1:50) of Effectene respectively. 
Cotransfections were performed in duplicate.
The results shown in Figure 4.15, pg 177, indicated the existence of an inversely proportional relationship 
between normalised firefly luciferase activity and DNA:Effectene ratio, and a directly proportional 
relationship between normalised firefly luciferase activity and the total amount of DNA transfected.
At each of the three DNA concentrations, levels of normalised luciferase activity were seen to decrease as 
the ratio between DNA and Effectene increased. Cotransfections performed at a DNA:Effectene ratio of 
1:50 directed lower levels of normalised firefly luciferase activities than those performed with the same 
amount of DNA but at a DNA:Effectene ratio of 1:10. This finding was in contrast to the data generated 
from the Effectene transfection of Jurkat cells, where, at each of the three DNA concentrations, 
cotransfections performed at a DNA:Effectene ratio of 1:50 directed the highest normalised firefly 
luciferase activities (Figure 4.12, pg 171). However, a similar pattern was observed when THP-1 cells 
were cotransfected with the Superfect reagent (Figure 4.14, pg 174).
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Similar to the data generated when Jurkat cells were cotransfected with Effectene (Figure 4.12, pg 171), 
levels of normalised firefly luciferase activity were found to increase at each of the DNA: Effectene ratios 
as the total amount of DNA within the cotransfection mixture was increased from 0.2pg to 0.4pg to 0.8pg 
(Figure 4.15, columns 1 vs. 4 vs. 7, and columns 2 vs. 5 vs. 8, pg 177). Following this, cotransfections 
performed with the greatest amount of DNA (0.8pg) at the lowest DNA:Effectene ratio, 1:10, were found 
to direct the highest levels of normalised firefly luciferase activity.
When the normalised firefly luciferase activity value obtained under optimal conditions for the Effectene 
transfection reagent (Figure 4.15, column 7, pg 177) was compared to the normalised firefly luciferase 
activity obtained in the optimal Superfect reagent transfection in THP-1 cells (Figure 4.14, column 1, pg 
174) it became clear that Effectene directed the highest transfection efficiency (Figure 4.16, pg 178). The 
cotransfection performed using 0.8pg of DNA at a 1:10 ratio with Effectene gave a normalised firefly 
luciferase activity value that was 5-fold higher than the activity directed when reporter vectors were 
cotransfected with lpg of DNA at a DNA:Superfect ratio of 1:2 (Figure 4.16, pg 178). Therefore, all 
further transfection experiments using THP-1 cells were performed in 6-well dishes, using 0.8pg of DNA 
at a 1:10 ratio with Effectene.
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Figure 4.16 Comparison of normalised firefly luciferase expression directed by 3E-ROD in the THP-1 
cell-line when cotransfected in optimal conditions using Superfect or Effectene as the transfection 
reagent.
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4.5.3 Further optimisation o f transient cotransfections using Superfect and Effectene 
transfection reagents.
4.5.3.1 Optimal cell density for greatest transfection efficiency
In view of the fact that large numbers of transfection experiments were to be performed during the course 
of this study, minimisation of the quantities of DNA, cells, and reagents used in each experiment was 
paramount. The optimisation of the concentrations of DNA and transfection reagents have been 
described above, however, the manufacturer’s instructions accompanying the Superfect and Effectene 
reagents indicated that each reagent could work over a range of cell densities. In an attempt to reduce the 
number of cell required to perform each experiment cotransfections were performed in six well dishes 
seeded with 1 x 106 cells/well rather than 2 x 106 cells/well using the optimised conditions described for 
the Superfect transfection of Jurkat cells and the Effectene transfection of THP-1 cells. Cotransfections 
were performed in duplicate and a mean normalised firefly luciferase activity for each cotransfection was 
determined (see sections 2.2.4.6, and 2.2.5). Results are presented as the mean normalised firefly 
luciferase activity for each duplicate cotransfection performed (Figure 4.17, pg 179).
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Figure 4.17 Comparison of normalised firefly luciferase activity detected when 1 x 106 and 2 x 106 Jurkat 
cells were cotransfected with 1800ng 3E-ROD and 200ng of pRL-TK (2fig total DNA) using 3.6pl of 
Superfect (DNA:Superfect ratio, 1:2) according to the protocol described in section 2.2.4.6.a.
At a cell density of 1 x 106 cells/well, levels of normalised firefly luciferase were reduced by 
approximately 12-fold in the Jurkat cell transfection (Figure 4.17, pg 179), and to undetectable levels 
within the THP-1 cell data set (data not shown). Based on these results both cell lines were transfected at 
a cell density of 2 x 106 cells/well.
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4.53.2 Optimal post-cotransfection conditions for greatest transfection efficiency
The greatest transfection efficiency in Jurkat cells had been achieved when the Superfect transfection 
reagent was used to cotransfect cells with 2pg of DNA at a DNA:Superfect ratio of 1:2. According to the 
manufacturers (Qiagen), transfection efficiency could be further enhanced under optimal Superfect 
transfection conditions by adding a washing step to the protocol 2 hours post-transfection. 2 x 106 Jurkat 
cells were cotransfected according to the conditions described in section 2.2.4.6a. Two hours post­
transfection cells were pelleted and resuspended in fresh complete medium (Appendix I). 48 hours post­
transfection cells were harvested and lysed (2.2.4.7) and normalised firefly luciferase activities were 
determined (2.2.5). Cotransfections were performed in duplicate. Results are presented as the mean 
normalised firefly luciferase activity for each duplicate cotransfection (Figure 4.18, pg 180).
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Figure 4.18 Comparison of normalised firefly luciferase activity detected following a cotransfection 
procedure including a washing step 2 hours post-transfection, and a cotransfection procedure without a 
washing step 2 hours post-transfection. Cotransfections were performed using 2 x 106 Jurkat cells under 
optimised conditions (section 4.5.2.1).
The results obtained following this procedure indicated that the additional washing step did not greatly 
improve the final level of gene expression (Figure 4.18, pg 180). Slightly lower levels of reporter 
expression were noted in the transfected cells that had been washed. Consequently, the extra washing 
step was not added to the final Superfect transfection protocol for Jurkat cells.
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4.6 Reproducibility of cotransfection
4.6.1 Variation o f luciferase expression within a duplicate cotransfection
In order to assess the variation in firefly and Renilla luciferase expression from duplicate cotransfections 
the normalised luciferase activities from the cotransfections of ten different HIV-2 LTR clones were 
plotted against the values obtained in the duplicate cotransfections. The high correlation coefficient 
obtained (R2 = 0.9848) when regression analysis was performed on this data set indicated that very little 
variation in firefly or Renilla luciferase expression occurred between wells transfected in duplicate 
(Figure 4.19, pg 181). Therefore, the normalised luciferase activity values obtained from duplicate 
cotransfections could be pooled without severely altering the final normalised luciferase expression value 
calculated to represent each HIV-2 LTR clone.
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Figure 4.19 Comparison of normalised firefly luciferase activity from duplicate cotransfections. This 
graph compares the normalised firefly luciferase activity expressed from each of the two replicates of a 
duplicate cotransfection, in ten instances (n=10). Ten different HIV-2 LTR clones were cotransfected 
into Jurkat cells in duplicate with the internal control vector pRL-TK at a ratio of 10:1. Regression 
analysis of well A chemiluminescent values plotted against well B chemiluminescent values are shown.
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4.6.2 Variation o f luciferase expression in cotransfections performed at two different time 
points
Plotting the normalised luciferase activities from the cotransfection of ten different HIV-2 LTR clones 
against the values taken from the same cotransfections performed one week later assessed the 
reproducibility of cotransfection (Figure 4.20, pg 182). The average normalised luciferase activity values 
taken from a triplicate cotransfection of each of the ten different HIV-2 LTR clones were plotted. The 
high correlation coefficient obtained (R2 = 0.8796) when regression analysis was performed on this data 
set indicated that very little variation was observed in the level of firefly and Renilla luciferase expression 
directed by the two reporter vectors when co-transfected at two different time points. This enabled the 
comparison of results obtained from LTR clones co-transfected at different time points, and ensured that 
any differences in activity resulting from cotransfection experiments could be noted and would not be as a 
result of the variation in the cotransfection efficiency of different experiments.
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Figure 4.20 Evaluation of cotransfection reproducibility. This graph compares normalised firefly 
luciferase activity expressed from the same clone cotransfected into Jurkat cells with the internal control 
vector pRL-TK, at two different time points (n=10). Regression analysis of well A chemiluminescent 
values plotted against well B chemiluminescent values is shown.
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4.7 Summary and discussion
This chapter focused on the optimisation of an efficient HIV-2 LTR cloning strategy, the development of 
a sensitive and reproducible reporter detection assay, and the evaluation of optimal cotransfection 
conditions within the Jurkat and THP-1 cell-lines, for the assessment of the activities of HTV-2 LTRs 
taken from a wide variety of viral sources.
The dual-luciferase reporter assay (Promega Ltd) offered several advantages over other available reporter 
assays for the analyses of genetic regulatory elements, the most important being the inclusion of an 
internal control vector, the assays’ extremely broad linear range of detection, and the speed at which the 
detection assay could be performed. The inclusion of an internal control vector enabled normalisation of 
the expression directed by the experimental promoter within the firefly luciferase reporter vector, 
effectively eliminating variability introduced into the assay by differences in transfection efficiencies and 
the number and health of the transfected cells. The broad linear range of the detection assay enabled the 
analysis of both large and small changes in promoter activity, while the speed of the detection assay 
ensured that large-scale comparative studies of HTV-2 LTR activity could be performed rapidly.
Selection of the experimental firefly luciferase reporter vector pGL3E (Promega Ltd), a reporter vector 
containing an SV40 enhancer but lacking a promoter region, ensured high levels of reporter gene 
expression in mammalian cell lines. Optimisation of linearisation and cloning techniques facilitated the 
rapid and efficient cloning of PCR amplified HIV-2 LTR sequences from diverse viral DNA sources into 
pGL3E, and resulted in the routine achievement of cloning efficiencies of up to 80%. A minimum of five 
HTV-2 LTR clones were obtained from each member of the CBL series of HTV-2 isolates and each of the 
six members of the Gambian HTV-2 cohort for use in the comparative analysis of HIV-2 LTR activity 
(Chapters 5, 6, and 7). In addition, three clones of the HTV-2 pRODio LTR were obtained for use as 
positive controls in the optimisation experiments outlined in this chapter.
Assessment of the sensitivity of the dual-luciferase detection assay showed a dynamic range spanning at 
least seven orders of magnitude, from 0.1 pg to 10pg (50pg/ml and 5mg/ml). Analysis of the stability of 
the signal emitted by the reaction catalysed by the firefly luciferase enzyme revealed only a negligible 
drop in activity over the entire dynamic range. Since the luciferase detection assay is performed in 96- 
well plates, which the luminometer reads in less than six minutes, any drop in activity that occurs in the 
wells over the course of plate reading will be negligible. Examination of the repeatability of the detection 
assay by regression analysis revealed very little variation in the normalised luciferase activity between
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wells assayed in duplicate. The sensitivity and repeatability of the luciferase detection assay ensured that 
reporter gene expression directed by promoters of varying activities could be measured in singlicate, 
accurately and reproducibly.
Evaluation of the optimal internal control vector -  experimental reporter vector cotransfection pairing 
revealed that the promoters within each of the three internal control vectors and the HIV-2 pRODio LTR 
inserted into pGL3E, experienced significant trans effects when cotransfected. Similar findings have 
been described by Farr and coworkers (Farr & Roman, 1992) when investigating the activity of the 
upstream regulatory region (URR) of a human papillomavirus (HPV6-W50). When cotransfected with a 
CAT reporter vector containing the URR and the SV40 early promoter the P-gal activity directed by the 
P-gal internal control vector pRSV P-gal was consistently found to be 7 -  10-fold lower than upon 
cotransfection with a CAT reporter vector lacking the URR (Farr & Roman, 1992). Of the three internal 
control vectors, the activity of the HSV-TK promoter contained within pRL-TK was least affected when 
cotransfected with the pGL3E reporter vector containing the HIV-2 pROD10 LTR, while the activity of 
the SV40 promoter was down-regulated the most. Compared to the CMV and SV40 promoters the TK 
promoter region is a weaker promoter region, directing low level rather than strong constitutive 
expression of Renilla expression in a variety of cell types. Therefore, as a promoter it might compete less 
for transcription factors with the HIV-2 LTR and explain the lower trans effects experienced by this 
promoter when cotransfected with 3E-ROD. Interestingly, the HTV-2 pROD10 LTR experienced the 
lowest trans effects when cotransfected with the SV40 and not the TK promoter. An explanation for this 
finding might lie in the fact that the SV40 promoter was the most downregulated of the three internal 
control vectors and was the least able therefore, to exert a competitive influence upon the transcription 
factors within the cell nucleus. However, it is apparent that the relationships between the cotransfected 
promoters and the competition for the transcription factors that bind to them are very complex. Since the 
TK promoter experienced the lowest trans effects when cotransfected with 3E-ROD clone, and the HTV-2 
pROD10 LTR experienced the second lowest trans effects when cotransfected with the vector containing 
the TK promoter, pRL-TK was selected for use as the internal control vector in all subsequent 
experiments.
Optimisation experiments performed to determine die optimal cotransfection ratio between the internal 
control vector and the experimental reporter vector revealed that the trans effects experienced between 
3E-ROD and pRL-TK could be reduced. The highest level of firefly luciferase expression was measured 
from the cotransfection performed at a ratio of 3E-ROD to pRL-TK of 50:1. Detection of Renilla
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luciferase expression at this ratio however, was only just above background. The optimal ratio of 
cotransfection has to be a compromise between a reduction of trans effects between the promoters, and 
the quantity of internal control vector required to give a reproducible and detectable level of reporter gene 
expression. Therefore, all subsequent cotransfections were performed at a 3E-ROD:pRL-TK: ratio of 
10:1. This ratio provided a 10-fold reduction in the trans effects between the two promoters, and ensured 
detectable levels of reporter gene expression.
Once optimised the dual-luciferase assay system was used to determine the optimal cotransfection 
conditions for both the Jurkat and THP-1 cell lines. Variation in DNA concentration and the ratio 
between transfection reagent and DNA had significant effects upon the transfection efficiency of both cell 
lines. When transfecting both Jurkat and THP-1 cells levels of normalised firefly luciferase activity were 
found to decrease as the level of Superfect reagent and total amount of DNA within the cotransfection 
mixture was increased. The reduction in reporter gene expression was a result of an increase in cell 
growth inhibition and cell death as the concentration of the two components was increased in the mixture, 
and could be verified visually as well as by dual luciferase assay. The reverse was true in Jurkat cells 
transfected with Effectene where levels of normalised firefly luciferase activity were found to increase as 
the concentration of Effectene and total DNA within the cotransfection mixture was increased, indicating 
that of the two reagents Superfect was more toxic than Effectene at higher concentrations in Jurkat and 
THP-1 cells. Despite this, under optimal conditions cotransfection of Jurkat cells using a low Superfect 
and total DNA concentration yielded 2-fold higher levels of normalised firefly luciferase activity than 
those measured from an optimal Effectene cotransfection of Jurkat cells. Superfect was chosen therefore 
as the reagent to transfect Jurkat cells with in all subsequent experiments. In THP-1 cells, the toxicity of 
the Superfect-DNA complex was so great that even at low concentrations the normalised firefly luciferase 
activities measured from these cotransfections were lower than most of the cotransfections performed 
using Effectene. The sensitivity of THP-1 cells to the toxicity of transfection reagents was also 
underlined by the fact that, at each of the three DNA concentrations, cotransfections performed with the 
1:50 DNA:Eflfectene ratio directed lower normalised firefly luciferase activities than the activities 
measured in the cotransfections performed at a DNA:Effectene ratio of 1:10. Under optimal 
cotransfection conditions the Effectene transfection technique yielded 5-fold higher levels of normalised 
firefly luciferase activity in THP-1 cells than the optimal Superfect technique for this cell-line, and was 
subsequently chosen as the transfection reagent for THP-1 cells. Interestingly, in line with the findings
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presented in this thesis, Qiagen now indicate in their technical resources manual that the Superfect 
reagent is not a suitable for the transfection of the THP-1 cell-line.
In an attempt to further optimise the cotransfection procedures for both Jurkat and THP-1 cells the effects 
of altering the cell density of cotransfection and including an additional washing process post-transfection 
were investigated. Reporter gene expression was reduced significantly in both Jurkat and THP-1 cells 
when the number of cells transfected was reduced from 2 x 106 cells to 1 x 106 cells. It is likely that the 
reduction in reporter gene expression is due to a smaller number of cells directing reporter gene 
expression rather than a decrease in the transfection efficiency/DNA uptake of the cells that are present. 
Following this, all subsequent cotransfections were performed using 2 x 106 Jurkat or THP-1 cells. 
Ultimately optimal conditions for transfection of both cell lines involved a compromise between reporter 
gene expression rates and cell death. Washing transfected Jurkat cells 2 hours post-transfection did not 
significantly increase normalised luciferase values or decrease growth inhibition and cell death, 
suggesting that the process of transfection rather than the presence of the transfection reagents in the cell 
media had greater effects upon cellular growth. Therefore, the additional washing step was not included 
in the final Jurkat cotransfection protocol.
Analyses of the reproducibility of cotransfection revealed no significant differences between the levels of 
normalised firefly luciferase activity taken from each well of a duplicate cotransfection. Furthermore, 
very little variation was detected between the normalised firefly luciferase values obtained from identical 
cotransfections performed one week apart. The reproducibility of the cotransfection protocols in addition 
to the inclusion of an internal control vector ensured that normalised firefly luciferase activity values 
obtained from replicate cotransfections could be pooled without severely altering the value calculated to 
represent each HTV-2 LTR clone, and that normalised firefly luciferase activity values obtained from 
cotransfections carried out at different time points could be reliably and confidently compared.
To conclude, a dual-luciferase reporter assay system capable of rapidly and reproducibly measuring die 
activity of cloned HIV-2 LTRs taken from diverse viral sources over a dynamic range extending at least 
seven orders of magnitude has been optimised. The cloning, cotransfection, and detection protocols 
utilised by the assay system have been developed to enable reproducible analyses of both large and small 
changes in HTV-2 LTR activity. In addition, optimisation of the system has ensured that results from 
assays performed at different time points can be reliably compared. Both cloning, transfection, and 
reporter assay protocols developed in this thesis are also being used to assess HTV-2 LTR activity in
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samples derived from the Caio cohort, Guinea Bissau (Okarofor et al, unpublished), and HIV-1 LTR 
activity in brain and lymph-node samples (Malik et al, unpublished).
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Chapter 5.
Functional Characterisation of the HIV-2 LTR in the CBL Series of HTV-2
Isolates.
5.1 Introduction
Following the identification of a second retrovirus in healthy female commercial sex-workers in Senegal 
in 1985 (Barin et a l, 1985), and the subsequent isolation of HIV-2 a year later, from patients with AIDS 
in Guinea Bissau and Cape Verde Islands (Clavel et al., 1986a, Brun-Vezinet et al., 1987), The Gambia 
has represented one of the major countries in the region with a significant prevalence of HTV-2 infection. 
While the prevalence of HTV-2 was very low in The Gambia in 1987 (A.Wilkins, unpublished 
observations), subsequent seroepidemiological studies have indicated a prevalence of around 1.8% to be 
present in the general population by the beginning of the 1990s (Wilkins et al, 1991a, Wilkins et al, 
1991b). HIV-2 is therefore thought to have been a relatively recent introduction into The Gambia, 
probably from nearby or neighbouring countries such as Senegal and Guinea Bissau (Schim van der Loeff 
& Aaby, 1999). Detailed studies concerning the natural history, epidemiology, and significance of HIV-2
in The Gambia have been conducted at the MRC laboratories, Fajara, located on the Atlantic coast of the 
country (Wilkins et al, 1991a, Wilkins et al., 1991b, Whittle et al., 1994, Ariyoshi et al, 1996, Whittle et 
al., 1998a).
Clinical, immunological and virological studies have led to the characterisation of HTV-2 infections, 
indicating that while HTV-2 is capable of acting as a pathogenic retrovirus, the vast majority of HTV-2 
infections are associated with a less aggressive disease course (Poulsen et al, 1989, Pepin et al, 1991b, 
Ricard et al, 1994, Norrgren et al, 1995, Ariyoshi et al, 1996, Lisse et al, 1996). In general, patients 
infected with HTV-2 experience a much more prolonged asymptomatic period of infection than had been 
previously characterised in HTV-1 infection (Pepin et al, 1991b, Whittle et al, 1994, Jaffar et al, 1997). 
Comparative epidemiological evidence has confirmed that progression to immunosuppresion and AIDS in 
the majority of cases of HIV-2 infection is slower than for HIV-1 (Adjorlolo-Johnson et al, 1994, Kanki 
et al, 1994, Marlink et al, 1994, Whittle et al, 1994, Poulsen et al., 1997). At the MRC hospital in The 
Gambia, individuals with more progressive HTV-2 infections have been identified, along with those who 
are asymptomatic (Poulsen et al, 1989, Ricard et al, 1994, Norrgren et al, 1995, Poulsen et al., 1997, 
Ariyoshi et al, 1998). Thus a broad spectrum of HTV-2 infections has been identified. The first isolates
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to be made from this country were made in collaboration with the Chester Beatty Laboratories and were 
designated the CBL series of isolates (Schultz et al, 1990).
A number of recent studies have chartered the association between levels of viral replication or viremia 
circulating within the peripheral blood of HIV-2 infected individuals, and the rate of progression to 
disease (Simon et al., 1993, Berry et al., 1998, Ariyoshi et al., 2000, Popper et al., 2000). A study by 
Ariyoshi et al has shown that base-line HIV-2 RNA load significantly predicts the rate of disease 
progression as determined by CD4+ decline or by death (Ariyoshi et al., 2000). HIV-2 infected 
individuals with high plasma viral loads were found to lose CD4+ cells rapidly and died quickly. In 
contrast, HIV-2 infected individuals with low plasma viral loads showed better or no disease progression. 
Several groups including Ariyoshi and colleagues have suggested that viral turnover is elevated within 
HIV-2 infected rapid progressors but restricted in HTV-2 infected individuals who show little or no 
disease progression (Beny et al., 1998, Grassly et al., 1998, Ariyoshi et al., 2000, Popper et al., 2000).
The factors involved in determining low-level viral replication in the majority of HIV-2 individuals, 
particularly during the asymptomatic period, and high viral replication in others, have yet to be 
determined
To assess the relationship between LTR function, replication capacity and, disease progression status in 
HIV-2 infection, a series of studies were undertaken. Initially, these were performed with the CBL series 
of isolates CBL-20 -  24, derived from Gambian HTV-2-infected individuals (Shultz et a l, 1990). 
Previous characterisation of the biological and molecular variability of these isolates revealed different 
replicative phenotypes in vitro and suggested that, as with HTV-1, a relationship existed between the in 
vitro cytopathogenicity of the different isolates and the clinical disease status of the patient from whom 
they were originally isolated (Shultz et al., 1990). Studies were then extended to include characterisation 
of naturally occurring HTV-2 LTR genotypes from two contrasting groups of HIV-2 infected Gambian 
individuals displaying different rates of disease progression and disease association. The following 
chapter describes the characterisation of LTR function within the CBL series of HTV-2 isolates. The 
activity of LTRs cloned from CBL 20 -  24 (described in Chapters 3 and 4) has been measured at basal 
and Tat-induced levels within two biologically relevant cell-lines, the Jurkat T-cell-like cell line and the 
monocyte-like THP-1 cell-line, using the optimised dual luciferase reporter assay system (described in
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Chapter 4). By comparing the HTV-2 CBL isolates key differences in HIV-2 LTR activity may be 
revealed.
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5.2 Summary of isolate details
Blood samples were taken from 20 anti-HIV-2 seropositive individuals attending the MRC hospital or the 
clinic for sexually transmitted diseases in Fajara, The Gambia and mononuclear cells were cultured for 
ten days (all procedures were performed by colleagues in The Gambia). In total, seven HIV-2 strains 
derived from different disease categories were isolated by colleagues at the Chester Beatty Laboratories, 
London (Shultz et al., 1990, CBL-20 -  CBL-26). We were able to obtain DNA from five of the original 
seven HIV-2 isolates (CBL-20 - 24) which differ in their growth rates, cytopathogenicity in vitro, and 
sensitivity to neutralising antibodies in patient sera. In addition, there is a close correlation between the in 
vitro cytopathogenicity of the different isolates and the clinical disease status of the individuals from 
whom they were obtained (Table 5.1, pg 192). The cytopathogenicity and replication of each of the 
isolates was assessed in several cell lines including peripheral blood mononuclear cells, MOLT4, H9, 
C8166 and CEM cell lines (by colleagues at the Chester Beatty Laboratories, London) (Schultz et al, 
1990). CBL-20 and CBL-21, two highly cytopathic strains, grew rapidly in primary culture and produced 
high levels of reverse transcriptase within 14 days, and were derived from patients who had progressed to 
AIDS (Table 5.1, pg 192). In contrast, CBL-22 and CBL-23 took somewhat longer to produce significant 
reverse transcriptase activity, and took slightly longer to appear in primary culture. CBL-22 was derived 
from an AIDS-related complex (ARC) patient who went on to die. CBL-23 was derived from an 
asymptomatic patient whose condition progressed to ARC (Table 5.1, pg 192). CBL-24 was the least 
cytopathic isolate of the five isolates analysed. This isolate grew only in the MOLT4 cell-line after 
several attempts, and was derived from an asymptomatic patient.
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Isolate Sex Age (yr) Clinical Status at 
time of isolation
Disease
Progression
CBL-20 M 28 AIDS, diarrhoea, 
wasting, oral thrush
Dead
CBL-21 F 34 AIDS, diarrhoea, 
wasting
AIDS
CBL-22 M 55 ARC, diarrhoea, 
wasting, oral thrush
Dead
CBL-23 F 31 Asymptomatic ARC
CBL-24 F 22 Asymptomatic PGL
Table 5.1 Clinical characteristics of individuals from whom the HIV-2 CBL isolates were obtained. 
Multiple LTRs were cloned from each of five members of the CBL series and were used to assess LTR 
function at the basal and Tat-induced level within the dual luciferase reporter assay system. (Reproduced 
from Shultz et al, 1990).
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5.3 Transcriptional activity of HIV-2 isolate-derived LTRs
The role of HIV-2 LTR function in determining replicative capacity and disease progression status was 
initially examined using LTRs cloned from five members of the CBL series of HTV-2 isolates.
5.3.1 Evaluation o f  the functional variability o f  LTRs taken from  a single HIV-2 isolate
The variation in basal activity directed by multiple LTRs cloned from a single CBL isolate was initially 
examined. This experiment provided data on the range of LTR activities present within a viral 
quasispecies and enabled a judgement to be made about the number of LTR clones required to give a 
representative view of the LTR activity of each isolate within comparative transfection experiments. 
CBL-22 was the randomly selected member of the CBL series chosen for this analysis.
Ten CBL-22 LTR clones (produced by the nested LTR PCR and restriction digest cloning procedures 
described in chapters 2 and 3) were cotransfected into Jurkat cells with Renilla luciferase internal control 
reporter vector pRL-TK at a ratio of 10:1 according to the protocol set out in section 2.2.4.6a. Exact 
DNA concentrations are given in the legend of Figure 5.1, pg 194. Each LTR clone was cotransfected in 
triplicate. Following 48h of incubation, cells were harvested, lysed, and basal CBL-22-LTR-directed 
firefly luciferase expression and RSV-TK promoter-directed Renilla luciferase expression was detected 
from each lysate using the dual-luciferase assay (see section 2.2.5). Background activity was assessed 
according to section 2.2.5.2 and subtracted from all corresponding measurements.
Three normalised basal activity values were calculated for each CBL-22 LTR clone by dividing the level 
of firefly luciferase expression by the level of Renilla luciferase expression measured in each well of the 
triplicate cotransfection. This experiment was repeated one week later using fresh Jurkat cells, and a 
second data set consisting of three normalised luciferase activity values for each of the CBL-22-LTR 
clones obtained. When tested by one-way ANOVA no significant difference was seen between the first 
and second data sets obtained one week apart for four CBL-22 LTR clones selected at random (p=0.15 -  
0.53). Therefore, a mean normalised basal activity value was calculated for each CBL-22 LTR clone by 
pooling the data from all six replicates (i.e. three normalised basal activity values from each of two 
triplicate transfections performed at different time points), without significantly altering the final 
normalised basal activity value representing the activity of the each LTR. Where analyses were 
subsequently carried out at more than one time, data from all time points were combined. The mean
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normalised basal activity values directed by each of the ten LTR clones from the CBL-22 isolate are 
shown in Figure 5.1, pg 194.
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Figure 5.1 Differential basal activity of ten CBL-22 LTR clones (n=l). The cloned LTRs were tested for 
basal activity in 2 x 106 Jurkat cells. Co-transfections were performed with 1.25pg CBL-22 LTR-pGL3E, 
0.125pg of pRL-TK, and 0.625pg of HSDNA. Luciferase activities directed by the HIV-2 LTRs were 
normalised with respect to the Renilla luciferase activity using the dual-luciferase assay system (Promega 
Ltd). Each value represents the mean normalised basal LTR activity of six cotransfections, with each 
error bar representing the standard deviation of the six individual values.
Each of the ten CBL-22 LTRs cloned into the firefly luciferase plasmid pGL3E were functional at the 
basal level, the lowest basal activity was directed by clone 22.9, (normalised luciferase activity -  1.36), 
while the highest basal activity was directed by the LTR clone 22.6 (normalised luciferase activity -  
46.53). This represented a 30 -  40-fold range in activity.
When tested by one-way ANOVA, statistically significant differences (p<0.0001) were found between 
the mean normalised basal activities of the ten CBL22 LTR clones. By comparing intra-clonal sampling 
variation and the variation between the mean basal LTR activities of the LTR clones in the analysis this 
test demonstrated that the mean basal activity of at least one of the clones was significantly different to 
the mean basal LTR activities of some or all of the remaining LTR clones in the analysis. This analysis 
showed that the inter-clone difference in LTR activity was greater than the variation between the six
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normalised activity values obtained for each LTR clone from two triplicate transfection experiments, and 
was unlikely, therefore, to be explained by sampling variation.
Multiple comparisons by Tukey-Kramer tests revealed that the mean normalised basal LTR activity of 
clone 22.6 was significantly higher (p<0.0001) than the mean normalised basal activities of the other nine 
CBL-22 LTR clones. However, significant differences were also found between the mean normalised 
basal LTR activities of clone 22.2 and 22.9 (p=0.0477), and clone 22.2 and 22.10 (p=0.0225), indicating 
that the significant differences suggested by the initial one way ANOVA above, were not solely generated 
by the activity of clone 22.6.
Taken together the results indicated that multiple LTR clones would give a more representative view of 
promoter activity within the viral quasispecies of an isolate than a single LTR clone. Since clones from 
each of the five CBL isolates were to be transfected in triplicate into both Jurkat and THP-1 cell lines, and 
were to be assessed for basal and Tat-induced activity within both cell lines, a practicable figure of five 
clones was chosen to represent the promoter region of each isolate.
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5.3.2 Functional analysis o f LTRs clonedfrom five HIV-2 isolates within the Jurkat ceU line
HIV-2 LTR functional studies were undertaken with the CBL series of HIV-2 isolates initially in the T- 
cell like Jurkat cell line. CBL-20 -  CBL24 were each represented by five LTR clones, produced as 
described in chapters 3 and 4. LTR function at both the basal and Tat-induced levels for each of the 
clones was assessed and compared using the optimised dual luciferase assay (see section 2.2.5).
5.3.2.1 Basal activity o f HIV-2 LTRs cloned from the CBL series o f HIV-2 isolates within the Jurkat cell- 
line
The basal activities of the LTRs cloned from HIV-2 isolates CBL-20 to CBL-24 were assessed in Jurkat 
cells using the Superfect transfection reagent (Qiagen) protocol described in section 2.2.4.6a. Each LTR 
clone was transfected in triplicate; precise DNA concentrations are given in the legend of Figure 5.2A, pg 
198. Luciferase enzyme activity was measured using the dual-luciferase assay system (Promega Ltd) and 
luminometry (Canberra-Packard Topcount) (see section 2.2.5). Firefly and Renilla luciferase background 
activities were assessed as described in section 2.2.5.2, and subtracted from all corresponding 
measurements. These cotransfections were performed in parallel to those described in section 5.3.2.2. 
Results are presented as the mean normalised basal activity for each LTR clone, calculated from the three 
normalised basal activity values of the triplicate transfection (Figure 5.2A, pg 198), and as a box plot 
representing the range of the five clonal basal LTR activity values measured for each CBL isolate (Figure 
5.2B, pg 198). The median basal LTR activity for each isolate is marked by a line, the box representing 
the distance between the first and third quartiles, and the leading and trailing ‘whiskers’ corresponding to 
the minimum and maximum respectively (Figure 5.2B, pg 198). Differences between LTR activities 
were compared by analysis of variance (ANOVA) and by the Tukey-Kramer test. Values of p<0.05 were 
considered statistically significant.
The results from the Jurkat data set revealed that each of the twenty-five cloned LTRs from the five 
members of the CBL series of HTV-2 isolates (CBL-20 -  CBL24) was able to direct a detectable level of 
basal activity within the Jurkat cell-line (Figure 5.2A, pg 198), although the LTRs within clones 21.5 and 
22.4, taken from CBL 21 and 22 respectively, displayed particularly low basal activities. Significant 
variation was observed between the basal activities of LTRs cloned from the same CBL isolate and LTRs 
cloned from different CBL isolates, with basal activities overall ranging from 0.88 to 19.30. In this cell- 
line however, the range of basal activities directed by the LTR clones within each isolate appeared to be 
greater in isolates which exhibited rapid growth in in vitro studies and were derived from individuals
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displaying significant disease progression such as CBL20 -  22 (Table 5.1, pg 192) (Shultz et al, 1990), 
compared to the intraisolate range of LTR activities directed by clones from the less cytopathic members 
of the CBL series which had been isolated from asymptomatic individuals such as CBL23 and 24 (Figure 
5.2B, pg 198). LTR clones from CBL-20,21, and 22 directed ranges of basal activities that were at least 
four times greater than the range of basal activities directed by LTR clones from CBL-23 and CBL-24 in 
this cell-line.
The highest basal activities were directed by LTR clones from CBL-20 and CBL-21, the two most 
cytopathic and rapidly replicating CBL isolates. The mean basal activities of the five LTR clones from 
CBL-20 and the five LTR clones from CBL-21 were 13.35 and 10.30 respectively. In contrast, LTR 
clones from isolate CBL-23, an isolate exhibiting comparatively poorer cytopathogenicity and slower 
grovth (Table 5.1, pg 192), directed the lowest basal activities. The mean basal activity directed by the 
five LTR clones from this isolate was 6.27, two-fold lower than the mean basal activity directed by the 
LTRs cloned from CBL-20. The mean basal activity of the five LTR clones from CBL-24, the second 
isohte derived from an asymptomatic individual, was also lower than the mean basal LTR activities of 
both CBL-20 and CBL-21.
When tested by one-way ANOVA however, the mean basal activities of the five CBL isolates were not 
fouid to be statistically significantly different from each other (p=0.2157) (Figure 5.2B, pg 198). 
Nevertheless, examination of the data does indicate a non-significant trend towards higher basal activities 
directed by LTRs cloned from isolates displaying rapid growth kinetics.
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Figure 5.2 (A) Normalised basal activities of 25 cloned LTRs from the CBL series of HIV-2 isolates in 
Jurkat cells (n=5). Each bar represents the mean normalised basal activity value calculated for each LTR 
clone from a triplicate transfection, with error bars representing the standard deviation of the three 
individual values. Cotransfections were performed in 2 x 106 Jurkat cells with 1.25pg HIV-2LTR- 
pGL3E, 0.125pg of pRL-TK and 0.625pg of HSDNA. (B) Box plot representing the range of basal 
activities directed by five clone for each CBL isolate, the median basal LTR activity for each isolate is 
marked by a line (n=5). No significant difference in basal LTR activity was noted between the five 
members of the CBL series p=0.215.
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5.3.2.2 Tat-induced activity o f  HIV-2 LTRs cloned from the CBL series o f  HIV-2 isolates in the Jurkat 
cell-line
In order to assess and compare the transcriptional response of the cloned LTRs produced in chapter 4 to 
the HIV-2 Tat protein (Tat2), a tat expression vector was included in the cotransfection mixture for both 
Jurkat and THP-1 cell lines. The HIV-2 Tat expression vector -  pRSVtat contains the first two exons of 
HIV-2 ROD Tat2, positioned directly downstream from an RSV promoter region (See Appendix II, 
Figure H.6, pg 353). This vector was a gift from Dr. Browning, University of Michigan, and has been 
used in several HTV-2 Tat studies.
Comparative transfection studies were performed with saturating concentrations of Tat2. In this respect, 
the transcriptional responses that were observed were unlikely to be limited by the amount of Tat2 
expressed within the cell, however, it must be noted that this protocol may have masked small 
transcriptional differences between the promoter regions that exist under biological conditions. Section
5.3.2.2 and 5.3.3.2 of this chapter describe the series of experiments undertaken to evaluate and assess the 
response of cloned HTV-2 LTRs to the HIV-2 Tat protein within both the Jurkat and THP-1 cell-lines.
5.3.2.2a Evaluation o f optimal Tat concentration for transactivation o f transcription within the 
Jurkat cell line.
Initially an experiment was undertaken to determine the optimal concentration of pRSV-tat expression 
vector required to direct the greatest transcriptional response within the Jurkat cell-line. The level of 
firefly luciferase expression directed by an LTR cloned from HTV-2 ROD following co-transfection with 
different concentrations of pRSV-tat was assessed and compared.
A constant amount of 3E-ROD vector DNA was cotransfected into freshly seeded Jurkat cells with the 
internal control reporter pRL-TK at a ratio of 10:1. A range of concentrations of pRSVtat expression 
vector was added to the set of cotransfection mixtures prior to transfection, ranging from lOOng to 
lOOOng. The total amount of DNA transfected was maintained at 2pg by supplementation with Herring 
Sperm DNA, (exact amounts given in the legend of Figure 5.3, pg 201). Normalised basal LTR activity 
was assessed by including a cotransfection performed in the absence of the pRSVtat vector. Cells were 
transfected using the Superfect protocol described in section 2.2.4.6a. A triplicate cotransfection was 
performed for each concentration within the range. Forty-eight hours post transfection cells were 
harvested by centrifugation, lysed, and the luciferase enzyme activity measured. Normalised absolute 
Tat-induced LTR activities were calculated for each transfection by dividing the firefly luciferase
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expression by the Renilla luciferase expression measured from each cell lysate. A mean value for each 
triplicate cotransfection was then calculated and divided by the normalised basal LTR activity obtained 
from the co-transfection performed in the absence of the pRSVtat vector in order to determine the fold 
increase in LTR activity above basal levels, or ft’ansactivation response, observed at the different pRSVtat 
concentrations. Plotting the frattsactivation response directed at the different concentrations of pRSVtat 
expression vector revealed that levels of Tat transactivation increased with increasing levels of Tat2 up to 
a concentration of 600ng (Figure 5.3, pg 201). At this concentration, the expressed Ta£2 protein induced 
a 100-fold increase in LTR activity above the basal level. A decrease in Tat tram activation was observed 
at concentrations greater than 600ng. For subsequent assessment of the /ransactivation response of LTR 
clones to the HIV-2 Tat protein by transfection of Jurkat cells, 600ng of pRSVtat expression vector were 
included in the co-transfection mixtures.
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Figure 5.3 Relative tra/wactivation of the HIV-2 LTR mediated by various levels of Tat2 in Jurkat cells. 
A constant level (ljag) of 3E-ROD (pGL3E containing the HIV-2 ROD LTR) was co-transfected with 
lOOng of pRL-TK and increasing levels (100-1000 ng) of pRSVtat (HIV-2 Tat2). The total amount of 
DNA transfected per culture was maintained at 2fig by supplementation with HSDNA. Firefly and 
Renilla luciferase activity was measured 48h post transfection and normalised absolute Tat-induced LTR 
activities were calculated for each transfection by dividing firefly luciferase expression by Renilla 
luciferase expression measured from each cell lysate. The fold increase in promoter activity observed at 
the different concentrations of pRSVtat expression vector was calculated by dividing the normalised 
absolute Tat-induced activity obtained in each co-transfection with the normalised basal LTR activity 
obtained from the co-transfection performed in the absence of the pRSVtat expression vector.
5.3.2.2b Comparison o f Tat-induced LTR activities directed by LTRs cloned from the CBL series 
o f HIV-2 isolates
The absolute Tat-induced activities of the LTRs cloned from HIV-2 isolates CBL-20 to CBL-24 were 
assessed using the dual luciferase assay system (see section 2.2.5). The twenty-five LTR clones 
representing the five CBL isolates were co-transfected into Jurkat cells with the internal control vector 
pRL-TK at a ratio of 10:1 and 600ng of the Tat2 expression vector pRSVtat (precise DNA concentrations 
are given in the legend of Figure 5.4A, pg 204). Co-transfections were performed in triplicate in six well 
dishes as described in Section 5.3.2.I. Normalised absolute Tat-induced LTR activities were calculated 
for each transfection lysate by dividing firefly luciferase expression by Renilla luciferase expression. 
Results are presented as the mean normalised absolute Tat-induced activity of each LTR clone, calculated 
from the three normalised absolute Tat-induced activities of the triplicate transfection (Figure 5.4A, pg
201
204), and as a box plot representing the range and median o f the five clonal absolute Tat-induced LTR 
activities measured for each CBL isolate (Figure 5.4B, pg 204). All values have had background 
subtracted. Differences between normalised absolute Tat-induced LTR activities were compared by 
analysis of variance (ANOVA) and by the Tukey-Kramer test Values of p<0.05 were considered 
statistically significant. In addition, normalised absolute Tat-induced (Figure 5.4A, pg 204) and basal 
(Figure 5.2B, pg 204) activity values were used to calculate the Tat responsiveness of each LTR clone by 
dividing the normalised absolute Tat-induced activity by the normalised basal activity for each LTR 
clone. Results are presented as the mean fold increase in LTR activity above basal levels for each CBL 
isolate in response to Tat2, with each value representing die mean Tat response of five LTR clones from 
each isolate (Figure 5.4C, pg 205).
The results from this experiment demonstrated that the activities of each of the twenty-five LTR clones, 
representing CBL-20 to CBL24, increased considerably over their basal levels when cotransfected with 
the HTV-2 Tat expression vector in Jurkat cells (Figure 5.2A and 5.4B, pg 204). Significant variation was 
observed between the absolute Tat-induced activities of LTRs cloned from the same CBL isolate and 
between LTRs cloned from different CBL isolates (Figure 5.4A, pg 204). However, similar to findings at 
the basal level of activity, less intra-isolate variation was observed between the Tat-induced activities of 
the LTRs cloned from isolates CBL-23 and CBL-24, the two HTV-2 isolates taken from asymptomatic 
individuals (Figure 5.4B, pg 204).
In addition to directing the highest basal activities, the LTRs cloned from CBL-20 were also found to 
direct the highest absolute Tat-induced activities (Figure 5.4A, pg 204) in this cell-line. The mean 
normalised Tat-induced activity of the five clones from this isolate was 301.11. In a difference to the 
basal activities of the LTRs in this cell-line however, LTRs cloned from isolate CBL-22, and not CBL-23, 
directed the lowest Tat-induced activities in response to the Tat protein. The mean normalised Tat- 
induced activity of the five clones from CBL-22 was 143.66, two-fold lower than the mean Tat-induced 
activity directed by the LTR clones from CBL-20. Overall, normalised absolute Tat-induced activities 
ranged from 44.77 directed by CBL-22 clone 22.4; to 381.54 directed by CBL-20 clone 20.5 (Figure 
5.4A, pg 204). The two clones that had displayed extremely low levels of basal activity within the Jurkat 
cell-line, 22.4 and 21.5 (Figure 5.2A, pg 204), were seen to direct significantly higher levels of 
transcription in the presence of the Tat protein, particularly clone 21.5 (Figure 5.4A, pg 204). However, 
clone 22.4 was still the least active of all the LTRs analysed in response to Tat.
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When tested by one-way ANOVA the mean absolute Tat-induced LTR activities of at least one of the five 
CBL isolates were found to be significantly different from the mean absolute Tat-induced LTR activities 
of the other CBL isolates (p=0.011). Multiple comparisons by Tukey-Kramer tests revealed that the Tat- 
induced activities of the LTRs from CBL-20 were not only higher but statistically higher than the 
activities of the LTRs from CBL-22 (T-K test P=0.008) and CBL-23 (T-K test P=0.0373), two strains 
exhibiting comparatively less cytopathogenicity and slower growth respectively (Table 5.1, pg 192).
Examination of the absolute Tat-induced activities of the twenty-five LTR clones has revealed a similar 
trend to that observed at the basal level within the Jurkat cell-line (Figure 5.2A, pg 198, and Figure 5.4A, 
pg 204). LTRs from isolates exhibiting the most rapid rates of replication i.e. CBL-20 and CBL-21, 
tended to have higher absolute Tat-induced activities than the LTRs from isolates exhibiting 
comparatively poorer growth kinetics and cytopathogenicity i.e.CBL-22 and CBL23. However, it must 
be noted that, on average, the absolute Tat-induced activities of the LTRs cloned from CBL-24, the least 
cytopathic and slowest growing of the CBL isolates analysed, were higher than the absolute levels of Tat- 
induced transcription directed by LTRs from CBL-22 and CBL-23, isolates exhibiting more rapid growth 
kinetics (Figure 5.4A and 5.4B, pg 204) (Table 5.1, pg 192).
Analyses of the mean Tat responsiveness or fold increase in activity above basal levels directed by the 
CBL LTR clones to the Tat protein, revealed some variation between the five isolates, transcriptional 
responses to Tat ranged from 18-fold (clones from CBL-21), to 27-fold (clones from CBL-23) (Figure 
5.4C, pg 205). LTRs that showed the highest mean fold increase in activity above basal levels in 
response to the Tat protein however, did not necessarily direct the highest absolute levels of Tat-induced 
activity. For example, LTRs cloned from CBL-23 were the second least active promoters at the Tat- 
induced level (Figure 5.4B, pg 204) when compared to LTRs from the other four CBL isolates, and yet 
directed the greatest mean fold increase in transcription above basal levels in response to Tat (Figure 
5.4C, pg 205).
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Figure 5.4 (A) Normalised absolute Tat-induced activities of 25 cloned LTRs from the CBL series of 
HIV-2 isolates in Jurkat cells (n=5). Each bar represents the mean absolute Tat-induced activity value 
calculated for each LTR clone from a triplicate transfection, with error bars representing the standard 
deviation of the three individual values. Cotransfections were performed in 2 x 106 Jurkat cells with 
1.25pg HIV-2LTR-pGL3E, 0.125pg of pRL-TK, 0.6pg of RSV-Tat and 0.025pg of HSDNA. (B) Box 
plot representing the range of absolute Tat-induced activities directed by five clones for each CBL isolate, 
the median Tat-induced LTR activity for each isolate is marked by a line (n=5). Analysis by one-way 
ANOVA revealed significant differences between the mean absolute Tat-induced LTR activities of the 
five isolates (p=0.011). (C) Mean Tat responsiveness of the LTRs cloned from each of the five CBL 
isolates (n=5). Tat responsiveness is measured as the fold increase in transcription following Tat 
transactivation and is calculated by dividing the mean normalised absolute Tat-induced activity of the five 
LTR clones from each isolate by the mean normalised basal activity of the five LTR clones from each 
isolate.
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5.3.3 Functional analysis o f LTRs clonedfrom five HIV-2 isolates within the THP-I cell line
HIV-2 LTR functional studies were next performed in the monocyte-like THP-1 cell line; using the same 
LTR clones as used in the studies with Jurkat cells. LTR function at both the basal and Tat-induced 
levels was assessed using the same methodologies.
5.3.3.1 Basal activity o f HIV-2 LTRs clonedfrom the CBL series o f HIV-2 isolates in the THP-1 cell-line 
The basal activities of the twenty-five LTR clones from the five CBL isolates were assessed in the 
monocyte-like THP-1 cell-line using the dual luciferase assay system (see section 2.2.5). Each clone was 
cotransfected in triplicate with the internal control plasmid pRL-TK at a ratio of 10:1 according to the 
Effectene transfection reagent protocol described in section 2.2.4.6b (precise DNA concentrations are 
given in the legend of Figure 5.5A, pg 208). Luciferase enzyme activity was measured using the dual- 
luciferase assay system (Promega Ltd) and luminometry (Canberra-Packard Topcount) (see section 
2.2.5). Firefly and Renilla luciferase background activities were assessed as described in section 2.2.5.2, 
and subtracted from all corresponding measurements. These cotransfections were performed in parallel 
to those described in section 5.3.3.2. Results are presented as the mean normalised based activity for each 
LTR clone, calculated from the three normalised basal activity values of the triplicate transfection (Figure 
5.5A, pg 208), and as a box plot representing the range of the five clonal basal LTR activity values 
measured for each CBL isolate (Figure 5.5B, pg 208). Differences between LTR activities were 
compared by analysis of variance (ANOVA) and by the Tukey-Kramer test. Values of p<0.05 were 
considered statistically significant.
As seen in the Jurkat cell-line, some level of basal activity was detected from each of the twenty-five LTR 
clones representing the five members of the CBL series of HIV-2 isolates (CBL-20 -  CBL24). However, 
cell-type-specific transcriptional differences were noted between the basal activities of the LTR clones in 
the THP-1 cell-line when compared to the basal activities of the same LTR clones when transfected into 
the Jurkat cell-line. In particular, whilst most active when transfected into Jurkat cells, the LTRs from 
CBL-20 and CBL-21 directed activities that were not significantly higher than the LTRs from the 
remaining three isolates when transfected into THP-1 cells. The highest mean basal LTR activity was 
calculated from the activities of five LTRs cloned from CBL-24, the isolate exhibiting the slowest growth 
kinetics of the five CBL isolates analysed (Table 5.1, pg 192), and not CBL-20 the most rapidly 
replicating isolate as observed in Jurkat cells (Figure 5.5B, pg 208). The mean basal LTR activity for
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CBL-24 in THP-1 cells was 0.58, five-fold higher than the lowest median basal LTR activity in THP-1 
cells, directed by the LTRs derived from isolate CBL-23 (Figure 5.5B, pg 208). The LTR clones from 
CBL-23 had also directed the lowest basal activities when transfected into Jurkat cells (Figure 5.2A and 
B, pg 198).
In general, as observed in Jurkat cells, the basal activities of the LTR clones in THP-1 cells were found to 
be variable within and between the different CBL isolates (Figure 5.5A and B, pg 208). Overall, the 
activities of the twenty-five clones ranged from 0.02 to 1.31. However, again as observed in Jurkat cells, 
very little variation was observed between the basal activities of the LTRs cloned from CBL-23, and, with 
die exception of clone 24.4, between the remaining four clones of CBL-24, the two isolates derived from 
asymptomatic individuals (Figure 5.5B, pg 208).
In contrast to the trend observed in the basal and absolute Tat-induced activities of the thirty LTR clones 
when transfected into the Jurkat cell-line, LTR clones from isolates displaying rapid growth kinetics 
(CBL-20, CBL-21) did not tend to be and more active at the basal level than the LTRs derived from the 
slower growing CBL isolates (CBL-23, CBL-24) when transfected into the THP-1 cell-line. When tested 
by one-way ANOVA, there was no overall statistical difference between the mean basal LTR activities of 
the five CBL isolates in the THP-1 cell-line (P=0.259).
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Figure 5.5 (A) Normalised basal activities of 25 cloned LTRs from the CBL series of HIV-2 isolates in 
THP-1 cells (n=5). Each bar represents the mean normalised basal activity value calculated for each LTR 
clone from a triplicate transfection, with error bars representing the standard deviation of the three 
individual values. Cotransfections were performed in 2 x 106 THP-1 cells with 0.6pg HIV-2LTR- 
pGL3E, 0.06pg of pRL-TK and 0.14pg of HSDNA. (B) Box plot representing the range of basal 
activities directed by five clone for each CBL isolate, the median basal LTR activity for each isolate is 
marked by a line (n=5). No significant difference in basal LTR activity was noted between the five 
members of the CBL series (p=0.259).
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5.3.3.2 Tat-induced activity o f HIV-2 LTRs clonedfrom the CBL series o f HIV-2 isolates within the THP- 
1 cell-line
5.3.3.2a Evaluation o f  optimal Tat concentration for transactivation o f transcription within the 
THP-1 cell line.
Before the Tat-induced activities of the twenty-five LTR clones could be assessed in the THP-1 cell-line, 
the optimal concentration of pRSV-tat expression vector required to direct the greatest transcriptional 
response in this cell-line was initially determined.
A constant amount of 3E-ROD vector DNA (pGL3E containing the HTV-2 pRODio LTR) was co­
transfected into freshly seeded THP-1 cells with the internal control reporter pRL-TK at a ratio of 10:1. 
A range of concentrations of pRSVtat expression vector was added to a set of co-transfection mixtures 
prior to transfection, ranging from 5ng to 500ng. Precise DNA concentrations within the transfection 
mixtures are given in the legend of Figure 5.6, pg 210. Basal LTR activity was assessed by including a 
co-transfection performed in the absence of the pRSVtat expression vector as described in section 5.3.3.1. 
The total amount of DNA transfected per 2 x 106 THP-1 cells was maintained at 0.8pg by 
supplementation with Herring Sperm DNA. At forty-eight hours post transfection cells were harvested by 
centrifugation, lysed and the luciferase activity measured. Normalised absolute Tat-induced LTR 
activities were calculated for each transfection and divided by the normalised basal LTR activity obtained 
from the co-transfection performed in the absence of the pRSVtat expression vector in order to determine 
the fold increase in LTR activity above basal levels, or rtransactivation response.
Plotting the Jransactivation response directed at the different concentrations of pRSVtat expression vector 
revealed that levels of Tat transactivation increased with increasing levels of pRSV Tat up to and 
including a concentration of 125ng (Figure 5.6, pg 210). At this concentration, the expressed Tat2 protein 
induced a 40-fold increase in LTR activity above basal levels. A decrease in transactivation was 
observed at concentrations greater than this. For subsequent assessment of the transactivation response of 
LTR clones to the HIV-2 Tat protein by transfection of THP-1 cells, 125ng of pRSVtat expression vector 
was included in the co-transfection mixture.
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Figure 5.6 Relative fraMsactivation of the HIV-2 LTR mediated by various levels of Tat2 in THP-1 cells. 
A constant level (300ng) of 3E-ROD (pGL3E containing the HIV-2 ROD LTR) was co-transfected with 
30ng of pRL-TK and increasing levels (5-500 ng) of pRSVtat (HIV-2 Tat2). The total amount of DNA 
transfected per culture was maintained at 0.8pg by supplementation with HSDNA. Firefly and Renilla 
luciferase activity was measured 48h post transfection and normalised absolute Tat-induced LTR 
activities were calculated for each transfection by dividing firefly luciferase expression by Renilla 
luciferase expression measured from each cell lysate. The fold increase in promoter activity observed at 
the different concentrations of pRSVtat expression vector was calculated by dividing the normalised 
absolute Tat-induced activity obtained in each co-transfection with the normalised basal LTR activity 
obtained from the co-transfection performed in the absence of the pRSVtat expression vector.
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5.3.3.2 b Comparison o f Tat-induced LTR activities directed by LTRs clonedfrom the CBL series 
o f HIV-2 isolates within the THP-1 cell-line 
The absolute Tat-induced activities of the twenty-five LTR clones were assessed in the THP-1 cell-line 
using the dual luciferase assay system (see section 2.2.5). Each LTR clone was cotransfected, in 
triplicate, with the internal control vector pRL-TK at a ratio of 10:1 and 125ng of the Tat2 expression 
vector pRSVtat (precise DNA concentrations are given in the legend of Figure 5.7, pg 214). Normalised 
absolute Tat-induced LTR activities were calculated for each transfection lysate by dividing firefly 
luciferase expression by Renilla luciferase expression. Results are presented in the same format used for 
the Jurkat data set. Differences between normalised absolute Tat-induced LTR activities were compared 
by analysis of variance (ANOVA) and by the Tukey-Kramer test. Values of p<0.05 were considered 
statistically significant.
As observed in Jurkat cells, the activity of each of the twenty-five LTR clones, representing CBL-20 to 
CBL24, was raised considerably over basal levels when cotransfected with the HIV-2 Tat expression 
vector into THP-1 cells (Figure 5.5A, pg 208, and Figure 5.7A, pg 213). Only LTRs within clones CBL- 
22.5 and CBL-23.4 appeared to direct particularly low absolute Tat-induced activities in this cell-line. 
Both clones had also directed low basal activities in this cell-line (Figure 5.5A, pg 208). Despite their 
low Tat-induced activities however, analysis of the responsiveness of each of these LTRs to the Tat 
protein revealed increases in activity above basal levels in excess of 17-fold.
Further comparison of the basal and Tat data obtained in THP-1 cells (Figure5.5A, pg 208, and Figure 
5.7A, pg 213) revealed however, that an LTR with a particularly low basal activity did not necessarily 
direct a particularly low Tat-induced activity. In particular clones 20.3, 21.4 and 22.4 had all shown 
comparatively low basal activities in THP-1 cells (Figure 5.5A, pg 208) and yet directed amongst the 
highest activities in response to the Tat protein within the same cell-line (Figure 5.7A, pg 213). Similarly, 
while some LTR clones directed both high basal and Tat-induced activities (such as 20.4 and 21.3), others 
that had been highly active at the basal level in THP-1 cells, such as 22.3 and 24.4, were only of average 
or below average activity at the Tat-induced level in the same cell-line. Comparable findings were also 
noted in the Jurkat data set.
Significant variation was observed between the absolute Tat-induced activities of the LTRs cloned from 
the same CBL isolate and LTRs cloned from different isolates within the CBL series when the LTR 
clones were transfected into THP-1 cells (Figure 5.7A, pg 213). Activities ranged from 1.53 directed by
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CBL-23 clone 23.4, to 21.11 directed by CBL-24 clone 24.3 (Figure 5.7A, pg 213). In this cell-line, as in 
the Jurkat cell-line, the lowest intra-patient variation was observed between the activities of LTRs cloned 
from CBL-23. The range of activities displayed by the clones from this isolate was two-fold lower than 
the intra-isolate range of LTR activities from CBL-22, the isolate displaying the greatest range of LTR 
activities in this cell-line.
LTRs cloned from CBL-24, the slowest growing of the CBL isolates, and not CBL-20 as observed in 
Jurkat cells, directed the highest mean absolute Tat-induced LTR activity within the THP-1 cell-line, 
while, in addition to displaying the narrowest range of activities, LTRs cloned from CBL-23, an isolate 
exhibiting more rapid growth kinetics than CBL-24, directed the lowest mean absolute Tat-induced LTR 
activity. The mean Tat-induced LTR activity of CBL-24 was 13.6, compared to the mean Tat-induced 
LTR activity of CBL-23,4.2.
Similar to the basal activity results for these clones when transfected into THP-1 cells, but in contrast to 
their activities when transfected into Jurkat cells, when tested by one-way ANOVA, the mean absolute 
Tat-induced LTR activities of the five CBL isolates in the THP-1 cell-line were not found to be 
statistically significantly different from each other (p=0.149). When transfected into THP-1 cells LTRs 
cloned from CBL isolates of rapid growth characteristics did not tend to direct higher activities than LTRs 
cloned from slower growing CBL isolates.
Analyses of the mean Tat responsiveness of the promoters to the Tat protein in THP-1 cells revealed 
some variation between the LTRs from the different CBL isolates. Transcriptional responses to Tat 
ranged from 23-fold (clones from CBL-24), to 35-fold (clones from CBL-23) (Figure 5.7C, pg 214). 
Similar to the Jurkat data set, LTRs that had directed the highest median absolute Tat-induced LTR 
activity, did not necessarily direct the greatest transcriptional response above basal levels in the presence 
of the Tat protein in THP-1 cells.
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Figure 5.7 (A) Normalised absolute Tat-induced activities of 25 cloned LTRs from the CBL series of 
HIV-2 isolates in THP-1 cells (n=5). Each bar represents the mean absolute Tat-induced activity value 
calculated for each LTR clone from a triplicate transfection, with error bars representing the standard 
deviation of the three individual values. Cotransfections were performed in 2 x 106 THP-1 cells with 
0.6pg HIV-2LTR-pGL3E, 0.06pg of pRL-TK, 0.125pg of RSV-Tat and 0.015pg of HSDNA (B) Box 
plot representing the range of absolute Tat-induced activities directed by five clone for each CBL isolate, 
the median Tat-induced LTR activity for each isolate is marked by a line (n=5). Analysis by one-way 
ANOVA revealed no significant differences between the mean absolute Tat-induced LTR activities of the 
five isolates (p=0.149). (C) Mean Tat responsiveness of the LTRs cloned from each of the five CBL 
isolates (n=5). Tat responsiveness is measured as the fold increase in transcription following Tat 
transactivation and is calculated by dividing the mean normalised absolute Tat-induced activity of the five 
LTR clones from each isolate by the mean normalised basal activity of the five LTR clones from each 
isolate.
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5.4 Summary and discussion
The basal and Tat-induced activities of LTRs directly cloned from the DNA of a series of HTV-2 isolates 
displaying different growth characteristics were compared in two biologically relevant cell-lines in order 
to examine the importance of promoter activity with respect to replicative capacity. Previous 
characterisation of the biological and molecular variability of the HIV-2 CBL isolates had suggested that, 
as with HIV-1, a relationship existed between the in vitro cytopathogenicity of the different isolates and 
the clinical disease status of the patient from whom they were originally isolated (Shultz et al., 1990). 
Therefore, comparative analysis of the LTRs from each of these isolates also examined the importance of 
promoter activity with respect to disease progression.
In order to determine the practicable number of LTR clones required to represent each CBL isolate within 
comparative transfection studies, the variation in basal activity directed by multiple LTRs cloned from a 
single CBL isolate, CBL-22, was initially examined. Using the optimised dual-luciferase assay system 
significant functional variation was demonstrated between the basal LTR activities of several of the ten 
LTRs cloned directly from CBL-22 isolate DNA (p<0.0001), with activities falling over a 34-fold range. 
The basal activity of LTR clone 22.6 was found to be statistically higher than all other LTRs cloned from 
this isolate, in addition, the LTR activity of clone 22.2 was found to be statistically higher than the LTR 
activities of clones 22.9, and 22.10. The differences in activities of the LTRs derived from CBL-22 likely 
reflect the existence of functionally significant polymorphisms within the core transcription factor 
binding elements of the LTR in the CBL-22 quasispecies, and also suggests that despite tissue culture 
adaptation and numerous passages in culture, functional variability persists within the quasispecies of the 
CBL series of HTV-2 isolates. Based on this result, and experimental design considerations it was 
concluded that multiple LTR clones would give a more representative view of promoter activity within 
the viral quasispecies of an isolate than a single LTR clone. Five LTR clones were chosen as a 
practicable number to represent each of the CBL isolates in the subsequent comparative transfection 
experiments.
Using the optimised dual-luciferase assay system a detectable level of basal activity was measured from 
each of twenty-five LTR clones, representing five members of the HTV-2 series of CBL isolates, in both 
the Jurkat and THP-1 cell-lines. Ten of the LTRs analysed were cloned from CBL-23 and CBL-24, the 
two isolates in the analyses whom were derived from asymptomatic individuals (Shultz et al., 1990). 
These data suggest therefore, that the asymptomatic state of the patients from whom isolates CBL-23 and
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CBL-24 were obtained was not determined by the existence of completely defective LTRs within the 
circulating quasispecies of these patients.
When tested by one-way ANOVA there was no overall statistical difference between die mean basal LTR 
activities of the five CBL isolates in either the Jurkat or THP-1 cell-line (p=0.2157, and p=0.259 
respectively). Examination of the basal data obtained within the Jurkat cell-line did indicate however, a 
non-significant trend towards higher and more varied basal activities being directed by the LTRs cloned 
from isolates that exhibited rapid growth kinetics and high cytotoxicity in several cell-lines (Shultz et al, 
1990) and were taken from patients displaying significant disease progression. The highest basal 
activities within the Jurkat cell-line were directed by the LTRs cloned from isolates CBL-20, 21, and 22. 
Moreover, the ranges of basal activity directed by the LTRs from each of these three isolates were on 
average four times greater than the range of basal activities directed by LTRs cloned from CBL-23 and 
CBL-24. In contrast, the lowest basal activities in Jurkat cells were directed by the LTRs cloned from 
CBL-23 and CBL-24; both isolates displayed comparatively slower growth kinetics than CBL-20 and 
CBL-21, were less cytopathogenic, and were obtained from patients who were asymptomatic at the time 
of virus isolation (Shultz et al, 1990).
Examination of the basal activities of the same LTRs when transfected into the THP-1 cell-line, did not 
reveal any similar trends in activity. In contrast to the Jurkat data, the LTRs cloned from CBL-24 (the 
isolate that displayed the slowest growth kinetics in vitro), directed the highest mean basal activities in 
THP-1 cells. The observation that several of the LTR clones had directed the highest activities in one 
cell-line but were not necessarily the most active LTRs when transfected into a second cell-line, is in 
agreement with previously published results analysing HIV-1 LTR activity (Corboy et al, 1992, Moses et 
al, 1994, Estable et al 1996, Krebs et al, 1998, McAllister et al, 2000), and indicates that some in vivo- 
selected HIV-2 LTRs may confer transcription and replication advantages in specific cell types. Only 
LTRs cloned from CBL-23 and LTR clone 22.4 were consistently found to direct low basal activities in 
both THP-1 and Jurkat cells, perhaps suggesting functionally significant sequence differences between 
the core transcription factor binding elements of these LTRs compared to the other LTRs in the analyses.
When evaluating the optimal Tat2 expression vector concentration for towwactivation of transcription 
within both Jurkat and THP-1 cells optimal f/wwactivation was achieved when 600ng of pRSVTat was 
cotransfected into Jurkat cells, and 125ng when cotransfected into THP-1 cells. Significant decreases in 
fra/wactivation were noted in concentrations exceeding the given amounts in both cell-lines. Similar
findings have been reported by Fenrick et al while investigating the relative /ransactivation of the HIV-1 
and HIV-2 LTRs by various levels of Tati and Tat2 (Fenrick et al, 1989). The observed decrease in 
ftwwactivation is thought to result from the toxicity of the Tat protein itself to the transfected cell.
At the Tat-induced level of activity each of the twenty-five LTR clones, representing CBL-20 to CBL24, 
directed a significant increase in activity above basal levels in both Jurkat and THP-1 cells when 
cotransfected with the Tat2 expression vector, a further indication that die LTRs cloned from each of the 
CBL isolates were fully functional. Within both cell-lines, variation was observed between the mean Tat 
responsiveness of the LTRs from each of the CBL isolates analysed, with Tat responsiveness being 
defined as the fold increase in activity above the basal activity of that LTR. On average, levels of 
transcription were found to increase between 25 and 40-fold above basal levels in the presence of Tat2. 
Interestingly, LTRs that directed the greatest fold increase in activity above their basal activities in 
response to Tat were not necessarily those LTRs that directed the highest absolute Tat-induced activities. 
For example, the LTRs from CBL-23 were on average the most Tat-responsive LTRs in both cell-lines 
however; they directed the lowest and second lowest absolute Tat-induced activities when transfected into 
THP-1 and Jurkat cells respectively. Therefore, the replicative capacities of the HIV-2 isolates appear to 
relate more to the actual magnitude of promoter activity than the responsiveness of the promoter to 
proteins such as Tat2.
Similar to results at the basal level of activity in Jurkat cells, LTRs cloned from the isolates exhibiting the 
most rapid rates of replication i.e. CBL-20 and CBL-21, tended to direct higher absolute Tat-induced 
activities within Jurkat cells than the activities of the LTRs from isolates exhibiting comparatively poorer 
growth kinetics and cytopathogenicity i.e. CBL-23. On average, the Tat-induced activities of the LTRs 
from CBL-20 were two-fold higher than the activities of CBL-22 and CBL23. Moreover, when tested 
statistically the mean Tat-induced activity of the LTRs from CBL-20 in Jurkat cells was found to be 
statistically significantly higher than the mean Tat-induced activity of the LTRs from CBL-22 (T-K test 
P=0.008) and CBL-23 (T-K test P=0.0373). LTRs cloned from CBL-20 had also directed the highest 
levels of basal activity within Jurkat cells, although statistical analysis had shown that the activities of the 
LTRs from this isolate were not statistically higher than the activities of the LTRs from the other viral 
isolates.
CBL-20 represents a markedly different in vitro characterised isolate phenotype compared to the 
phenotypes exhibited by CBL-22 and CBL-23. CBL-20 is highly cytopathic, exhibits rapid growth, and
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was derived from an AIDS patient, while strains of CBL-22 and CBL-23 exhibit poorer 
cytopathogenicity, slower growth, and were derived from an ARC and an asymptomatic patient 
respectively (Shultz et al, 1990). It has been suggested that differences in the basal and inducible 
activities of LTRs from HIV-1 viral isolates may contribute to the variability in the replicative capacity of 
HTV strains, with higher activities providing replicative advantage (Golub et al, 1990, Englund et al, 
1991, Zhang el al, 1997a, Berkhout et al, 1999). In a study performed by Golub et al, a 3-fold 
difference between the basal activities of the LTRs from two intrapatient HIV-1 isolates was found to be 
responsible for a three-fold difference in replication between the two HIV-1 isolates (Golub et al, 1990). 
Moreover, Anderson and co-workers demonstrated that the 1.6 to 2-fold higher Tat-induced activity of 
the LTR from infectious SIVma(. molecular clone SIVmac239 when compared to the LTR of SIVmac251 
paralleled the higher levels of virus and viral RNA found in macaques infected with this clone compared 
to those infected with SIVmac251 (Anderson & Clements, 1992). Monkeys infected with SIVmac239 had 
persistent viremia and usually followed an acute disease course, whereas SIVI1UC251 -infected animals had 
transient viremia, little virus in tissue and followed a more prolonged chronic disease course. Therefore, 
it is possible that the statistically significant 2-fold difference observed between the Tat-induced activities 
of the LTRs cloned from CBL-20, when compared to CBL-22 and CBL-23, may in part determine the 
different replicative capacities of the three isolates. Similarly, the observed differences may in turn 
reflect differences in the overall promoter activity of the likely phenotypes circulating within the patients 
from whom the isolates were derived, and the difference in the progression status of the three patients 
from whom the isolates were obtained.
Nevertheless, while directing higher activities, the differences observed between the activities of the 
LTRs from CBL-21, also a rapidly replicating viral strain, and the activities of LTRs from the remaining 
four isolates, and between LTRs from CBL-20 and CBL24, the viral strains exhibiting the most extreme 
differences in growth kinetics and cytopathogenicity, all within the Jurkat cell-line, were not found to be 
statistically significant (P=0.5227).
In addition, when transfected into the THP-1 cell-line the LTRs cloned from the rapidly replicating 
isolates were not any more active at the Tat-induced level than the LTRs cloned from the isolates 
displaying slower growth kinetics. LTRs cloned from CBL-24 (the least cytopathic and slowest growing 
of the CBL isolates), and not CBL-20 (the most rapidly growing and cytopathic CBL isolate), directed the 
highest mean absolute Tat-induced activity. In contrast to the statistical differences observed between the 
mean Tat-induced LTR activities of CBL-20, CBL22, and CBL23 within the Jurkat data set, when tested
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by one-way ANOVA, the mean Tat-induced LTR activities of the five CBL isolates were statistically 
indistinguishable from each other in THP-1 cells.
In summary, significant differences have been noted between the mean basal and Tat-induced LTR 
activities of the CBL series when transfected into the T-cell-like Jurkat cell-line. In general, the LTRs 
cloned from the cytopathic, rapidly replicating isolates isolated from patients with either AIDS or ARC 
tended to have higher activities than the LTRs cloned from slower growing, less cytopathic isolates 
isolated from asymptomatic individuals. When the same LTR clones were transfected into the monocyte­
like THP-1 cell-line however, the mean basal and Tat-induced LTR activities of the members of the CBL 
series were found to be statistically indistinguishable from each other. In THP-1 cells, LTRs cloned from 
the cytopathic, rapidly replicating isolates were not any more likely to have higher activities than the 
LTRs cloned from slower growing and less cytopathic isolates. In fact, LTRs derived from the least 
cytopathic and slowest growing isolate directed the highest levels of basal and Tat-induced activities in 
this cell-line.
The observation of such cell-type-specific transcriptional differences and of the cell-type-specific trends 
towards higher basal and Tat-induced activities directed by the LTRs from the rapidly replicating isolates 
in Jurkat cells, raises the possibility that some HIV-2 LTRs could confer transcriptional and replicative 
advantage within specific cell-types. In this instance when transfected into a T-cell-like cell-line, LTRs 
cloned from rapidly replicating isolates derived from patients displaying significant disease progression 
appear to have transcriptional advantage over LTRs cloned from isolates exhibiting slower growth 
kinetics that were derived from asymptomatic patients. Interestingly, the range of basal and Tat-induced 
activities directed by the LTRs cloned from CBL-20,21, and 22 were found to be larger in the THP-1 and 
more particularly the Jurkat cell-line, than the range of basal and Tat-induced activities directed by LTR 
clones taken from CBL-23 and CBL-24.
Cell-type-specific transcriptional differences between the activities of HTV-1 LTRs have been 
demonstrated extensively (Corboy et al, 1992, Moses et al., 1994, Estable et al. 1996, Krebs et al., 1998, 
Jeeninga et al., 2000), as has the tissue-compartmentalised phylogenetic clustering of HIV-1 LTR 
variants (Ait-Khaled et al., 1995, Corboy & Garl, 1997), leading to the suggestion that the LTR is 
involved in cell type-specific gene expression and viral replication (Ait-Khaled et al, 1995, Corboy & 
Garl, 1997, Krebs et al, 1998, Jeeninga et al, 2000). More recently, evidence has been presented to 
suggest that in this role the HTV LTR is also a potential contributor to viral tropism (Corboy & Garl,
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1997, McAllister et al, 2000). The identification by Clark et al (Clark et al, 1995) of a binding site 
(peri-KB) within the HIV-2 LTR that was required for transcription within monocytic but not T cell-lines 
has indicated that the HIV-2 LTR could also contribute to cell type-specific gene regulation, viral 
replication, and viral tropism. It is interesting to note that the activities of the LTRs from CBL-20 and 
CBL-24 in particular, appear to reflect the tropism of the viral isolates from whom they were derived. 
LTRs from CBL-20, the isolate that grew rapidly in primary culture (reverse transcriptase activity -  
6000cpm in 5 days, Schultz et al., 1990) and T cell-like cell-lines such as CEM, H9, and MOLT4, 
directed the highest activities when transfected into the T-cell-like Jurkat cell-line. Whereas, LTRs from 
CBL-24, the isolate that grew slowly in primary culture (reverse transcriptase activity -  6000cpm in 28 
days, Schultz et al, 1990) and could only be grown in the T cell-like MOLT4 cell-line after several 
attempts directed some of the lowest activities in the Jurkat cell-line. In contrast, the LTRs from this 
isolate directed the highest activities when transfected into the monocyte-like THP-1 cell-line. The 
significance of these findings to HTV-2 pathogenesis requires further investigation. Nevertheless, since in 
vitro culturing of HIV places viral isolates within highly selective environments the conclusions that can 
be drawn from this data set are limited and must be made with caution. However, the findings appear to 
indicate that the HIV-2 LTR maybe contributing to cell-type specific gene expression and perhaps viral 
tropism. The next chapter in this thesis describes the functional analysis of LTRs cloned from the 
uncultured PBMCs of HIV-2 infected patients displaying either long-term non-progression, or rapid 
progression to symptomatic disease.
The results from chapter 5 have demonstrated that the optimised dual luciferase assay system is capable 
of reproducibly detecting statistically significant differences between the activities of HIV-2 LTRs 
derived from different DNA sources in different cell-lines. This has enabled reliable comparative 
analyses of HTV-2 LTR function to be achieved.
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Chapter 6. 
Functional Characterisation of Naturally Occurring HTV-2 LTR Genotypes from 
LTNP and RP Gambian Patients.
6.1 Introduction
Unlike HIV-1 few naturally occurring HTV-2 LTR genotypes have been functionally characterised (Tong- 
Starksen et al, 1990, Arya, 1991, Markovitz et al., 1992, Hannibal et al, 1993, Hilfinger et al 1993, 
Hannibal et al, 1994, Clark et al, 1995). In order to investigate further any correlation between LTR 
activity and disease progression rates in HIV-2 infected individuals, and to extend the findings presented 
in Chapter 5, the activity of LTRs cloned directly from the uncultured PBMCs of HIV-2 patients with 
non-progressing disease and patients showing progressive disease were assessed and compared. Patients 
with relatively rapid progressing HIV-2 AIDS, with disease courses similar to HTV-1 infection, have been 
observed both in The Gambia (Ariyoshi et al, 2000) and among West Africans resident in Europe (van 
der Ende et al, 1996). However, rapid progression is generally uncommon amongst HIV-2 infections. 
Therefore, comparing the function of LTRs from these unusual patients with LTR function in more 
typical slow progressors may reveal key differences in promoter activity.
We have examined the function of LTRs cloned from the uncultured PBMCs of three LTNP and three RP 
HIV-2 infected patients (described in Chapter 3) from The Gambia. These individuals were identified as 
HIV-2 seropositive at the MRC hospital, Fajara, and were recruited into a longitudinal study for a period 
of clinical follow-up extending at least 56 months. The basal and Tat-induced activities of multiple LTR 
clones from each of the six patients have been measured in two biologically relevant cell-lines, the Jurkat 
T-cell-line and the monocytic THP-1 cell-line, using the optimised dual luciferase assay system 
(described in Chapter 4).
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6.2 Summary of patient details
PBMC samples were obtained from six HIV-2 seropositive patients attending the MRC hospital in Fajara, 
The Gambia (procedures were performed by colleagues at the MRC laboratories, Fajara, The Gambia). 
Each of the six patients had been recruited to a longitudinal study in which patient samples were taken at 
six monthly intervals (Ariyoshi et al, 2000). Disease progression rates were determined based on clinical 
data, decline of CD4% over the period of follow-up (determined by colleagues at the MRC laboratories, 
Fajara, The Gambia), and plasma viral load measurements (determined by Dr. N. Berry, NIBSC, 
London). Rapid progressor (RP) patients were defined as those with CD4 declining from greater than 
20% to less than 13% within 20 months, and whose viral load measurements exceeded 50,000 copies/ml 
(RP1-RP3). Long-term non-progressor (LTNP) patients had stable CD4 counts for more than 56 months, 
and had viral load measurements of <1000 copies/ml (LTNP1-LTNP3). LTRs were cloned from PBMC 
samples obtained as close to the time of RNA viral load measurements as possible.
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MRC Sample 
code (assigned 
sample number)
Longitudinal RNA 
(Load measurements — 
date and (copies/ml))
(determined by Dr.N.Beny, 
NIBSC, London)
Date of 
PBMC 
sample from 
which LTRs 
were cloned
CD4% at time 
of LTR cloning
(determined by 
colleagues at MRC 
Laboratories, Fajara, 
The Gambia)
Disease Status [
N72617 (LTNP1) 27/08/91 -undetectable 
13/06/95- 2568
09/11/93 41 Non-progressor
N71746 (LTNP2) 08/10/91 -undetectable 
23/06/92-undetectabIe 
07/06/94- undetectable
22/06/93 49 Non-progressor
N15120 (LTNP3) 30/04/92-undetectable 
27/08/92-undetectable 
17/05/94 undetectable
06/06/96 48 Non-progressor
N72462 (RP1) 13/08/92 -100,000 19/10/93 9 Rapid progressor
W1333 (RP2) 18/08/92-55,450 18/08/92 22 Rapid progressor
N74044 (RP3) 06/10/92 - 500,000 
07/01/93 - 99,500 
14/06/94 -183,000
14/06/94 13 Rapid progressor
Table 6.1 Origin of the PBMC samples from HIV-2 infected individuals. Multiple LTRs were cloned 
from each of the six patients and were used to assess LTR function at the basal and Tat-induced level. 
Undetectable RNA load measurements are defined as those < 200copies/ml.
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Figure 6.1 Graphical representations of the longitudinal CD4 and CD8 % profiles of the three LTNP 
patients in the analyses (determined by colleagues at the MRC Laboratories, Fajara, The Gambia). Red 
diamond symbols represent the date of the PBMC sample from which LTRs were directly cloned. Blue 
square symbols represent the date at which plasma HIV-2 RNA has been measured.
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63  Transcriptional activity of naturally occurring HIV-2 LTR genotypes from RPs
and LTNPs
Assessing and comparing the activities of LTRs cloned directly from the uncultured PBMCs of six 
patients in total examined the role of HIV-2 LTR function in determining disease progression status 
further. Three patients had been characterised as long-term non-progressors (LTNPs), the remaining 
three patients were characterised as rapid progressors (RPs) (see Table 6.1, pg 223, and Figures 6.1, pg 
224, and 6.2, pg 225).
6.3.1 Evaluation o f  intrapatient LTR functional variability
In order to enable a judgement to be made about the number of LTR clones required to give a 
representative view of the LTR activity within each patient in subsequent comparative transfection 
experiments, the variation in the basal activities of naturally occurring HTV-2 LTR genotypes derived 
directly from the PBMCs of two HIV-2 infected Gambian patients, one randomly selected from each 
progression group, was examined.
Sixteen LTR clones (eight from long-term non-progressor 3 - LTNP3, eight from rapid progressor 2 - 
RP2) produced using the nested LTR PCR -  restriction digest cloning procedures described in Chapter 4 
were cotransfected into Jurkat cells, in triplicate, with the internal control vector pRL-TK at a ratio of 
10:1, using the Superfect transfection reagent protocol described in section 2.2.4.6a. Precise DNA 
concentrations within the transfection mixtures are given in the legend of Figure 6.3, pg 228. Luciferase 
activities derived from the HIV-2 promoters are expressed as normalised activities by dividing the firefly 
luciferase expression by the Renilla luciferase expression measured using the dual-luciferase assay 
system (Promega Ltd) and luminometry (Canberra-Packard Topcount) from each cotransfection. Results 
are presented as the mean normalised basal activity value for each LTR clone, calculated from the three 
normalised basal activity values of each triplicate cotransfection. Differences between LTR activities 
were compared by analysis of variance (ANOVA) and by the Tukey-Kramer test. Values of p<0.05 were 
considered statistically significant.
When transfected into Jurkat cells the LTRs within each of the sixteen reporter constructs, eight cloned 
from LTNP3 and eight cloned from RP2, had a detectable basal activity (Figure 6.3A, pg 228). Basal 
LTR activity was found to be variable between the eight LTRs cloned from each of the two patients. The
226
basal activities directed by the LTRs from RP2 varied over a 7-fold range (Figure 6.3A, pg 228) whilst 
the basal activities of LTRs from LTNP3 varied over a 6-fold range (Figure 6.3B, pg 228).
When tested by one-way ANOVA the differences observed between the mean normalised basal activities 
of the eight clones derived from RP2 and the eight clones derived from LTNP3 were found to be 
statistically significant (ANOVA p=0.0024 and p=0.0115 respectively). This analysis demonstrated that 
at least one of the eight LTR clones in each patient data set directed a mean basal activity that was 
significantly different from the mean basal LTR activities of the remaining LTR clones from that patient 
which would not be explained by sampling variation.
Multiple comparisons within the RP2 data set (Figure 6.3A, pg 228) by Tukey-Kramer tests revealed that 
the mean normalised basal LTR activity of clone RP2.7 was significantly higher than the mean 
normalised basal activities of six of the seven other RP2 LTR clones (T-K test p=0.02 -  0.002). The 
activity of the LTR within this clone was at least two-fold and in some cases up to six-fold greater than 
the activities of the other LTR clones in this data set. RP2.4 was the only LTR clone from RP2 that 
directed a level of basal activity that, while lower, was not statistically different from the activity of the 
LTR within clone RP2.7. The basal activity of the LTR within clone RP2.4 was found to be statistically 
higher than the activities of clones RP2.2 (T-K test p=0.05) and RP2.6 (T-K test p=0.04).
Within the LTNP3 data set (Figure 6.3B, pg 228) the basal activity of LTR clone LTNP3.1 was found to 
be significantly higher than the basal activities of clones LTNP3.5 (T-K test p=0.02) and LTNP3.8 (T-K 
test p=0.03). The activity of the LTR within clone LTNP3.1 exceeded the activities of these two clones 
by five-fold.
Since statistically significant differences were observed between the basal activities of LTRs cloned from 
the same patient the results indicated the necessity for multiple LTR clones to give a more representative 
view of naturally occurring promoter activity within the viral quasispecies of each Gambian HIV-2 
infected patient than a single LTR clone. Since clones from each of six Gambian patients were to be 
transfected at least in triplicate into two different cell lines within the subsequent comparative analyses, 
and were to be assessed for basal and Tat-induced activity within both cell lines, a practicable figure of 
five clones was chosen to represent the promoter region within the quasispecies of each Gambian patient.
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Figure 6.3 (A) Differential normalised basal activity of eight LTR clones from RP2. (B) Differential 
normalised basal activity of eight LTR clones from LTNP3. The cloned LTRs were tested for basal 
activity in 2 x 106 Jurkat cells. Cotransfections were performed with 1.26pg HIV-2LTR-pGL3E, 0.14pg 
of pRL-TK and 0.6pg of HSDNA. Background luciferase activity was assessed by performing a 
transfection with 1.26pg pGL3E and 0.74pg of HSDNA, and was subtracted from all measurements. 
Each bar represents the mean normalised basal activity value calculated for each LTR clone from a 
triplicate transfection, with error bars representing the standard deviation of the three individual values. 
Luciferase activities derived from the HIV promoters were normalised by dividing the firefly luciferase 
expression by the Renilla luciferase expression measured from each cell lysate.
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6.3.2 Functional analysis o f LTRs cloned from LTNP and RP patient PBMCs within the
Jurkat ceU line
HIV-2 LTR functional studies were initially undertaken within the T-cell like Jurkat cell line. LTR 
function at the basal and Tat-induced levels for each of the six HIV-2 infected Gambian patients, three 
LTNPs and three RPs, was assessed and compared, each patient was represented by five LTR clones 
produced as described in Chapter 4.
6.3.2.1 Basal activity o f HIV-2 LTRs clonedfrom Gambian cohort patients
The level of basal activity directed by LTRs cloned from six Gambian HTV-2 infected patients was 
assessed using the optimised dual luciferase assay system (see section 2.2.5). A total of thirty LTR 
clones, five from each of the six patients (produced by the nested-PCR and restriction digest cloning 
procedures described in Chapters 3 and 4), were cotransfected in triplicate into Jurkat cells with the 
Renilla luciferase internal control vector pRL-TK at a ratio of 10:1 according to the protocol described in 
section 2.2.4.6a (precise DNA concentrations are given in the legend of Figure 6.4A, pg 232). Luciferase 
activities derived from each of the thirty HIV-2 promoters were then normalised with respect to Renilla 
luciferase activity by dividing the firefly luciferase expression by the Renilla luciferase expression 
measured from each cotransfection (see section 2.2.5). Over the course of the study this entire 
experiment was repeated a total of three times, and in parallel to the Tat activity analyses (see section 
6.3.2.2). Results are presented as the mean normalised basal activity value for each LTR clone, 
calculated from nine normalised basal activity values obtained in three independent triplicate 
cotransfections (Figure 6.4A, pg 232), and as a box plot representing the range of the five clonal basal 
LTR activity values measured for each Gambian patient (Figure 6.4B, pg 233). The range of the fifteen 
clonal basal LTR activities for each progression group and the range of the three mean basal LTR 
activities calculated for the three patients in each of the two progression groups are also presented as box 
plots (Figure 6.5A, pg 234, and Figure 6.5B, pg 234, respectively). A line marks the median basal LTR 
activity for each patient or progression group, the box representing the distance between the first and third 
quartiles, the leading and trailing ‘whiskers’ corresponding to the minimum and maximum respectively 
(Figure 6.4B, pg 233, 6.5A, pg 234, and 6.5B, pg 234). Differences between LTR activities were 
compared by analysis of variance (ANOVA) and by the Tukey-Kramer test. Values of p<0.05 were 
considered statistically significant.
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Each of the thirty LTR clones taken from a total of six Gambian patients, three LTNP, three RP, was 
found to direct a detectable level of basal activity when transfected into Jurkat cells (Figure 6.4A, pg 
232). Significant variation was observed between the basal activities of LTRs cloned from the same 
Gambian patient and between the basal activities of LTRs cloned from different Gambian patients. The 
greatest intra-patient ranges in basal activity were seen between LTRs cloned from RP2 and RP3 (Figure 
6.4A, pg 232, and 6.4B, pg 233), the range of activities directed by the LTRs cloned from RP3 was at 
least two-fold greater than the intra-patient ranges of all three LTNPs and one RP, RP1.
Overall, LTRs cloned from the RP group of patients directed basal activities ranging from 4.52 to 12.80 
with a median basal activity of 7.62 (n=15) (Figure 6.5A, pg 234). The median basal activity of the LTR 
clones from the LTNP group of patients was lower than that directed by LTRs from the RP group of 
patients at 5.89 (n=15), with activities ranging from 2.45 to 8.91. One way ANOVA analysis of the basal 
activities of the thirty LTR clones when grouped as two progression groups (n=30), revealed that within 
Jurkat cells the mean basal LTR activity of the group of fifteen RP LTR clones was statistically 
significantly higher (ANOVA p=0.008) than the mean basal LTR activity of the group of fifteen LTNP 
LTR clones (Figure 6.5A, pg 234). However, when this analysis was performed comparing the three 
LTNP patient mean basal activity values (calculated from the five clonal LTR activities for each patient) 
with the three RP patient mean basal activity values, the difference between the mean basal activities of 
the two progression groups became non-significant (ANOVA p=0.254) (Figure 6.5B, pg 234).
Of the thirty HTV-2 LTR clones tested, those cloned from RP2 and RP3 directed the highest overall levels 
of basal LTR activity within the Jurkat cell-line. Clones RP3.5, RP3.1, RP2.5 and RP2.3 were the most 
active LTRs at the basal level, whilst the lowest basal activities within this cell-line were directed by the 
five LTRs cloned from LTNP1 (Figure 6.4A, pg 232). On average, the basal LTR activities of both RP2 
and RP3 were at least three fold higher than the mean basal activity of the five LTR clones from LTNP1.
When the mean basal LTR activities of the six patients were individually tested and compared by one­
way ANOVA, the mean basal LTR activity of at least one of the six Gambian patients was found to be 
statistically significantly different to the mean basal LTR activities of the remaining patients in the 
analysis (ANOVA p<0.0001) (Figure 6.4B, pg 233). This test demonstrated that in at least one instance 
the difference between the individual patient means was greater than the intrapatient variation in LTR 
activity and was unlikely therefore to have occurred as a result of sampling variation. Multiple 
comparisons by Tukey-Kramer tests revealed that with the exception of RP1, the mean basal activity of
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LTRs from LTNP1 was significantly lower than the mean basal LTR activities of all other patients, both 
LTNP and RP, in the analyses (T-K test p=0.0219 - <0.0001). The analyses also demonstrated that the 
mean basal LTR activities of two of the RP patients, RP2 and RP3, were statistically significantly higher 
than the activities of LTRs from two of the LTNP patients, LTNP1 (T-K test p<0.0001, p<0.0001) and 
LTNP2 (T-K test p=0.0096, p=0.0138), in addition to RP1 (T-K test p=0.0018, p=0.0026), which, of the 
three RP patients, directed the lowest overall levels of basal transcription in this cell-line. LTR clones 
from LTNP3 directed a mean basal LTR activity (7.02) that, while lower than the mean basal LTR 
activities of RP2 (9.35) and RP3 (9.20), was not statistically distinguishable from them (T-K test p=0.19,
p=0.26).
Examination of these data has indicated a non-significant trend in basal LTR activity within the Jurkat 
cell-line. LTRs cloned from patients displaying rapid rates of disease progression, high levels of plasma 
viremia and low CD4 counts, (Rapid progressors) (Table 6.1, pg 223), tended to be more active at the 
basal level within the Jurkat cell-line than LTRs cloned from patients who, for a prolonged period of time 
have shown no signs of clinical progression, have high CD4 counts and have no detectable plasma 
viremia (Long-term non-progressors) (Table 6.1, pg 223).
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Figure 6.4 (A) Normalised basal activities of 30 cloned LTRs in Jurkat cells (n=6). Five LTR clones 
represent each of six Gambian HIV-2 seropositive patients, three characterised as LTNPs, three as RPs. 
Each bar represents the mean normalised basal activity value calculated for each LTR clone from nine 
normalised basal activity values obtained in three independent triplicate cotransfections, with error bars 
representing the standard deviation of the nine individual values. Cotransfections were performed in 2 x 
106 Jurkat cells with 1.25 pg HIV-2LTR-pGL3E, 0.125pg of pRL-TK and 0.625pg of HSDNA.
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Figure 6.4 (B) Box plot representing the range of basal activities directed by the five LTR clones from 
each of six patients in Jurkat cells, the median basal LTR activity for each patient is marked by a line 
(n=6). Testing by one-way ANOVA revealed that the mean basal LTR activity of at least one of the six 
patients was statistically different from the other patients in the analyses (p=0.0001). Multiple 
comparisons by Tukey-Kramer tests revealed that the mean basal LTR activity of LTNP 1 was, with the 
exception of RP1, significantly lower than all other patients both LTNP and RP (p=0.0219 -  <0.0001). 
Furthermore, the mean basal LTR activities of RP2 and RP3 were statistically significantly higher than 
LTNP1 (pO.OOOl, p<0.0001) and LTNP2 (p=0.0096, p=0.0138), in addition to RP1 (p=0.0018,
p=0.0026).
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Figure 6.5 (A) Box plot representing the range of basal LTR activities directed by the fifteen clones from 
each progression group in Jurkat cells (n=6). Each progression group consisted of three patients from 
whom five LTRs were cloned. Characterisation of patients was based on clinical data available (Table 
6.1, pg 223, and Figures 6.1, pg 224, and 6.2, pg 225). Testing by one-way ANOVA revealed that the 
mean basal LTR activity of the RP group of clones was statistically higher than the mean basal LTR 
activity of the LTNP group of clones (n=30, p=0.008). (B) Box plot representing the range of the three 
mean patient basal LTR activities in each progression group (n=6). Statistical comparison of the mean 
basal LTR activities of the two progression groups using the three patient means from each group (n=6) 
revealed that the difference between the mean basal LTR activities of the two groups became non­
significant (p=0.254).
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6.3.2.2 Tat-induced activity o f HIV-2 LTRs cloned from the Gambian cohort patients in the Jurkat cell- 
line
In order to assess and compare the transcriptional response to HIV-2 Tat directed by the HIV-2 LTR 
genotypes cloned from the three LTNP and three RP Gambian patients, the HIV-2 Tat expression vector 
RSV-tat was included in the cotransfection mixtures for both Jurkat and THP-1 cell lines.
The thirty LTR clones, five from each of the six Gambian patients were cotransfected into the T-cell like 
Jurkat cell-line with the Renilla luciferase internal control plasmid pRL-TK at a ratio of 10:1 and 600ng 
of the Tat2 expression vector pRSVtat. Cotransfections were performed in triplicate using the Superfect 
protocol for the transfection of Jurkat cells (see section 2.2.4.6a). The experiment to determine the basal 
LTR activity of the Gambian LTR clones, (as described in section 6.3.2.1), was performed in parallel to 
the Tat experiment described below. Normalised absolute Tat-induced LTR activities derived from each 
of the HIV-2 promoters were normalised with respect to Renilla luciferase activity by dividing the firefly 
luciferase expression by the Renilla luciferase expression measured from each cotransfection (see section 
2.2.5). Over the course of the study this entire experiment was repeated a total of three times.
Results are presented as the mean normalised absolute Tat-induced activity for each LTR clone, 
calculated from nine normalised absolute Tat-induced activity values obtained in the three independent 
triplicate transfections (Figure 6.6A, pg 239), and as a box plot representing the range and median of the 
five clonal absolute Tat-induced LTR activity values measured for each patient (Figure 6.6B, pg 240). 
The range of the fifteen clonal absolute Tat-induced LTR activities for each progression group and the 
range of the three mean Tat-induced LTR activities calculated for the three patients in each of the two 
progression groups are also presented as box plots (Figure 6.7A, pg 241, and Figure 6.7B, pg 241, 
respectively). Differences between normalised absolute Tat-induced LTR activities were compared by 
analysis of variance (ANOVA) and by the Tukey-Kramer test. Values of p<0.05 were considered 
statistically significant.
In addition to plotting the normalised basal (Figure 6.4A, pg 232) and absolute Tat-induced activities of 
the thirty LTR clones (Figure 6.6A, pg 239) these values have been used to calculate the Tat 
responsiveness of each LTR clone by dividing the normalised absolute Tat-induced activity by the 
normalised basal activity for each LTR clone. Results are presented as the mean fold increase in LTR 
activity above basal levels directed by each LTR clone in response to Tat2 (Figure 6.8, pg 242).
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When cotransfected into Jurkat cells, with the exception of clones from LTNP1, each of the LTRs derived 
from the remaining five patients directed significantly higher activities in the presence of Tat2 than they 
had directed at the basal level (Figure 6.4A, pg 232, and 6.6A, pg 239). Strikingly, none of the five LTR 
clones from LTNP1 directed any increase in activity above basal levels when cotransfected with the Tat2 
expression vector into Jurkat cells.
As observed at the basal level of activity within the Jurkat cell-line considerable variation was observed 
between the normalised absolute Tat-induced activities of LTRs cloned from the same patient and 
between LTRs cloned from different patients (Figure 6.6A, pg 239). Of the six patients analysed, the 
greatest intra-patient variation was observed between the activities of the LTRs cloned from each of the 
three RP patients (Figure 6.6B, pg 240). The intrapatient ranges of LTR activity for RP1, RP2, and RP3 
were, in each case, at least two-fold greater than the ranges of activities directed by the five LTRs from 
each of the three LTNP patients. In addition, the range of Tat-induced activities directed by the five LTR 
clones from RP3 was found to be 2-fold greater than the range of activities directed by LTRs from the 
two other RP patients in the analyses, RP1 and RP2.
Overall, LTRs cloned from the RP group of patients directed absolute levels of Tat-induced activity 
ranging from 180.56 to 665.48 with a median Tat-induced activity of 348.3 (Figure 6.7A, pg 241). The 
median Tat-induced activity of LTRs from the LTNP group of patients was significantly lower than that 
directed by LTRs from the RP group of patients at 162.5, with activities ranging from 1.51 to 206.40. On 
average, RP Tat-induced LTR activities were three times higher than LTNP Tat-induced LTR activities.
With the exception of clone RP1.1, the absolute Tat-induced activities of fourteen of the fifteen LTRs 
from the RP group of patients were higher than the absolute Tat-induced activities directed by each of the 
fifteen LTR clones from the three LTNP patients (Figure 6.6A, pg 239). Moreover, the median Tat- 
induced LTR activities for each of the three RP patients were higher than the median Tat-induced LTR 
activities for the three LTNP patients within the Jurkat cell-line (Figure 6.6B, pg 240).
One-way ANOVA analysis of the absolute Tat-induced activities of the thirty LTR clones when grouped 
into two progression groups (n=30), revealed that within Jurkat cells the mean Tat-induced LTR activity 
of fifteen clones from three RP patients was statistically significantly higher (ANOVA p<0.0001) than the 
mean Tat-induced LTR activity of fifteen clones from three LTNP patients (Figure 6.7A, pg 241). 
However, as observed at the basal level of activity, when this analysis was performed comparing the three 
RP patient mean Tat-induced activity values (calculated from the five clonal values for each patient) with
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the three LTNP patient mean Tat-induced activity values, the difference between the mean Tat-induced 
activities of the two progression groups became non-significant (ANOVA p=0.0595) (Figure 6.7B, pg
241).
Of the thirty LTR clones tested the highest absolute normalised Tat-induced activities were directed by 
LTRs from RP3 (Figure 6.6A, pg 239). Particularly high levels of activity were directed by LTRs clones 
RP3.3, RP3.1 and RP3.2. Of the LTRs that did produce a /rarasactivation response to the Tat2 protein 
LTRs cloned from LTNP2 directed the lowest absolute Tat-induced activities. On average, the absolute 
Tat-induced activities of LTRs cloned from this patient were three-fold lower than the activities directed 
by the LTRs from RP3.
Statistical analysis of the mean absolute Tat-induced LTR activities of the six Gambian patients when not 
grouped as two progression groups revealed that at least one of the patient means was statistically 
significantly different to the mean absolute Tat-induced LTR activities of the other patients in the analysis 
(ANOVA n=30, p<0.0001). Multiple comparisons between the six patient means by Tukey-Kramer tests 
revealed the mean absolute Tat-induced activity of LTRs from LTNP1 to be significantly lower than the 
mean Tat-induced LTR activities of the remaining five Gambian patients (T-K test pO.OOOl -  
p=0.0045). In addition, the mean absolute Tat-induced activity of LTRs from RP3 was significantly 
higher than the mean Tat-induced LTR activities of all five Gambian patients (T-K test p=0.0032 - 
<0.0001), including RPI (T-K test p=0.0002) and RP2 (T-K test p=0.0032). The mean absolute Tat- 
induced activity of LTRs from RP2 was also found to be statistically significantly higher than both 
LTNP1 (T-K test p<0.0001) and LTNP2 (T-K test p=0.0314), however, although higher than the mean 
absolute Tat-induced activity of LTNP3 the mean activity of RP2 was not significantly higher than that of 
LTNP3 (T-K test p=0.0573). The mean absolute Tat-induced activity of LTRs from RPI, while higher, 
was not statistically higher than the mean activities of either LTNP2 (T-K test p=0.261) or LTNP3 (T-K 
test p=0.396).
As seen with the basal activities of the thirty LTR clones, examination of the data has indicated a non­
significant (p=0.0595) trend in the Tat-induced activities of the same thirty LTRs within the Jurkat cell- 
line. The Tat-induced activities of the LTRs cloned from the RP patients in the analyses tended to be 
significantly higher within the Jurkat cell-line than the Tat-induced activities of the LTRs cloned from the 
LTNP patients.
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Similar findings were also observed when the Tat responsiveness of each LTR clone was examined. The 
Tat responsiveness of each LTR clone corresponds to the fold-increase in LTR activity above basal levels 
that is directed by the HIV-2 LTR when in the presence of the HIV-2 Tat protein. Significant variation 
was observed between the Tat responsiveness of each of the thirty LTR clones (Figure 6.8, pg 242). In 
general, LTR clones that had directed the highest absolute levels of Tat-induced activity also showed the 
greatest fold increase in activity above basal levels. For example, the highest absolute level of Tat- 
induced activity was directed by the LTR clone RP3.3 (Figure 6.6A, pg 239). This clone also showed the 
greatest fold-increase in activity above its basal activity (Figure 6.8, pg 242), and was therefore the most 
active and the most responsive of the thirty LTRs in the presence of the Tat2 protein in this cell-line. 
However, this was not seen with every LTR clone. In particular, LTR clones from RP2 on average, 
directed higher absolute levels of Tat-induced activity than LTR clones from RPI (Figure 6.6A, pg 239). 
When the mean Tat responsiveness of the LTRs from the two patients were compared, however, the 
LTRs from RPI directed a higher fold increase in activity above basal levels on average (Figure 6.8, pg
242), and was therefore more Tat-responsive than the LTRs from RP2, even though the absolute activity 
of these LTRs in the presence of Tat2 was lower.
LTRs cloned from the three LTNP patients promoted a response to Tat that was on average 19-fold higher 
than basal activities, while the response directed by LTRs from the three RP patients was on average, 48- 
fold above basal activities. Even if the values corresponding to LTNP1, whose LTRs had not responded 
to Tat2, were removed from the analyses, the average Tat response directed by LTRs from LTNP2 and 
LTNP3 was 29-fold above basal levels, still considerably lower than the 48-fold observed on average 
with the LTRs derived from the three RP patients.
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Figure 6.6 (A) Normalised absolute Tat-induced activities of 30 cloned LTRs in Jurkat cells (n=6). Five 
LTR clones represent each of six Gambian HIV-2 seropositive patients, three characterised as LTNPs, 
three as RPs. Each bar represents the mean normalised Tat-induced activity value calculated for each 
LTR clone from nine normalised Tat-induced activity values obtained in three independent triplicate 
cotransfections, with error bars representing the standard deviation of the nine individual values. 
Cotransfections were performed in 2 x 106 Jurkat cells with 1.25pg HIV-2LTR-pGL3E, 0.125pg of pRL- 
TK, 0.6pg of RSV-Tat and 0.025pg of HSDNA.
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Figure 6.6(B) Box plot representing the range of absolute Tat-induced activities directed by the five LTR 
clones from each of six patients in Jurkat cells, the median Tat-induced LTR activity for each patient is 
marked by a line (n=6). Testing by one-way ANOVA revealed that the mean Tat-induced LTR activity 
of at least one of the six patients was statistically different from the other patients in the analyses 
(p<0.0001). Multiple comparisons by Tukey-Kramer tests revealed that the mean Tat-induced LTR 
activity of LTNP1 was significantly lower than all other patients both LTNP and RP (p=0.0045 -  
<0.0001). In addition, the mean Tat-induced LTR activity of RP3 was statistically significantly higher 
than all other patients both LTNP and RP (p=0.0032 - <0.0001). The mean Tat-induced LTR activity of 
RP2 was also found to be statistically significantly higher than LTNP1 (p<0.0001) and LTNP2 
(p=0.0314).
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Figure 6.7 (A) Box plot representing the range of Tat-induced LTR activities directed by the fifteen 
clones from each progression group in Jurkat cells (n=6). Each progression group consisted of three 
patients from whom five LTRs were cloned. Characterisation of patients was based on clinical data 
available (Table 6.1, pg 223). Testing by one-way ANOVA revealed that the mean Tat-induced LTR 
activity of the RP group of clones was statistically higher than die mean basal LTR activity of the LTNP 
group of clones (n=30, p<0.0001). (B) Box plot representing the range of the three mean patient Tat- 
induced LTR activities in each progression group (n=6). Statistical comparison of the mean Tat-induced 
LTR activities of the two progression groups using the three patient means from each group (n=6) 
revealed that the difference between the mean Tat-induced LTR activities of the two groups became non­
significant (p=0.0595).
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Figure 6.8 Mean Tat responsiveness of the LTRs cloned from each of the six Gambian patients (n=6). 
Tat responsiveness is measured as the fold increase in LTR activity following cotransfection with the 
pRSV-Tat expression vector and is calculated by dividing the mean normalised absolute Tat-induced 
activity of each LTR clone by the mean normalised basal activity of the same LTR clone.
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6.3.3 Functional analysis o f LTRs cloned from LTNP and RP patient PBMCs within
the THP-1 cell line
LTR activity at the basal and Tat-induced levels was assessed in a second biologically relevant cell-line, 
the monocyte-like THP-1 cell-line. LTR function was assessed and compared using the same 
methodologies.
6.3.3.1 Basal activity o f HIV-2 LTRs clonedfrom Gambian cohort patients in THP-1 cells 
The basal activities directed by the thirty LTR clones, five from each of the six Gambian HIV-2 infected 
patients, LTNP1-3 and RP1-3, were assessed using the optimised dual luciferase assay system (see 
section 2.2.5). Each LTR clone was cotransfected in triplicate with the Renilla luciferase internal control 
vector pRL-TK at a ratio of 10:1 using the Effectene™ reagent protocol for the transfection of THP-1 
cells (see section 2.2.4.6b). Over the course of the study this experiment was repeated a total of three 
times, and in parallel to the Tat activity analyses (see section 6.3.3.2). Luciferase activities derived from 
each of the HIV-2 promoters within the thirty LTR clones were normalised with respect to Renilla 
luciferase activity by dividing the firefly luciferase expression by the Renilla luciferase expression 
measured from each cotransfection (see section 2.2.5), and have been presented in the same format as 
used for the Jurkat data set (Section 6.3.2.1).
As seen at the basal level in Jurkat cells, when transfected into THP-1 cells each of the thirty LTR clones, 
taken from the three LTNP and three RP patients, directed a detectable level of basal activity (Figure 
6.9A, pg 246). However, the overall levels of basal activity directed by each of the LTRs within the 
THP-1 cell-line were considerably less than observed within the Jurkat cell-line and activities fell over a 
narrower range.
Variation was observed between the basal activities of LTRs cloned from the same Gambian patient and 
between LTRs cloned from different Gambian patients. As observed in the Jurkat cell-line, the greatest 
intra-patient range of basal LTR activities was directed by LTRs cloned from RP3 (Figure 6.9A, pg 246, 
and B, pg 247). The range of activities directed by the LTRs from this patient was between two and four­
fold wider than the range of activities directed by LTRs cloned from the other patients in the analyses.
A greater degree of overlap was observed between the basal activities of the thirty LTRs when transfected 
into THP-1 cells than had been observed between the activities of the same thirty clones when transfected 
into Jurkat cells. Overall, RP basal LTR activity ranged from 0.27 to 1.14, whilst the LTNP basal LTR
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activity ranged from 0.13 to 0.91 (Figure 6.9A, pg 246, and Figure 6.10A, pg 248). The median basal 
LTR activities for the two progression groups were very similar at 0.48 (RP group) and 0.54 (LTNP 
group) (Figure 6.10A, pg 248). One-way ANOVA analysis of the basal activities of the thirty LTR 
clones when grouped as two progression groups (n=30), revealed that, unlike the basal activities of the 
same clones when transfected into Jurkat cells, the mean basal LTR activity of the LTNP group of clones 
was not significantly different (ANOVA p=0.57) from the mean basal LTR activity of the RP group of 
clones when transfected into THP-1 cells. Similarly, when this analysis was performed comparing the 
three LTNP patient mean basal activity values (calculated from the five clonal values for each patient) 
with the three RP patient mean basal activity values, no statistical difference was noted between the mean 
basal LTR activities of the two groups (ANOVA p=0.78) (Figure 6.1 OB, pg 248).
Of the thirty LTR clones tested, those cloned from RP3 directed the highest overall levels of basal activity 
within the THP-1 cell-line. LTRs cloned from this patient also directed amongst the highest basal 
activities when transfected into the Jurkat cell-line. The lowest LTR activities observed within the THP-1 
cell-line were also directed by LTRs that had directed the lowest activities when transfected into Jurkat 
cells, and were cloned from LTNP1. However, cell-type specific transcriptional differences were noted 
between the basal activities of some LTR clones when transfected into the Jurkat and THP-1 cell-lines. 
In particular, LTRs cloned from RP2 had directed on average, the highest mean basal activity in Jurkat 
cells, with approximately three-fold higher activities than those directed by LTNP1. In the THP-1 cell- 
line LTR clones from RP2 directed on average the second lowest mean basal activity, the lowest 
belonging to the LTRs from LTNP1. The mean basal LTR activities of these two patients were 
indistinguishable within the THP-1 cell-line.
When the mean basal LTR activities of the six patients were individually tested and compared by one way 
ANOVA, the mean basal LTR activity of at least one of the six Gambian patients was found to be 
statistically significantly different to the mean basal LTR activities of the remaining patients in the 
analysis (ANOVA p=0.0016) (Figure 6.9B, pg 247). Multiple comparisons between the LTR activities of 
the individual patients by Tukey-Kramer tests revealed that the mean basal activity of LTRs from RP3 
was significantly higher than the activities of LTRs from RPI (T-K test p=0.013), RP2 (T-K test 
p=0.018), and LTNP1 (T-K test p=0.0023). The mean basal LTR activities of the remaining patients in 
the analyses were however, indistinguishable from each other statistically.
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Thus in contrast to the findings in the Jurkat cell-line, examination of basal activities of the same thirty 
LTR clones in THP-1 cells has not revealed a trend in basal LTR activity. LTRs cloned from RP patients 
were not any more likely to be significantly more active at the basal level within the THP-1 cell-line than 
the LTRs cloned from LTNP patients in the analyses.
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Figure 6.9 (A) Normalised basal activities of 30 cloned LTRs in THP-1 cells (n=6). Five LTR clones 
represent each o f six Gambian HIV-2 seropositive patients, three characterised as LTNPs, three as RPs. 
Each bar represents the mean normalised basal activity value calculated for each LTR clone from nine 
normalised basal activity values obtained in three independent triplicate cotransfections, with error bars 
representing the standard deviation o f the nine individual values. Cotransfections were performed in 2 x 
106 THP-1 cells with 0.6pg HIV-2LTR-pGL3E, 0.06pg of pRL-TK and 0.14pg of HSDNA.
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Figure 6.9(B) Box plot representing the range of basal activities directed by the five LTR clones from 
each of six patients in THP-1 cells, the median basal LTR activity for each patient is marked by a line 
(n=6). Testing by one-way ANOVA revealed that the mean basal LTR activity of at least one of the six 
patients was statistically different from the other patients in the analyses (p=0.0016). Multiple 
comparisons by Tukey-Kramer tests revealed that the mean basal LTR activity of RP3 was statistically 
significantly higher than the activities of LTRs from LTNP1 (p=0.0023), RPI (p=0.013) and RP2
(p=0.0018).
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Figure 6.10 (A) Box plot representing the range of basal LTR activities directed by the fifteen clones 
from each progression group in THP-1 cells (n=6). Each progression group consisted of three patients 
from whom five LTRs were cloned. Characterisation of patients was based on clinical data available 
(Table 6.1, pg 223, and Figures 6.1, pg 224, and 6.2, pg 225). Testing by one-way ANOVA revealed that 
there was no statistical difference between the mean basal LTR activities of the RP and LTNP group of 
clones (n=30, p<0.57). (B) Box plot representing the range of the three mean patient basal LTR activities 
in each progression group (n=6). Statistical comparison of the mean basal LTR activities of the two 
progression groups using the three patient means from each group (n=6) also revealed no difference 
between the mean basal LTR activities of die two groups (p=0.78).
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6.3.3.2 Tat-induced activity o f HIV-2 LTRs cloned from the Gambian cohort patients in the THP-1 cell- 
line
As described in section 6.3.2.2, assessment and comparison of the transcriptional response to HTV-2 Tat 
directed by the HIV-2 LTR genotypes cloned from the three LTNP and three RP Gambian patients was 
achieved by including the HIV-2 Tat expression vector RSV-tat in the cotransfection mixtures for both 
Jurkat and THP-1 cell lines.
The thirty LTR clones, five from each of the six Gambian patients were cotransfected into the monocyte­
like THP-1 cell-line with the Renilla luciferase internal control plasmid pRL-TK at a ratio of 10:1 and 
125ng of the Tat2 expression vector pRSVtat. Cotransfections were performed in triplicate using the 
Effectene protocol described in section 2.2.4.7b. The experiment to determine the basal LTR activity of 
the Gambian LTR clones, (as discussed in section 6.3.3.1), was performed in parallel to the Tat 
experiment described below. Absolute Tat-induced LTR activities derived from each of the HIV-2 
promoters within the thirty LTR clones were normalised with respect to Renilla luciferase activity by 
dividing the firefly luciferase expression by the Renilla luciferase expression measured from each 
cotransfection and have been presented in the same format as used for the Jurkat data set (Section 
6.3.2.2). Over the course of the study, this experiment was repeated three times.
In addition, the normalised basal (Figure 6.9A, pg 246) and absolute Tat-induced activity (Figure 6.11 A, 
pg 253) values have been used to calculate the Tat responsiveness of each LTR clone by dividing the 
normalised absolute Tat-induced activity by the normalised basal activity for each LTR clone. Results 
are presented as the mean fold increase in LTR activity above basal levels for each LTR clone in response 
to Tat2 (Figure 6.13, pg 256).
As seen in the Jurkat cell-line, with the exception of clones from LTNP1, the activity of each of the LTRs 
derived from the remaining five patients was increased significantly above basal levels when 
cotransfected with the Tat2 expression vector in THP-1 cells (Figure 6.11 A, pg 253). The five LTR 
clones from LTNP1 that had appeared unresponsive to Tat2 in Jurkat cells also failed to direct any 
significant increase in activity when cotransfected into THP-1 cells with the Tat2 expression vector.
As noted in all previously described experiments considerable intra- and inter-patient variation was 
observed between the activities of the thirty LTR clones (Figure 6.11 A, pg 253). Similar to findings at 
the basal level of activity within the THP-1 cell-line, the range of Tat-induced activities directed by the 
thirty LTR clones was much lower and narrower than the range of activities observed in the Jurkat cell-
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line. Such differences in magnitude and range of LTR activities between different cell types have been 
well documented in previous HTV-1 LTR studies and are thought to result from differences in the 
concentrations of particular transcription factors within each cell type.
Despite the smaller overall range of activities, the highest levels of intra-patient variation were again 
observed between the activities of the LTRs cloned from the RP group of patients. As observed in Jurkat 
cells, the ranges of Tat-induced activity directed by the five LTRs from each of the three RP patients were 
higher than the ranges of Tat-induced activities directed by LTRs from both LTNP1 and LTNP 2 (Figure 
6.11 A, pg 253, and B, pg 254). Although, in contrast to the Jurkat data set, the range of activities directed 
by LTRs from LTNP3 was as great as the ranges observed for RP2 and RP3. Within the THP-1 cell-line 
the greatest intra-patient range of Tat-induced activities was directed by LTRs from RP1.
Of the thirty LTR clones analysed, LTRs cloned from RP3 directed the highest absolute Tat-induced 
activities within the THP-1 cell-line, while LTRs cloned from LTNPl directed the lowest Tat-induced 
activities (Figure 6.11 A, pg 253). This had also been the case when the thirty LTR clones were 
transfected into the Jurkat cell-line (Figure 6.6A, pg 239). Overall, LTRs cloned from the RP group of 
patients directed absolute levels of Tat-induced activity ranging from 5.80 to 19.84 with a median Tat- 
induced activity of 12.33 (Figure 6.11 A, pg 253, and Figure 6.12A, pg 255). The median Tat-induced 
activity of LTRs from the LTNP group of patients was found to be significantly lower than that directed 
by LTRs from the RP group of patients at 6.40, with activities ranging from 0.29 to 15.68.
One-way ANOVA analysis of the absolute Tat-induced activities of the thirty LTR clones when grouped 
as two progression groups (n=30), revealed that within the THP-1 cell-line, as observed within the Jurkat 
cell-line (ANOVA p<0.0001), the mean Tat-induced LTR activity of the fifteen clones from three RP 
patients was statistically significantly higher (ANOVA p<0.0022) than the mean Tat-induced LTR 
activity of fifteen clones from three LTNP patients. On average RP LTR clones were twice as active at 
the Tat-induced level in THP-1 cells than the LTRs derived from the LTNP patients. However, when 
statistical analysis was performed comparing the three RP patient mean Tat-induced activity values 
(calculated from the five clonal values for each patient) with the three LTNP patient mean Tat-induced 
activity values, the difference between the mean Tat-induced activities of the two progression groups 
became non-significant (ANOVA p=0.214) (Figure 6.12B, pg 255).
Similar to findings at the basal level of LTR activity within both Jurkat and THP-1 cell-lines, cell-type 
specific transcriptional differences were noted between the Tat-induced activities of the LTRs when
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transfected into the two cell-lines. For example, the LTR within clone LTNP3.1 was one of the least 
active promoters at the Tat-induced level when transfected into Jurkat cells (Figure 6.6A, pg 239) and yet 
directed one of the highest Tat-induced activities when transfected into THP-1 cells (Figure 6.11 A, pg 
253). In addition, LTR clones RP1.2 and RP1.3 had directed Tat-induced activities in Jurkat cells that 
were considerably higher than the activities of the LTR clones from LTNP3 (Figure 6.6A, pg 239). 
However, when transfected into THP-1 cells the Tat-induced activities of all five LTR clones from 
LTNP3 were higher than the activities of RP1.2 and RP1.3 (Figure 6.11A, pg 253).
Statistical analyses of the mean absolute Tat-induced LTR activities of the six Gambian patients when not 
grouped as two progression groups revealed that at least one of the patient means was statistically 
significantly different to the mean absolute Tat-induced LTR activities of the other patients in the analysis 
(ANOVA n=30, p<0.0001). Multiple comparisons between the mean Tat-induced LTR activities of each 
of the individual Gambian patients by Tukey-Kramer tests revealed that the mean absolute Tat-induced 
activity of LTRs from LTNP1 was significantly lower than the mean Tat-induced LTR activities of the 
remaining five Gambian patients (T-K test p<0.0001 -  p=0.0035). In addition, as observed in the 
analyses of the Tat-induced activities within the Jurkat cell-line (section 6.3.2.2), the mean absolute Tat- 
induced activity of LTRs from RP3 was significantly higher than the mean Tat-induced LTR activities of 
all five Gambian patients, including RP1 and RP2, the two other patients within the RP group (T-K test 
p<0.0001 -  p=0.034). While the mean absolute Tat-induced activity of RP2 was higher than the mean 
Tat-induced LTR activities of LTNP 1 and LTNP2, the difference was only significant in the case of RP2 
vs. LTNP1. Differences between the mean absolute Tat-induced activities of LTRs from the remaining 
patients in the analyses were not statistically significant.
As seen with the basal and Tat-induced activities of the thirty LTR clones within the Jurkat cell-line 
(Figure 6.4A, pg 232, and 6.6A, pg 239), examination of the THP-1 Tat-induced activity data has 
indicated a non-significant (ANOVA, /7=0.214) trend in the Tat-induced activities of the same thirty 
LTRs within the THP-1 cell-line (Figure 6.11A, pg 253). The Tat-induced activities of the LTRs cloned 
from the RP patients tended to be higher within the THP-1 cell-line than the Tat-induced activities of the 
LTRs cloned from the LTNP patients in the analyses.
Similar findings were also observed when the Tat responsiveness of each LTR clone in THP-1 cells was 
examined (Figure 6.13, pg 256). Significant variation was observed between the Tat responsiveness of 
each of the thirty LTR clones, however, in general, LTR clones that had directed the highest absolute
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levels of Tat-induced activity also showed the greatest fold increase in activity above basal levels. On 
average, LTRs cloned from the three LTNP patients promoted a response to Tat that was 11-fold higher 
than basal activities, while the response directed by LTRs from the three RP patients was on average, 24- 
fold above basal activities. Even after the values corresponding to LTNP1, whose LTRs had not 
responded to Tat2, were removed from the analyses, the average Tat response directed by LTRs from 
LTNP2 and LTNP3 was 16-fold above basal levels, still lower than the 24-fold observed on average with 
the LTRs derived from the three RP patients.
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Figure 6.11(A) Normalised absolute Tat-induced activities of 30 cloned LTRs in THP-1 cells (n=6). Five 
LTR clones represent each of six Gambian HIV-2 seropositive patients, three characterised as LTNPs, 
three as RPs. Each bar represents the mean normalised Tat-induced activity value calculated for each 
LTR clone from nine normalised Tat-induced activity values obtained in three independent triplicate 
cotransfections, with error bars representing the standard deviation of the nine individual values. 
Cotransfections were performed in 2 x 106 THP-1 cells with 0.6pg HIV-2LTR-pGL3E, 0.06pg of pRL- 
TK, 0.125pg of RSV-Tat and 0.015pg of HSDNA.
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Figure 6.11(B) Box plot representing the range of absolute Tat-induced activities directed by the five 
LTR clones from each of six patients in THP-1 cells, the median Tat-induced LTR activity for each 
patient is marked by a line (n=6). Testing by one-way ANOVA revealed that the mean Tat-induced LTR 
activity of at least one of the six patients was statistically different from the other patients in the analyses 
(p<0.0001). Multiple comparisons by Tukey-Kramer tests revealed that the mean Tat-induced LTR 
activity of LTNP1 was significantly lower than all other patients both LTNP and RP (p=0.0035 -  
<0.0001). In addition, the mean Tat-induced LTR activity of RP3 was statistically significantly higher 
than all other patients both LTNP and RP (p=0.0034 - <0.0001).
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Figure 6.12 (A) Box plot representing the range of Tat-induced LTR activities directed by the fifteen 
clones from each progression group in THP-1 cells (n=6). Each progression group consisted of three 
patients from whom five LTRs were cloned. Characterisation of patients was based on clinical data 
available (Table 6.1, pg 223, and Figures 6.1, pg 224, and 6.2, pg 225). Testing by one-way ANOVA 
revealed that the mean Tat-induced LTR activity of the RP group of clones was statistically higher than 
the mean basal LTR activity of the LTNP group of clones (n=30, p=0.0022). (B) Box plot representing 
the range of the three mean patient Tat-induced LTR activities in each progression group (n=6). 
Statistical comparison of the mean Tat-induced LTR activities of the two progression groups using the 
three patient means from each group (n=6) revealed that the difference between the mean Tat-induced 
LTR activities of the two groups became non-significant (p=0.214).
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Figure 6.13 Mean Tat responsiveness of the LTRs cloned from each of the six Gambian patients (n=6). 
Tat responsiveness is measured as the fold increase in LTR activity following cotransfection with the 
pRSV-Tat expression vector and is calculated by dividing the mean normalised absolute Tat-induced 
activity of each LTR clone by the mean normalised basal activity of the same LTR clone.
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6.4 Summary and discussion
In order to examine further the relationship between HIV-2 LTR activity and pathogenesis of HIV-2 
infections, the basal and Tat-induced activities of LTRs cloned directly from the uncultured PBMCs of 
two contrasting groups of HIV-2 infected individuals were assessed and compared in two biologically 
relevant cell-lines.
The practicable number of LTR clones required to represent each of six Gambian patients in subsequent 
comparative transfection experiments was initially determined in an experiment performed to assess the 
intra-patient variation in basal LTR activity within the quasispecies of both a rapid progressor (RP2) and 
long-term non-progressor patient (LTNP3). Using the optimised dual luciferase assay system significant 
intra-patient variation was demonstrated between the basal activities of LTRs cloned from both the rapid 
progressor and long-term non-progressor viral populations. When transfected into Jurkat cells, the basal 
activities directed by the LTRs from RP2 fell over a 7-fold range whilst the basal activities of LTRs from 
LTNP3 fell over a slightly smaller range extending 6-fold. Statistically significant differences were noted 
between the activities of several of the LTR clones within both data sets. It was decided therefore, that 
multiple LTR clones would give a more representative view of naturally occurring promoter activity 
within the viral quasispecies of each Gambian HTV-2 infected patient. A practicable number of five LTR 
clones were chosen to represent each of the Gambian patients in the subsequent comparative transfection 
experiments.
6.4.1 Are LTNP LTRs completely defective?
When transfected into both Jurkat and THP-1 cells, the results demonstrated that each of the thirty LTR 
clones, five from each of the three rapid progressor and the three long-term non-progressor patients, were 
able to direct a detectable level of transcription at the basal level. Moreover, at the Tat-induced level of 
transcription the results from both cell-lines demonstrated that, with the exception of LTRs from LTNP1, 
the activities of the LTRs from five of the six Gambian patients increased significantly over basal levels, 
albeit to varying degrees, in the presence of the HTV-2 Tat protein. Since some degree of activity, either 
basal or Tat-induced, was detected from each of the thirty LTR clones, including the fifteen derived from 
the three LTNP patients, these data indicate that long-term non-progression in HIV-2 infection per se 
does not appear to be determined by the presence of completely inactive LTRs within the circulating 
quasispecies of these patients.
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The low basal activity and lack of Tat responsiveness displayed by the LTRs from LTNP1 however, may 
reflect the existence of a viral population with significantly reduced promoter function circulating within 
this patient Similarly reduced LTR function in a patient characterised as a long-term survivor (LTS) of 
HIV-1 infection has been reported by Zhang and co-workers (Zhang et a l, 1997b). Nucleotide sequence 
analyses of the LTRs from this patient revealed multiple G-to-A hypermutations within several of the 
core transcription factor binding sites, including the NF-kB, SP-1, and TAR elements. The functional 
effects of these mutations were severe and were proposed as the possible explanation for the long-term 
survival of this patient (Zhang et al, 1997b). It was envisaged that nucleotide sequence analysis of the 
LTRs cloned from LTNP1 would also reveal significant polymorphism within the TAR and core 
transcription factor binding elements of these promoters, which could explain their severely reduced 
function. If this is the case, it may also be likely that the freedom from clinical illness experienced 
specifically by LTNP1 is related to the structural and functional defects of the promoter regions 
circulating within the quasispecies of this patient. Nucleotide sequence analyses of the LTRs cloned from 
LTNP1 were required to confirm this and are detailed in Chapter 7.
6.4.2 Variation in the function o f naturally occurring HIV-2 LTR genotypes
In accordance with reports outlining the function of naturally occurring HIV-1 LTR genotypes (Michael 
et al, 1994, Estable et al, 1996, Rousseau et al, 1997, Zhang et al, 1997b), a wide range of variation 
was observed between the activities of the thirty LTR clones analysed. Interestingly, significant 
differences were demonstrated between the intra-patient ranges of LTR activity from each patient in the 
analyses. Within THP-1 cells, and more particularly within Jurkat cells, the range of basal and Tat- 
induced LTR activities from each of the RP patients tended to be greater than the ranges of activities 
directed by the LTRs cloned from each of the three LTNP patients. In Jurkat cells, the ranges of basal 
LTR activity from both RP3 and RP2 were wider than the ranges of activities directed by LTR clones 
from LTNP1,2 and 3. Moreover, the ranges of Tat-induced LTR activity from all three RP patients were, 
in each case, at least two-fold greater them the intra-patient ranges of Tat-induced activities directed by 
LTRs from each of die three LTNP patients in Jurkat cells and, both LTNP1 and LTNP2 in THP-1 cells. 
Notably, the range of basal and Tat-induced activities directed by the LTR clones from RP3 in Jurkat 
cells was not only greater than the ranges directed by LTRs from each of the three LTNP patients, but 
also greater than the ranges directed by the two other patients within the RP group.
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Taken together, these data suggest that variation in promoter function exists within the quasispecies of 
each of the six Gambian patients in the analyses. Perhaps more importantly, they indicate that the level of 
variation in LTR function may differ between individuals, with a trend towards greater intra-patient 
variation in LTR activity within the quasispecies of RP patients being noted in the Jurkat cell-line, and, to 
a lesser extent within the THP-1 cell-line. Similar findings were noted in the analyses of the CBL isolates 
(Chapter 5), with the LTR activities of the more rapidly replicating isolates (CBL-20 and CBL21) that 
were derived from AIDS patients being more variable than the activities of the LTRs from the slower 
growing isolates that were derived from asymptomatic individuals (CBL-23 and CBL-24). Interestingly, 
this finding has not been reported by any of the HIV-1 studies that have compared the activities of LTRs 
from groups of LTS and RP patients (Rousseau et al, 1997, Zhang et al., 1997b, Quifiones-Mateu et al, 
1998). It is possible that the intra- and inter-patient variation observed in both the basal and Tat-induced 
LTR activities could result from transfection and/or detection system variation, however the likelihood of 
such variation being introduced is significantly reduced by the use of an internal control vector and the 
dual luciferase assay system. Moreover, there would be no reason for more variation to be introduced 
into the transfection and/or detection procedures used to assess the activities of the RP LTRs since both 
groups of LTR clones were treated in exactly the same manner within the same experiment. It is likely 
therefore; that the differences observed in intrapatient variation reflect genuine differences between the 
variation in LTR activity of the viral phenotypes circulating within each of the patients of the two 
progression groups, and indicate that promoter activity is more variable in patients exhibiting rapid 
progression to disease. It would be interesting to note whether the observed differences in the variation of 
LTNP and RP LTR function relate to differences in LTR sequence variation between the two progression 
groups. The relationship between LTR sequence and function is investigated in Chapter 7.
6.4.3 Comparison o f LTNP and RP Basal LTR activities
Previous studies comparing the activity and nucleotide sequences of HIV-1 LTRs derived from long-term 
survivors (LTS) and typical progressors have failed to establish a general correlation between structural 
or functional LTR defects and disease progression (Estable et a l, 1996, Rousseau et a l, 1997, Zhang et 
al, 1997b, Quifiones-Mateu et al, 1998, Visco-Comandini et al, 1999, G6mez-Romdn et al, 2000). A 
more recent study by Fang et al however, indicated that the transition from nonprogressive to progressive 
infection within an HIV-1-infected individual correlated with specific sequence changes in the LTRs 
circulating within that individual (Fang et al, 2001). There appears to be the potential therefore, to select
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for variation within the LTR that can lead to a more (or less) pathogenic phenotype. The data described 
below represents the first comparative functional analyses of the LTR region from LTNP and RP HIV-2- 
infected individuals.
Significant differences were noted between the overall basal LTR activities of the LTNP and RP groups 
when analysed, according to the cell-type transfected. Transfection experiments within Jurkat cells 
demonstrated that the RP LTRs tended to be more active at the basal level than the LTNP LTRs. 
Statistical comparison of the two progression groups showed that the mean basal activity of the fifteen RP 
LTR clones was significantly higher than the mean basal LTR activity of the fifteen LTNP LTR clones 
(p<0.008). However, when the analysis was reduced to comparing the mean basal LTR activities of each 
of the three LTNP patients with the mean basal LTR activity of each of the three RP patients, (calculated 
from the five clonal activities from each patient), the statistical difference between the two progression 
groups became non significant (p=0.254), making the overall trend observed in Jurkat cells statistically 
non-significant.
When analysed individually the mean basal LTR activities of two of the rapid progressor patients, RP2 
and RP3, were found to be significantly higher in Jurkat cells than the mean basal activities of LTRs from 
two of the long-term non-progressor patients, LTNP1 (p<0.0001, p<0.0001) and LTNP2 (p=0.0096, 
p=0.0138), and higher though not statistically higher than the mean basal LTR activity of LTR clones 
from the third LTNP patient, LTNP3. Interestingly, the mean basal LTR activity of RP1 was found to be 
lower than the mean basal LTR activities of both LTNP3 and LTNP2, indicating that despite the general 
trend not all RP LTRs had higher basal activities than LTRs from LTNP patients in this cell-line. When 
tested statistically the activities of clones from LTNP1 were found to be significantly lower than the mean 
LTR activities of all patients in the analyses, with the exception of RP1.
While transfection experiments within THP-1 cells demonstrated that the LTRs cloned from RP3 directed 
the highest basal activities and the LTRs cloned from LTNP1 directed the lowest basal activities, overall 
the LTRs cloned from the rapid progressor patients in the analyses were not found to be any more likely 
to have a higher basal activity in THP-1 cells than the LTRs cloned from the long-term non-progressor 
patients. Statistical analyses performed with the THP-1 data set when grouped together as two 
progression groups revealed no statistical differences between the clonal (n=30) or the patient (n=6) mean 
basal LTR activities of the two progression groups in this cell-line (p=0.67 (n=30) and p=0.78 (n=6)).
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Therefore, comparison of the basal activities of the thirty LTRs when transfected into THP-1 and Jurkat 
cells has revealed a difference between the patterns of activities directed by the LTRs in the two cell- 
lines. Not all of the LTRs that had displayed high levels of basal activity in one cell-line directed 
correspondingly high levels when transfected into the second cell-line. However, LTRs from LTNP1 and 
RP3 were found to direct the lowest and highest average basal activities respectively in both cell lines. 
The non-significant trend observed in the LTR activities of the thirty LTR clones when transfected into 
Jurkat cells provides additional evidence that some naturally occurring HIV-2 LTR genotypes can exhibit 
cell-type specificity in their function, and demonstrates more importantly that LTRs cloned from RP 
patients appear to exhibit transcriptional advantage at the basal level over LTRs cloned from LTNP 
patients in the T-cell-like Jurkat cell-line.
6.4.4 Comparison o f LTNP and RP Tat-induced LTR activities
Examination of the Tat-induced activities of the thirty HTV-2 LTR clones revealed a similar but more 
pronounced trend in activity than that initially observed in the basal activities of these clones when 
transfected into Jurkat cells. On average, RP LTRs were found to be three times more active at the Tat- 
induced level in the Jurkat cells and twice as active in THP-1 cells than the LTNP LTRs. The activity of 
the RP LTRs in Jurkat cells was shown to increase on average 48-fold above basal levels in the presence 
of Tat compared to the average 19-fold increase observed with LTNP LTRs. Similarly, in THP-1 cells 
RP LTRs directed on average a 24-fold increase in activity above basal levels compared to the 11-fold 
average increase demonstrated by LTRs from the LTNP group of patients. Even following the removal of 
the data from LTNP1 the average LTNP Tat-induced LTR activity was still only found to be 29-fold 
above basal levels compared to the average 48-fold increase observed with RP LTRs in Jurkat cells, and 
16-fold vs. the 11-fold average increase in THP-1 cells.
In both cell-lines, although most notably in Jurkat cells, the mean Tat-induced activities of the fifteen RP 
LTR clones was found to be statistically significantly higher than the mean Tat-induced activities of the 
fifteen LTNP LTR clones (Jurkat, p<0.0001, THP-1, p<0.0022). As observed at the basal level of activity 
however, when statistical analysis was performed comparing just the three patient mean Tat-induced 
activity values from each progression group, the difference between the mean Tat-induced activities of 
the two progression groups became non-significant in both cell-lines (Jurkat, p=0.0595, THP-1, p=0.214).
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The basis for the observed general trend lies in the statistically significant differences noted between the 
mean Tat-induced LTR activities of the individual patients in the analysis. In both Jurkat and THP-1 cell- 
lines the mean Tat-induced LTR activities of two of the RP patients, RP2 and RP3, were found to be 
consistently and significantly higher than the mean Tat-induced LTR activities of two of the LTNP 
patients, LTNP1 and LTNP2. Where the trend was most pronounced, in Jurkat cells, the mean Tat- 
induced LTR activities of RP1, RP2 and RP3 were found to be higher than all three of the LTNP patients.
It is possible that the significant differences in the function of the LTRs from the RP and LTNP patients 
arise from differences between the core transcription factor binding elements of the LTRs from these 
different patients. In particular, throughout these functional analyses the LTRs from LTNP1 and RP3 
have exhibited functional characteristics that distinguish them from the other patients in the analyses. In 
contrast to the severely reduced function displayed by the LTRs from LTNP1, the LTRs cloned from RP3 
have directed activities at both basal and Tat-induced levels in both cell-lines that are either significantly 
and/or statistically higher than the activities of the LTRs cloned from the other LTNP and RP patients in 
the analyses. It is likely therefore, that the LTRs from RP3 have differences at the structural level as well 
as at the functional level from the other LTRs in the analyses. Nucleotide sequence analyses of the LTRs 
from this patient in addition to LTNP1 would therefore, be of interest and are detailed in Chapter 7. In 
addition, the LTRs from RP1 were consistently found to direct the lowest activities of the three RP 
patients in the analyses in both Jurkat and THP-1 cells. It is also possible that sequence differences exist 
between the core transcription factor binding elements of the LTRs from RP1 and those from RPs 2 and 3 
that may account for the differences in function observed between these promoters.
In summary, we have shown that LTRs cloned directly from the PBMCs of patients exhibiting rapid 
progression to disease tended to have higher basal and Tat-induced activities when transfected into Jurkat 
cells than the LTRs cloned from patients exhibiting long-term non-progression. A similar but less 
pronounced trend was also observed in the absolute Tat-induced activities of the thirty LTRs when 
transfected into the monocyte-like cell-line, although overall the activities of the LTRs from the two 
contrasting groups of patients were more similar in THP-1 cells. The higher activities of the RP LTRs 
may reflect the existence of quasispecies within these patients with comparatively enhanced promoter 
activity. Conversely, the lower activities of the LTNP LTRs may reflect the existence of quasispecies 
within these patients with comparatively reduced promoter activity. By nature of the relationship 
between promoter activity, replicative capacity, and the rate of virus production, a higher rate of virus 
production and increased speed of symptomatic disease development could be predicted in an individual
262
containing a quasispecies of higher promoter activity when compared to an individual containing a 
quasispecies of low promoter activity. Significantly, the more pronounced difference between RP and 
LTNP LTR activity observed in Jurkat cells compared to THP-1 cells raises the possibility that the RP 
LTRs may provide transcriptional and replicative advantage within particular cell types.
The basis for the significant differences in basal and Tat-induced activity such as those observed between 
clones from RP3 and LTNP1 when transfected into Jurkat cells, and the more subtle overall differences 
observed between the mean basal and Tat-induced LTR activities of the progression groups as a whole 
when transfected into Jurkat and THP-1 cells, may lie in sequence differences between the transcription 
factor binding elements within the LTRs analysed. In characterising sequence changes to SP-1 binding 
sites in the HTV-1 LTR, McAllister et al demonstrated that substitutions within these sites resulted in 
greater transcriptional and replicative effects within the T-cell-like Jurkat cell-line when compared to the 
monocyte-like U937 cell-line (McAllister et al., 2000). Similarly, Hilfinger et al demonstrated that 
changes to the cis-acting synergistic binding sites within the modulatoiy region of the HIV-2 LTR had a 
greater effect upon inducible transcription within immature monocytic cells such as HL-60s compared to 
die effects within mature monocytic cells such as THP-ls (Hilfinger et al., 1993). In this vein, it is 
possible that the LTNP LTR sequences contain transcription factor binding site mutations that have a 
greater effect on LTR function in Jurkat cells when compared to THP-1 cells. In an attempt to determine 
a structural basis for the functional findings presented in this chapter, nucleotide sequence analysis was 
performed upon the thirty naturally occurring HIV-2 LTR genotypes. The findings of these analyses are 
presented in Chapter 7.
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Chapter 7. 
Further Characterisation of Naturally Occurring HTV-2 LTR Genotypes using 
Nucleotide Sequence Analyses. 
7.1 Introduction
The analysis of DNA structure and its relationship to gene expression has been markedly facilitated by 
the development of powerful techniques for the sequencing of DNA molecules. Fluorescent dye-primer 
sequencing has been utilised in this chapter to determine the nucleotide sequence of each of the thirty 
cloned LTR genotypes described in the previous chapter. It is possible that the overall differences in 
activity observed between the LTNP and RP LTRs when analysed as two groups and, more probably, the 
comparatively low and high activities of LTRs from individual patients such as LTNP1 and RP3 
respectively, could result from differences in the actual nucleotide sequences of the LTRs themselves. By 
determining and comparing the nucleotide sequences of the thirty cloned LTRs it was hoped that a greater 
understanding of the overall relationship between LTR structure, function, and disease progression status 
would be achieved.
7.2 Dye-primer cycle sequencing of naturally occurring HIV-2 LTR genotypes 
from LTNPs and RPs
7.2.1 Sequencing Oligonucleotides
Since the sequencing protocol described in section 2.2.6 routinely resulted in 400 accurately sequenced 
bases from the 3’ end of the primer, to ensure the entire 764bp cloned LTR region was sequenced, three 
fluorescent dye labelled primers were designed. Two primers were designed to flank the cloned LTR 
region and were therefore located within the pGL3E firefly luciferase vector. The third primer was 
designed to bind to a sequence 317bp from the 5’ end of the cloned LTR region; this conferred overlap of 
the flanking sequencing fragments and enabled a complete and accurate sequence to be obtained. The 
three overlapping but non-contiguous sequencing profiles were subsequently aligned into a contiguous 
sequence by downloading the computer-generated information into a sequencing programme called 
Sequencher (Gene Codes Corporation). All primers used in the sequencing reactions are listed in Table 
2.6, pg 124.
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7.3 Sequence analysis of LTR quasispecies from LTNP and RP patients
7.3.1 Rapid subtyping o f the naturally occurring LTNP and RP LTR genotypes
Prototypic HTV-2 subtype A (HIV-2ROD), B (HTV-2D2o5) and simian-like strains (HIV-2F0784) can be 
differentiated by a 40- to 44bp signature sequence (nucleotides -169 to -125) within the U3 section of the 
HIV-2 LTR (Berry et a l, 2001). The subtype of the LTR sequences from each of the six Gambian 
patients was determined by aligning a 30bp section of this signature sequence from each of the six 
patients with the corresponding sequence from prototypic HTV-2 subtype A, B and SIV-like strains 
(Figure 7.1, pg 266).
Each of the six Gambian LTR sequences, one sequence from each patient, were found to be 
phylogenetically most related to the HTV-2 strain belonging to subtype A, the most common HIV-2 
subtype in West Africa (Figure 7.1, pg 266). Little homology was observed between the six Gambian 
LTR sequences and the viruses with subtype B (HTV-2D2o5) or SIV-like (HIV-2 F0794) LTR sequences.
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PuBl pets
HIV-2 subtype A
Gambian cloned 
LTRs
TAAA: GACAGGAACAGCTATACTTGGTCAGGG ROD
 : AG........................... C.......................................  RP3
 GAGA...................................................................... RP2
AG A...........................T--A--C......A.....  RP1
AA...................................................................... LTNP3
AA......................A............................................  LTNP2
CAA...................................................................... LTNP1
HIV-2 subtype B C GA- C -G • • • • •  • • I II • I• • A—AG-AA-T A : ••• D205
SIV-Uke F0784
-174 -144
Figure 7.1 Alignment of six Gambian cloned LTR sequences (one from each patient) nucleotides -174 to -144, with a prototypic Subtype A (HIV-2R0D), B (HrV-2D2o5), and 
SIV-like (HIV-2fo784) LTR sequence.
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7.3.2 Nucleotide sequence variation in naturally occurring HIV-2 LTR genotypes from  LTNP 
and RP patients
All thirty contiguous Gambian LTR sequences (five sequences from each of six patients) were then 
aligned and compared with reference to other HIV-2 subtype A sequences in the Los Alamos database 
(Los Alamos laboratory, 1997, Figure 7.2, pg 268) in order to determine genetic mutations. In addition, 
the degree of sequence diversity displayed by the cloned LTNP and RP LTR sequences was quantitatively 
analysed and compared using Kimura’s two-parameter model (Section 7.3.3).
Comparison of the LTR sequences within the alignment (Figure 7.2, pg 268) revealed numerous 
nucleotide transitions throughout the cloned LTR sequences compared to the other prototypic subtype A 
HIV-2 sequences. All thirty contiguous sequence profiles were approximately the same length as the 
sequence profile of the prototypic subtype A HTV-2 strain ROD. This revealed that none of the LTR 
sequences cloned from either LTNP or RP patients contained any significant naturally occurring length 
polymorphisms, insertions, or deletions.
No characteristic sequence pattern distinguishing the long-term non-progressor LTR sequences from the 
rapid progressor LTR sequences was observed, however, when compared to the other reference sequences 
individual patient sequences could be distinguished from each other by characteristic patient specific 
sequence patterns within the alignment (Figure 7.2, pg 268)
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Figure 7.2. Thirty LTR sequences, five from each of six Gambian HIV-2 infected individuals (LTNP1, 2, and 3)(RP1, 2 and 3) were aligned with reference to the 
consensus sequences of the LTR regions of subtype A HIV-2 and prototypic HIV-2ROd from the HIV-2 sequence database from Los Alamos Laboratory. The sequences 
are ordered by patient identifier number at the beginning of each sequence, with RPs at the top and LTNPs at the bottom. The consensus of clade A and the HIV-2 ROd  
sequence is listed at the top of the alignment. A dash indicates identity with the sequence in consensus A. A semicolon indicates a gap introduced to preserve the 
alignment. Sites corresponding to transcription factor-binding sites (PuBl, PuB2, pets, Peri-xB, xB, SP1, TATA, TAR bulge and loop) are boxed. Bases highlighted in 
blue indicate a position where a novel mutation was observed.
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7.3.2.1 In vivo HIV-2 LTR sequences from nucleotides -556 to -110
Analysis of the regulatory region of the HTV-2 LTR sequences revealed that some degree of sequence 
variation existed within the inducible m-acting transcription factor binding sites located between 
nucleotides -175 to -110. When compared to the HIV-2 subtype A consensus, only 43% of the Gambian 
sequences had conserved PuBl binding sites (nucleotides -174 to -161). Sequences from RP1, RP2, and 
LTNP1, bore single A or C base insertions at position 5 within the PuBl site (Figure 7.2, pg 268). 
Notably sequences from RP1 also contained a G-to-A mutation at position 11 of the PuBl site. The G-to- 
A change occurred within the 5’-AGGAA-3’ pentanucleotide core of PuBl, the region of the site which 
acts as the specific binding motif for the Ets related proto-oncogenic transcription factor, Elf-1 (Leiden et 
al., 1992, Markovitz et al, 1992).
The second purine-rich site within the regulatory region of the HTV-2 LTR was more conserved among 
the Gambian HTV-2 LTR sequences. All sequences taken from the six study patients contained consensus 
PuB2 binding sites (nucleotides -142 to -136).
Eighty four percent of the Gambian LTR sequences had a strictly conserved 5’-TTGGTCAGGG-3’ 
consensus sequence for the T-G rich pets site (nucleotides -152 to -144), the only variant found was 5’- 
TTAGCCAAGG-3’, this variant was identified in 100% of sequences taken from RP1 (Figure 7.2, pg 
268).
Several of the thirty Gambian LTR sequences displayed mutations within the 5’ half of the peri-KB site 
(nucleotides -127 to -111), the inducible cell-type specific transcription factor-binding element of the 
regulatory region. LTR sequences from RP1 were found to contain a single G base insertion between the 
first two bases of the peri-xB site (Figure 7.2, pg 268). Sequences from LTNP3 showed a deletion of the 
G base located at position 1 of this binding site. The 3’ half of the peri-xB site however, was found to be 
entirely conserved amongst the thirty LTR sequences.
Of the six patients analysed, only LTR sequences from RP3 and LTNP2 were found to have consensus 
sequences at all four m-acting transcription factor binding elements within the regulatory region of the 
LTR. LTR sequences from RP1 were found to display the greatest number of nucleotide sequence 
changes within the regulatory c/s-acting transcription factor binding elements, having mutations in the 
PuBl, pets, and peri-xB sites.
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73.2.2 In vivo HIV-2 LTR sequences from nucleotides -110 to +1.
The NF-kB and SP1 binding sites located within the core region of the HTV-2 LTR remained largely 
conserved amongst the naturally occurring HTV-2 LTR sequences from both the LTNP and RP patients. 
A strikingly high number of G-to-A transitions were noted however, in both the NF-kB and SP1 binding 
sites of the sequences from LTNP1. All sequences derived from this patient displayed a G-to-A transition 
at position 2 of the NF-kB site (Figure 7.2, pg 268). In addition, multiple G-to-A hypermutations were 
observed within the central G-C rich core of all three SP-1 sites in 100% of all LTNP1 sequences.
The degree of sequence variation observed within the TATA box region of the Gambian LTR sequences 
was much less compared to that observed in the upstream c/s-acting transcription factor binding elements 
in the regulatory region. The TATA box motif was conserved in all thirty LTR sequences when 
compared to the HIV-2 ROD sequence. However, all sequences derived from LTNP3 exhibited changes 
to highly conserved bases in the sequences flanking the TATA box. Sequences from this patient 
contained a T-to-C transition 5’ to, and a G-to-C transversion directly 3’ to the TATA box motif at 
positions -43 and -24 respectively (Figure 7.2, pg 268). In addition, all sequences from this patient 
contained a single base deletion at position -35, relative to the start site of transcription. The base 
changes at all three positions were not found in any HTV-2 or SIV sequences within the AIDS database.
HIV-2 initiator element sequence variants were identified in the LTR sequences from LTNP2. All 
sequences derived from this patient displayed a T base deletion at position -2 and an A base insertion at 
position -4 relative to the start site of transcription.
In contrast to the sequences from LTNP1, 2 and 3, LTR sequences from each of the three RP patients 
contained consensus sequences at each of the transcription factor binding elements within die core region 
of the HIV-2 LTR (nucleotides -110 - +1).
73.2.3 In vivo HIV-2 LTR sequences from nucleotides +1 to +198
As with the core enhancer elements of the HTV-2 LTR, the degree of sequence variation within the TAR 
element of the thirty LTR sequences was much less in comparison to the variation observed within the 
upstream inducible transcription factor binding elements of the regulatory region. Changes to highly 
conserved bases within both stem-loop 1 and stem-loop2 of the TAR element were observed however, 
within the LTR sequences from LTNP1 and LTNP2 (Figure 7.2, pg 268, and 7.3, pg 276). The most
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striking changes were observed within the LTR sequences from LTNP1. As observed in the NF-kB and 
SP-1 sites of this patient, multiple G-to-A hypermutations were also observed throughout the TAR region 
of all sequences from this patient The most significant of those were located within the highly conserved 
hexanucelotide loop motifs of both stem-loop 1 and 2, the motifs of TAR that act as recognition sites for 
the cellular cofactor for Tat -  cyclin T1 (Bieniasz et al, 1998, Fujinaga et al., 1998, Garber et al., 1998a, 
Garber et al, 1998b, Wei et al., 1998, Richter et al, 2002a, Richter et al, 2002b). A G-to-A transition 
was observed at the third base within both loop motifs (+36 and +70 respectively from the transcriptional 
start site), changing the hexanucleotide loop sequence from 5’-CTGGGA-3’ to 5’-CTAGGA-3’ in stem- 
loopi, and 5’-CTGGGT-3’ to 5’-CTAGGT-3’ in stem-loop2 (Figure 7.3, pg 276). In addition, the G base 
at position +40 within the loop motif of stem-loop 1 had also been changed to an A base. The latter 
mutation is predicted to alter the base-pairing at the base of the unpaired loop in the first stem-loop 
structure, effectively increasing the number of unpaired residues within the loop from six to eight. Each 
of the five LTR sequences from LTNP-1 also contained G-to-A hypermutations at positions +112 and 
+120 of the TAR element. The mutation at +112 is located within the promoter-distal arm of stem-loop 
3, a structure that has been shown to be functionally redundant in the Tat transactivation process (Fenrick 
et al, 1989, Rhim & Rice, 1993). However, the G-to-A change at position +120 of TAR is predicted to 
affect the base pairing of the stem at the base of the TAR element, since the G base usually positioned at 
+120, basepairs with a C base located at position +4 of TAR (Figure 7.3, pg 276).
All sequences derived from LTNP2 showed a C-to-T base transition at position +78 of the TAR element 
(Figure 7.3, pg 276). This mutation occurs at a highly conserved base located on the promoter distal arm 
of stem-loop2. The C base located at +78 usually basepairs with a G base at position +61, directly below 
the Tat-binding bulge of stem-loop2. The mutation observed at position +78 in the sequences from 
LTNP2 is predicted to affect the base-pairing interactions within the Tat-binding bulge region of stem- 
loop2.
In contrast to the LTR sequences derived from LTNP patients 1 and 2, the TAR sequence elements of the 
LTR sequences derived from all three RP’s and LTNP3 were entirely conserved and displayed no 
sequence variation from sequences within the AIDS database.
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Figure 7.3 Schematic representations of the structures of a) wild-type HIV-2 ROD TAR RNA, b) LTNP1 HIV-2 TAR RNA and c) LTNP3 HIV-2 TAR RNA. Nucleotide 
bases highlighted in blue within both the TAR structures of LTNP1 and LTNP2 indicate a position where a novel mutation was observed.
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7.3.3 Quantitative analyses o f sequence diversity within the naturally occurring HIV-2 LTNP 
and RP LTR genotypes
To delineate further the genetic features of the Gambian HTV-2 LTR sequences, the degree of sequence 
diversity that the LTNP and RP LTRs showed from the consensus subtype A HIV-2 LTR sequence was 
quantitatively analysed and compared using Kimura’s two-parameter model. Any deviation from the 
consensus A sequence was considered as a single mutation. In calculations of percentage variation, each 
duplication or deletion was counted as a single mutation. The G-to-A mutation rate was calculated as the 
number of G-to-A substitutions divided by the number of G sites. The general mutation rates and the 
specific G-to-A substitution rates displayed in the whole LTR sequence and at single LTR functional sites 
were determined for each of the thirty LTR sequences and are presented in Table 7.1, pg 279.
7.3.3.1 General mutation rates in the whole LTR sequence and at single LTR functional sites 
When analysing the general mutation rate of the LTR as a whole, little difference was observed between 
the average mutation rates exhibited by the LTNP and RP LTR sequences (Table 7.1, pg 279). On 
average, LTNP LTRs showed 9.7% sequence diversity from the consensus subtype A sequence, while 
LTRs from the RP group of patients displayed 9.3% sequence diversity. Individual general mutation rates 
ranged from 8.8 to 11.0% for the LTNP group of patients and from 8.4 to 10.8% for the RP group of 
patients. Of the six patients analysed, LTR sequences from LTNP1 were found to display the highest 
rates of mutation (11.0%), while LTR sequences from RP3 exhibited the lowest rate of mutation (8.4%).
In contrast, analyses of the general mutation rate at single LTR functional sites within the LTNP and RP 
groups of LTR sequences revealed that the average rate of mutation at single LTR functional sites was 
significantly higher in the LTNP group of LTR sequences when compared to the average rate observed 
within the RP group of LTR sequences (2.8%, SD 0.95 (n=15) versus 1.1%, SD 1.82, (n=15); p  = 0.0024) 
(Table 7.1, pg 279). On average, mutation rates at single LTR functional sites within LTNP LTR 
sequences were 2.5 times higher than the same rates observed within the RP LTR sequences. Individual 
patient average general mutation rates at single LTR functional sites ranged from 1.5% (LTNP3) to 5.3% 
(LTNP1) for patients in the LTNP group, and from 0% (RP3) to 2.11% (RP1) for patients in the RP 
group. Statistical comparison of the three patient averages from each progression group was found to 
reduce the statistical significance of the difference between the average general mutation rate at single 
LTR functional sites for the two progression groups from 0.0024 to 0.28. Of the six patients analysed, 
LTR sequences from LTNP1 were found to display the highest rate of mutation at single LTR functional
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sites (5.3%), whilst LTR sequences from RP3 displayed consensus sequences at all single LTR functional 
sites, having an average general mutation rate of 0%.
7.3.3.2 G-to-A substitution rates in the whole LTR sequence and at single LTR functional sites 
The average rate of G-to-A substitutions in the whole LTR was also found to be different for the two 
groups of LTR sequences (Table 7.1, pg 279). LTR sequences from the LTNP group of patients 
exhibited on average, twice the number of G-to-A substitutions observed in the RP LTR sequences. The 
average G-to-A substitution rate observed throughout the whole LTR for sequences from the LTNP group 
was 4.6% (SD 4.0), by comparison the same rate measured in the LTR sequences from the RP group of 
patients was on average, only 2.0% (SD l . \ ) (p  = 0.022 - n=30, p  = 0.41 - n=6). Individual patient G-to- 
A mutation rates ranged from 1.2 to 10.1% in the LTNP group, with sequences from LTNP2 and LTNP1 
displaying the lowest and highest rates respectively in this group, and from 0.7 to 2.9% in the RP group of 
patients, with sequences from RP3 and RP2 displaying the lowest and highest rates respectively in the RP 
group of patients.
Similarly, when G-to-A mutation rates at single LTR functional sites within both the LTNP and RP group 
of LTR sequences were calculated, LTR sequences from the LTNP group of patients were found to 
exhibit five times the number of G-to-A substitutions at single LTR functional sites compared to single 
LTR functional sites in RP LTR sequences (Table 7.1, pg 279). On average, the G-to-A substitution rate 
observed at single functional sites in the LTNP LTR sequences was 5.7%. By comparison, the mean G- 
to-A substitution rate observed at single functional sites in the RP LTR sequences was only 1.1%. The 
difference observed between the average mutation rates of the two groups of sequences however, was not 
found to be statistically significant (p = 0.052 -  n=30). The individual G-to-A mutation rates at single 
functional LTR sites for the LTNP group of patients ranged from 0% (LTNP3) to 16.67% (LTNP1), and 
from 0% (RP2 and 3) to 3.3% (RP1) in the RP group. Only LTR sequences from RP1 of the RP group of 
patients were found to contain G-to-A substitutions within single LTR functional sites, the single LTR 
functional sites within the sequences from RP2 and RP3 failed to display any such substitutions. 
Strikingly, the G-to-A substitution rate observed at single functional sites in the LTRs from LTNP1 was 
found to be 16.7%, more than five times higher than the rate observed in any of the other LTR sequences 
analysed.
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General 
mutation rate 
in whole LTR 
(%)
General 
mutation rate 
at single 
functional 
LTR sites (%)
G-to-A 
substitution 
rate in whole 
LTR (%)
G-to-A 
substitution 
rate at single 
functional 
LTR sites (%)
LTNP1 11.0 5.3 10.1 16.7
LTNP2 8.8 1.6 1.2 0.3
LTNP3 9.4 1.5 2.6 0
LTNP
Average
9.7 2.8 4.6 5.7
RP1 8.8 2.1 2.5 3.3
RP2 10.8 1.1 2.9 0
RP3 8.4 0 0.7 0
RP
Average
9 3 1.1 2.0 1.1
Table 7.1 Average nucleotide variation in naturally occurring HIV-2 LTR genotypes cloned directly from 
LTNP and RP PBMCs. Analysis was performed using Kimura’s two-parameter model. Any deviation 
from the consensus A sequence was considered as a single mutation. In calculations of percentage 
variation, each duplication or deletion was counted as a single mutation. The G-to-A mutation rate was 
calculated as the number of G-to-A substitutions divided by the number of G sites. The general mutation 
rates and the specific G-to-A substitution rates displayed in the whole LTR sequence and at single LTR 
functional sites were determined for each of the thirty LTR sequences and averaged for each of the six 
patients.
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7.3.3.3 Intra and Interpatient sequence diversity
The extent of viral quasispecies heterogeneity within both the LTNP and RP group of patients was 
measured by calculating the intrapatient diversity exhibited by the LTR sequences from each patient in 
both progression groups, and the interpatient diversity displayed between sequences from each of the 
three patients in each progression group. Calculations were performed using Kimura’s two-parameter 
model.
Analysis of the intrapatient diversity of the LTR sequences cloned from each of the six Gambian patients 
revealed a similar degree of diversity between the sequences from each of the patients in both groups. 
Individual intrapatient variation values for the three LTNP patients ranged from 0.3% (LTNP1 and 3) to 
3.6% (LTNP2), with an average LTNP intrapatient variation value of 1.4%, and from 1.0% (RP3) to 3.8% 
(RP1) for each of the three RP patients, with an average intrapatient variation value of 2.0% for the RP 
group of patients. Of the six patients analysed the five LTR sequences from both LTNP1 and LTNP3 
showed the least intrapatient nucleotide sequence variation (0.3%), whilst the five LTR sequences from 
RP1 displayed the greatest intrapatient nucleotide sequence variation (3.8%).
The pairwise comparison of DNA distances between the three patients within each of the two progression 
groups revealed that the average interpatient variation observed between the sequences from the three 
different patients in each progression group was not only similar but identical for the two progression 
groups. In both groups, the mean value of interpatient variation was 10.5%. Interpatient variation values 
for the three LTNP patients ranged from 7.5% (LTNP2 vs. LTNP3) to 12.0% (LTNP1 vs. LTNP3), and 
from 8.6% (RP3 vs. RP1) to 12.0% (RP2 vs. RP1) for the three RP patients.
7.3.3.4 In vivo HIV-2 LTRs consist o f two uncoupled loci
Mutation rates in the nef-LTR overlap region (nucleotides -556 - -172) of the thirty LTR sequences were 
found to be significantly higher than in the untranslated region of the LTR sequences (nucleotides -171 - 
+198) (11.9 versus 6.9% on average). This nearly twofold-greater variability in the Nef-coding 
sequences compared with the LTR noncoding sequences has been extensively reported in previous HIV-1 
LTR studies (McNeamey et al, 1995, Estable et al., 1996), and here, as in those studies, suggests a 
stronger functional constraint for the latter region of the HTV-2 LTR, and suggests independently 
evolving loci.
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7.4 Summary and discussion
Extensive analyses of the HIV-1 LTR in long-term survivors of HIV-1 infection have suggested that 
truncations and single point mutations in functional sites of the LTR are associated with impaired 
replication and attenuated pathogenesis (Fujii et al, 1997, Rousseau et al, 1997, Zhang et al, 1997b, 
Fang et al, 2001). In addition, a high G-to-A mutation rate in crucial sites of the HTV-1 LTR (Zhang et 
al, 1997b) and in the gag gene (Huang et al, 1998b) have been previously reported by others and 
suggested as a possible cause of clinical long-term non-progression. However, while structural and 
functional defects in the HTV-1 LTR have been linked to the well being of individual HTV-1-infected 
long-term survivors no correlation has been found between the HTV-1 LTR and long-term non­
progression in general. In conjunction with detailed functional analyses, we have analysed and compared 
thirty Gambian LTR sequences from three LTNP and three RP patients in an attempt to examine further 
the relationship between the HTV-2 LTR and the pathogenesis of HTV-2 infection.
Alignment of the thirty Gambian LTR sequences with other prototypic subtype A HIV-2 LTR sequences 
revealed that all Gambian sequence profiles conformed to the HTV-2 subtype A consensus. None of the 
LTR sequences, from either LTNP or RP patients, contained any significant naturally occurring length 
polymorphisms, insertions, truncations, or deletions. Furthermore, we failed to identify any characteristic 
sequence pattern that distinguished a LTNP LTR sequence from a RP LTR sequence; sequence 
differences that were noted appeared to be patient-specific rather than progression group-specific. These 
findings are similar to those previously published in a number of HTV-1 LTR studies (Estable et al, 1996, 
Rousseau et al, 1997, Zhang et al, 1997b, Quiflones-Mateu et al, 1998, Visco-Comandini et al, 1999, 
G6mez-Romdn et al, 2000) and indicate that discrete differences in LTR sequence rather than significant 
LTR deletions or insertions are more likely to play a role in the determination of HTV-2 pathogenesis by 
the promoter region.
Analyses of the intra and interpatient sequence diversity for the six patients revealed that while the 
average interpatient variation was identical within each of the two progression groups (10.5%), on 
average the level of intrapatient variation was slightly higher within RP patients compared to LTNP 
patients (2.0% vs. 1.4% respectively). Initially, this finding appears to correlate with the results from the 
functional analyses, whereby the activities of LTRs from each of the RP patients were found to be more 
variable than the activities of LTRs from each of the LTNP patients. However, the RP patient that had 
directed the most variable LTR activities (RP3) was not found to display the greatest intrapatient
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sequence variation, in fact, of the three RP patients RP3 exhibited the least intrapatient LTR sequence 
variation. It is likely therefore, that the different positions of the sequence changes between LTRs from 
the same patient rather than the actual number of changes between the sequences play a more important 
role in determining intrapatient variation in LTR function.
Consistent with other reports comparing the genetic diversity within HTV-1 LTS and TP LTR nucleotide 
sequences (Huang et al, 1995a, Zhang et al., 1997b, Quifiones-Mateu et al, 1998, Visco-Comandini et 
al, 1999), the general mutation rate for the entire HTV-2 LTR region was found to be similar for the 
LTNP and RP groups of patients (9.7% vs. 9.3% respectively). However, significant differences were 
observed between the two progression groups when the G-to-A mutation rate for the HTV-2 LTR as a 
whole and both the general and G-to-A mutation rates at individual functional sites within the HTV-2 LTR 
were compared. LTR sequences from the LTNP group of patients were found to exhibit on average two­
fold higher (p = 0.022, n=30) rates of G-to-A mutations throughout the LTR sequence as a whole. 
Moreover, on average, LTNP LTRs displayed 2.5 times more general mutations at single functional sites 
in the LTR (p = 0.0024, n=30), and five-fold higher (p = 0.052, n=30) rates of G-to-A substitutions at 
single LTR functional sites, than observed in the RP LTR sequences. These results suggest a relationship 
between HTV-2 LTR sequence variation and disease progression status, and differ from the majority of 
studies where this parameter was found to be similar between the LTRs of LTS and TP of HTV-1 
infection (Estable et al, 1996, Zhang et al, 1997b, Quifiones-Mateu et al, 1998, Visco-Comandini et al, 
1999, G6mez-Romdn et al, 2000).
Analysis of which single LTR functional sites were mutated amongst the sequences from the six patients 
revealed that in addition to the LTNP LTR sequences exhibiting higher average rates of mutation within 
the functional sites of the LTR, the sites that were mutated in these sequences were those located in the 
core and TAR regions of the LTR. LTR sequences from all three LTNP patients were found to contain 
point mutations within one or more of the core transcription factor binding elements involved in the 
recognition of general transcription factors required for transcription initiation. In addition, LTR 
sequences from two of the three LTNP patients displayed changes to highly conserved bases within the 
TAR element of the LTR. In contrast, the LTR sequences from the three RP patients contained 100% 
consensus sequences at all binding motifs within both the core and TAR regions of the LTR.
Of the core and TAR element mutations observed within the LTNP sequences, the most severe were 
located within the sequences from LTNP1. Multiple G-to-A hypermutations were observed within the
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NF-kB, SP-1, and TAR binding sites of all LTRs cloned from this patient The negative effects on viral 
transcription caused by mutations within conserved HTV-2 NF-kB (c Hannibal et al, 1993, Hilfinger et 
al, 1993, Hannibal et al 1994) and SP-1 sites (Arya & Gallo, 1988, Tong-Starksen et al, 1990, 
Pagtakhan & Tong-Starksen, 1997) are well documented. It is probable that the multiple hypermutations 
observed within the NF-kB and SP-1 binding sites of the sequences from LTNP1 would severely reduce 
NF-kB and SP-1 protein binding, significantly impacting LTR function, and likely explain the low basal 
activity of the LTRs from this patient.
In addition, it is likely that the multiple G-to-A transitions exhibited within the TAR hexanucleotide loop 
motifs of stem-loop 1 and 2 explain the failure of the LTR sequences from LTNP1 to respond to Tat2 in 
any way in functional studies. In determining the specific HIV-1 TAR loop sequence and functional 
groups required for CycTl-Tat-TAR ternary complex formation Richter et al have demonstrated that the 
guanidine bases located at position 32 and 34 within the HTV-1 hexanucelotide loop are essential for 
CycTl-Tat binding to TAR RNA (Richter et al, 2002a, Richter et al, 2002b) (Figure 7.4, pg 284). The 
guanidine base at position 32 has an 06  hydrogen bond acceptor from a carbonyl group that has been 
shown to be critical for the interaction between the CycTl-Tat complex and TAR By substituting G32 
with an A base Richter et al demonstrated that CycTl-Tat binding was reduced to less than 40% capacity 
(Richter et al, 2002a). The sequences from LTNP1 contain a G-to-A mutation at the G base located in 
the position equivalent to G32 in the HTV-2 loop motifs of both stem-loop 1 (G36) and stem-loop 2 (G70) 
(Figure 7.4, pg 284). It is likely that these G-to-A changes result in a similar reduction in CycTl-Tat2 
binding to TAR This in turn would result in a reduction in the level of transcription directed by the LTRs 
from LTNP1 in the presence of Tat2. Moreover, since both stem-loopi and stem-loop2 contain this 
mutation, the second stem-loop structure would not be able to perform its well-documented partial rescue 
of TAR function in the context of a mutated stem-loopi (Fenrick et al, 1989, Berkhout et al, 1990, Rhim 
&Rice, 1993, Garcia-Martinez et al., 1995, Browning etal., 1997).
The explanation for the complete abrogation of Tat-induced transcription directed by the LTRs from 
LTNP1 likely lies in the fact that the loop motif in stem-loopi of LTNP 1 also contains a G-to-A change at 
the base of the loop (G40), at the position equivalent to G36 in the HIV-1 TAR loop. The G at this 
position usually basepairs with the C base in the opposite arm of the stem and forms the first basepair 
below the hexanucelotide loop motif (see Figure 7.4, pg 284). The substituted A base at this position in 
stem-loop 1 of LTNP 1 would effectively increase the loop motif from hexanucelotide to octanucleotide,
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since the A would be unable to basepair with the C base. In characterising the interactions between the 
bases within the HIV-1 loop motif and the CycTl-Tat complex, Richter et al suggested the presence of a 
putative base pair between the first and fifth bases of the hexanucelotide loop, creating a single A base 
bulge at position 35 (Richter et al., 2002a, Richter et al., 2002b) (Figure 7.4, pg 284). It has been 
proposed that the presence of this bulge is important for distortion of the backbone RNA structure and the 
enhanced accessibility of the functional groups on G32 and G34 involved in the recognition of the 
CycTl-Tat protein complex (Richter et al., 2002a, Richter et al., 2002b). Since the sequences from 
LTNP1 contain a change to the G base at position 40 at the base of the loop, the single-nucleotide A base 
bulge would be changed to a dinucleotide A base bulge (Figure 7.4, pg 284). Based on the importance of 
the structure and sequence of this region of the motif to the CycTl-Tat-TAR interaction, it is likely that 
this change disrupts the accessibility of the CycTl-Tat2 complex to the functional groups involved in 
TAR2 binding and contributes significantly to the abrogation of Tat response directed by the LTRs from 
this patient.
Finally, HIV-2 Tat-SPl transcriptional synergy has been reported (Blau et al., 1996, Pagtakhan & Tong- 
Starksen, 1997). Since all three SP1 sites, in addition to the TAR element within the LTR sequences 
from LTNP1 are mutated, it is unlikely that such transcriptional synergy is possible in this case. Taken 
together, it is likely that the multiple G-to-A hypermutations throughout the LTR sequences from LTNP1 
account for the dramatically reduced basal and completely abrogated Tat rramactivated activity of the 
LTRs from this patient. It is likely that these findings reflect the presence of a viral population with a 
severely attenuated replicative capacity circulating within LTNP1 and suggests an explanation for the 
long-term non-progression experienced by this patient.
Di-nucleotide
bulge
TAR RNA TAR2 RNA TAR2 RNA
H I V - 1  w t  H I V - 2  w t  H I V - 2  L T N P 1
Figure 7.4 Schematic representation of the CycTl-Tat-TAR ternary complex for HIV-1 wt, HIV-2 wt, 
and HIV-2 LTNP1 (adapted from Richter et al., 2002a).
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All LTR sequences taken from LTNP2 were found to contain a single T base deletion and a single A base 
insertion at positions -2  and -4  respectively, relative to the start site of transcription. The nucleotides 
within this region of the LTR encode an initiator element that matches the loose consensus sequence for 
mammalian Inr activity of YCA+1NTYY where Y is a pyrimidine and N is any nucleotide (Javerhery et 
al, 1994). Mutation of the base at position -2 within a mammalian Inr has been shown to reduce 
promoter strength by approximately two-fold (Javerhey et al, 1994). Similarly changes within the core 
of the HTV-1 Inr element have been shown to dramatically reduce transcription initiation rates and limit 
Tat responses (Zenzie-Gregory et al, 1993, Rittner et al, 1995). Furthermore, changes to nucleotides 
between bases -6  to +30, encompassing the Inr consensus sequence of HTV-2 have been shown to reduce 
the transcriptional activity of the HTV-2 promoter (Jones et al, 1988).
LTR sequences from LTNP2 were also found to display a C to T transition at position +78 within the 
second stem-loop region of the TAR element. Since residue +78 basepairs with the G residue at position 
+61 at the base of the second trinucleotide bulge, the change to a T base at position +78 is likely to 
adversely affect base pairing interactions within the bulge region to which Tat2 specifically binds 
(Peterlin & Jones, 1994). Nevertheless, as the mutation displayed by sequences from LTNP2 occurs 
within the second stem loop structure of the HTV-2 TAR element in the context of a fully functional stem- 
loop 1, the transcriptional effects of this point mutation are likely to be small. It is possible that the 
combined effects of the changes to the HTV-2 Inr and TAR sequence elements of LTNP2 result in the 
reduction in basal and Tat-induced transcriptional activity directed by the LTRs from this patient.
LTR sequences from LTNP3 were found to contain two base changes and a single base deletion within 
sequences flanking the TATA box motif. While very little data exists concerning the functional 
significance of these sequences within the HTV-2 LTR, several studies have demonstrated that site- 
directed mutagenesis of the nucleotides flanking the HTV-1 TATA box results in marked decreases in 
basal and Tat-induced gene expression (Garcia et al, 1989, Berkout & Jeang, 1992, Ou et al, 1994, 
Rittner et al, 1995). It has been suggested that the sequences 5’ and 3’ to the HIV-1 TATA box might 
help regulate the binding affinity of members of pre-initiation complex (Berkout & Jeang, 1992, Ou et al, 
1994, Rittner et al, 1995). In eukaryotic transcription, the sequences located nine base pairs upstream, 
and seven base pairs downstream of the eukaryotic TATA element (Lagrange et al, 1998, Littlefield et 
al, 1999) form the “IIB recognition element” (BRE), a bipartite motif bound by the basal transcription 
factor TFIIB. The role that this transcription factor plays in the formation of the transcription initiation 
complex is essential since, as well as binding to TFIID, TFIIB can also interact RNA polymerase II itself
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(Tschochner et al, 1992, Ha et al, 1993). If, as with the other core elements of the HIV-2 LTR, the 
sequences flanking the HTV-2 TATA box function in an analogous manner to those within the HTV-1 and 
eukaryotic promoters, the mutations displayed by the sequences from LTNP3 might be expected to impair 
either the binding or regulation of transcription factors involved in transcription initiation such as TFIIB, 
and result in a decrease in the activity of LTRs from this patient.
Of the three RP patients, only LTR sequences from RP1 showed any significant nucleotide sequence 
variation within the functional sites of the LTR. LTR sequences from this patient displayed changes to 
the PuBl, pets, and peri-icB sites within the regulatory region of the HTV-2 LTR. Significantly, the 
mutation within the PuBl site is located within the pentanucleotide core motif of the site. This motif acts 
as the recognition sequence for the ets-related transcription factor Elf-1, and changes to it have been 
shown to markedly reduce the transcriptional activity of the HTV-2 LTR in vitro (Leiden et al, 1992, 
Markovitz et al, 1992, Hannibal et al, 1993, Hannibal et al, 1994). In addition, mutagenic studies using 
in vitro assay systems have demonstrated the existence of a synergystic relationship between the ex­
acting binding elements within the regulatory region of the HTV-2 LTR, since mutation of any of these 
sites results in a significant reduction in LTR function (Markovitz et al, 1992, Hannibal et al, 1993, 
Hilfinger et al, 1993, Hannibal et al, 1994). Interestingly, in functional analyses the LTR sequences 
from RP1 were consistently found to be less active than the LTRs from both RP2 and RP3, patients 
whose LTRs contained consensus sequence motifs at most, or in the case of RP3, all regulatory, core and 
TAR elements of the LTR. It is possible that the mutations displayed within the PuBl and pets sites of 
the LTRs from RP1 result in the disruption of transcription factor binding and synergystic interactions, 
and contribute to the comparatively reduced activity of the LTRs from this patient.
Of the six patients analysed, LTR sequences from RP3 were the only sequences to display 100% 
consensus sequence motifs at each of the single LTR functional sites within the LTR. Mutation rates, 
both general and G-to-A, at single LTR functional sites within the sequences from this patient were 0% in 
both cases. In addition, of the five patients that did bear mutations within one or more of the functional 
LTR sites, LTR sequences from RP2 showed the next lowest rates of mutation. Sequences from this 
patient showed a general mutation rate at single functional LTR sites of 1.1% and a G-to-A substitution 
rate at single functional LTR sites of 0%. Functional analyses of the basal and Tat-induced activities of 
the LTR sequences from RP2 and RP3 revealed that the sequences from both patients were consistently 
the most active of the LTRs tested.
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In summary, while we were unable to detect a sequence motif that distinguished LTNP from RP LTRs, 
and failed to correlate LTR truncation, insertion or deletion with clinical long-term non-progression, we 
have shown the average general and specific G-to-A mutation rates to be higher within the single 
functional sites of LTNP LTRs when compared to RP LTR sequences. Moreover, of the functional sites 
within the HTV-2 LTR, LTR sequences from LTNP patients tended to display mutations within the highly 
conserved sites of the core and TAR regions of the LTR, while mutations within RP LTRs tended to 
occur within the less conserved transcription factor binding sites of the regulatory region of the LTR. 
Mutation of the highly conserved core transcription factor binding elements within the HIV-2 LTR has 
been shown to markedly reduce the basal activity of the HTV-2 LTR. Similarly, mutation of the stem- 
loop motifs within the TAR element of the HTV-2 LTR have been shown to significantly reduced the Tat- 
induced activity of the LTR. Therefore, it is possible that the general trend towards lower basal and Tat 
activities displayed by the LTNP LTRs within functional studies results from the higher average rate of 
mutation in the core and TAR transcription factor binding elements of the LTRs from these patients.
Significantly, the LTRs that had displayed exceptionally low (LTNP1) and notably high (RP3) basal and 
Tat-induced activities in the functional analyses were found to exhibit the highest and lowest rates of 
mutation respectively, throughout the LTR as a whole and at single functional LTR sites. Taken together 
our analyses indicate the existence of a relationship between the rate of mutation at single LTR functional 
sites, LTR activity, and clinical progression status. It is possible that the mutations within the LTNP LTR 
sequences have a greater effect upon function in Jurkat cells than THP-1 cells explaining the more 
pronounced difference in promoter activities observed between the two progression groups. However, 
studies performed with a greater number of clinically characterised patients in addition to SDM 
investigation of the mutations observed within the LTR sequences would be required to confirm such 
findings.
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Chapter 8.
General Discussion and Conclusions.
8.1 General discussion
Since its initial isolation from patients with AIDS in Guinea Bissau and Cape Verde Islands in 1986 
(Clavel et al, 1986a), Human immunodeficiency virus type 2 (HIV-2) has been shown to be endemic in 
many West African countries including The Gambia, Guinea Bissau, Senegal, The Ivory Coast and Ghana 
(Decock & Brun Vezinet, 1989). Effective antiviral treatment and longitudinal clinical follow-up of the 
infected individuals within these populations while theoretically possible, is made practically impossible 
due to the economic cost of such schemes coupled with the rural and scattered nature of the populations 
requiring treatment. Therefore, the most likely means to prevent the spread of HTV-2 'infection and 
AIDS in these populations would be the provision of effective preventative and/or prophylactic vaccines.
Cohort studies in West Africa have demonstrated a markedly longer period of asymptomatic infection and 
prolonged survival in the majority of HTV-2-infected individuals compared to HTV-1 (Poulsen et al, 
1989, Wilkins et al, 1993, Whittle et al, 1994). Mortality rate ratios for HTV-2 are only 2:1 - 4:1 
compared to uninfected controls (Ricard et al, 1994, Poulsen et al, 1997, Berry et al, 2002, Schim van 
der Loeff et al, 2002), and are ten-fold lower than mortality rate ratios observed in HTV-1 infection, 
where ratios exceed 20:1 (Muldor et al, 1994, Morgan et al, 1997, Nunn et al, 1997, Todd et al, 1997). 
Rates of both heterosexual and perinatal transmission are also significantly lower for HTV-2 than for HIV- 
1 (Adjorlolo-Johnson et al, 1994, Kanki et al, 1994, Cavaco-Silva et al, 1998, O’Donovan et al, 2000), 
this has resulted in a markedly different pattern of spread for the two infections. While the rapid spread 
of HTV-1 has lead to the emergence of a worldwide pandemic, HIV-2 infections have remained endemic 
and largely confined to the countries within West Africa (Remy, 1998). Taken together, HTV-2 is 
considered a less pathogenic virus than HTV-1. However, some cases of rapidly progressing HTV-2 AIDS 
following a more HTV-1-like disease course have been described both in The Gambia, and among West 
Africans resident in Europe (van der Ende et a l, 1996, Ariyoshi et al, 1998).
The relationship between plasma viral loads and HTV pathogenesis has been widely documented; levels 
of virus found in the peripheral blood of HIV-1 and HTV-2-infected individuals have been shown to 
predict the rate of CD4+ decline and are clearly associated with differences in rates of disease progression 
(Ho et al, 1995, Wei et al, 1995, Ariyoshi et al, 2000, Berry et al, 2002). Significantly, recent analyses
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have demonstrated that HTV-1 and HIV-2 infections can be differentiated by RNA plasma viral load at 
the early stage of disease (Berry et al, 1998, Andersson et al, 2000). RNA virus is readily detectable in 
the plasma of the vast majority of HTV-1 infected individuals with a CD4% >28, while it is detected in 
only one third of matched HTV-2 infected subjects (Berry et al., 1998). Following seroconversion, the 
plasma virus set point has been shown to be up to 28-fold lower in recent HTV-2 seroconverters when 
compared to recent HTV-1 seroconverters (Andersson et al., 2000). Furthermore, the lower levels of 
plasma viremia that characterise the asymptomatic phase of HTV-2 infection can remain unchanged for 
periods in excess of five years (Berry et al., 2002), or even persist until the symptomatic stages of disease 
(Andersson et al., 2000). Significantly higher levels of plasma viremia are observed throughout the 
asymptomatic phase of HTV-1 infection and viral loads are only comparable between the two infections in 
the late stages of disease. In contrast to this, cellular proviral loads have been shown to be similar within 
HTV-1 and HTV-2 infected patients throughout the course of infection (Berry et al., 1994, Ariyoshi et al, 
1996, Norrgren et al., 1997b, Berry et al., 1998, Sarr et al, 1999, Popper et al., 2000). Since the number 
of integrated proviral templates are similar between the two infections it has been suggested that the 
reduced number of circulating virions within the plasma of HTV-2 infected individuals result from a lower 
rate of virus production from these templates in HTV-2 infection compared to HTV-1 infection. Taken 
together, it is thought that the diminished pathogenicity of HTV-2 may be due to a lower rate of viral 
production within HTV-2 infected individuals.
Since the reduction in the number of CD4 cells and resultant immune deficiency is directly related to the 
level of viremia within an HIV-infected individual, the prolonged maintenance of a reduced level of 
circulating virus within an HTV-2 infected individual results in a slower destruction of their immune 
system via direct (cytotoxic) and indirect (apoptosis) mechanisms. A number of studies have 
demonstrated that the rate of total lymphocyte apoptosis is lower in HTV-2 infection compared with HIV- 
1 (Jaleco et al., 1994, Michel et al, 2000); similar observations have also been made in macaques 
infected with HTV-2 (Dittmer et al, 1996). In addition, Sousa et al have recently demonstrated that 
higher proportions of CD4 and CD8 cells taken from HTV-2-infected individuals retain the ability to 
produce IL-2 when compared to the proportions taken from HTV-1 infected individuals with equivalent 
CD4 T cell counts (Sousa et al., 2001).
In accordance with the cause-effect mathematical model proposed by Nowak for disease progression in 
HIV-1, a decreased rate of virus production effectively increases the time taken to reach the viral diversity 
threshold (Nowak et al, 1991). Nowak suggests that throughout the asymptomatic phase of infection a
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slow but steady increase occurs in the number of genetically distinct viral strains. Eventually a finite viral 
diversity threshold is reached, below which the immune system is able to regulate viral population 
growth, but above which the viral population induces the collapse of the CD4 T-cell population. The 
model predicts the appearance of more highly pathogenic strains once host immunological pressures have 
been removed (Nowak et al, 1991). How the “virulent” viruses evolve or emerge in an HIV-infected 
host is not yet known. One suggestion is that such viruses while present throughout infection are 
effectively suppressed by antiviral activity, and re-emerge when antiviral activity is lost, or redevelop by 
genetic escape. Another possibility is that as immune antiviral activity reduces an increase in replicative 
cycles allows a relatively non-pathogenic infecting strain to mutate over time and acquire virulence. 
What is clear in HTV-2 infection is that the mechanism that results in the eventual increase in virus 
production and immune damage is more protracted within an HIV-2 infected individual than in an HTV-1 
infected individual.
It has been suggested that the lower rate of virus production and the extended phase seen during most 
HTV-2 infections could be due to a more effective immunological response towards the viral population 
that reduces viral replication and antigenic diversity to undetectable levels (Gotch et al, 1993, Rowland- 
Jones et al, 1995, Bertoletti et al, 1998, Whittle et al, 1998), effectively increasing the time taken to 
reach the viral diversity threshold. While limited, some immunologic studies have demonstrated several 
features of the immune response to HTV-2 that do distinguish it from HTV-1 infection. In contrast to the 
majority of HTV-1 infected individuals (McAdam et al, 1998), HTV-2-infected individuals often have a 
strong CTL response to HTV-2, which in some but not all cases show cross-clade reactivity to HTV-1 CTL 
epitopes (Bjorling et al, 1993, Gotch et al, 1993, Rowland-Jones et al, 1995, Bertoletti et al, 1998, 
Dorrell et al, 2001). In addition, sera from some HTV-2-infected individuals have been found to contain 
broadly reactive neutralising antibodies showing extensive cross-reactivity to HIV-1, heterologous HIV- 
2, and STV isolates (Robert Guroff et al, 1992, Bjorling et al, 1993). Nevertheless, these findings are not 
consistently identified in every HTV-2 long-term non-progressor. Moreover, several investigators have 
suggested that what appears to be a more effective immune response against HTV-2 may be a result of, 
rather than the cause of a viral population with a lower replicative capacity (Desrosiers, 1999, Berry et al, 
2002).
Much attention has been given to potential associations between the genetic background of the host and 
the rate of disease progression in HIV-1 and HIV-2 infection. Homozygosity for a 12-bp deletion within 
the coding sequence for chemokine receptor CCR-5 (CCR5-Delta32) has been associated with a reduced
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susceptibility to HIV-1 infection (Dean et al., 1996, Liu et al., 1996). Similarly, polymorphic allelic 
variants of the chemokine receptor CCR-2, and the gene encoding stromal derived factor -  1 (SDF-1), the 
natural ligand for CXCR-4, are believed to be involved with delay in HTV-1 disease progression (Binley 
et al, 1998, Winkler et al, 1998, Carrington et al, 1999). However, all such variants are rare in North, 
West, and Sub-Saharan African populations when compared to Caucasian populations making it unlikely 
that chemokine receptor variation plays a dominant mechanistic role in nonprogression among HTV-2- 
infected individuals.
The rate of disease progression in HTV-1 seropositive individuals has also been linked with the HLA class 
I genotype (Steel et al, 1988, Kaslow et al, 1990, Kaslow et al, 1996, Magierowska et al., 1999). 
Certain class I molecules, such as HLA B14 and HLA C8, are consistently linked with slow progression 
in HTV-1 infection while others, such as HLA A29, All ,  B22 and the extended haplotype HLA 
A1/B8/DR3, are linked with rapid progression (Westby et al., 1996, Hendel et al., 1999). Studies on 
persistently seronegative and apparently uninfected prostitutes in The Gambia, whose initial exposure is 
most likely to have been to HTV-2, have suggested an association between the resistance of these 
individuals to HTV infection and their cross-reactive HLA-B35 restricted CTL response (Rowland-Jones 
et al., 1995, Bertoletti et al, 1998, Dorrell et al, 2001). In addition, a recent study examining the 
relationship between HLA type, plasma viral load and survival among dually infected individuals 
revealed that patients with HLA type B58, or B35, B53, and B58 together, exhibited lower HTV-1 plasma 
viral loads and slower disease courses (Alabi et al., 2003). However, larger prospective studies are 
required to confirm this finding. Therefore the relationships between HLA class I genotypes and disease 
progression rates remain complex, require extensive analyses with HTV-infected populations, and are 
unlikely to solely account for nonprogression in either HTV-1 or HIV-2 infection per se.
Alternatively, the extended asymptomatic phase seen during most HTV-2 infections could be virally 
determined by regions within the HTV-2 genome that relate directly to gene regulation and virus 
expression. By directing lower levels of virus production during infection virally encoded factors rather 
than immunological responses might determine a longer period of time ensuing before significant 
immunological damage occurs and/or the finite viral diversity threshold is reached. In turn, virally 
determined lower levels of virus production could be more effectively contained by immune surveillance. 
Cases of rapidly progressing disease might arise in this model due to the emergence of highly pathogenic 
strains that had acquired virulence through virally driven genetic diversity and selection of HIV-2
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genomes with enhanced replicative capacities (Grassly et al, 1998, Kimata et al, 1999), or via initial 
infection with a highly pathogenic viral strain.
To date, few studies exist investigating the virally encoded determinants of HIV-2 pathogenesis (Albert et 
al, 1990, Tong-Starksen et al, 1990, Hannibal et al, 1993, Akimoto et al, 1998, Grassly et al, 1998, 
Sekigawa et al, 1998, Reeves et al, 1999, Kokkotou et al, 2000). The vast majority of data that have 
been collected thus far centres around the HTV-2 envelope and the differences that exist between its 
interactions with cellular receptors when compared to HTV-1. In general, HTV-2 strains use a wider range 
of coreceptors compared to HTV-1, potentially enabling infection of a broader range of cell-types in vivo 
(Guillon et al, 1998, McNight et al, 1998, Owen et al, 1998, Unutmaz et al, 1998, Reeves et al, 1999, 
Liu et al, 2000, Reeves & Dorns, 2002). Moreover, in contrast to HIV-1, many primary HTV-2 isolates 
have been shown to infect cells independently of CD4 (Clapham et al, 1992, Endres et al, 1996, Reeves 
et al, 1999, Simmons et al, 2000, Lin et al, 2001). This most recent discovery has been suggested to 
reflect a more ‘open’ HIV-2 Env glycoprotein conformation that might result in more effective immune 
recognition of HIV-2 and explain the prolonged survival of HTV-2-infected individuals when compared to 
HTV-1 (Reeves & Dorns, 2002). However, the implications of CD4-independent virus infection for HTV- 
2 pathogenesis and its significance in vivo have yet to be explored, and may simply represent another 
mechanism by which the virus can establish a more successful virus-host relationship than that observed 
in HTV-1 infection.
The other region of the HTV-2 genome that has received investigative attention in the context of disease 
progression rate is the nef gene. In 1998, Switzer et al suggested a role for nef in the pathogenesis of 
HTV-2 infection (Switzer et al, 1998). This study demonstrated that the prevalence of truncated Nef 
proteins was higher in HTV-2 asymptomatics when compared to the frequency found in HIV-1 
equivalents (Switzer et al, 1998). However, despite this finding Nef truncation was still only identified 
in 10% of the HTV-2-infected asymptomatic patients tested. More recently, a study performed by Padua 
and coworkers (Padua et al, 2003) has identified a mutation within the tetra-proline motif of the Nef 
protein of HIV-2 asymptomatic individuals who also had low levels of peripheral viral RNA (11 of 26 
asymptomatics - 42.3%). This mutation was not identified in any of the symptomatic individuals (11 of 
11 symptomatics) within the study; the functional significance of this sequence change has yet to be 
determined. To date, a general explanation for the lower rate of virus production and the prolonged 
period of clinical long-term non-progression in HTV-2 infection has not been found.
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Productive infection by HIV is dependent on continued activation of infected target cells (Finzi, 1998); 
lower production of virus in HIV-2-infected cells could reflect a lower activation state in those cells or 
that HIV-2 is less responsive to such activation. The LTR of both HTV-2 and HTV-1 regulates the 
expression of the proviral DNA in response to cellular transactivation signals. This region of die virus 
exerts therefore, a direct influence upon the rate of virus production. Sequence variations in the HTV LTR 
might affect the interaction with cellular factors and alter viral gene expression and the production of 
progeny virions in infected cells. Thus, natural LTR variations could have a significant impact on the 
efficiency of viral replication and the clinical course of HIV infection. The inherent pathogenicity of the 
HTV-1 LTR has been demonstrated in vitro whereby variant 5’ LTR sequences have been shown to 
determine differences between the replicative capacities of particular HTV-1 (Golub et al, 1990, Zhang et 
al, 1997a) and STV (Anderson & Clements, 1992) strains. Duplication of the complete SP1 region 
through prolonged culturing of an attenuated HIV-1 subtype B virus has been described, the LTR variant 
containing six SP1 sites was a stronger promoter and yielded a fitter virus (Berkout et al, 1999). 
Similarly, uncultured HTV-1 LTR variants containing additional SP-1 binding sites have been shown to 
outgrow isogenic constructs with three SP-1 sites (Koken et al, 1992).
More recently, functional distinctions in LTR architecture among HTV-1 subtypes have been identified, 
raising the possibility that regulatory divergence among the subtypes of HTV-1 has occurred (Montano et 
al, 1997, Naghavi et al, 1999, Hunt & Tiemessen, 2000, Jeeninga et al, 2000, Hunt et al, 2001, 
Rodenburg et al, 2001, Novitsky et al, 2002, Roof et al, 2002, Scriba et al, 2002). Transcriptional 
analyses performed by Jeeninga et al demonstrated that subtype E LTRs were consistently 2-3-fold more 
active at the basal level when compared to the LTRs of other subtypes A through G (Jeeninga et al, 
2000). When recombinant viruses were constructed; core promoter elements from subtype E were found 
to confer profound replicative advantage to subtypes with less active LTRs. A study by Verhoef et al has 
suggested that a single-nucleotide deletion in the upstream NF-kB element converts the site into a GABP 
binding element, contributing to the improved replication observed in subtype E viruses (Verhoef et al, 
1999). Similarly, within the same region of the LTR, several groups have demonstrated that a potential 
third NF-KB element within the subtype C LTR confers transcriptional and replicative advantage to 
subtype C virions (Hunt & Tiemessen, 2000, Hunt et al, 2001, Rodenburg et al, 2001, Novitsky et al, 
2002, Roof et al, 2002, Scriba et al, 2002). Since subtypes C and E have become the most prevalent and 
rapidly transmissible HTVs worldwide it has been suggested that this divergent transcriptional regulation 
may go some way towards explaining the observed differences in HTV transmission and pathogenesis.
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Analyses of primary HIV-1 LTRs have revealed that basal and Tat-induced transcriptional activities vary 
considerably in infected individuals, and a variety of deletions and mutations have been detected 
(Delassus et al., 1992, Koken et a l, 1992, Micheal et al, 1994, Estable et a l, 1996 Kirchoff et a l, 1997, 
Rousseau et al, 1997, Zhang et a l, 1997b, Krebs et a l, 1998, Quifiones-Mateu et al, 1998, Gomez- 
Roman et a l, 2000). Mutation at NF-kB and SP-1 sites and partial deletions of the HIV-1 LTR have been 
described in HTV-1 LTS with persistently undetectable virus in plasma (Fujii et al, 1997, Rousseau et al, 
1997, Zhang et al, 1997b, Fang et al, 2001) as has a higher G-to-A mutation rate in crucial sites of the 
LTR (Zhang et al, 1997b, providing a possible genetic explanation for the low viral load and prolonged 
asymptomatic state in these individuals. Moreover, by analysing 20 complete HTV-1 RNA genomic 
sequences a recent study by Fang et al correlated the transition from long-term non-progressive to rapidly 
progressive infection with sequence changes to an SP-1 binding site and adjacent promoter within the 
HTV-1 LTR (Fang et al, 2001). While correlations have been found between HTV-1 LTR polymorphism 
and the progression status of individual cases, to date, a relationship between HTV-1 LTR defects or 
genetic diversity and disease progression in general has yet to be established (Estable et al, 1996, 
Rousseau et al., 1997, Zhang et al, 1997b, Quifiones-Mateu et al., 1998, Visco-Comandini et al., 1999, 
G6mez-Romdn et al., 2000).
In contrast to HTV-1, few functional studies exist concerning the HTV-2 LTR. Those that do exist have 
outlined significant differences between the structure and regulation of transcription from the two 
promoter regions (Markovitz et al., 1990, Markovitz et al, 1992, Hannibal et al., 1993, Hilfinger et al, 
1993, Hannibal et al., 1994, Clark et al, 1995, Faulkner et al, 2001). While the regulation of inducible 
promoter function in activated T cells is determined predominantly by the two NF-kB sites in the HTV-1 
LTR (Nabel & Baltimore, 1987), HIV-2 LTR activation in T cells requires complex stereospecific 
interactions between the transcription factors that bind to at least four synergystic c/s-acting binding 
elements (Markovitz et al., 1992, Hannibal et al., 1993, Hilfinger et al., 1993, Hannibal et al, 1994, Clark 
et al, 1995). Studies have shown that the HTV-1 LTR is stimulated more effectively by TNF-a, a 
cytokine that acts primarily through NF-kB elements to activate virus replication in any T cell bearing its 
receptor. The HIV-2 LTR however, appears to be more effectively stimulated by the calcium-mediated 
signal transduction pathway activated by soluble anti-CD3 antibodies and TCR mediated antigen 
recognition (Hannibal et al., 1993, Hilfinger et al., 1993, Hannibal et al., 1994). This method of 
activation is clonally specific and thus a more limited event. Since the regulation of the HTV-2 LTR 
significantly differs from the HTV-1 LTR, it has been suggested that the HTV-2 LTR could hold the key to
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explaining the long clinical latency seen during HIV-2 infection, perhaps by contributing to a reduced rate 
in virus production or attenuated viral phenotype. Similarly, it is possible that a difference in HIV-2 LTR 
activity or regulation might determine the difference between the progression rates of the majority LTNP 
HIV-2-infected individuals and the cases of rapidly progressing HIV-2 AIDS, with enhanced or reduced 
promoter activity providing a possible mechanism for controlling the rate of antigenic diversification and 
consequent time taken to reach the viral diversity threshold.
The objectives of this project were two-fold. Firstly, to develop and optimise efficient PCR- 
amplification, cloning, transfection and detection procedures for the rapid and reproducible recovery and 
measurement of HIV-2 LTRs and their activities. This enabled a thorough examination of the biological 
significance of functional diversity of HTV-2 LTR genotypes with respect to viral pathogenicity and 
clinical disease. We hoped to elucidate functional differences between the HTV-2 LTRs cloned from 
patients and viral isolates with diverse in vitro phenotypes that may possibly lead to answers regarding 
the suggestion that the long clinical latency seen during HIV-2 infection is due to an ‘attenuated’ viral 
phenotype. Secondly, we examined the nucleotide sequence diversity of HTV-2 LTR genotypes in order 
to identify any correlation between LTR sequence polymorphism, LTR function, and disease progression 
rate, or outcome.
We have developed a limiting-dilution sensitive nested PCR that is capable of amplifying 764bp of the 3’ 
HTV-2 LTR from a single molecule of HIV-2. This has enabled the amplification of the HTV-2 LTR from 
molecular clone, isolate, and high and low copy number patient-derived PBMC DNA. PCR amplicons 
generated by this procedure can be cloned into the experimental firefly luciferase reporter vector - pGL3E 
(Promega) using an optimised restriction digest cloning protocol that routinely achieves cloning 
efficiencies of up to 80%. HTV-2 LTR clones can then be co-transfected with an internal control vector 
into several different cell-lines using optimised co-transfection protocols that have been shown to be 
reliable and reproducible within each of the cell-lines used. The inclusion of an internal control vector, 
whose activity is used to normalise expression directed from the experimental reporter vector, has 
effectively eliminated inherent experimental variability’s that arise from differences in transfection 
efficiencies and the number and health of cultured cells. This has enabled normalised luciferase activity 
values obtained from co-transfections carried out at different time points and in different cell-lines to be 
compared. Finally, the optimised dual-luciferase reporter detection assay has enabled the rapid and 
reproducible measurement of the activity of each cloned HTV-2 LTR in this study over a dynamic range 
spanning at least seven orders of magnitude. The efficiency and reproducibility of the nested-PCR,
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cloning, transfection and reporter detection assay protocols developed in this thesis have also enabled 
HTV-2 LTR activity to be assessed in samples derived from the Caio cohort, Guinea Bissau (Okarofor,L 
et al unpublished). Furthermore, reaction conditions and techniques have been utilised to measure and 
compare the activities of LTRs derived from HTV-l-infected brain and lymph node tissue samples (Malik 
et al unpublished). The development of such a system therefore, constitutes a valuable addition to the 
currently available tools for those wishing to measure and compare promoter activity in functional 
characterisation studies.
PCR amplification of the HTV-2 LTR from molecular clone, isolate, and RP patient DNA was highly 
successful and readily achieved using a (non-optimal) nested PCR of high stringency. In contrast, 
amplification of the HTV-2 LTR from LTNP patient-derived PBMC DNA proved to be more difficult 
using the high stringency PCR, and was only achieved by doubling the initial first round DNA 
concentration and reducing the annealing temperature of the second round PCR from 54 -  50°C. Previous 
studies concerned with PCR amplification from HTV-2 infected PBMC material have experienced similar 
difficulties when trying to amplify from asymptomatic patient samples. A study by Simon et al found 
that the ability to detect the HIV-2 genome by PCR was a reflection of the level of virus within the 
patient, and correlated with CD4 count. Patients exhibiting CD4+ counts of >500 x 106/1 were less likely 
to carry detectable levels of HTV-2 DNA than patients exhibiting CD4+ counts of <200 x 106/1. A 
characteristic of the Gambian LTNP patients is very low to undetectable plasma viral loads (1 copy 1000 
to 1 copy in 10,000 CD4+ cells); in contrast, rapidly progressing Gambian patients exhibit high plasma 
viral loads (up to 1 copy in 10 CD4+ cells). It is likely therefore, that amplification from the three LTNP 
samples initially failed, in part, because of the very low levels of proviral copies within the PBMC 
derived DNA. The limiting dilution sensitivity of the optimised HTV-2 LTR nested PCR has enabled the 
amplification of the 764bp LTR region from all available DNA sources.
Various cloning and transfection techniques are currently available for use in molecular characterisation 
studies however; each must be optimised for the particular system within which they will be applied. By 
increasing the vector to inset ratio within the cloning reaction we were able to routinely achieve 70 -  80% 
cloning efficiencies. Similarly, increasing the ratio at which the luciferase vectors were cotransfected 
reduced trans effects between them in cotransfection reactions. Extensive optimisation of the transfection 
techniques available for each cell-line used in this study enabled detectable and reproducible firefly and 
Renilla luciferase measurements to be made, and ensured that normalised luciferase activity values 
obtained from co-transfections carried out at different time points could be compared. Washing
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transfected cells 2 hours post-transfection was not found to significantly increase normalised luciferase 
values or decrease growth inhibition and cell death. However, cell density was found to significantly 
alter reporter gene expression, with lower levels of gene expression being measured at lower cell 
densities. Optimal reporter gene expression was obtained when 2 x 106 Jurkat or THP-1 cells were 
transfected.
Under optimal conditions, analyses of the reproducibility of the dual luciferase detection assay and 
reproducibility of co-transfection revealed no significant differences between the levels of normalised 
luciferase activity taken from each well assayed in duplicate (R2 = 0.9888), or from each well of a 
duplicate co-transfection (R2 = 0.9848). Furthermore, very little variation was detected between the 
normalised luciferase values obtained from identical co-transfections performed one week apart (R2 = 
0.8796). The sensitivity and repeatability of the optimised protocols within the dual luciferase detection 
assay system has ensured that reporter protein expression directed by promoters of varying activities can 
be measured in singlicate, accurately and reproducibly.
Preliminary studies into the functional characterisation of the HIV-2 LTR were performed on a series of 
Gambian isolates (CBL20-24). CBL-20 and CBL-21 were derived from AIDS/ARC patients whereas 
CBL-23 and CBL-24 were derived from asymptomatic individuals. Analysis of these materials was 
instructive both in terms of the work-up of the technology and in generating preliminary data to enable 
the study to be extended to primary uncultured PBMC samples. However, the culturing of viruses in 
vitro may not provide a completely accurate representation of the viral population originally circulating in 
the patient when the isolate was first made, thus analyses of this kind require this observation to be taken 
into account.
Functional characterisation of the LTRs derived from the CBL series of HTV-2 isolates by the dual 
luciferase assay system, identified significant variation between the activities of LTRs cloned from the 
same and from the different CBL isolates when tested in both the Jurkat and THP-1 cell-lines 
(representing T-cell and macrophage-like cell lines respectively). This variation appeared to be 
reproducible, and is at least in part likely to be a reflection of viral polymorphism within each HTV-2 
isolate. It has been known for some time that HIV exists as a quasispecies or ‘swarm’ of viruses in vivo, 
where cellular proviruses are present as a library of similar, though not identical, sequences (Goodenow et 
al, 1989). The demonstration of the transcriptional heterogeneity within and between the HTV-2 LTR 
clones from the five HIV-2 isolates not only reflects this finding but demonstrates that functional
297
heterogeneity can persist despite the artificial selection conditions of culturing. This in turn allowed 
instructive data to be obtained and encouraged further study of viral populations in vivo.
Interestingly, examination of the LTR activities at both the basal and Tat-induced levels revealed a non­
significant trend towards higher basal and Tat-induced activities in Jurkat cells for the LTRs cloned from 
the more rapidly replicating CBL isolates, CBL-20 and CBL-21. The mean Tat-induced activity of the 
LTRs from CBL-20 was found to be statistically higher than two of the less rapidly replicating isolates 
(CBL-22 and CBL-23) in Jurkat cells. In addition, the intraisolate range of LTR activities from both 
CBL-20 and CBL-21 were greater than the intraisolate activity ranges of LTRs from the other CBL 
isolates in the Jurkat cell-line.
Differences of only two- and three-fold in the basal activity of the HTV-1 LTR have previously been 
shown to determine the different replicative capacities of two closely related HIV-1 isolates (Golub et al, 
1990). Therefore, it is possible that the range of basal and Tat-induced LTR activities of CBL-20 and 
CBL-21 in Jurkat cells reflect the phenotypes of these isolates and broadly correlate with the progression 
rates of the patients from whom these isolates were derived. However, while this non-significant trend in 
LTR activity was observed in Jurkat cells, there was no overall association between either basal or Tat- 
induced LTR activity and viral phenotype in vitro. This finding is in agreement with two studies 
performed with the cultured LTR quasispecies of slowly and rapidly replicating HTV-1 isolates 
(McNeamey et al, 1995, Simm et al, 1996) which failed to distinguish between the HTV-1 isolates on 
the basis of transcriptional activity. There may be a number of explanations for these findings.
In some respects it is not surprising that higher levels of LTR activity were observed in patients with 
more advanced disease, although whether a more active LTR is having a causal effect on disease 
progression or merely a reflection of it is not known. One possible interpretation is that the clinical status 
of the HIV-2 infected individuals from whom the CBL isolates were derived is not determined solely by 
the LTR. However, this does not preclude the possibility that the non-significant trend in activities 
observed in the Jurkat cell-line might prove significant in different cell-types in vivo and may therefore 
contribute in some way to determining their differing in vitro phenotypes. The differing pattern of LTR 
activities observed in the THP-1 cell-line gave the first indication in this thesis that the activity of the 
HTV-2 LTR may be related to cell-type. It is also possible that functional differences that may have 
existed between the LTRs of the CBL isolates before prolonged passage in culture may have been 
distorted due to the highly selective culture environment. The broader criticism that the use of in vitro
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viral isolates is unrepresentative of the viral swarm in vivo precludes over-interpretation of these findings.
Based on the data generated in the CBL series study we were encouraged to go forward and investigate 
LTR activity with respect to disease progression using PBMC derived DNA that had not been subjected 
to the selective pressures of in vitro culturing. The basal and Tat-induced activities of LTRs amplified 
from the PBMC-derived DNA of two clinically contrasting groups of HTV-2 seropositive patients were 
compared in both the Jurkat and the THP-1 cell-line. Significantly, some level of transcriptional activity 
was detected from the HTV-2 LTRs taken from each of the three LTNP and three RP patients within the 
analyses. This finding, along with the observations made with the LTRs of CBL isolates 23 and 24 
indicates that the prolonged freedom from clinical illness experienced by the long-term non-progressing 
and asymptomatic HTV-2 patients does not result from the presence of a transcriptionally attenuated 
quasispecies within these patients.
Similar to findings from several HTV-1 LTR studies (Fujii et al., 1997, Rousseau et al., 1997, Zhang et 
al., 1997b), we did identify one individual whose clinical long-term non-progression is most likely 
explained by defective LTR sequences. LTRs cloned from patient LTNP1 were found to direct 
consistently low basal activities which were not increased by any detectable amount in the presence of the 
HTV-2 Tat protein. In both Jurkat and THP-1 cell lines the activities of LTRs from the remaining five 
LTNP and RP patients were found to increase over basal levels by at least 15-fold. These data 
demonstrate that the function of the LTRs from LTNP1 was severely impaired. Cloning of LTRs from 
this and other patients was performed on at least two separate occasions by bulk PCR using fresh aliquots 
of PBMC derived DNA. Therefore, it is likely that the LTRs used to represent LTNP1 in these analyses 
reflect the circulating LTR genotypes within this individual, rather than LTRs containing errors 
introduced during the process of PCR amplification or a minority LTR species. When compared to the 
HTV-2 ROD LTR, sequences from LTNP1 contained multiple G-to-A hypermutations within the NF-kB, 
SP-1, and TAR binding elements of the LTR. Such hypermutations are expected to have a significant 
impact on the function of the LTR since they are within critical core promoter binding motifs. Mutations 
of this kind are predicted to severely disrupt the binding of the transcription factors NF- kB and SP1 and 
the cellular cofactor for Tat -  CycTl respectively (Arya & Gallo, 1988, Markovitz et al., 1990, Tong- 
Starksen et al., 1990, Markovitz et al, 1992, Pagtakhan & Tong-Starksen, 1997 Richter et al, 2002a, 
Richter et al., 2002b). In 1997, during the genotypic and phenotypic characterisation of LTR sequences 
from LTS of HTV-1 infection, Zhang and co-workers identified LTRs from a LTS patient (Pt5) that
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exhibited similar G-to-A hypennutations to those identified in the LTR sequences of LTNP1 (Zhang et 
al, 1997b). Analysis of LTR function by luciferase reporter assay system revealed that the activities of 
the LTR sequences from Pt 5 were severely blunted. Similarly, when whole infectious virus studies were 
performed, no detectable level of viral transcription was found in PBMC infected by proviral constructs 
containing Pt 5 LTR sequences. From these data Zhang et al concluded that it was likely that the viruses 
in Pt 5 were some-what attenuated, and that Pt 5’s functionally defective LTR provided some explanation 
for his prolonged period of well-being (Zhang et al, 1997b). While we have not performed whole 
infectious viruses studies with the LTR sequences from LTNP1, we have observed similar structural and 
functional finding to those identified by Zhang and co-workers. It is probable therefore, that the 
undetectable plasma viral loads and prolonged freedom from clinical illness exhibited by LTNP1 are in 
part explained by attenuation of LTR function.
Regarding LTR function in the context of progression groups, significant variation was observed between 
the basal and Tat-induced activities of the LTNP and RP LTRs. We have shown that LTRs cloned 
directly from the PBMCs of patients exhibiting long-term non-progression direct markedly lower levels 
of activity on average than the activities of LTRs from patients exhibiting unusually rapid progression to 
disease. While no direct correlation between LTR activity and disease progression status has been 
identified, a non-significant trend towards lower LTNP LTR activity has been observed in both Jurkat and 
THP-1 cell-lines. This observation was most evident at the Tat-induced level of activity within Jurkat 
cells. LTNP LTRs were found to be, on average, three times less active than the RP LTRs. Moreover, 
when analysed individually, the average LTR activities of two of the three LTNP patients were found to 
be statistically significantly lower than the LTRs of the two most active RP patients. These findings 
differ from a number of HIV-1 LTR studies that have found no association between LTR activity and 
progression status when LTR function in long-term survivors and typical progressors of HIV-1 infection 
was compared (Estable et al, 1996, Rousseau et al, 1997, Zhang et al, 1997b, Quiflones-Mateu et al, 
1998, G6mez-Rom£n et al, 2000). Most were performed using comparable reporter assays and similar 
cell-lines, ruling out the possibility that the differing conclusions result from different techniques. Rather, 
the differences noted within the analyses presented in this thesis are genuine and reproducible and likely 
represent a functional difference between the activities of the promoter regions of the virions circulating 
within the LTNP and RP patients in these analyses. As stated at the outset of this thesis, this is the first 
functional comparison of naturally occurring HIV-2 LTR genotypes in the context of disease progression 
and pathogenesis and the results are therefore novel.
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An explanation for the non-significant trend observed in LTR activities may lie in the differences noted 
between the rates of mutation within the LTNP and RP LTRs. The nucleotide sequence analyses 
performed upon the HTV-2 LTR sequences in this study suggest that there may be a correlation, albeit 
non-significant, between the rate of mutation at single functional sites, HIV-2 LTR activity, and clinical 
progression status. While the general mutation rate throughout the LTR as a whole was found to be 
similar between the two progression groups, the findings outlined in chapter 7 demonstrated that LTR 
sequences from the LTNP group of patients had on average 2.5 times more general mutations at single 
functional sites than the RP group of LTR sequences. Moreover, on average, LTNP LTRs contained 
twice the number of G-to-A mutations throughout the entire LTR sequence, and five times the number of 
G-to-A mutations at single functional sites when compared to RP LTR sequences.
Though in the absence of site-directed mutagenesis (SDM) analysis it is difficult to say what the 
functional effect of the higher rate of mutation at single functional LTR sites in LTNP LTRs would be, it 
is likely to result in some kind of transcriptional disadvantage. Significantly, the two patients that 
exhibited the highest rates of mutation were the LTNPs that directed the lowest LTR activities. 
Conversely, the two patients that exhibited the lowest rates of mutation were the RPs that directed the 
highest LTR activities. Most importantly, sequence changes within the LTNP LTRs were located almost 
entirely within the core transcription factor binding sites of the HIV-2 promoter, while RP LTRs 
displayed 100% consensus sequences for each of the binding sites within this region. Any mutations that 
were noted within the binding sites of the RP LTRs were located within the less conserved binding sites 
of the modulatory region of the LTR. It is therefore, not surprising that the LTNP LTR sequences tended 
to direct lower basal and Tat-induced activities than the RP LTRs. Changes to the functional sites within 
the core promoter region are predicted to have a significantly greater impact upon LTR function than 
changes to those elements situated further upstream since they are directly involved in binding the 
transcription factors involved in the assembly of the PIC (Arya & Gallo, 1988, Markovitz et al, 1990, 
Tong-Starksen et al, 1990, Markovitz et al, 1992). In accordance with this, LTRs from RP1 that 
contained changes within the modulatory binding sites were shown to retain a greater ability to respond to 
the Tat protein than the LTRs from the three LTNP patients that contained changes within core promoter 
binding sites, despite the LTRs from RP1 having relatively low basal activities. It is possible that the 
lower basal and Tat-induced activity of the LTNP LTRs results from a reduction in the rate of pre- 
initiation complex (PIC) assembly caused by the effects of sequence changes within the binding elements 
located in the core region of the promoter. Mutations such as G-to-A substitutions result in completely
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different functional groups being presented for interaction with the transcription factor binding proteins, 
and cause a reduction in the binding affinity and recruitment of those factors. Nevertheless, it is notable 
that these analyses did not identify a structural motif that distinguished the LTRs from LTNP and RP 
patients.
Numerous HTV-1 reports have correlated genetic diversity with disease progression, with greater 
sequence diversity being noted in viral populations of individuals who remain asymptomatic for a 
prolonged period of time compared to individuals showing more rapid progression to disease (Delwart et 
al, 1994, Lukashov et al., 1995, Wolinsky et al., 1996). This observation is thought to be determined by 
constraints placed upon the viral genome by the immune system. The higher rate of mutation at single 
functional sites observed within the LTRs from the LTNP patients in these analyses appear in part to 
reflect this finding. However, while a number of individual cases of long-term non-progression in HIV-1 
infection have been correlated with a higher rate of mutation within the promoter region (Fujii et al, 
1997, Zhang et al, 1997b, Fang et al, 2001), no definite correlation has been made between the rate of 
mutation within the LTR region of the viral genome and the rate of disease progression in HTV-1 
infection per se. Therefore, analyses of a larger number of HTV-2 infected individuals would be required 
to confirm any association between mutation rates in the LTR, transcriptional activity, and progression 
status in HTV-2 infection.
Interestingly, the significance of the trends and associations noted between mutation rates, LTR activity, 
and progression status appear to be related to cell-type, with the greatest differences between the LTR 
activities of the two progression groups being noted in the T-cell-like cell-line. The LTR has been shown 
to be important in determining the cell tropism of a number of virus from the Lentivirus genus including, 
equine infectious anaemia virus (EIAV) (Carvalho et al, 1993, Maury et al, 1997, Maury, 1998, Payne et 
al, 1999, Maury et al, 2000, Hines et al, 2004), feline immunodeficiency virus (FTV) (Poeschla et al, 
1998), and maedi-visna virus (MMV) (Andresdottir et al, 1998, Agnarsdottir et al, 2000). Moreover, 
cell-type specific differences in the activity of LTRs have been widely documented in HTV-1 analyses 
(Corboy etal., 1992, Chang eta l, 1993, Moses et al, 1994, Ait-Khaled et al, 1995, Canonne-Hergaux et 
al, 1995, Estable et al, 1996, Corby & Garl, 1997, Henderson & Calame, 1997, Krebs et al, 1997, 
Jeeninga et al, 2000, McAllister, et al, 2000). It has been demonstrated that some in v/vo-selected LTRs 
can confer transcription and replication advantages in specific cell types leading to suggestions that 
several non-envelope factors, including the HTV LTR, may play an important role in determining cellular 
tropism in HTV-1 infection (Chang et al, 1993, Ait-Khaled et al, 1995, Henderson & Calame, 1997,
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Krebs et al, 1997, Jeeninga et al, 2000, McAllister, et al, 2000). In accordance with this, Reed- 
Inderbitzin et al recently demonstrated that it was possible to alter the cell tropism of HIV-1 by making 
substitutions within the enhancer region of the LTR, indicating for the first time that macrophage 
specificity of productive HTV replication could be mediated by LTR sequences (Reed-Inderbitzin et al, 
2003). Since the cellular tropism of HIV may play an important role in disease progression, with primary 
stages of infection being associated with viral species exhibiting macrophage-tropic non-syncytium- 
inducing replication characteristics and clinical disease progression being associated with the 
development of viral species exhibiting T-cell-tropic, syncytium-inducing phenotypes, it may be of 
significance that the RP LTRs in our analyses were found to direct significantly higher levels of 
transcription within the Jurkat T-cell-like cell-line than the LTRs from the LTNP patients. If in 
comparison to RP patients, long-term non-progressors of HTV-2 infection possess a viral population that 
directs viral gene expression and subsequent virus production at a lower level within cells that the virus 
preferentially replicates, the result could be a slower rate of immune damage via direct (cytotoxic) and 
indirect (apoptotic) mechanisms, and a slower rate of disease progression. In this sense it could be 
suggested that in the vast majority of cases HIV-2 is behaving more akin to a classical lentivirus (Gorrell 
et al, 1992, Maury, 1994) than HTV-1, tending to be macrophage-tropic, or at least not showing the 
rapid/high replication properties within T cells demonstrated by HTV-1. Conversely if the rapid 
progressors of HTV-2 infection possess LTRs that provide transcriptional and thus replicative advantage 
within T cells in an ‘HTV-1-like’ manner, this may in turn influence the rate of virus production, rate of 
viral diversity, rate of immune damage and finally rate of progression to disease. Importantly, the 
findings derived from both the CBL isolate and Gambian patient cohort analyses indicate that the HTV-2 
LTR may be involved in determining cell-type-specific transcription and replication. It is possible that 
the mutations that occur within the core transcription binding sites of the LTNP LTRs are tolerated less 
well in Jurkat cells than in THP-ls, leading to the more pronounced difference in LTR activity observed 
between the progression two groups in Jurkat cells.
It cannot be ignored that the data set within which these observations have been made is small (n=6), 
therefore analyses of HTV-2 LTR sequence and function within larger populations and/or cohorts would 
be required to investigate fully the role that the HTV-2 LTR plays in the pathogenesis of HTV-2 infection. 
The study number may provide one explanation as to why the findings presented here contradict those 
reported in the analyses of HTV-1 LTR function in LTS of HTV-1 infection. Numbers in the HTV-1 
studies have ranged from eight patients (Rousseau et al, 1997, Zhang et al, 1997b) up to 42 patients
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(Estable et al., 1996, Quifiones-Mateu et al, 1998), it is possible that the statistical significance of the 
findings presented in this thesis would be reduced were the numbers of patients in the study to be 
increased. Nevertheless, the differences that were noted between the progression groups as a whole in 
terms of LTR function and structure were in many cases statistically significant when the data from the 
fifteen LTR sequences as opposed to the three patient averages from each group were compared. 
Therefore, it maybe that increasing the patient number in the study would strengthen the significance of 
these findings.
In making the case for the causal involvement of the HIV-2 LTR in determining pathogenesis, the 
pathogenic influence of the LTR has been demonstrated in a number of other retroviral infections. For 
example, both the latency period of disease induction and the pathogenic/oncogenic potential of the avian 
leukosis virus group have been found to correlate with LTR transcriptional activity (Tsichilis & Lazo, 
1991). In addition, acquisition of virulence by some strains of simian immunodeficiency virus has been 
associated with changes to viral genetic elements including the LTR region (Novembre et al., 1993, 
Flaherty et al., 1997, Karlsson et al., 1997). Similarly, a recent study by Grassley et al revealed a 
significant correlation between the death of HTV-2 infected individuals and viral genetic identity when 
LTR, gag, andpol sequences were jointly aligned (Grassley et al, 1998). Finally, the analyses performed 
by Fang et al in 2001 indicated that progression to symptomatic disease following a prolonged period of 
asymptomatic HIV-1 infection could be associated with sequence changes to the HTV LTR region (Fang 
et al., 2001). It is possible therefore, that the differences in promoter activity that have been noted 
between the LTNP and RP patients in the analyses could reflect a mechanism by which, in the majority of 
infections, the HIV-2 LTR helps to determine the establishment of a more low-key and sustainable virus- 
host relationship than observed in HTV-1 or rapidly progressing HTV-2 infection. Analyses performed by 
Jordan et al have indicated that the basal activity of the HTV-1 LTR varies considerably depending on the 
integration site (Jordan et al., 2001). It is possible that the site of integration within host cell DNA could 
further compound LTR activity in LTNPs that may already be compromised.
What is apparent is the need for further investigation of the pathogenic significance of the differences in 
activity observed between the LTNP and RP LTRs in vivo. It would be interesting to determine whether 
the observed transcriptional differences translate into replicative differences between proviral constructs 
containing the LTNP and RP LTRs analysed within this study. Transcriptional differences noted between 
HTV-1 LTRs in reporter gene analyses performed by Jeeninga et al were found to confer significant and 
comparative replicative differences to constructs containing the promoter regions under investigation
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(Jeeninga et al, 2000). Similarly, Zhang and coworkers demonstrated that the levels of transcription 
directed by HTV-1 LTRs in the context of whole infectious virus studies were remarkably consistent with 
the results obtained using the luciferase gene alone (Zhang et al., 1997). From this it is possible to 
assume that the modest average two- (THP-1 cells) to three-fold (Jurkat cells) difference observed 
between the Tat-induced activities of the LTNP and RP LTRs could also reflect and confer significant 
differences to the replicative capacities of the viral populations circulating within the infected individuals 
from which they were taken. Similarly, this may in part influence the difference between the levels of 
viremia observed in the two groups of patients, with LTNP LTRs of lower activity directing lower levels 
of gene expression and virus production than RP LTRs of higher activities directing higher rates of gene 
expression and virion production. Since the level of virus production within HTV infection is thought to 
be related to the rate of disease progression and pathogenesis it is possible that the difference observed 
between the activities of the LTRs from the LTNP and RP patients are related to the differences between 
the rates of disease progression shown by the two groups.
Taken together the data presented in this thesis have indicated the existence of a non-significant trend 
towards lower LTR activity in HIV-2-infected patients exhibiting long-term non-progression. Since the 
observed trends are non-significant and we have failed to distinguish between LTNP and RP patients 
based upon LTR activity or structural LTR motifs alone it is unlikely that the HTV-2 LTR is the sole 
determinant of HIV-2 pathogenicity. Rather, the findings presented here indicate that the HTV-2 LTR 
may play a contributoiy role in determining pathogenesis via its influence upon gene expression and virus 
production, and have indicated that this role may be cell-type-specific. The data do not rule out the 
possibility that the proviral DNA in the LTNP and RP patients contain deletions or mutations in regions 
of the LTR that have yet to be identified as important for replication. Neither do they preclude the 
possibility that the differences in activities between the two groups that have been noted in the cell-lines 
tested could be greater within other cell-lines. However, they do suggest that long-term non-progression 
in HTV-2 infection is a multifactorial process almost definitely involving both host and viral determinants. 
In this vein, the analyses presented here does not exclude the possibility that other regions of the HTV-2 
genome within each of the infected patients are playing a more significant role in the determination of 
rate of disease progression within each individual, or that the differences in LTR activity observed in this 
study merely reflect the appearance of more highly pathogenic strains during the development of 
symptomatic disease. Indeed, caution needs to be taken in drawing conclusions from the presented data 
as only the proviral population was sampled to compare LTR populations in LTNP and RP groups.
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Archival populations may be misleading, so for a more accurate reflection of the impact that LTR 
sequences variation could have on influencing HTV-2 biology LTR sequences in plasma virus populations 
should also be studied. However, one of the confounding issues here concerns the very low levels of 
HTV-2 RNA circulating in the plasma of a true long-term non-progressor of HTV-2 infection. If ultra­
sensitive RT-PCR methodologies were to be employed for this analysis high sample input volumes would 
be required and availability of such material is a significant problem. Hence, the low level of viral 
replication in true HTV-2 LTNPs presents considerable technical obstacles if one wishes to study the 
properties of virus populations which may be regarded as low-level replication competent viruses. How 
the sequence of these virus populations differs from proviral species in HTV-2 infections is not known but 
would be an interesting lead to follow up with the methodologies described. These issues underline the 
need for further research into the pathogenic determinants of HTV-2 infection. In conclusion, the findings 
presented in this thesis have provided a unique insight into the genotypic and phenotypic characteristics 
of naturally occurring HTV-2 LTRs and may be important for the future development of treatments or 
vaccines for both HTV-2 and HIV-1 infection.
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Appendix I. 
Chemicals and Buffer formulae.
TE buffer:
lOmM Tris-HCl (pH 7.6), ImM EDTA 
Phosphate buffered saline (PBS):
150mM NaCl, 15mM KH2P04, 63mM Na2HP04xH20,26mM  KC1, pH 7.2
PCR and cloning reagents:
10 x Pfu Turbo reaction buffer:
lOOmM KC1, lOOmM (NH4 )2 S0 4 , 200mM Tris-HCl (pH 8.8), 20mM MgS0 4 , 1% Triton X-100 and 
1 mg/ml nuclease-free BSA
50 x Tris Acetate EDTA (TAE):
242g/L Tris base, 57.1ml/L glacial acetic acid, 37.2g/L EDTA, adjusted to pH 8.1 
1% Agarose gel:
1 x TAE buffer containing 1.5 to 2% (w/v) agarose (Promega) and 0.5mg/ml ethidium bromide
Agarose gel loading buffer (10x1:
40% sucrose, 0.1% Orange G in dH20
lkb DNA Marker (Life Technologies):
20(il lkb marker: diluted in 200pl of TE and 80pl of loading dye 
Buffer H:
50mM Tris-HCl, lOmM MgCl2, lOOmM NaCl, ImM Dithioerythriol, pH 7.5 
10 x T4 DNA ligase buffer:
200mM TrisCl (pH 7.6), 50mM MgCl2, 50mM dithiothreitol, 500pg/ml bovine serum albumin, 0.5M 
ATP
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DNA concentration assay diluent:
lOmM Tris HC1, pH 7.5, containing ImM EDTA, lOOmM NaCl
Bacterial solutions:
2 x TY Broth:
16g/IL Bacto-tryptone, lOg/L Bacto-yeast extract, NaCl 5g/L, pH7.0 
2 x TY Agar:
2 x TY broth with 1.5% (w/v) Difco Bacto agar 
Antibiotic Solution:
Ampsicillin stock solution lOOmg/ml in dH20  stored at -20°C. Working stock concentration 50pg/ml 
Calcium Chloride Bacterial Transformation Buffer:
lOOmM Calcium Chloride, 47g CaCl2.H20 , dissolved in 100ml of dH20  and sterilised by autoclaving, 
stored at -20°C
Tissue culture media:
Complete medium DMEM:
Dulbecco’s Modified Eagle’s Medium supplemented with 10% FCS, 5mM L-glutamine, lOOU/ml 
penicillin, lOOpg/ml streptomycin, 0.075% sodium bicarbonate. Stored at 4°C.
Complete medium RPMI 1640:
RPMI 1640 supplemented with 10% FCS, 5mM L-glutamine, lOOU/ml penicillin, lOOpg/ml 
streptomycin, 0.075% sodium bicarbonate. Adjusted to pH 7.0 with NaOH. Stored at 4°C.
2 x Hepes Buffered Saline:
8.18g NaCl, 5.95g HEPES (tissue culture grade), 0.2g Na2HP04, 400ml dH20  adjusted to pH 7.1 with 
NaOH, topped up to 500ml with dH20 . Filter sterilised and stored at 4°C.
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Freezing Medium:
10% DMSO, 40% FCS, 50% DMEM/RPMI 
Luciferase reporter assay reagents:
Reagients including Passive Lysis Buffer, Luciferase assay reagent II, and Stop & Glo™ all supplied by 
Promega. Composition undisclosed.
Sequencing reagents:
Thermo Seauenase ore-mixed cvcle sequencing kit:
This kit contains pre-mixed A, C, G, and T reagents. Each reagent contains Thermo Sequenase DNA 
polymerase, and the corresponding dNTPs and ddNTPs. Exact reagent compositions are undisclosed 
(Amersham Life Science).
10 x Tris Borate EDTA (TBE1:
1 lOg/L Tris base, 55g/L boric acid, 9.3g/L EDTA, adjusted to pH 8.3
10% ammonium persulphate solution (APS): 
lg  APD dissolved in 10ml dH20
6% denaturing polvacrvlamide/urea sequencing gel:
1 lg urea, 3ml bisacrylamide (contains 40% w/v acrylamide -  2.105% w/v bisacrylamide), 1.5ml 40% 
acrylamide (acrylamide:bisacrylamide ratio 19:1), 3ml of lOx TBE, 12.4ml dH20 , . Polymerised by the 
addition of 150pl of 10% ammonium persulphate solution (APS) and 15pl TEMED to 30ml of gel mix.
Sequencing gel tank buffer 1 x TBE:
60ml 10 x TBE in 540ml dH20
Denaturing loading dve:
90% (v/v) formamide
Isoelectric solution:
Loading dye/salt solution/dH20 , in a ratio of 2:1:1
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Appendix II.
Plasmid Maps.
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Figure II. 1: Schematic map for pGL3-Enhancer (pGL3E) (Promega). This reporter vector contains the firefly luciferase (Photinus pyralis) gene. The polylinker 
region located upstream of the luciferase gene allowed the rapid and efficient insertion of HIV-2 LTR. The Mlu I and Bbl II sites were utilised in this study. 
Expression of firefly luciferase was under the direct control o f the HIV-2 promoter. The SV40 enhancer located downstream o f the firefly luciferase gene aided 
the verification of functional promoter elements inserted into pGL3E by increasing the level of firefly luciferase gene transcription. In addition, an ampicillin- 
resistance gene, P-lactamase, and a high copy number prokaryotic origin of replication allowed pGL3E selection, maintenance, and manipulation in E.coli hosts. 
The SV40 late poly(A) signal increased the efficiency of transcription, termination and polyadenylation of the luciferase transcripts.
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Figure II.2: Schematic map for pGL3-Control (pGL3C) (Promega). This reporter vector contains the firefly luciferase (Photinus pyralis) gene under the control 
of the SV40 promoter, resulting in strong expression of luc+. This reporter vector was used as a positive control for firefly luciferase expression in the 
experiments performed to determine the trans effects experienced by cotransfected vectors (Chapter 4).
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Figure II.3: Schematic map for pRL-TK (Promega). This internal control reporter vector contains the Renilla luciferase (Renilla reniformis) gene under the 
control of the herpes simplex virus thymidine kinase (HSV-TK) promoter, providing low to moderate levels of Renilla luciferase expression in cotransfected 
mammalian cells. This reporter vector was chosen for use as the internal control vector in cotransfections performed with pGL3E containing HIV-2 LTR inserts. 
(Chapter 4, 5, and 6). Cotransfections were performed at an experimental reporter vector:internal control vector ratio of 10:1.
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Figure II.4: Schematic map for pRL-CMV (Promega). This internal control reporter vector contains the Renilla luciferase (Renilla reniformis) gene under the 
control of the cytomegalovirus (CMV) promoter, providing high levels of Renilla luciferase expression in cotransfected mammalian cells. This reporter vector 
was used in the assessment of the optimal experimental reporter: internal control vector pairing (Chapter 4).
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Figure II.5: Schematic map for pRL-SV40 (Promega). This internal control reporter vector contains the Renilla luciferase {Renilla reniformis) gene under the 
control of the SV40 promoter, providing high levels of Renilla luciferase expression in cotransfected mammalian cells. This reporter vector was used in the 
assessment of the optimal experimental reporter: internal control vector pairing (Chapter 4).
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Figure II.6: Schematic map for RSVtat2 (kind gift from Dr.Browning, University of Michegan). This vector was used for the expression of HIV-2 Tat (ROD) 
when transfected into mammalian cell-lines. Expression of the first two exons of HIV-2 Tat (ROD) is under the control of the Rous Sarcoma Virus (RSV) 
promoter.
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